

ANNUAL REPORT

2024-2025



Central Council for Research in Unani Medicine
Ministry of Ayush, Government of India

Annual Report

2024-2025



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Ministry of Ayush, Government of India



Published by
CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Ministry of Ayush, Government of India
61–65, Institutional Area, Janakpuri, New Delhi – 110 058
Telephone: +91-11-28521981, 28525982
Website: <https://ccrum.res.in>
E-mail: unani-medicine@ccrum.res.in
unanimedicine@gmail.com

Printed at
Hi-Tech Graphics
F-28/3, Okhla Industrial Area, Phase-II,
New Delhi-110 020

CONTENTS

1. OVERVIEW	5
1.1. Objectives of the Council	5
1.2. Programme-wise Achievements	5
2. MANAGEMENT	11
2.1. Governing Body	11
2.2. Executive Committee	12
2.3. Standing Finance Committee	12
2.4. Scientific Advisory Committee	13
2.4.1. Research Sub-Committees	13
2.4.1.1. Preclinical Research Sub-committee	13
2.4.1.2. Clinical Research Sub-committee	14
2.4.1.3. Fundamental Research Sub-committee	14
2.4.1.4. Literary Research Sub-committee	14
2.4.1.5. Drug Standardization Sub-committee	15
2.4.1.6. Survey and Cultivation of Medicinal Plants Sub-committee	15
2.5. Institutional Ethics Committee	16
2.5.1. Central Ethics Committee	16
2.5.2. Institutional Ethics Committee	16
2.6. Organisational Set-Up	24
2.7. Institutional Multidisciplinary Research Advisory Committee (IMRAC)	31
2.8. Budget (Actual Expenditure)	34
3. TECHNICAL REPORT	35
3.1. Intramural Research	35
3.1.1. Centre-wise Activities	35
3.1.2. Programme-wise Activities	41
3.1.2.1. Survey and Cultivation of Medicinal Plants Programme	41
3.1.2.2. Drug Standardization Research Programme	45
3.1.2.3. Clinical Research Programme	63
Preclinical Studies	63
Clinical Studies	65
Randomised Controlled Trials	70
Validation of Unani Pharmacopoeial Drugs	73
Validation of Regimenal Therapies	89
Validation of Fundamentals	91
Research-oriented Healthcare	95
3.1.2.4. Literary Research	97
3.2. Studies under IMR Policy	98
3.3. Collaborative Research	102
3.4. Publications	126
3.4.1. Books, Monographs, Reports, etc.	126
3.4.2. Research Papers	128
3.5. Extension of Healthcare Services	150
3.5.1. School Health Programme	150
3.5.2. Unani Medical Centres in Allopathic Hospitals	151
3.5.3. Health Melas / Camps	151

3.5.4. Activities under Gender Component Plan for Women	152
3.5.5. Activities in the North-Eastern Region	152
3.5.6. Ayush Wellness Centre - President Estate	152
3.5.7. All India Ayurveda Institute, New Delhi	153
3.5.8. Mobile Healthcare Programme under Scheduled Caste Sub-Plan	153
3.5.9. Mobile Healthcare Programme under Tribal Sub Plan	153
3.6. Linking Education with Research	154
3.7. Studentship Programme for Unani Research (SPUR)	154
3.8. Pharmacovigilance program of ASU & H drugs	155
3.9. Transfer of Technology for Commercialization	156
3.10. Strategic MoUs for Advancing Research and Development	156
4. INFORMATION, EDUCATION & COMMUNICATION	161
4.1. Library Services	161
4.2. Organization of Conferences, Seminars, Workshops, etc.	162
4.2.1 Unani Day 2025 and International conference on Unani Medicine	162
4.2.2. National Seminar on Ilaj-bit-Tadbeer (Regimenal Therapy)	164
4.2.3. Orientation cum Induction Workshop on Core Research Programmes of CCRUM, Research Methodology and HRD for Research Officers (Unani)/Scientist Level-1	165
4.2.4. National Seminar on “Harnessing Artificial Intelligence and Machine learning for Ayush: Prospects and Challenges”	166
4.2.5. Workshop cum Hands on Training on “Preventive and Therapeutic approaches for Musculoskeletal disorders through Ilaj-bit-Tadbeer (Regimenal Therapy) - Recent initiatives”	167
4.2.6. National Seminar on “Collaborative Activities – A Means to Integrate Ayush Systems into Mainstream Healthcare”	168
4.2.7. National Webinar on Biomedical Ethics	169
4.2.8. Orientation cum Induction Program for Investigators on “Statistics related work of CCRUM”	169
4.2.9. Awareness Program on Pharmacovigilance	170
4.2.10. Training on “Public Procurement Principles and GeM Portal”	170
4.2.11. Awareness and Orientation Programme on the Prevention of Sexual Harassment (POSH) Act	171
4.2.12. National Webinar on e-Granthalaya 4.0	171
4.2.13. A Pharmacovigilance Awareness Program	172
4.2.14. Other Events	172
4.3. Participation in Training and Capacity Building Programmes	176
4.4. Participation in Arogya Fairs/ Expos	179
4.5. Participation in Promotion of Official Language	182
4.6. Appointments	185
4.7. Promotions	187
4.8. Retirements	187
4.9. Deaths	188
5. FINANCIAL STATEMENT	189
5.1. Audit Report	189
5.2. Audited Statement of Accounts	194
5.3. Notes on Accounts	240

1. OVERVIEW

1.1. Objectives

The Central Council for Research in Unani Medicine (CCRUM) is an autonomous organization under the Ministry of Ayush, Government of India. It was established on March 30, 1978 under the Societies Registration Act, 1860 and started functioning from January 10, 1979. The main objectives of the CCRUM are as follows:

- To formulate aims and patterns of research on scientific lines in Unani Medicine.
- To undertake any research or other related programmes in Unani Medicine including undergraduate, postgraduate and post-doctoral educational programmes in Unani Medicine.
- To prosecute and assist in research, propagation of knowledge and experimental measures generally in connection with the causation, mode of spread, treatment and prevention of diseases.
- To initiate, aid, develop and coordinate scientific research in different aspects, fundamental and applied aspects of Unani Medicine and to promote and assist institutions of research for the study of diseases, their prevention, causation, treatment, management and other remedial measures.
- To provide technical and financial support for research for the furtherance of objectives of the Central Council.
- To exchange information with other institutions, associations and societies interested in the objectives similar to those of the Central Council and specially in observation and study of diseases across the globe, East Asia and in India, in particular.
- To prepare, print, publish and exhibit any papers, posters, pamphlets, periodicals, standard treatment protocols and books for furtherance of the objectives of the Central Council and to contribute to development of such literature.

1.2. Programme-wise Achievements

During the reporting period, the Central Council for Research in Unani Medicine (CCRUM) demonstrated significant progress in its core research domains, which include the Survey and Cultivation of Medicinal Plants, Drug Standardization Research, Pre-clinical and Clinical Research, Fundamental Research, and Literary Research. These key areas constituted the foundation of the Council's efforts to advance the field of Unani Medicine. Operating through a well-established network of 24 centres across the country, the Council not only strengthened its research

initiatives but also expanded its scope to supplementary domains such as research-oriented healthcare and the extension of healthcare services.

The Council's clinical institutes, units, and centres played a pivotal role in promoting and delivering Unani healthcare to diverse communities, thereby contributing to the overall health and well-being of the population. Furthermore, the Council actively engaged in Information, Education, and Communication (IEC) activities, reinforcing its commitment to public awareness and outreach.

Under the Survey and Cultivation of Medicinal Plants Programme, ethno-pharmacological surveys were conducted in different forest divisions/areas. As a result of these surveys, 2,876 botanical specimens were collected and 976 plant species identified. Later, herbarium sheets of 938 specimens including new and previous collections containing their basic details were prepared and 447 index cards were updated. A total of 371 herbarium sheets were digitized as well. The survey teams collected 6,328 saplings of important medicinal species for plantation and 215.4 kg of raw drugs. The surveyors recorded 238 folk medicinal claims from the tribal inhabitants and other rural folks of the study areas. Experimental and large-scale cultivation of some important medicinal species was also undertaken which yielded 531.97 kg of raw drugs. A total of 411 common species of medicinal plants used in Unani Medicine were maintained in the nurseries of the CCRUM centres.

Under the Drug Standardization Research Programme, SOPs for manufacture of 36 Unani formulations and their pharmacopoeial standards were developed. Besides, pharmacopoeial monographs for 16 single drugs were developed in accordance with the PCIM&H format for Pharmacopoeial Standards and phyto-constituents were isolated from 04 Unani single drugs at RRIUM, Srinagar and the Chemical Research Unit located AMU, Aligarh. The drug testing laboratory at the RRIUM, Chennai analysed 42 drug samples received from different organizations.

Under the Preclinical and Clinical Research Programme, preclinical safety evaluation studies, clinical studies on validation of safety and efficacy of classical/pharmacopoeial formulations, regimen therapies and fundamentals of Unani Medicine continued. Besides, research under Intramural Research (IMR) policy and Collaborative Research also continued.

Preclinical safety and pharmacological studies were undertaken on 06 Unani drugs at RRIUM, Srinagar and NRIUMSD, Hyderabad.

In clinical research, 08 randomised controlled trials (RCTs) were conducted. Besides, 45 studies for clinical validation of Unani pharmacopoeial formulations in different diseases were conducted, 19 clinical validation studies were initiated, and 20 new clinical validation studies were allotted. Various regimen therapy procedures were

performed on 44,024 patients of different diseases. *Hijama bila-Sharṭ* (dry cupping) was performed on 4,888 patients, *Hijama bi'l-Sharṭ* (wet cupping) on 3,104, *Hijama bi'l-Nar* (fire cupping) on 1,150, *Hijama Muzliqa* (moving cupping) on 6,830, *Hammam al-Bukhar* (steam bath) on 1,986, *Dalk Mu'tadil* (moderate massage) on 1,609, *Hammam Yabis* (sauna) on 21, *Naṭul* (fomentation) on 329, *Inkibab* (vaporization) on 4,328, *Mundij-Mushil* therapy on 70, *Ta'liq* (leeching) on 213, *Takmid* (fomentation) on 1,628, *Faṣd* (venesection) on 23, and other therapies (*Amal-i-Kayy* or cauterization, cleaning & dressing, and mechanical massage) on 2,058 patients.

Under the validation of fundamentals of Unani Medicine, 03 genetic studies were completed and technical reports have been published and released on the Unani day 2025. Besides 12 Fundamental Research projects are in progress. Clinical assessment of *Mizāj* (temperament) of 300 patients was done and susceptibility of acquiring diseases in relation to the temperament of the patients was studied.

The CCRUM also undertakes research in collaboration with other prestigious institutes. During the reporting period, 61 collaborative studies continued/were initiated at different collaborating institutions. Besides the books/monograph, the Council has published 255 research papers in peer reviewed/index journals during the reporting period.

The Council has published Urdu translation of the Arabic book *Man La Yahzuruhu al-Tabib* and Persian book *Kitab al-AbniyaanHaqaiq al-Adwiya* under Literary research programme. Besides, *Unani Chikitsa mein Saadhaaran Upchaar ki Pustika*, Manual and Training Module for Geriatric Health Care in Unani Medicine was also published. Standard Treatment Guidelines on Management of Common Musculoskeletal Disorders in Unani Medicine was also prepared and submitted to Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India.

During the reporting period, CCRUM's quarterly peer-reviewed English journal, Hippocratic Journal of Unani Medicine, has gone online and was published by Wolters Kluwer India Pvt Ltd (MedKnow). The work on revision and updating of NUMC Version 1.0 continued, and numerous new codes were developed for adding them in NAMASTE Portal and AHMIS. Besides, retrieval and compilation of NUMC data from NAMATE-P was also carried out.

Research-oriented healthcare services continued at GOPDs and special OPDs of clinical centres of the CCRUM. During the reporting period, a total of 9,91,450 beneficiaries comprising 6,19,006 in GOPDs, 1,29,120 in Geriatric OPDs, 28,852 in RCH / MCH OPDs, 1,49,585 in NCD OPDs and 64,887 in OPDs for Post-trial Treatment Access (PTA) were treated at different centres. In-Patient Department (IPD) services continued at seven peripheral institutes of the council and a total of 14,500 beneficiaries were treated.

Under the Mobile Clinical Research Programme, 32 rural pockets/urban slums covering over 7.96 lakh population were adopted and a total of 37,138 patients were treated with Unani Pharmacopoeial formulations in 435 mobile visits made to these pockets during the reporting period.

Under the School Health Programme, a total of 4,249 school children were covered in 114 visits and their health check-up was conducted. Of them, 3,293 children were found suffering from different ailments who were treated with Unani Pharmacopoeial Formulations.

During the period, the Unani Medical Centres functioning under the AYUSH co-location initiative treated 34,171 patients at Dr. Ram Manohar Lohia Hospital, 26,821 at Deen Dayal Upadhyay Hospital, and 27,065 at VMMC & Safdarjung Hospital in New Delhi.

At Ayush Wellness Centre established in President Estate, 3,327 patients were treated in Unani OPD and 2,862 patients in Regimenal Therapy Section.

At All India Institute of Ayurveda, New Delhi, 3,391 patients were treated in Unani OPD and 2,707 in Regimenal Therapy Section by Unani Physician.

Under the Gender Component Plan for Women, 5,25,513 female patients were treated in different OPDs. Clinical studies on the diseases specific to women, such as *Sayalan al-Rahim* (leucorrhoea), *Su al-Qinya* (anaemia), *Ihtibas al-Tams* (amenorrhoea) and *Kasrat al-Tams* (menorrhagia) also continued.

Under the Activities in North Eastern Region, 74,305 patients were treated for their common and chronic ailments at RRIUM, Silchar, and CRU, Imphal and 1,124 in Regimenal Therapy Section by Unani Physician.

Under the Special Component Plan – Scheduled Caste Sub-Plan (SCSP) and Tribal Sub-Plan (TSP), 13.74 lakhs total population including 8.63 lakhs SC population were covered under SCSP, whereas 93 thousand total population including 69 thousand ST population were covered under TSP. A total of 1,68,247 and 60,955 individuals benefited from SCSP and TSP, respectively.

The academic activities under the postgraduate programme in Unani Medicine successfully continued. A total of 33 new scholars in addition to continuing MD (Unani) students were actively engaged in academic, research and training activities at NRIUMSD, Hyderabad, and RRIUM, Srinagar.

During the reporting period, Studentship Programme for Unani Research (SPUR) was introduced by the CCRUM with 25 studentships after getting approval from the Ministry of Ayush. Out of the 108 SPUR proposals received, 25 were selected, and

the work on the approved studies is continuing.

Under the Pharmacovigilance Programme, 119 ADRs were reported and a dozen of activities and events were organized for creating awareness.

For transfer of technology for commercialization, the CCRUM has undertaken two products – one Unani Toothpaste for Dental Care and Unani Regimen for Vitiligo through National Research Development Corporation (NRDC).

Collaborative partnerships are essential for advancing research, fostering innovation, and building capacity across various disciplines. For the CCRUM, these partnerships enable access to diverse expertise, support interdisciplinary research, and promote Unani medicine nationally and globally. Through well-structured, the CCRUM facilitates knowledge exchange, skill enhancement, and joint initiatives in critical areas such as drug discovery, safety and efficacy studies, standardization, and molecular research. By leveraging the collective resources and expertise of its partners, the CCRUM strengthens its research impact, addresses contemporary healthcare challenges, and integrates Unani principles into modern healthcare, reinforcing its role in public health and policy.

During the reporting period, the CCRUM signed Memorandums of Understanding (MoUs) with 09 leading research institutions, universities, and scientific organizations. An MoU was signed between CCRUM and School of Persian Medicine, Tehran University of Medical Sciences, Iran for cooperation in the field of Unani and Persian medicine on November 20, 2024

During the period under report, the CCRUM celebrated Unani Day 2025 and organized two-day international conference on the theme “Innovations in Unani Medicine for Integrative Health Solutions – A Way Forward” at Vigyan Bhawan, New Delhi during 11-12 February, 2025. Smt. Droupadi Murmu, the Hon’ble President of India inaugurated the International Conference in which 22 International delegates from 09 countries had participated. The event highlighted advancements in Unani medicine and its role in integrative healthcare. Barley based Unani Ahaar was launched during the event.

Apart from this, the CCRUM organized more than 63 conferences, seminars, workshops and other such events and provided its workforce to participate in more than 50 training and capacity building programmes.

The CCRUM participated in 30 Arogya fairs/health camps/health melas and similar events to propagate Unani Medicine and highlight its activities and achievements.

The Council continued the promotion of the Official Language and organized Hindi Pakhwada at the headquarters and different centres. Quarterly workshops on Hindi

language were also organized. The CCRUM attained success in official language review of 02 of its institutes conducted by the third sub-committee of the Committee of Parliament on Official Language.

In summary, 2024–2025 was a year of accomplishments for the CCRUM, marking progress in research, education, and healthcare service delivery, solidifying its role in advancing Unani Medicine. The council aims to build on these achievements for sustained growth and greater impact in the coming years.

New Delhi
December, 2025



Dr. N. Zaheer Ahmed
Director General

2. MANAGEMENT

The management of the affairs of the CCRUM is entrusted to the Governing Body (GB), the Executive Committee (EC) and the Standing Finance Committee (SFC). The research activities are conducted with the recommendations of the Scientific Advisory Committee and ethical clearance of the Institutional Ethics Committee (IEC).

2.1. Governing Body

The constitution of the GB of the CCRUM as of March 31, 2025 was as given below:

President

Minister Incharge, Ministry of Ayush

Vice-President-I

Minister of State, Ministry of Ayush

Vice-President-II

Secretary, Ministry of Ayush

Official Members

- Financial Advisor, Ministry of Ayush
- Special Secretary / Additional Secretary / Joint Secretary (dealing with CCRUM), Ministry of Ayush
- Advisor (Unani), Ministry of Ayush
- Director, National Institute of Unani Medicine, Bengaluru

Non-Official Members

- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi
- Prof. Mohammad Idris, Ayurvedic & Unani Tibbia College, New Delhi
- Prof. S. J. B. Bokhari, Government Nizamia Tibbi College, Hyderabad
- Prof. Irfan Ahmad, Unani Medical College, Prayagraj, Uttar Pradesh
- Dr. Mohd. Zafar Hasan, Private Practitioner, Bhopal
- Prof. Sunil Kohli, Hamdard Institute of Medical Sciences & Research, New Delhi
- Dr. Swaran Jeet Singh Flora, Former Director, National Institute of Pharmaceutical Education and Research, Raebareli
- Dr. Rajeev Kumar Sharma, Former Director, Pharmacopoeial Laboratory for Indian Medicine, Ghaziabad
- Dr. Kommu Nagaiah, Senior Principal Scientist, Indian Institute of Chemical Technology, Hyderabad

Member Secretary

- Director General, CCRUM

2.2. Executive Committee

The constitution of the EC at the end of the reporting period was as given below:

Chairperson

Secretary, Ministry of Ayush, Government of India

Official Members

- Financial Advisor, Ministry of Ayush, Government of India
- Special Secretary/Additional Secretary/Joint Secretary (dealing with CCRUM), Ministry of Ayush, Government of India
- Adviser (Unani), Ministry of Ayush, Government of India
- Director, National Institute of Unani Medicine, Bengaluru

Non-Official Members

- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi
- Prof. S. J. B. Bokhari, Government Nizamia Tibbi College, Hyderabad
- Prof. Irfan Ahmad, State Unani Medical College, Prayagraj, Uttar Pradesh
- Dr. Swaran Jeet Singh Flora, Former Director, National Institute of Pharmaceutical Education and Research, Raebareli, Uttar Pradesh
- Dr. Kommu Nagaiah, Indian Institute of Chemical Technology, Hyderabad

Member Secretary

- Director General, CCRUM

2.3. Standing Finance Committee

The composition of the SFC at the end of the reporting period was as follows:

- | | | |
|--|---|------------------|
| • Special Secretary/Additional Secretary/Joint Secretary (dealing with CCRUM), Ministry of Ayush, Government of India | : | Chairperson |
| • Financial Advisor or his nominee not below the rank of Deputy Secretary, Integrated Finance Division, Ministry of Ayush, Government of India | : | Member |
| • Adviser (Unani), Ministry of Ayush, Government of India | : | Member |
| • Prof. Aftab Ahmad, Jamia Hamdard, New Delhi | : | Member |
| • Dr. Swaran Jeet Singh Flora, Former Director, National Institute of Pharmaceutical Education and Research, Raebareli, Uttar Pradesh | : | Member |
| • Director General, CCRUM | : | Member-Secretary |

2.4. Scientific Advisory Committee

The following was the composition of the SAC as on March 31, 2025:

- Prof. Asim Ali Khan, Former Director General, CCRUM, New Delhi : Chairperson
- Prof. Saiyad Shah Alam, Director, National Institute of Unani Medicine, Bengaluru : Member
- Prof. Md. Idris, A&U Tibbia College, New Delhi : Member
- Prof. Asia Sultana, Ajmal Khan Tibbiya College, AMU, Aligarh : Member
- Prof. Syed Imamuddin Ahmed, Former Principal, Government Unani Medical College, Chennai : Member
- Prof. D. S. Arya, Department of Pharmacology, AIIMS, New Delhi : Member
- Dr. Jugal Kishore, VMMC & Safdarjung Hospital, New Delhi : Member
- Dr. Veena Gupta, Senior Scientist, ICAR-National Bureau of Plant Genetic Resources, New Delhi : Member
- Dr. K. Nagaiah, Chief Scientist, Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad : Member
- Director General, CCRUM : Member Secretary

2.4.1. Research Sub-Committees

The SAC is assisted by the following six research sub-committees, namely Preclinical Research Sub-committee, Clinical Research Sub-committee, Fundamental Research Sub-committee, Literary Research Sub-committee, Drug Standardization Sub-committee, and Survey and Cultivation of Medicinal Plants Sub-committee.

2.4.1.1. Preclinical Research Sub-committee

- Prof. Md. Idris, A&U Tibbia College, New Delhi : Chairperson
- Prof. Ghulamuddin Sofi, National Institute of Unani Medicine, Bengaluru : Member
- Dr. Hina Tabassum, Scientist-E, ICMR, New Delhi : Member
- Dr. H. N. Yadav, Department of Pharmacology, AIIMS, New Delhi : Member
- Prof. (Dr.) Abul Kalam Najmi, Department of Pharmacology, Jamia Hamdard, New Delhi : Member
- Prof. Mohd. Aftab Ahmad, Jamia Hamdard, New Delhi : Member

- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.2. Clinical Research Sub-committee

- Prof. Aleemuddin Quamri, National Institute of Unani Medicine, Bengaluru : Chairperson
- Dr. R. M. Pandey, Department of Biostatistics, AIIMS, New Delhi : Member
- Dr. Tanica Lyngdoh, Scientist-E, Indian Council of Medical Research, New Delhi : Member
- Dr. Rohit Kumar, VMMC & Safdarjung Hospital, New Delhi : Member
- Dr. Syed Shariq Naeem, JN Medical College, AMU, Aligarh : Member
- Prof. Arshiya Sultana, National Institute of Unani Medicine, Bengaluru : Member
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.3. Fundamental Research Sub-committee

- Dr. Kumar Swamy Thangaraj, Former Director, Centre for DNA Fingerprinting and Diagnostics, Hyderabad : Chairperson
- Prof. K. M. Y. Amin, Ajmal Khan Tibbiya College, AMU, Aligarh : Member
- Dr. B. Vijaylakshmi, Institute of Genetics, Hyderabad : Member
- Dr. Aloka Nanda, Consultant, NRIUMSD, Hyderabad : Member
- Prof. Syed Ziaur Rahman, JN Medical College, AMU, Aligarh : Member
- Prof. Ashhar Qadeer, Ajmal Khan Tibbiya College, AMU, Aligarh : Member
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.4. Literary Research Sub-committee

- Hakim Wasim Ahmad, Former Deputy Director, CRIUM, Lucknow : Chairperson
- Prof. (Dr.) Neshat Quaiser, Department of Sociology, Jamia Millia Islamia, New Delhi : Member

- Dr. M. Raziul Islam, Eminent Scholar of Unani Medicine, : Member
New Delhi
- Prof. Abdul Haseeb Ansari, National Institute of Unani : Member
Medicine, Bengaluru
- Dr. Wasim Ahmad, National Institute of Unani Medicine, : Member
Bengaluru
- Dr. Mohammad Akram, Department of Arabic, University of : Member
Delhi, New Delhi
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.5. Drug Standardization Sub-committee

- Prof. Dr. Rajendran Aanaimuthu, Proprietor, Life Care Phyto : Chairperson
Labs, Chennai
- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi : Member
- Dr. Shariq Shamsi, National Institute of Unani Medicine, : Member
Bengaluru
- Dr. A. Jayanthi, Pharmacopoeia Commission of Indian : Member
Medicine and Homoeopathy, Ghaziabad
- Dr. Mohd. Mujeeb, Department of Pharmacognosy & : Member
Phytochemistry, Jamia Hamdard, New Delhi
- Dr. Santosh Joshi, Hamdard Laboratories India, Ghaziabad : Member
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.6. Survey and Cultivation of Medicinal Plants Sub-committee

- Dr. A. Ameer Jahan, Advisory Committee Chairman, Tamil : Chairperson
Nadu State Medicinal Plants Board, Chennai
- Prof. Tajuddin, Ajmal Khan Tibbiya College, AMU, Aligarh : Member
- Dr. Athar Ali Khan, Department of Botany, AMU, Aligarh : Member
- Dr. Vinay Kumar Singh, Former Assistant Director (Botany), : Member
CCRUM, New Delhi
- Dr. Shahidul Khair, Former Research Officer (Botany), : Member
CCRUM, New Delhi
- Prof. Mohd. Mujeeb, Department of Pharmacognosy & : Member
Phytochemistry, Jamia Hamdard, New Delhi

- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.5. Institutional Ethics Committee

It is mandatory that all the proposals on biomedical research involving human participants are approved by a duly constituted ethics committee to protect their welfare and rights. At the end of the reporting period, there were 18 Institutional Ethics Committees (IEC) functioning at various institutes/units of the CCRUM. These committees review and approve research proposals involving human participants. They also examine the compliance with regulatory requirements, applicable guidelines and laws. Besides, the CCRUM has a Central Ethics Committee (CEC) at its headquarters to examine the multi-centric clinical trials or human clinical trials which may have to be carried out in certain specific conditions like COVID-19 pandemic or any other clinical trials referred to it by the CCRUM headquarters for examination and approval. The composition of the CEC as well as IEC as on March 31, 2025 was as follow:

2.5.1. Central Ethics Committee

- Prof. Sunil Kohli, Hamdard Institute of Medical Sciences and Research, New Delhi : Chairperson
- Dr. Jugal Kishore, Department of Community Medicine, VMMC and Safdarjung Hospital, New Delhi : Member
- Dr. Yasmeen Shamsi, School of Unani Medical Education & Research, Jamia Hamdard, New Delhi : Member
- Prof. Aftab Ahmad, School of Unani Medical Education & Research, Jamia Hamdard, New Delhi : Member
- Shri Shive Rattan Sharma, Senior Consultant (Legal), CCRUM, New Delhi : Member
- Dr. Mohammad Akram, Department of Arabic, University of Delhi, New Delhi : Member
- Prof. Shahina Tabassum, Zakir Husain Delhi College, University of Delhi, New Delhi : Member
- Assistant Director (Unani), CCRUM Headquarters : Member Secretary

2.5.2. Institutional Ethics Committee

National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad

- Dr. K. Nagaiah, Chief Scientist, CSIR-Indian Institute of Chemical Technology, Hyderabad : Chairperson

- Prof. Chennakesavulu Dara, ESIC Medical College & : Member
Hospital, Hyderabad
- Prof. Maqbool Hussain, Government Nizamia Tibbi College, : Member
Hyderabad
- Dr. M Mohammed Idris, Senior Principal Scientist, CSIR- : Member
CCMB, Hyderabad
- Shri Abdul Fatah Khan, Advocate, Hyderabad : Member
- Shri Nasirul Haq, Former Administrative Officer, Telangana : Member
Electrical Department
- Hafez Mohammed Ajaz Ahmed, Hyderabad : Member
- Dr. Qamar Uddin, Research Officer (Unani) Scientist-IV, : Member Secretary
NRIUMSD, Hyderabad

Central Research Institute of Unani Medicine (CRIUM), Lucknow

- Dr. Kauser Usman, Department of Medicine, King George's : Chairperson
Medical University, Lucknow
- Dr. Tarique Mahmood Ansari, Faculty of Pharmacy, Integral : Member
University, Lucknow
- Prof. Abdul Haleem, Principal, Eram Unani Medical College, : Member
Lucknow
- Sh. Jamal Saeed Siddiqui, Advocate, Civil Court, Lucknow : Member
- Sh. Maqsood Ahmad Khan, Ashrafiya Education Society, : Member
Lucknow
- Prof. Shabbir Ahmad Nadwi, Former Head, Department of : Member
Arabic, University of Lucknow
- Sh. Abdul Jabbar, Khurram Nagar, Lucknow : Member
- Dr. Mahboobus Salam, Research Officer (Unani), CRIUM, : Member Secretary
Lucknow
- Dr. Najmus Sehar, Research Officer (Unani), CRIUM, : Alternate Member
Lucknow Secretary

Regional Research Institute of Unani Medicine (RRIUM), Chennai

- Hakim Syed Imamuddin Ahmed, Former Principal, : Chairperson
Government Unani Medical College, Chennai
- Dr. P. Elango, Professor & Head, Department of : Member
Pharmacology, Bharat Medical College & Hospital, Chennai
- Dr. R. Ilavarasan, Assistant Director Incharge, CSM Drug : Member
Research Institute of Ayurveda, Chennai

- Dr. V. Md. Habibullah, Head, Department of Jarahat, : Member
Government Unani Medical College, Chennai
- Dr. Syed Hissar, Scientist E, ICMR-NIRT, Chennai : Member
- Dr. K. Amjath Khan, Advocate, Madras High Court, Chennai : Member
- Dr. C. Ponnuraja, Scientist E, NIRT, Chennai : Member
- Dr. M. Habibullah Jamali, Assistant Professor, The New : Member
College, Chennai
- Mrs. R. Naseema Begum, Stenographer, RRIUM, Chennai : Supporting Staff
Member
- Dr. Athar Parvez Ansari, Research Officer (Unani) Scientist- : Alternate Member
II, RRIUM, Chennai Secretary
- Dr. Farooqui Shazia Parveen, Research Officer (U), : Member Secretary
RRIUM, Chennai

Regional Research Institute of Unani Medicine (RRIUM), Srinagar

- Prof. Zulfikar Ali Bhat, Dean, School of Applied Science & : Chairperson
Technology, University of Kashmir, Srinagar
- Prof. M. Salim Khan, Head, Department of Social and : Member
Preventive Medicine, Government Medical College,
Srinagar
- Dr. Zubair Ashai, Associate Professor, Government Medical : Member
College, Srinagar
- Dr. Showkat Hussain Yattoo, Administrator, Jammu & : Member
Kashmir Ayush Board
- Shri Sajad Buchh, Advocate, Srinagar : Member
- Dr. Saima Farhad, Assistant Professor, University of : Member
Kashmir, Srinagar
- M. Ishtiyahq Ahmad Nadwi, Hazrat Bal, Srinagar : Member
- Shri Gh. Mohd. Bhat, Hazrat Bal, Srinagar : Member
- Dr. Arsheed Iqbal, Research Officer (Unani) Scientist-IV, : Member Secretary
RRIUM, Srinagar

Regional Research Institute of Unani Medicine (RRIUM), Aligarh

- Prof. K. M. Y. Amin, Ajmal Khan Tibbiya College, Aligarh : Chairperson
Muslim University, Aligarh
- Prof. M. Tanzeel Ahmad, Ajmal Khan Tibbiya College, : Member
Aligarh Muslim University, Aligarh

- Dr. Syed Shariq Naeem, Department of Pharmacology, JNMC, Aligarh Muslim University, Aligarh : Member
- Dr. Rizwan Ahmed, JNMC, Aligarh Muslim University, Aligarh : Member
- Ms. Asma Farheen, Lawyer, Aligarh : Member
- Dr. Qari Hamid Mian Qadri, Aligarh Muslim University, Aligarh : Member
- Dr. Rehana Ahmed, Social Worker, JNMC, Aligarh Muslim University, Aligarh : Member
- Dr. Parvez Khan, Research Officer Incharge, Scientist-IV, RRIUM, Aligarh : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), New Delhi

- Prof. Prem Kapoor, Head, Department of Medicine, Hamdard Institute of Medical Sciences & Research, New Delhi : Chairperson
- Prof. Muhammad Hussain, Department of Biotechnology, Jamia Millia Islamia, New Delhi : Member
- Dr. Habeebul Rahiman V. M., Department of Social Work, Jamia Millia Islamia, New Delhi : Member
- Prof. Surender Singh, Department of Pharmacology, AIIMS, New Delhi : Member
- Dr. Arif Zaidi, Former Dean, School of Unani Medical Education and Research, Jamia Hamdard, New Delhi : Member
- Prof. Muhammad Akram, School of Unani Medical Education and Research, Jamia Hamdard, New Delhi : Member
- Dr. Sheikh Aquil, Department of Urdu, Satyavati College, New Delhi : Member
- Shri Mobashshir Sarwar, Advocate, Delhi High Court : Member
- Dr. Priyanka Verma, Research Officer (Biochemistry), RRIUM, New Delhi : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Mumbai

- Dr. Ranjit Mankeshwar, Head, Department of PSM, Grant Govt. Medical College & Sir J. J. Group of Hospitals, Mumbai : Chairperson
- Dr. Sadiq Bapumiya Patel, Clinical Pharmacologist, Mumbai : Member

- Dr. Partitosh Baghel, Consultant Physician, Fortis, Mumbai : Member
- Dr. Qazi Rashid Anwar, Unani Physician, MIJ Tibbia, S. L. Rahija Hospital, Mumbai : Member
- Shri Faridul Haq Khan, Advocate, Mumbai : Member
- Shri Farid Alam Qureshi, Social Worker, Mumbai : Member
- Shri Abbas Ali Riyasat, Teacher, Mumbai : Member
- Dr. Nikhat Shaikh, Research Officer (Unani) Scientist-III, RRIUM, Mumbai : Alternate Member Secretary
- Dr. Masroor Qureshi, Research Officer (Unani) Scientist-IV, RRIUM, Mumbai : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Kolkata

- Dr. Santanu Munshi, Professor & Head, Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata : Chairperson
- Prof. Md. Tajuddin, Professor & Head, Eilm-ul-saidla, The Calcutta Unani Medical College & Hospital, Kolkata : Member
- Prof. Parimal Karmakar, Jadavpur University, Kolkata : Member
- Md. Imtiyaz, Secretary, Sankalp Today (NGO), Kolkata : Member
- Smt. Sima Perween, Advocate, Kolkata : Member
- Shri Haider Ali, President, Howrah Health Awareness Mission, Kolkata : Member
- Syed Md. Mubashshir Nasim, President, Quranic Education, Howrah : Member
- Shri Anirban Goswami, Investigator (Statistics), RRIUM, Kolkata : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Patna

- Prof. S. K. Sinha, Patna Medical College, Patna : Chairperson
- Dr. Rehman Mannan, Assistant Professor, Department of Physiology, AIIMS, Patna : Member
- Prof. Shahnawaz Akhtar, Government Tibbi College & Hospital, Patna : Member
- Shri Nadeem Akhtar, Advocate, Patna High Court, Patna : Member
- Dr. Haroon Rasheed, State Project Officer, ADARSH, Patna : Member

- Dr. Syed Shah Shamimuddin Munemi, Department of : Member
Arabic, Oriental College, Patna
- Shri Md. Fahim, Patna : Member
- Dr. Mohd. Manzar Alam, Research Officer (Unani) Scientist- : Secretary
II, RRIUM, Patna
- Dr. Zikra Teseen, Research Officer (Unani), RRIUM, Patna : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Bhadrak

- Prof. Debashish Hota, Head, Department of Pharmacology, : Chairperson
AIIMS, Bhubaneswar
- Dr. Jhasaketan Mohanty, Former Sr. Medicine Specialist, : Member
District Headquarters Hospital, Bhadrak
- Dr. Sayed Mozammil Ali, Medical Officer (Unani), : Member
Government Unani Dispensary, Balasore
- Shri S. K. Noor Muzaffar Alam, Advocate, Bhadrak : Member
- Shri S. M. Farooque, Secretary, Fellowship (NGO), Bhadrak : Member
- Shri Basant Kumar Nayak, Bhadrak : Member
- Dr. Abdur Rasheed, Research Officer (Unani), RRIUM, : Member Secretary
Bhadrak

Regional Research Institute of Unani Medicine (RRIUM), Silchar

- Dr. Dolly Roy, Chairperson / Associate Professor of : Chairperson
Pharmacology, Silchar Medical College and Hospital,
Silchar
- Dr. Riturag Thakuria, Assistant Professor, Department of : Member
Medicine, Silchar Medical College and Hospital, Silchar
- Dr. Vivek Verma, Assistant Professor, Department of : Member
Statistics, Assam University
- Dr. Wahiduzzaman, Former Deputy Director, RRIUM, Patna : Member
- Shri Ramizur Rahman Barlaskar, Advocate, Silchar Bar : Member
Association, Silchar
- Shri Lutfur Rahman Laskar, Secretary, Bank Sangha : Member
(NGO), Neairgram, Cachar
- Maulana Ikramuddin Mazumder, Assistant Teacher, : Member
Ghoniwala Hafizia Madrasa, Silchar
- Shri Saleh Ahmed Mazumder, Silchar : Member
- Dr. Abdullah, Research Officer (Unani), RRIUM, Silchar : Member Secretary

- Dr. Nazim Hussain, Research Officer (Unani), RRIUM, : Alternate Member
Silchar Secretary

Clinical Research Unit (CRU), Meerut

- Dr. Surbhi Gupta, Head, Department of Pharmacology, : Chairperson
Subharti Medical College, Meerut
- Dr. Sabahatullah, Physician, Amroha : Member
- Dr. Mohd Asif Khan, Consultant Physician, Meerut : Member
- Dr. Mushtaq Hussain, Allama Iqbal Unani Medical College, : Member
Muzaffarnagar
- Mohd. Aslam, Advocate, Collectorate of Meerut : Member
- Mohd. Akhlaq, Imam, Chhoti Masjid Sotiganj, Meerut : Member
- Mohd. Parvaz, Social Worker, Meerut : Member
- Shri Sarfaraz Ahmad, Social Worker, Meerut : Member
- Dr. Shagufta Parveen, Research Officer (Unani), CRU, : Member Secretary
Meerut

Regional Research Centre (RRC), Prayagraj

- Dr. Khurshid Parveen, Professor, MLN Medical College, : Chairperson
Prayagraj
- Dr. Zubair Ahmad Khan, Ex-Deputy Director, CCRUM, New : Member
Delhi
- Prof. Irfan Ahmad, State Unani Medical College, Prayagraj : Member
- Prof. Najeeb Hanzla Ammar, State Unani Medical College, : Member
Prayagraj
- Shri Vinay Singh, Advocate, High Court of Judicature, : Member
Prayagraj
- Shri Anwar Azam Islahi, Prayagraj : Member
- Shri Janey Alam, Prayagraj : Member
- Dr. Ashok Kumar, Research Officer Incharge, RRC, : Member Secretary
Allahabad

Clinical Research Unit (CRU), Burhanpur

- Dr. Ranjendra Sighal, Director, Icon Hospital, Burhanpur : Chairperson
- Dr. Syed Mohd Abbas Zaidi, Assistant Professor, HSZH : Member
Government Unani Medical College, Bhopal
- Dr. Mazhar Subhan Ansari, Assistant Professor (Ilmul : Member
Advia), Saifia Hamidia Unani Tibbiya College, Burhanpur

- Maulana Shaikh Javed Qasmi, Burhanpur : Member
- Shri Waseem Khan, Advocate, Burhanpur : Member
- Shri Rizwan Abbas, Rotarian, Social Worker, Director Red Cross Society, Burhanpur : Member
- Shri Mohammad Ismail Khan, Burhanpur : Member
- Dr. Fahmi Husna Seemab, Pathologist, District Hospital, Burhanpur : Member
- Dr. Haider Ali Ansari, Research Associate (Unani), CRU, Burhanpur : Member Secretary

Clinical Research Unit (CRU), Kurnool

- Dr. Habeebullah, Dr. Abdul Haq Unani Medical College, Kurnool : Chairperson
- Dr. M. Ramesh, Research Officer (Unani) Scientist-III, Clinical Research Unit, Kurnool : Member Secretary
- Dr. Abdur Rahim Quazi, Rtd. CMO (Unani), CGHS, Government of India : Member
- Dr. G. Bhanu Prakash, Assistant Professor, Kurnool Medical College, Kurnool : Member
- Shri A. S. Omar Javeed, Advocate, Kurnool : Member
- Shri Syed Zakir Ahmed Rasheedi, Social Worker & Arabic Lecturer, Dr. Abdul Haq Unani Medical College, Kurnool : Member
- Shri Syed Abid Hussain, Retired Admin & Accounts Officer, Dr. Abdul Haq Unani Medical College, Kurnool : Member

Clinical Research Unit (CRU), Bengaluru

- Prof. Abdul Nasir Ansari, National Institute of Unani Medicine, Bengaluru : Chairperson
- Prof. Ghulamuddin Sofi, National Institute of Unani Medicine, Bengaluru : Member
- Dr. Madhu Kumar, Consultant, Bengaluru : Member
- Dr. Fayaz Ahmed Shariff, Govt. Unani Medical College, Bengaluru : Member
- Shri Naveen Kumar M, City Civil Court, Labour Court & High Court of Karnataka, Bengaluru : Member
- Shri Agha, Social Worker, Bengaluru : Member
- M. Iqbal Khasmi, Vijayanagar, Bengaluru : Member

- Dr. Syed Sadullah Hadi, Research Officer (Unani) Scientist- IV, CRU, Bengaluru : Member Secretary

Clinical Research Unit (CRU), Kerala

- Dr. Iftikharuddin Khan, Markaz Unani Medical College, Kozhikode, Kerala : Chairperson
- Dr. N. P. Hamsa, Medical Superintendent, Lakshmi Hospital, Kerala : Member
- Dr. Shakker Ali K. A., Medical Officer (Unani), Government Unani Dispensary, Kasargod, Kerala : Member
- Adv. C.P. Muhammed, Aluva, Kerala : Member
- Shri Abdul Salam, Secretary, Safa Charitable Trust, Edathala : Member
- Shri Layaq Ali, Gram Panchayat, Edathala, Kerala : Member
- Shri Jamal Tannari Moulvi, Faculty, Al-Kausariya Arabic College, Edathala, Kerala : Member
- Dr. M. A. Waheed, Research Officer (Unani), CRU, Kerala : Member Secretary

Clinical Research Unit (CRU), Bhopal

- Prof. A.K. Shrivastav, Head, Department of Pharmacology, Gandhi Medical College, Bhopal : Chairperson
- Dr. Nikhil Gupta, Assistant Professor, General Medicine, GMC College, Bhopal : Member
- Dr. Mirza Gufran Baig, Unani Medical Officer, State Unani Dispensary, Ginnori, Bhopal : Member
- Syed Shahid Parvez, Advocate Bhopal, District Court : Member
- Dr. Sufyan Hassan Nadwi, Bhopal : Member
- Danish Khan, Bhopal : Member
- Dr. Vandana Rajak, Research Officer (Unani), CRU, Bhopal : Member Secretary
- Dr. Mohammad Abdullah, Research officer Incharge, CRU, Bhopal : Alternate Member Secretary

2.6. Organisational Set-Up

The CCRUM is headquartered in New Delhi and has a network of 24 institutes/centre/units functioning in different parts of the country. These institutes/centre/units are as follows:

Centre	Number
National Research Institute of Unani Medicine for Skin Disorders	01
Central Research Institute of Unani Medicine	01
Regional Research Institute of Unani Medicine	09
Regional Research Centre	01
Clinical Research Unit	08
Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine	01
Drug Standardization Research Institute	01
Drug Standardization Research Unit	01
Unani Wing at Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi	01

The CCRUM centres are located in different States. The following is the State-wise institutional network.

Andhra Pradesh

- Clinical Research Unit (CRU), Kurnool

Assam

- Regional Research Institute of Unani Medicine, Silchar

Bihar

- Regional Research Institute of Unani Medicine (RRIUM), Patna

Delhi

- Regional Research Institute of Unani Medicine (RRIUM), New Delhi
- Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine (HAKILHRUM), New Delhi
- Drug Standardization Research Unit (DSRU), New Delhi
- Unani Wing at Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi
- Unani Medical Centre (Extension Centre of RRIUM, New Delhi), Dr. Ram Manohar Lohia Hospital, New Delhi
- Unani Speciality Centre (Extension Centre of RRIUM, New Delhi), Deen Dayal Upadhyay Hospital, New Delhi
- Unani Medical Centre (Extension Centre of RRIUM, New Delhi), VMMC & Safdarjung Hospital, New Delhi
- Unani Clinic (Extension Centre of RRIUM, New Delhi), All India Institute of Ayurveda, New Delhi

Jammu & Kashmir

- Regional Research Institute of Unani Medicine (RRIUM), Srinagar

Karnataka

- Clinical Research Unit (CRU), Bengaluru

Kerala

- Clinical Research Unit (CRU), Edathala (Alwaye) with an extension centre at Pattiam, Kannur

Madhya Pradesh

- Clinical Research Unit (CRU), Bhopal
- Clinical Research Unit (CRU), Burhanpur

Maharashtra

- Regional Research Institute of Unani Medicine (RRIUM), Mumbai
- Co-location centre of RRIUM at J.J. Hospital, Mumbai

Manipur

- Clinical Research Unit (CRU), Imphal

Goa

- Clinical Research Unit (CRU), Ribandar

Odisha

- Regional Research Institute of Unani Medicine (RRIUM), Bhadrak

Tamil Nadu

- Regional Research Institute of Unani Medicine (RRIUM), Chennai

Telangana


- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad

Uttar Pradesh

- Central Research Institute of Unani Medicine (CRIUM), Lucknow
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Drug Standardization Research Institute (DSRI), Ghaziabad
- Regional Research Centre (RRC), Prayagraj
- Clinical Research Unit (CRU), Meerut


West Bengal

- Regional Research Institute of Unani Medicine (RRIUM), Kolkata



Organizational set-up of CCRUM

CCRUM Headquarters




*With three extension centres in New Delhi


**With one extension centre in Pattiam

***With one extension centre in Mumbai

Institutional Network of CCRUM



Organizational Structure at CCRUM Headquarters



2.7. Institutional Multidisciplinary Research Advisory Committee (IMRAC)

The Institutional Multidisciplinary Research Advisory Committee (IMRAC) is a scientific review body within research institutions, primarily in medical and health sciences. It evaluates research proposals for scientific merit, feasibility, and interdisciplinary relevance before ethical review. IMRAC includes external experts from various disciplines to ensure comprehensive guidance. It supports researchers by improving study design and aligning projects with institutional capabilities. IMRAC plays a vital role in enhancing the quality and integrity of institutional research.

The IMRAC has been constituted in the institutes/units functioning under the Council. The details are as follows:

National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad

- Dr. Mohammed Ataulah Shareef, Former Deputy Director, NRIUMSD, Hyderabad : Chairperson
- Dr. K. Suresh Babu, Senior Principal Scientist, CSIR-IICT, Hyderabad : Member
- Dr. Mohammad Idris, Senior Principal Scientist, CSIR-CCMB, Hyderabad : Member
- Dr. L. Rasingam, Scientist-E, Deccan Regional Centre (Botanical Survey of India), Hyderabad : Member
- Dr. Chennakesavulu Dara, Professor, General Medicine, ESIC Medical College & Hospital, Hyderabad : Member
- Dr. Younis Iftikhar Munshi, Director Incharge, NRIUMSD, Hyderabad : Member-Secretary

Central Research Institute of Unani Medicine (CRIUM), Lucknow

- Prof. Kausar Usman, Department of Internal Medicine, King George Medical University, Lucknow : Chairperson
- Dr. Mehboob Shubhani Siddiqui, Professor, Era Lucknow Medical College & Hospital, Lucknow : Member
- Prof. Syed Misbahul Hasan, Dean, Faculty of Pharmacy, Director, Internal Quality Assurance Cell Integral University, Lucknow : Member
- Dr. Abdul Qawi, Prinipal, Stte Takmeel Ut Tibb College, Lucknow : Member
- Prof. Sarvesh Singh, Department of Pharmacology, King George Medical University, Lucknow : Member
- Dr. Najmus Saher, Deputy Director, Central Research Institute of Unani Medicine, Lucknow : Member-Secretary

Regional Research Institute of Unani Medicine (RRIUM), Chennai

- Prof. S. Elunialai, Registrar, University of Madras, : Chairperson
Chepauk, Chennai
- Prof. Dr. G. Nandhini Devi, Director, Centre for : Member
Technology in Traditional Medicine, Anna University,
Chennai
- Dr. Syed Hisar, Scientist-E (Medical), ICMR-National : Member
Institute for Research in Tuberculosis, Chennai
- Prof. K.M. Ram Kumar, Department of Biotechnology, : Member
School of Bioengineering, SRM Institute of Science and
Technology, Kattankulathur
- Prof. V. Habibullah, Department of Jarihat, Government : Member
Unani Medical College, Arumbakkam, Chennai
- Prof. K. Pandian, Head, Department of Inorganic : Member
Chemistry, University of Madras, Chennai
- Dr. Athar Parvez Ansari, Research Officer (Unani) : Member-
scientist-II, Regional Research Institute of Unani
Medicine, Chennai Secretary

Regional Research Institute of Unani Medicine (RRIUM), Srinagar

- Dr. Saleem, Head, Department of Community Medicine, : Chairperson
GMC, Srinagar
- Prof. Geer Mohd. Ishaq, Faculty of Pharmacology, : Member
University of Kashmir
- Prof. Manzoor Ahmad, Department of Botany, University : Member
of Kashmir
- Prof. Riyaz Ahmad, Faculty of Veterinary Sciences, : Member
SKUAST-K, Srinagar
- Dr. Rabiya, Head, Biochemistry / Biotechnology : Member
- Dr. Zahoor, Medical Officer, ISM : Member

Regional Research Institute of Unani Medicine (RRIUM), Aligarh

- Prof. Tanzeel Ahmad, Department of Moalijat, Ajmal Khan : Chairperson
Tibbiya College, Aligarh Muslim University, Aligarh
- Prof. Mohd. Anwar, Department of Ilaj Bit Tadbeer, Ajmal : Member
Khan Tibbiya College, Aligarh Muslim University, Aligarh
- Prof. S. Ziaur Rehman, Chairman, Department of : Member
Pharmacology, Jawaharlal Nehru Medical College, Aligarh
Muslim University, Aligarh
- Dr. V.K. Singh, Former Assistant Director (Botany), Central : Member
Council for Research in Unani Medicine, New Delhi
- Prof. Moinuddin, Department of Biochemistry, Jawaharlal : Member
Nehru Medical College, Aligarh Muslim University, Aligarh

- Dr. Tabassum Nawab, Assistant Professor, Department of Community Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh : Member
- Dr. Parvez Khan, Research Officer (Unani) Scientist-IV, Regional Research Institute of Unani Medicine, Aligarh : Member-Secretary

Regional Research Institute of Unani Medicine (RRIUM), New Delhi

- Prof. Jugal Kishore, Former Head, Department of Community Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi : Chairperson
- Dr. Habib-Ur-Rehman, Associate Professor, Department of Social Work, Jamia Millia Islamia, New Delhi : Member
- Dr. Mohammad Maaz, Associate Professor & Head, Mahiyatul Amraaz, SUMER, Jamia Hamdard, New Delhi : Member
- Dr. Khan Afreen Mushtaq Ahmed, Associate Professor, Department of Medicine, HIMSR, Jamia Hamdard, New Delhi : Member
- Prof. Mariyam Sardar, Department of Biosciences, Jamia Millia Islamia, New Delhi : Member
- Dr. Musheer Ahmed, Assistant Professor, Department of Computer Engineering, Faculty of Engineering and Technology, Jamia Millia Islamia, New Delhi : Member
- Prof. Abdul Kalam Najmi, Department of Pharmacology, SPER, Jamia Hamdard, New Delhi : Member
- Dr. Ziaul Haq Siddiqui, Deputy Director, Regional Research Institute of Unani Medicine, New Delhi : Member-Secretary

Regional Research Institute of Unani Medicine (RRIUM), Kolkata

- Dr. Israr Ahmad Ansari, CMO (Unani), CGHS, Kolkata : Chairperson
- Dr. Anjan Adhikari, Medical Superintendent cum Vice Principal, Medical College & Hospital, Kolkata : Member
- Prof. Md. Tajuddin, Head, Ilmul Saidla, Calcutta Unani Medical College, Kolkata : Member
- Shri Gopal Krishna, Scientist- C, Botanical Survey of India, Kolkata : Member
- Dr. Mohd. Masihuzzaman Ansari, Research Officer Incharge, Regional Research Institute of Unani Medicine, Kolkata : Member-Secretary

Regional Research Institute of Unani Medicine (RRIUM), Patna

- Dr. Wasimuddin, Director (Unani), Department of Ayush, Patna : Chairperson
- Dr. Surendra Kumar, Former Professor of Medicine, Patna Medical College & Hospital, Patna : Member

- Dr. Krishna Kumar Singh, Assistant Director, Ayurveda : Member
Research Institute, CCRAS, Patna
- Dr. Avinash Kumar, Research Officer Incharge, Clinical : Member
Verification Unit (H), Patna
- Dr. Sikandar Ali Khan, Former Research Officer, Regional : Member
Research Institute of Unani Medicine, Patna
- Dr. Md. Mahfoozur, Principal, Government Tibbi College & : Member
Hospital, Patna
- Dr. Mohammad Yusuf Ansari, Professor (Ilmul Adbiya), : Member
Government Tibbi College & Hospital, Patna
- Dr. Asif Hussain, Principal, Sufiya Unani Medical College & : Member
Research Centre, Motihari, Bihar
- Dr. Md. Manzar Alam, Research Officer (Unani), Regional : Member
Research Institute of Unani Medicine, Patna
- Dr. Zikra Tahseen, Research Officer (Unani), Regional : Member
Research Institute of Unani Medicine, Patna
- Dr. Mumtaz Ahmad, Deputy Director, Regional Research : Member-Secretary
Institute of Unani Medicine, Patna

2.8 Budget (Actual Expenditure)

The centre-wise actual expenditure of the Council during 2024-25 was as follows:

S. No.	Name of State	Total
1	Andhra Pradesh	
	(i) CRU, Kurnool	1,57,23,884.00
2.	Assam (NER)	
	(i) RRIUM, Silchar	6,49,34,097.00
3	Bihar	
	(i) RRIUM, Patna	5,92,83,927.00
4.	Jammu & Kashmir	
	(i) RRIUM, Srinagar	15,49,69,019.00
5	Karnataka	
	(i) CRU Bangalore	1,91,45,530.00
6.	Kerala	
	(i) CRU, Alwaye	89,21,661.00
7.	Madhya Pradesh	
	(i) CRU, Burhanpur	1,20,94,818.00
	(ii) CRU, Bhopal	2,25,47,221.00
8.	Maharashtra	
	(i) RRIUM, Mumbai	6,84,13,501.00
9.	Manipur (NER)	
	(i) Imphal	15,53,126.00
10.	New Delhi	
	(i) HAKILHRUM	4,15,20,857.00

	(ii) RRIUM, NEW DELHI	13,91,93,729.00
	(iii) HQRS, NEW DELHI	46,86,72,670.00
	(iv) DSRU, NEW DELHI	1,89,09,958.00
11.	Odisha	
	(i) RRIUM, Bhadrak	6,06,68,274.00
12	<u>Tamil Nadu</u>	
	(i). RRIUM, Chennai	12,75,52,333.00
13	Telangana	
	(i) NRIUMSD, Hyderabad	31,54,48,612.00
14	<u>Uttar Pradesh</u>	
	(i) DSRI, Ghaziabad	3,21,19,339.00
	(ii) CRIUM, Lucknow	13,27,96,397.00
	(iii) RRC, Allahabad	2,74,43,587.00
	(iv) RRIUM, Aligarh	9,33,11,441.00
	(v) CRU, Meerut	2,52,00,760.00
15	<u>West Bengal</u>	
	(i) RRIUM, Kolkata /Howrah	2,80,14,663.00
	Total Rs.	1,93,84,39,404.00

3. TECHNICAL REPORT

3.1. Intramural Research

3.1.1. Centre-wise Activities

CENTRE	ACTIVITIES
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad	• Pre-clinical Research Programme • Survey and Cultivation of Medicinal Plants Programme • Drug Standardization Research Programme • Clinical Research Programme ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimen Therapies • Fundamental Research Programme • Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD) • Outreach activities ○ Mobile Clinical Research Programme

	○ School Health Programme ○ Mobile Healthcare Program under Schedule Caste Sub-Plan ● IEC Activities
Central Research Institute of Unani Medicine (CRIUM), Lucknow	● Clinical Research Programme ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimen Therapies ● Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD) ● Outreach activities ○ Mobile Clinical Research Programme ○ School Health Programme ○ Mobile Healthcare Program under Schedule Caste Sub-Plan ● IEC Activities
Regional Research Institute of Unani Medicine (RRIUM), Chennai	● Survey and Cultivation of Medicinal Plants Programme ● Drug Standardization Research Programme ● Clinical Research Programme ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimen Therapies ● Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD) ● Outreach activities ○ Mobile Clinical Research Programme ○ School Health Programme ○ Mobile Healthcare Program under Schedule Caste Sub-Plan ● IEC Activities
Regional Research Institute of Unani Medicine (RRIUM), Bhadrak	● Clinical Research Programme ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimen Therapies ● Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD)

	• Outreach activities ○ Mobile Healthcare Program under Tribal Sub Plan • IEC Activities
Regional Research Institute of Unani Medicine (RRIUM), Patna	• Clinical Research Programme ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimen Therapies • Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD) • Outreach activities ○ Mobile Clinical Research Programme ○ School Health Programme ○ Mobile Healthcare Program under Schedule Caste Sub-Plan • IEC Activities
Regional Research Institute of Unani Medicine (RRIUM), Aligarh	• Survey and Cultivation of Medicinal Plants Programme • Clinical Research Programme ○ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme • Outreach activities ○ School Health Programme ○ Mobile Healthcare Program under Schedule Caste Sub-Plan • IEC Activities
Regional Research Institute of Unani Medicine (RRIUM), Mumbai	• Clinical Research Programme ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimen Therapies • Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme • Outreach activities ○ Mobile Clinical Research Programme ○ School Health Programme ○ Mobile Healthcare Program under Schedule Caste Sub-Plan

	• IEC Activities • Unani Clinic at J.J. Hospitals
Regional Research Institute of Unani Medicine (RRIUM), Srinagar	• Pre-clinical Research Programme • Survey and Cultivation of Medicinal Plants Programme • Drug Standardization Research Programme • Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs ◦ Validation of Regimen Therapies • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme ◦ In-patients Department (IPD) • Outreach activities ◦ Mobile Clinical Research Programme ◦ School Health Programme ◦ Mobile Healthcare Program under Tribal Sub-Plan • IEC Activities
Regional Research Institute of Unani Medicine (RRIUM), Kolkata	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • Outreach activities ◦ Mobile Healthcare Program under Schedule Caste Sub-Plan • IEC Activities
Regional Research Institute of Unani Medicine (RRIUM), New Delhi	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs ◦ Validation of Regimen Therapies • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme ◦ In-patients Department (IPD) • Outreach activities ◦ Mobile Clinical Research Programme ◦ School Health Programme ◦ Mobile Healthcare Program under Schedule Caste Sub-Plan

	• IEC Activities • Unani Specialty Clinics at Allopathic Hospitals
Regional Research Centre (RRC), Prayagraj	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • Outreach activities ◦ Mobile Clinical Research Programme ◦ Mobile Healthcare Program under Schedule Caste Sub-Plan • IEC Activities
Regional Research Institute of Unani Medicine (RRIUM), Silchar	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs ◦ Validation of Regimen Therapies • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • IEC Activities
Clinical Research Unit (CRU), Bengaluru	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • Outreach activities ◦ Mobile Healthcare Program under Schedule Caste Sub-Plan • IEC Activities
Clinical Research Unit (CRU), Meerut	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • Outreach activities ◦ Mobile Healthcare Program under Schedule Caste Sub-Plan • IEC Activities

Clinical Research Unit (CRU), Bhopal	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • Outreach activities ◦ Mobile Healthcare Program under Schedule Caste Sub-Plan • IEC Activities
Clinical Research Unit (CRU), Burhanpur	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • Outreach activities ◦ Mobile Healthcare Program under Tribal Sub-Plan • IEC Activities
Clinical Research Unit (CRU), Edathala	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • IEC Activities
Clinical Research Unit (CRU), Kurnool	• Clinical Research Programme ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • Outreach activities ◦ Mobile Healthcare Program under Tribal Sub-Plan • IEC Activities
Clinical Research Unit (CRU), Goa	• Research-oriented Healthcare ◦ General Outpatient Department (GOPD) Programme • Outreach activities • IEC Activities
Clinical Research Unit (CRU), Imphal	• Research-oriented Healthcare ◦ General Outpatient Department (GOPD)

	Programme • Outreach activities • IEC Activities
Drug Standardization Research Unit (DSRU), New Delhi	• Drug Standardization Research Programme • IEC Activities
Drug Standardization Research Institute (DSRI), Ghaziabad	• Drug Standardization Research Programme • IEC Activities
Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine (HAKILHRUM), New Delhi	• Literary Research Programme • Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme • IEC Activities
Unani Wing at Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi	• Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme • IEC Activities
Clinical Research Unit (CRU), Imphal	• Research-oriented Healthcare ○ General Outpatient Department (GOPD) Programme • IEC Activities

3.1.2. Programme-wise Activities

3.1.2.1 Survey and Cultivation of Medicinal Plants Programme

The Council has a programme for extensive survey of medicinal plants in different parts of the country, primarily with a view to collect and identify medicinal plants and record basic data on ethno-pharmacological uses of plants from the tribal and other rural folks of the study area. The broad objectives of the programme are:

- To survey, collect and identify medicinal plants in different forest zones of the country;
- To study distribution, availability, ethno-pharmacological uses and threats of medicinal plants;
- To carry out experimental and field-scale cultivation of medicinal plants;

- To maintain a herbarium of medicinal plants and raw drugs for demonstration purposes;
- To maintain a demonstrable herb garden;
- To document folk knowledge on medicinal uses of plants;
- To collect samples of genuine drugs from the forests for pharmacopoeia standardization; and
- To develop nurseries of medicinal plants for demonstration purpose with a view to popularize them among masses.

This programme is carried out at the following research centres:

- National Research Institute of Unani Medicine for Skin Disorders, Hyderabad
- Regional Research Institute of Unani Medicine, Chennai
- Regional Research Institute of Unani Medicine, Srinagar
- Regional Research Institute of Unani Medicine, Bhadrak
- Regional Research Institute of Unani Medicine, Aligarh

Ethnopharmacological Survey

Under this programme, the Council undertook ethno-pharmacological surveys in different Forest Divisions/areas during the period under report. These include Theni, Mudumalai Tiger Reserve Forest Division of Tamil Nadu; Hyderabad, Asifabad Forest Division of Telangana; Nandyal, Chittoor, Tirupati Forest Division of Andhra Pradesh; Khordha Forest Division of Odisha., Tangmarg, Budgam, Kupwara, Baramulla Forest Division of Union Territory of Jammu and Kashmir. As a result of the survey tours conducted, 2,876 botanical specimens were collected by the surveyors. During the period under report 976 plant species were identified.

Sapling and Raw Drug Collections

The survey team members collected 6,328 saplings of important medicinal species for plantation in the Herbal Garden and nursery attached to the Institutes. The survey teams also collected 215.4 kg of raw drugs and sent them to the pharmacy section of NRIUMSD, Hyderabad and RRIUM, Chennai for preparation of Unani formulations.

Herbarium

The plant specimens collected from the study areas, including previous collection, were mounted on herbarium sheets. During the reporting period, 938 herbarium sheets were prepared and information pertaining to the botanical name, family, local name, Unani name (wherever available), date of collection, brief morphological features and medicinal / other uses of the plants were recorded on each herbarium sheet. Besides, 447 index cards were updated.

Digitization and Documentation of Herbarium Specimens

Under this activity, 371 herbarium sheets were digitized by the Council's research centres at Chennai and Hyderabad.

Folk Claims

The surveyors enquired from the local communities about traditional uses of plants after obtaining oral informed consent. The information was systematized taxonomically and efforts were made to develop a database for comparative analysis of the information recorded. As a result, 238 folk medicinal claims were recorded from the tribal inhabitants and other rural folks of the study areas. The Council publishes the information in the form of books providing details comprising botanical name and family, synonym, local name, Unani name, habit and habitat, wild or cultivated, medicinal efficacy claimed and name of the tribe, locality, collection number, part(s) used, mode of application, and biodynamic notes.

Experimental and Field-Scale Cultivation of Medicinal Plants

Under this activity, the Council cultivates some important medicinal plants used in Unani medicines. These include *Alsi* (*Linum usitatissimum* L.), *Arusaa* (*Justicia adhatoda* L.), *Atrilal* (*Ammi majus* L.), *Afsanteen* (*Artemisia absinthium* L.), *Babchi* (*Psoralea corylifolia* L.), *Gaozaban* (*Borago officinalis* L.), *Gulnar Farsi* (*Punica granatum* L. abortive var.), *Gurmar buti* (*Gymnema sylvestre* (Retz.) R Br. ex Sm.), *Gul-e-Baboona* (*Matricaria chamomilla* L.), *Gilo* (*Tinospora cordifolia* (Willd.) Miers), *Irsa* (*Iris ensata* Thunb), *Kalonji* (*Nigella sativa* L.), *Khulanjan* (*Alpinia galanga* (L.) Willd.), *Nagdon* (*Artemisia nilagirica* (C.B.Clarke) Pamp), *Darmana Turki* (*Artemisia maritima* L.), *Sudab* (*Ruta graveolens* L.), etc. As a result of the field-scale cultivation, 531.97 kg

of raw drugs were obtained from NRIUMSD, Hyderabad, RRIUM Aligarh, Chennai, Srinagar and supplied to the pharmacy section of NRIUMSD, Hyderabad and RRIUM, Chennai for preparation of Unani formulations.

Herbal Garden and Nursery of Medicinal Plants

With a view to popularizing medicinal plants among the masses, the Council maintained a total of 161 species in the Herbal Garden at NRIUMSD, Hyderabad; 73 species at RRIUM, Chennai; 93 species at RRIUM, Srinagar; and 84 species at RRIUM, Aligarh. Some of the important and interesting species grown under this activity include: *Abhal* (*Juniperus communis* L.), *Amla* (*Phyllanthus emblica* L.), *Anaar* (*Punica granatum* L.), *Ashok* (*Saraca asoca* (Roxb.) Willd.), *Atrilal* (*Ammi majus* L.), *Afsanteen* (*Artemisia absinthium* L.), *Arusa* (*Justicia adhatoda* L.), *Aspaghol* (*Plantago ovata* Forssk.), *Asl al-Soos* (*Glycyrrhiza glabra* L.), *Asrol* (*Rauvolfia serpentina* (L.) Benth. ex Kurz.), *Bed Mushk* (*Salix caprea* L.) *Bijasar* (*Pterocarpus marsupium* Roxb.), *Belgiri* (*Aegle marmelos* (L.) Correa.), *Babchi* (*Psoralea corylifolia* L.), *Banafsha* (*Viola odorata* L.), *Bed-mushk* (*Salix caprea* L.), *Bhangra* (*Eclipta prostrata* (L.) L.), *Brinjasif* (*Achillea millefolium* L.), *Bunafsha* (*Viola odorata* L.), *Fufal* (*Areca catechu* (L.f.) Willd.), *Gaozaban* (*Borago officinalis* L.), *Ghikawar* (*Aloe vera* (L.) Burm.f.), *Gulnar Farsi* (*Punica granatum* L. abortive var.), *Gurmarbuti* (*Gymnema sylvestre* (Retz.) R. Br.ex Sm.), *Hina* (*Lawsonia inermis* L.), *Irsa* (*Iris ensata* Thunb), *Jadwar* (*Delphinium denudatum* Wall. ex Hook.f. & Thoms.), *Kasni* (*Cichorium intybus* L.), *Kaju* (*Anacardium occidentale* L.), *Khulanjan* (*Alpinia galanga* Willd.), *Konch* (*Mucuna pruriens* L.), *Mako* (*Solanum americanum* Mill.), *Marorphali* (*Helicteres isora* L.), *Muleem* (*Gloriosa superba* L.), *Muqil* (*Commiphora mukul* (Hook. ex Stocks) Engl.), *Palas* (*Butea monosperma* (Lam.) Taub.), *Qinnab* (*Cannabis sativa* L.), *Qurtum* (*Carthamus tinctorius* L.), *Qust* (*Saussureacostus* (Falc.) Lipsch.) *Rasan* (*Inula racemosa* C.B. Clarke), *Revandchini* (*Rheum emodi* Wall ex Meissn), *Sadabahar* (*Catharanthus roseus* (L.) G. Don), *Sandal Surkh* (*Pterocarpus santalinus* L.f.), *Satawar* (*Asparagus racemosus* Willd.), *Suddab* (*Ruta graveolens* L.), *Raihan* (*Ocimum tenuiflorum* L.), *Tagar* (*Valeriana jatamansi* Jones), *Toke-balooch* (*Ginkgo biloba* L.) *Turbud* (*Ipomoea turpethum* R. Br.), *Ood-e-Saleb* (*Paeonia emodi* Wallichex Royel) *Waj* (*Acorus calamus* L.) *Zeeraj-Makki* (*Verbascum thapsus* L.) etc.

3.1.2.2. Drug Standardization Research Programme

The Drug Standardization Research Programme is mainly concerned with evolving pharmacopoeial standards for single and compound drugs of Unani medicine included in various volumes of *National Formulary of Unani medicine (NFUM)* and *Essential Drugs List*. The Standardization process encompasses a comprehensive evaluation of Unani drug in respect to their pharmacognostical, physico-chemical, pharmacological profile in order to study the various qualitative and quantitative characteristics of drugs. The work on compound formulation includes development of Standard Operating Procedure (SOPs) for their method of preparation and subsequently formulating their pharmacopoeial standards. These developed pharmacopoeial standards are published in the form of monographs in various volumes of Unani Pharmacopoeia of India, Part-I (Single drug) and Part-II (Compound formulation). Besides, the programme undertakes standardization of investigational drugs for clinical trials conducted by the CCRUM as well as the analysis of heavy metals, microbial load, aflatoxins and pesticide residues in drugs. Chemical investigations of Unani medicinal plants are also integral part of this programme. The standardization work is carried out in accordance with the format approved by the Scientific Advisory Board of Pharmacopoeia Commission for Indian Medicine & Homoeopathy, Government of India through the following research centers:

- Drug Standardization Research Institute (DSRI), Ghaziabad
- Drug Standardization Research Unit (DSRU), New Delhi
- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
- Regional Research Institute of Unani Medicine (RRIUM), Chennai
- Regional Research Institute of Unani Medicine (RRIUM), Srinagar

During reporting period, following work was carried out:

Development of SOPs for Method of Preparation of Unani Formulations and their Pharmacopoeial Standards

Under the programme, SOPs for method of preparation and Pharmacopoeial standards of the following 36 Unani formulations were developed:

S. N.	Formulation	S.N.	Formulation
1.	<i>Habb-e-Iyarij</i>	19.	<i>Namak-e-Shaikh ur Raees</i>
2.	<i>Qurs-e-Anjabar</i>	20.	<i>Safoof-e-Muqliyasa</i>
3.	<i>Kushta-e-Hajar-ul Yahood</i>	21.	<i>Safoof-e-Mulaiyan</i>
4.	<i>Kushta-e- Jast</i>	22.	<i>Safoof-e-Sailan</i>
5.	<i>Kushta-e-Khabs-ul-Hadeed</i>	23.	<i>Safoof-e-Sat-e-Gilo</i>
6.	<i>Kushta-e-Kharmohra</i>	24.	<i>Safoof-e-Suranjan Zafrani</i>
7.	<i>Kushta-e-Marjan Sada</i>	25.	<i>Safoof-e-Tehal Naushadri</i>
8.	<i>Kushta-e-Marwareed</i>	26.	<i>Safoof-e-Tabkheer</i>
9.	<i>Qurs-e-Isqeel</i>	27.	<i>Safoof-e-Teen</i>
10.	<i>Laboob-e-Barid</i>	28.	<i>Qurs-e-Deedan</i>
11.	<i>Laboob-e-Sagheer</i>	29.	<i>Qurs-e-Habis</i>
12.	<i>Majoon-e-Jalinoos lului</i>	30.	<i>Qurs-e-Mulaiyan</i>
13.	<i>Majoon-e-Juntyana</i>	31.	<i>Araq-e-Afsanteen</i>
14.	<i>Araq-e-Juzam</i>	32.	<i>Sharbat-e-Unnab</i>
15.	<i>Sharbat-e-Banafsha</i>	33.	<i>Sharbat-e-Deenar</i>
16.	<i>Raughan-e-Darchini</i>	34.	<i>Raughan-e-Bed Anjeer</i>
17.	<i>Araq-e-Bed Mushk</i>	35.	<i>Raughan-e-Chahar Barg</i>
18.	<i>Araq-e-Bed Sada</i>	36.	<i>Safoof-e-Ziabetus Sada</i>

Development of Pharmacopoeial Standards of Single Drugs

Under the programme, the monographs of the following 16 single drugs in accordance with PCIM&H format were developed:

S. No.	Drug	Scientific Name	Part studied
1.	<i>Jawansa</i>	<i>Alhagi pseudalhag I (Bieb.) Desv.</i>	Whole plant
2.	<i>Dhamasa</i>	<i>Fagonia cretica L.</i>	Whole Plant
3.	<i>Behroza</i>	<i>Pinusrox burghii Sagrent</i>	Exudate
4.	<i>Behroza</i>	<i>Pinusrox burghii Sagrent</i>	Root
5.	<i>Khaksi</i>	<i>Sisymbrium irio L.</i>	Seed

6.	<i>Kishmish</i>	<i>Vitis vinifera</i> L.	Dried Fruit
7.	<i>Mainphal</i>	<i>Catunaregam spinosa</i> (Thunb.) Triveng	Fruit
8.	<i>Kanakana</i>	<i>Cinchona officinalis</i> L.	Stem Bark
9.	<i>Izkhir</i>	<i>Cymbopogon jwarancusa</i> (Jones) Schult.	Whole Plant
10.	<i>Khurfa</i>	<i>Portulaca oleracea</i> L.	Whole Plant
11.	<i>Mazu</i>	<i>Quercus infectoria</i> Oliv.	Gall
12.	<i>Ajwayan Desi</i>	<i>Trachyspermum ammi</i> (L.) Sprague	Fruit
13.	<i>Kath Safayd</i>	<i>Acacia leucophloeia</i> Willd.	Stembark
14.	<i>Baobarang</i>	<i>Embelia ribes</i> Burm.f.	Fruit
15.	<i>Sandal Surkh</i>	<i>Pterocarpuss antalinus</i> L. f.	Heart Wood
16.	<i>Sandal Safayd</i>	<i>Santalum album</i> L.	Heart Wood

Isolation of Phyto-constituents from Unani single drugs

The work for isolation of phyto-constituents was allotted to RRIUM, Srinagar and CRU, AMU, Aligarh on following 04 drugs:

S. No.	Centre	Single Drug	Botanical Name	Part
1.	RRIUM, Srinagar	Zafran	<i>Crocus sativus</i> L.	Style & Stigma
2.		Bhojpatr	<i>Betulautilis</i> D. Don	Stembark
3.	CRU, AMU, Aligarh	Jawzbuwa	<i>Myristica fragrans</i> Houtt.	Kernel
4.		Mako	<i>Solanum americanum</i> Mill.	Whole Plant

Besides standardization of single and compound drugs, the National Formulary of Unani Medicine Part-I consisting of 441 Unani formulations was revised by including formulation composition, quantity of raw drugs, botanical names of ingredients and their part used, diacritical marks, therapeutic indications and doses as per standard format issued by PCIM&H. The list of revised formulations are as follows:

Sl. No.	Formulation No.	Name of Formulation
Hububwa Aqras		
1.	1:1	<i>Banadiq-UI-Bazoor</i>
2.	1:2	<i>Habb-e-Ahmar</i>
3.	1:3	<i>Habb-e-Ambar</i>
4.	1:4	<i>Habb-e-Ambar Momyaee</i>
5.	1:5	<i>Habb-e-Azaraq</i>
6.	1:6	<i>Habb-e-Bawaseer Amiya</i>

Sl. No.	Formulation No.	Name of Formulation
7.	1:7	<i>Habb-e-Bawaseer Damiya</i>
8.	1:8	<i>Habb-e-Bohat-us-Saut Haad</i>
9.	1:9	<i>Habb-e-Bohat-us-Saut Muzmin</i>
10.	1:10	<i>Habb-e-Bukhar</i>
11.	1:11	<i>Habb-e-Dabba-e-Atfal</i>
12.	1:12	<i>Habb-e-Deedan</i>
13.	1:13	<i>Habb-e-Falij</i>
14.	1:14	<i>Habb-e-Falij Mulayyin</i>
15.	1:15	<i>Habb-e-Ghafis</i>
16.	1:16	<i>Habb-e-Ghariqoon</i>
17.	1:17	<i>Habb-e-Hamal</i>
18.	1:18	<i>Habb-e-Hilteet</i>
19.	1:19	<i>Habb-e-Hindi Chashm</i>
20.	1:20	<i>Habb-e-Hindi Mohallil</i>
21.	1:21	<i>Habb-e-Hindi Mumsik</i>
22.	1:22	<i>Habb-e-Hindi Qabiz</i>
23.	1:23	<i>Habb-e-Hindi Sual</i>
24.	1:24	<i>Habb-e-Hindi Zeeqi</i>
25.	1:25	<i>Habb-e-Ayarij</i>
26.	1:26	<i>Habb-e-Jadwar</i>
27.	1:27	<i>Habb-e-Jalinoos</i>
28.	1:28	<i>Habb-e-Jawahar</i>
29.	1:29	<i>Habb-e-Jund</i>
30.	1:30	<i>Habb-e-Kabid Naushadari</i>
31.	1:31	<i>Habb-e-Kattha</i>
32.	1:32	<i>Habb-e-Khabs-UI-Hadeed</i>
33.	1:33	<i>Habb-e-Kibreet</i>
34.	1:34	<i>Habb-e-Marwareed</i>
35.	1:35	<i>Habb-e-Miskeen Nawaz</i>
36.	1:36	<i>Habb-e-Momyaee Sada</i>
37.	1:37	<i>Habb-e-Mubarak</i>
38.	1:38	<i>Habb-e-Mudir</i>
39.	1:39	<i>Habb-e-Mumsik</i>
40.	1:40	<i>Habb-e-Mumsik Qawi</i>
41.	1:41	<i>Habb-e-Munaish</i>
42.	1:42	<i>Habb-e-Muntin Akbar</i>
43.	1:43	<i>Habb-e-Muqil</i>
44.	1:44	<i>Habb-e-Mushil</i>
45.	1:45	<i>Habb-e-Mushil Dimaghi</i>
46.	1:46	<i>Habb-e-Mushillstisqaee</i>
47.	1:47	<i>Habb-e-Nishat</i>
48.	1:48	<i>Habb-e-Nuqra</i>
49.	1:49	<i>Habb-e-Pachlona</i>
50.	1:50	<i>Habb-e-Papita Desi</i>
51.	1:51	<i>Habb-e-Papita Wilayati</i>

Sl. No.	Formulation No.	Name of Formulation
52.	1:52	<i>Habb-e-Pechish</i>
53.	1:53	<i>Habb-e-Raal</i>
54.	1:54	<i>Habb-e-Rasaut</i>
55.	1:55	<i>Habb-e-Shabyar</i>
56.	1:56	<i>Habb-e-Shifa</i>
57.	1:57	<i>Habb-e-Shaheeqa</i>
58.	1:58	<i>Habb-e-Sil</i>
59.	1:59	<i>Habb-e-Siyah Chashm</i>
60.	1:60	<i>Habb-e-Suranjan</i>
61.	1:61	<i>Habb-e-Surfa</i>
62.	1:62	<i>Habb-e-Surfa Qawi</i>
63.	1:63	<i>Habb-e-Surkhbada</i>
64.	1:64	<i>Habb-e-Tabasheer</i>
65.	1:65	<i>Habb-e-Tinkar</i>
66.	1:66	<i>Habb-e-Tap Balghami</i>
67.	1:67	<i>Habb-e-Tursh Mushtahi</i>
68.	1:68	<i>Habb-e-Usara</i>
69.	1:69	<i>Habb-e-Zahar Mohra</i>
70.	1:70	<i>Qurs-e-Anjabar</i>
71.	1:71	<i>Qurs-e-Ghafis</i>
72.	1:72	<i>Qurs-e-Gulnar</i>
73.	1:73	<i>Qurs-e-Gulnar Farsi</i>
74.	1:74	<i>Qurs -e-Habis</i>
75.	1:75	<i>Qurs-e-Isqil</i>
76.	1:76	<i>Qurs-e-Kafoor</i>
77.	1:77	<i>Qurs-e-Kahruba</i>
78.	1:78	<i>Qurs-e-Kaknaji</i>
79.	1:79	<i>Qurs-e- Mukhaddir</i>
80.	1:80	<i>Qurs -e-Mulayyin</i>
81.	1:81	<i>Qurs -e-Munawwim Barid</i>
82.	1:82	<i>Qurs -e-Musallas</i>
83.	1:83	<i>Qurs-e-Sartan</i>
84.	1:84	<i>Qurs-e-Shadnaji</i>
85.	1:85	<i>Qurs-e-Tabasheer Kafoori Luluvi</i>
86.	1:86	<i>Qurs-e-Tabasheer Mulayyin</i>
87.	1:87	<i>Qurs-e-Tabasheer Qabiz</i>
88.	1:88	<i>Qurs-e-Tutiya-e-Kabir</i>
89.	1:89	<i>Qurs-e-Zarishk</i>
90.	1:90	<i>Qurs-e-Ziabetus Khaas</i>
91.	1:91	<i>Qurs-e-Ziabetus Sada</i>
Jawhar		
92.	2:1	<i>Jauhar-e-Munaqqa</i>
93.	2:2	<i>Jauhar-e-Seen</i>
Kuhlwa Shiyaf		
94.	3:1	<i>Aksireen</i>

Sl. No.	Formulation No.	Name of Formulation
95.	3:2	<i>Barood-e- Kafoori</i>
96.	3:3	<i>Kohl-e-Bayaz</i>
97.	3:4	<i>Kohl Chikni-Dawa</i>
98.	3:5	<i>Kohl-e-Jawahar</i>
99.	3:6	<i>Kohl-e-Roshnai</i>
100.	3:7	<i>Kohl-e-Sadaf</i>
101.	3:8	<i>Kohl-e-Yasmeen</i>
102.	3:9	<i>Shiyaf-e-Abyaz</i>
Kushtajat		
103.	4:1	<i>Kushta-e-Abrak Safaid</i>
104.	4:2	<i>Kushta-e-Abrak Siyah</i>
105.	4:3	<i>Kushta-e-Aqeeq</i>
106.	4:4	<i>Kushta-e-Baiza-e-Murgh</i>
107.	4:5	<i>Kushta-e-Busad</i>
108.	4:6	<i>Kushta-e-Faulad</i>
109.	4:7	<i>Kushta-e-Gaodanti</i>
110.	4:8	<i>Kushta-e-Hajr-UI-Yahood</i>
111.	4:9	<i>Kushta-e-Jast</i>
112.	4:10	<i>Kushta-e-Khabs-UI-Hadeed</i>
113.	4:11	<i>Kushta-e-Kharmohra</i>
114.	4:12	<i>Kushta-e-Marjan Jawaharwala</i>
115.	4:13	<i>Kushta-e-Marjan Sada</i>
116.	4:14	<i>Kushta-e-Marwareed</i>
117.	4:15	<i>Kushta-e-Mirgang</i>
118.	4:16	<i>Kushta -e-Musallas</i>
119.	4:17	<i>Kushta-e-Nuqra</i>
120.	4:18	<i>Kushta-e-Qalai</i>
121.	4:19	<i>Kushta-e-UI-Aiyal</i>
122.	4:20	<i>Kushta-e-Sadaf</i>
123.	4:21	<i>Kushta-e-Samm-UI-Faar Aatishaki</i>
124.	4:22	<i>Kushta-e-Samm-UI-Faar Qawi</i>
125.	4:23	<i>Kushta-e-Sang-e-Sar-e-Maahi</i>
126.	4:24	<i>Kushta-e-Sankh</i>
127.	4:25	<i>Kushta-e-Seemab</i>
128.	4:26	<i>Kushta-e-Tila</i>
129.	4:27	<i>Kushta-e-Zumarrud</i>
Maajun		
130.	5:1	<i>Anoshdaru</i>
131.	5:2	<i>Anoshdaru Luluvi</i>
132.	5:3	<i>Anqaruya Kabir</i>
133.	5:4	<i>Barshasha</i>
134.	5:5	<i>Dawa-UI-Kurkum</i>
135.	5:6	<i>Dawa-UI-Luk</i>
136.	5:7	<i>Dawa-UI-Misk Motadil Jawahar Wali</i>
137.	5:8	<i>Dawa-UI-Misk Motadil Sada)</i>

Sl. No.	Formulation No.	Name of Formulation
138.	5:9	Dayaquza
139.	5:10	Halwa-e-Baiza-e-Murgh
140.	5:11	Halwa-e-Gazar
141.	5:12	Itrifal Deedan
142.	5:13	Itrifal Ghudadi
143.	5:14	Itrifal Kabir
144.	5:15	Itrifal Kishneezi
145.	5:16	Itrifal Mulayyin
146.	5:17	Itrifal-e-Muqil Mulaiyin
147.	5:18	Itrifal Sagheer
148.	5:19	Itrifal Shahtra
149.	5:20	Itrifal Ustukhuddus
150.	5:21	Itrifal Zamani
151.	5:22	Jawarish-e-Aamla Sada
152.	5:23	Jawarish Anarain
153.	5:24	Jawarish-e-Bisbasa
154.	5:25	Jawarish Falafili
155.	5:26	Jawarish Fanjnosh
156.	5:27	Jalinoos
157.	5:28	Jawarish Kamooni
158.	5:29	Jawarish-e-Kundur
159.	5:30	Jawarish-e-Mastagi
160.	5:31	Jawarish-e-Narmushk
161.	5:32	Jawarish-e-Ood Sheerin
162.	5:33	Jawarish-e-OodTursh
163.	5:34	Jawarish-e-Podina
164.	5:35	Jawarish Safarjali Qabiz
165.	5:36	Jawarish Shahi
166.	5:37	Jawarish Shahar Yaran
167.	5:38	Jawarish-e-Tamar Hindi
168.	5:39	Jawarish-e-Utraj
169.	5:40	Jawarish-e-Zanjabeel
170.	5:41	Jawarish Zarooni Sada
171.	5:42	Jawarish-e-Zarishk
172.	5:43	Khamira-e-Abresham Arshadwala
173.	5:44	Khamira-e-Abresham Sada
174.	5:45	Khamira-e-Banafsha
175.	5:46	Khamira-e-Gaozaban- Ambari Jawaharwala
176.	5:47	Khamira-e-Gaozaban Sada
177.	5:48	Khamira-e-Khashkhaash
178.	5:49	Khamira-e-Marwareed
179.	5:50	Khamira-e-Sandal Sada
180.	5:51	Khamira-e-Ustukhuddus
181.	5:52	Khamira-e-Yashab
182.	5:53	Khamira-e-Zahar Mohra

Sl. No.	Formulation No.	Name of Formulation
183.	5:54	<i>Laoq-e-Abhal</i>
184.	5:55	<i>Laoq-e-Badam</i>
185.	5:56	<i>Laoq-e-Behidana</i>
186.	5:57	<i>Laoq-e-Hulba</i>
187.	5:58	<i>Laoq-e-Katan</i>
188.	5:59	<i>Laoq-e-Khiyarshambar</i>
189.	5:60	<i>Laoq Nazli</i>
190.	5:61	<i>Laoq-e-Sapistan</i>
191.	5:62	<i>Laoq Shamoon</i>
192.	5:63	<i>Laoq Zeequn-Nafas</i>
193.	5:64	<i>Laboob Barid</i>
194.	5:65	<i>Laboob Kabir</i>
195.	5:66	<i>Laboob Sagheer</i>
196.	5:67	<i>Majoon-e-Aarad-e-Khurma</i>
197.	5:68	<i>Majoon Antaki</i>
198.	5:69	<i>Majoon-e-Aqrah</i>
199.	5:70	<i>Majoon-e-Asl-e-Baladur</i>
200.	5:71	<i>Majoon-e-Azaraq</i>
201.	5:72	<i>Majoon-e-Baladur</i>
202.	5:73	<i>Majoon Bandkushad</i>
203.	5:74	<i>Majoon-e-Chobchini</i>
204.	5:75	<i>Majoon Dabeed-ul-Ward</i>
205.	5:76	<i>Majoon Falasfa</i>
206.	5:77	<i>Majoon Falaksair</i>
207.	5:78	<i>Majoon Fanjnosh</i>
208.	5:79	<i>Majoon Fotnaji</i>
209.	5:80	<i>Majoon-e-Hajr-ul-Yahood</i>
210.	5:81	<i>Majoon Hamal Ambari Alwi</i>
211.	5:82	<i>Majoon-e-Ispand Sokhtani</i>
212.	5:83	<i>Majoon Jalali</i>
213.	5:84	<i>Majoon Jalinoos Luluvi</i>
214.	5:85	<i>Majoon Jograj Gugul</i>
215.	5:86	<i>Majoon-e-Juntiayana</i>
216.	5:87	<i>Majoon Kalkalanaj</i>
217.	5:88	<i>Majoon-e-Khabsul-Hadeed</i>
218.	5:89	<i>Majoon Khadar</i>
219.	5:90	<i>Majoon-e-Kundur</i>
220.	5:91	<i>Majoon Lana</i>
221.	5:92	<i>Majoon Masik-ul-Boul</i>
222.	5:93	<i>Majoon Mughalliz</i>
223.	5:94	<i>Majoon Muluki</i>
224.	5:95	<i>Majoon-e-Mundi</i>
225.	5:96	<i>Majoon-e-Muqil</i>
226.	5:97	<i>Majoon Muqawwi-e-Rahem</i>
227.	5:98	<i>Majoon Musaffi-e-Khoon</i>

Sl. No.	Formulation No.	Name of Formulation
228.	5:99	<i>Majoon Najah</i>
229.	5:100	<i>Majoon-e-Nankhwah</i>
230.	5:101	<i>Majoon-e-Piyaz</i>
231.	5:102	<i>Majoon Rahul Momineen</i>
232.	5:103	<i>Majoon-e-salab</i>
233.	5:104	<i>Majoon-e-Sangdana-e-Murgh</i>
234.	5:105	<i>Majoon-e-Seer Alvi Khani</i>
235.	5:106	<i>Majoon Sohag Sonth</i>
236.	5:107	<i>Majoon Suparipak</i>
237.	5:108	<i>Majoon-e-Suranjan</i>
238.	5:109	<i>Majoon Talkh</i>
239.	5:110	<i>MajoonTalkh Deedani</i>
240.	5:111	<i>Majoon-e-Teewaaj</i>
241.	5:112	<i>Majoon-e-Ushba</i>
242.	5:113	<i>Majoon Zabeeb</i>
243.	5:114	<i>Mufarreh Barid</i>
244.	5:115	<i>Mufarreh Barid Jawaharwali</i>
245.	5:116	<i>Mafarreh Barid Qawi</i>
246.	5:117	<i>Mufarreh Motadil</i>
247.	5:118	<i>Mafarreh Sosambari</i>
248.	5:119	<i>Mufarreh Yaqooti Barid</i>
249.	5:120	<i>Mufarreh Yaqooti Motadil</i>
250.	5:121	<i>Sabadaritoos</i>
251.	5:122	<i>Tiryaq Afaee</i>
252.	5:123	<i>Tiryaq Arba</i>
253.	5:124	<i>Tiryaq Nazla</i>
254.	5:125	<i>Tiryaq Samania</i>
255.	6:1	<i>Marham-e-Aahak</i>
256.	6:2	<i>Marham Ajeeb</i>
257.	6:3	<i>Marham Basaliqoon</i>
258.	6:4	<i>Marham Dakhilyun</i>
259.	6:5	<i>Marham Ejaz</i>
260.	6:6	<i>Marham Gulabi</i>
261.	6:7	<i>Marham-e-Jadwar</i>
262.	6:8	<i>Marham Kafoori</i>
263.	6:9	<i>Marham-e-Khanazeer</i>
264.	6:10	<i>Marham-e-Kharish</i>
265.	6:11	<i>Marham-e-Qooba</i>
266.	6:12	<i>Marham-e-Raal</i>
267.	6:13	<i>Marham-e-Raskapoor</i>
268.	6:14	<i>Marham Sabz</i>
269.	6:15	<i>Marham-e-Ushaq</i>
270.	6:16	<i>Marham-e-Zangar</i>
271.	6:17	<i>Qairooti-e-Aarad-e-Karsana</i>
272.	6:18	<i>Qairooti Bazr-e-Katan</i>

Sl. No.	Formulation No.	Name of Formulation
273.	6:19	<i>Qairooti Mohallil</i>
274.	6:20	<i>Qairooti Musakkin</i>
275.	6:21	<i>Zimad-e-Asfar</i>
276.	6:22	<i>Zimad-e-Jalinoos</i>
277.	6:23	<i>Zimad-e-Khanazeer</i>
278.	6:24	<i>Zimad-e-Kibreer</i>
279.	6:25	<i>Zimad-e-Mohallil</i>
280.	6:26	<i>Zimad-e-Mubarrid</i>
281.	6:27	<i>Zimad-e-Sumbul-Ut-Teer</i>
282.	6:28	<i>Zimad-e-Tehal</i>
283.	6:29	<i>Zimad-e-Warm-e-Pistan</i>
284.	6:30	<i>Zimad-e-Warm Unsaya in Haad</i>
285.	6:31	<i>Zimad-e-Waram-e-Unsayain Muzmin</i>
<i>Murabbajat wa Gulqand</i>		
286.	7:1	<i>Murabba-e-Aamla</i>
287.	7:2	<i>Murabbā-e-Anannas</i>
288.	7:3	<i>Murabba-e-Behi</i>
289.	7:4	<i>Murabba-e-Belgiri</i>
290.	7:5	<i>Murabba-e-Gazar</i>
291.	7:6	<i>Murabba-e-Halela</i>
292.	7:7	<i>Murabba-e-Seb</i>
293.	7:8	<i>Murabba-e-Waj</i>
294.	7:9	<i>Murabba-e-Zanjabeel</i>
295.	7:10	<i>Gulqand-e-Amaltas</i>
296.	7:11	<i>Gulqand-e-Gulab</i>
297.	7:12	<i>Gulqand-e-Gurhal</i>
298.	7:13	<i>Gulqand-e-Hina</i>
299.	7:14	<i>Gulqand-e-Khashkhash</i>
300.	7:15	<i>Gulqand-e-Neem</i>
301.	7:16	<i>Gulqand-e-Sewti</i>
<i>Roghaniyat</i>		
302.	8:1	<i>Roghan-e-Aamla</i>
303.	8:2	<i>Roghan-e-Aqrab</i>
304.	8:3	<i>Roghan-e-Azaraq</i>
305.	8:4	<i>Roghan-e-Babuna Sada</i>
306.	8:5	<i>Roghan-e-Babuna Qawi</i>
307.	8:6	<i>Roghan-e-Badam Sheerin</i>
308.	8:7	<i>Roghan-e-Baiza-e-Murgh</i>
309.	8:8	<i>Roghan-e-Baladur</i>
310.	8:9	<i>Roghan-e-Banafsha</i>
311.	8:10	<i>Roghan-e-Bedanjeer</i>
312.	8:11	<i>Roghan-e-Chahar Barg</i>
313.	8:12	<i>Roghan-e-Darchini</i>
314.	8:13	<i>Roghan-e-Gul</i>
315.	8:14	<i>Roghan-e-Haft Barg</i>

Sl. No.	Formulation No.	Name of Formulation
316.	8:15	<i>Roghan-Heel-Khurd</i>
317.	8:16	<i>Roghan-e-Ispand</i>
318.	8:17	<i>Roghan-e-Jauzbua</i>
319.	8:18	<i>Roghan-e-Jauz Hindi</i>
320.	8:19	<i>Roghan-e-Jauzmasil</i>
321.	8:20	<i>Roghan-e-Kadu Sheerin</i>
322.	8:21	<i>Roghan-e-Kahu</i>
323.	8:22	<i>Roghan-e-Khashkhaash</i>
324.	8:23	<i>Roghan Laboob Saba</i>
325.	8:24	<i>RoghanLaboob Saba Barid</i>
326.	8:25	<i>Roghan-e-Maghz-e-Tukhm-e-Kaddu</i>
327.	8:41	<i>Tilla Mubahhi</i>
328.	8:42	<i>Tila Mulazziz</i>
329.	8:43	<i>Tila Mumsik</i>
330.	8:44	<i>Tila Musakkin</i>
331.	8:45	<i>Tila Surkh</i>
Sayyalat		
332.	9:1	<i>Araq-e-Afsanteen</i>
333.	9:2	<i>Araq-e-Ajeeb</i>
334.	9:3	<i>Araq-e-Ajwain</i>
335.	9:4	<i>Araq-e-Ambar</i>
336.	9:5	<i>Araq-e-Aswad Barid</i>
337.	9:6	<i>Araq-e-Badiyan</i>
338.	9:7	<i>Araq-e-Bayd Mushk</i>
339.	9:8	<i>Araq-e-Bed Sada</i>
340.	9:9	<i>Araq-e-Chobchini</i>
341.	9:10	<i>Araq-e-Gaozaban</i>
342.	9:11	<i>Araq-e-Gulab</i>
343.	9:12	<i>Araq-e-Heel Khurd</i>
344.	9:13	<i>Araq-e-Juzam</i>
345.	9:14	<i>Araq-e-Kasni</i>
346.	9:15	<i>Araq-e-Keora</i>
347.	9:16	<i>Araq-e-Mako</i>
348.	9:17	<i>Araq-e-Mundi</i>
349.	9:18	<i>Araq-e-Musaffi-e-KhoonQawi</i>
350.	9:19	<i>Araq-e-Nana</i>
351.	9:20	<i>Qatoor-e-Ramad Qawi</i>
352.	9:21	<i>Sikanjabeen Buzoori Motadil</i>
353.	9:22	<i>Sikanjabeen Lemuni</i>
354.	9:23	<i>Sikanjabeen Nanaee</i>
355.	9:24	<i>Sikanjabeen Sada</i>
356.	9:25	<i>Sharbat-e-Anar Sheerin</i>
357.	9:26	<i>Sharbat-e-Anjabar</i>
358.	9:27	<i>Sharbat-e-Banafsha</i>
359.	9:28	<i>Sharbat Buzoori Motadil</i>

Sl. No.	Formulation No.	Name of Formulation
360.	9:29	<i>Sharbat Deenar</i>
361.	9:30	<i>Sharbat Ejaz</i>
362.	9:31	<i>Sharbat-e-Khashkhaash</i>
363.	9:32	<i>Sharbat-e-Nilofar</i>
364.	9:33	<i>Sharbat-e-Sadr</i>
365.	9:34	<i>Sharbat-e-Toot Siyah</i>
366	9:35	<i>Sharbat-e-Unnab</i>
Safufat		
367	10:1	<i>Ayarij Faiqra</i>
368	10:2	<i>Ayarij Loghaziya</i>
369.	10:3	<i>Jawahar Mohra</i>
370.	10:4	<i>Namak Shaikh-ur-Raees</i>
371.	10:5	<i>Safoof-e-Amla</i>
372.	10:6	<i>Safoof-ul-Amlah</i>
373.	10:7	<i>Safoof-e-Baras</i>
374.	10:8	<i>Safoof-e-Chobchini</i>
375.	10:9	<i>Safoof Chutki</i>
376.	10:10	<i>Safoof-e-Dama</i>
377.	10:11	<i>Safoof Habis-Ud-Dam</i>
378.	10:12	<i>Safoof-e-Habb-Ur-Rumman</i>
379.	10:13	<i>Safoof-e-Hajr-UI-Yahood</i>
380.	10:14	<i>Safoof-e-Hazim</i>
381.	10:15	<i>Safoof-e-Hazim Kalaan</i>
382.	10:16	<i>Safoof Indrijulab</i>
383.	10:17	<i>Safoof-e-Khardal</i>
384.	10:18	<i>Safoof-e-Kishneez</i>
385.	10:19	<i>Safoof-e-Lajward</i>
386.	10:20	<i>Safoof Masik-ul-Boul</i>
387.	10:21	<i>Safoof Muqliyasa</i>
388.	10:22	<i>Safoof Mohazzil</i>
389.	10:23	<i>Safoof Moya</i>
390.	10:24	<i>Safoof Mudirr-e-Haiz</i>
391.	10:25	<i>Safoof Mulayyin</i>
392.	10:26	<i>Safoof Musammin</i>
393.	10:27	<i>Safoof Mushil</i>
394.	10:28	<i>Safoof-e-Nana</i>
395	10:29	<i>Safoof-e-Qaranfal</i>
396	10:30	<i>Safoof-e-Sailan</i>
397.	10:31	<i>Safoof-e-Satt-e-Gilo</i>
398.	10:32	<i>Safoof-e-Satt-e-Gilo Sartani</i>
399.	10:33	<i>Safoof-e-Suranjan</i>
400.	10:34	<i>Safoof Surkh</i>
401.	10:35	<i>Safoof-e-Suranjan Zafrani</i>
402.	10:36	<i>Safoof-e-Suzak</i>

Sl. No.	Formulation No.	Name of Formulation
403.	10:37	<i>Safoof-e-Suzak Qawi</i>
404.	10:38	<i>Safoof-e-Tabkheer</i>
405.	10:39	<i>Safoof-e-Teen</i>
406.	10:40	<i>Safoof-e-Tehal</i>
407.	10:41	<i>Safoof-e-Tehal Naushadri</i>
408.	10:42	<i>Safoof-e-Ziabetus Sada</i>
409.	10:43	<i>Safoof-e-Ziabetus Dulabi</i>
410.	10:44	<i>Safoof-e-Ziabetus Qawi</i>
411.	10:45	<i>Sanoon-e-Ahmar</i>
412.	10:46	<i>Sanoon-e-Chobchini</i>
413.	10:47	<i>Sanoon-e-Missi</i>
414.	10:48	<i>Sanoon-e-Mujalli</i>
415.	10:49	<i>Sanoon-e-Mukhrij-e-Rutubat</i>
416.	10:50	<i>Sanoon-e-Muluk</i>
417.	10:51	<i>Sanoon-e-Mustahkam-e-Dandan</i>
418.	10:52	<i>Sanoon-e-Tambaku</i>
419.	10:53	<i>Sanoon-e-Zard</i>
420.	10:54	<i>Zaroor-e-Qula Abyaz</i>
421.	10:55	<i>Zaroor-e-Anzaroot</i>
422.	10:56	<i>Zuroor-e-Asiqoolan</i>
423.	10:57	<i>Zaroor-e-Gaozaban</i>
424.	10:58	<i>Zaroor-e-Kath</i>
425.	10:59	<i>Zaroor-e-Murdar Sang</i>
426.	10:60	<i>Zaroor-e-Qula</i>

During the reporting period, apart from standardization work, the following samples were analysed at Drug Testing Laboratory, RRIUM Chennai and technical report was submitted to respective clients:

S. No.	Name of the Samples	Source of the Samples	Parameters Analyzed
1.	<i>Coded Unani Drug</i>	Annaiviolet Arts and Science College Menambedu, Ambattur, Chennai	Powder Microscopy Analysis
2.	Marzanjosh (<i>Origanum vulgare</i> L)	NIUM, Bangaluru	HPTLC

3.	Silymarin & Curcumin	Sri Ramachandra of Pharmacy, Chennai	HPTLC Quantification
4.	NM (Coded)	Sri Sairam Siddha Medical College & Research Centre, Chennai - 44	Microbial Load, Anti-microbial Activity, Aflatoxin, HPTLC, Heavy metals
5.	Brahmi Nei	Dr. Menaka, Department of Pothu Maruthuvam, Governemnt Siddha Medical College, Chennai	Specific Gravity, Acid Value, Saponification, Iodine, Peroxide, Refractive Index, Rancidity values, HPTLC, Heavy Metals, Microbial loads, Aflatoxin, Anti-Oxidants, Ant diabetics, Preliminary phytochemical analysis
6.	Padigara Paneer	Government Siddha Medical College, Chennai	Anti-microbial activity
7.	Pirandai Vadagam	Government Siddha Medical College, Chennai	Microbial Load, Anti-microbial activity, Aflatoxin, HPTLC, Heavy metals
8.	Athimathura Choornam	Government Siddha Medical College, Chennai	Microbial Load, Anti-microbial Activity, Aflatoxin, HPTLC, Heavy metals
9.	Coded drug 1 & 2	Bharathi Women's College, Chennai	HPTLC
10.	KGK (Coded)	National Institute of Siddha, Tambaram, Chennai	Microbial Load, Aflatoxin, HPTLC
11.	Sangkaara Vairavam	Government Siddha Medical College, Chennai	Microbial Load, Anti-microbial Activity, Aflatoxin, HPTLC, Heavy metals

12.	Vengara Chunnam	Government Siddha Medical College, Chennai	Microbial Load, Aflatoxin, Heavy metals, LOD, Ash Value
13.	Peenisa Chooranami	Government Siddha Medical College, Chennai	Microbial Load, Anti-microbial Activity, Aflatoxin, HPTLC, Heavy metals
14.	Seenthil Chooranam	Government Siddha Medical College, Chennai	Anti-Diabetic activity
15.	Sample 1, 2 & 3 (Coded)	Soka Ikeda College of Arts and Science for Women, Chennai	Volatile oil extraction
16.	Sivanarvembu Kuzhu thailam	National institute of Siddha, Chennai	Anti-oxidant, pH, Specific Gravity, Refractive index, Iodine value, Saponification, Acid value, Peroxide value, HPTLC, Heavy metals
17.	Soosika Chooranam	Government Siddha Medical College, Chennai	Microbial Load, Aflatoxin, HPTLC, Heavy metals
18.	Adathodai Girutham	Government Siddha Medical College, Chennai	Microbial load, Aflatoxin, fat content, Acid value, Refractive index, Specific gravity, Iodine value, Peroxide value, Rancidity, Preliminary Phytochemistry, HPTLC, Heavy metals
19.	Kariyabolam	National institute of Siddha, Chennai	Microbial load & Aflatoxin.
20.	Matbookhe Aftimoon	National institute of Siddha, Bengaluru	Qualitative HPTLC analysis

21.	Plant IA (Coded)	Vels Institute of Science, Chennai	HPTLC
22.	Kai Kaal Erichal Kudineer	Government Siddha Medical College, Chennai	Phytochemical, HPTLC, Heavy metal, Total Ash, Acid insoluble ash, Water extractive, alcohol extractive, pH, antimicrobial activity.
23.	Coded Samples 1&2	Loyela College, Chennai	Anti-Microbial activity
24.	Coded Sample 1,2,3,4,5	Loyela College, Chennai	Anti-Microbial activity
25.	Pomegranate Seed	Ethiraj College for Women, Chennai	Anti-microbial, HPTLC, Primary phytochemical analysis
26.	Plant IA & Nanoparticle (Coded)	Vels Institute of Science, Chennai	Anit-microbial
27.	Athimathura Choornam	Government Siddha Medical College, Chennai	Preliminary Phytochemical analysis
28.	NM (Coded)	Sri Sairam Siddha Medical College & Research Centre, Chennai	Preliminary Phytochemical analysis
29.	04 Red Rice Samples (Coded)	SRM Institute of Science and Technology, Kattankalathur, Chengalpattu	Anti-microbial activity
30.	Viruchigam	Government Siddha Medical College, Chennai	Quality control studies

31.	Saathiladhi Chooranam	Government Siddha Medical College, Chennai	Organoleptic, pH, LoD, Ash, Acid insoluble Ash, Water extraction, Alcohol Extraction, Preliminary phytochemical, HPTLC, Heavy metals, Microbial-, Aflatoxin
32.	Chandraprakasa Mathirai	Government Siddha Medical College, Chennai	Organoleptic, pH, LoD, Ash, Acid insoluble Ash, Water extraction, Alcohol Extraction, Disintegration test, Freability test, Hardness test, Bulk density test, Preliminary phytochemical, HPTLC, Heavy metals, Microbial, Aflatoxin
33.	Kadukkai Mathirai	Government Siddha Medical College, Chennai	Heavy metals
34.	Little millet, kodo millet and Seaneed	SRM Institute of Science and Technology, Chennai	HPTLC
35.	Ormocarpum Cochinchinense	SRM Institute of Science and Technology, Chennai	HPTLC
36.	Kukkuladhi Rasayanam	National Institute of Siddha, Chennai	Heavy metals
37.	Kalladaipuku Kudineer	Government Siddha Medical College, Chennai	Organoleptic, physicochemical, phytochemical, microbial, aflatoxin, HPTLC
38.	Inji Rasayanam	Government Siddha Medical College, Chennai	Organoleptic, physicochemical, phytochemical, microbial, aflatoxin, HPTLC

39.	Vallarai Chooranam	Government Siddha Medical College, Chennai	organoleptic, physicochemical, phytochemical, microbial, aflatoxin, HPTLC, anti-microbial, anti-fungal
40.	Fungal metabolite & colletotrichum Siamense	Doss Vaishnav College, Chennai	HPTLC
41.	Fungal metabolite & Chaetomium globosum	Doss Vaishnav College, Chennai	HPTLC
42.	Lauq E Katan Lozenges	Government Unani Medical College, Chennai	Quality control studies

3.1.2.3 Clinical Research Programme

Preclinical Studies

During the reporting period, preclinical safety and efficacy studies on several Unani formulations were conducted at National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad and Regional Research Institute of Unani Medicine (RRIUM), Srinagar. Below are the details of each study.

Acute and Repeated Dose 90-Day oral toxicity on *Qurs-e-Sumbul* (QS) in rats

Qurs-e-Sumbul (QS) is a traditional Unani formulation in the form of tablet that is used for various ailments particularly those related to the nervous system, blood purification, and digestive disorders. It is particularly anti-inflammatory in action and is extensively used in gastritis and hepatitis. *Sumbul-ut-teeb* which is the main ingredient is known for its strong odour and is known to have anti-convulsant, antioxidant, anti-inflammatory and hepatoprotective properties.

Study was conducted to assess the acute and repeated dose 90-day oral toxicity of QS in rats. Acute oral toxicity of QS was assessed by administering a single dose of 2000 mg/kg bw in accordance with OECD-425 guidelines and observed for signs & symptoms of toxicity and lethality for 14 days post-treatment. No treatment related gross pathological abnormalities were observed. The repeated dose 90 day oral toxicity was assessed by administering 400, 800 and 1200 mg/kg bw/day of QS. The study findings have not shown any toxicologically significant alteration in terms of survival, behaviour pattern, body weight, feed intake, urine examination, hematology, clinical chemistry and relative organ weight in any QS treated group as compared to vehicle control. The conclusive statement regarding the safety of QS would require additional assessment through histopathological findings which was yet to be completed. However, the initial results indicate that QS can be considered safe for its intended use.

Evaluation of Hepatoprotective Activity of *Qurs-e-Sumbul* in rats.

The hepatoprotective potential of *Qurs-e-Sumbul* (QS) was evaluated against paracetamol (PCT)-induced toxicity. The findings indicated that repeated oral administration of QS for 11 days at doses of 400 and 800 mg/kg significantly improved hepatic injury markers and creatinine levels compared to the PCT control group. Additionally, the hepatoprotective potential of QS was assessed against hepatotoxicity induced by anti-tubercular drugs isoniazid (H), rifampicin (R), and pyrazinamide (Z) with repeated oral administration for 31 days in rats.

The study results showed that administration of these anti-tubercular drugs did not cause a significant increase in liver transaminase activity which is generally considered an established serum marker of liver injury. However, elevated levels of urea and uric

acid were observed, suggesting possible renal toxicity induced by the HRZ regimen. Histopathological analysis reports will provide further insight into these observations.

Acute and Repeated Dose 90-Day Oral Toxicity Study on *Habb-e-Ikhtelaj* (HIK).

Habb-e-Ikhtelaj (HIK) is a Unani medicine in the form of pill that is traditionally used for melancholic disorders such as depression, anxiety, insomnia, mania etc. It is *Munaqqi-e-Dimagh* in action i.e. it clears toxic humours from brain. Its therapeutic dose is 3-5 gms. The present study was designed to evaluate acute and repeated dose 90-day oral toxicity studies of HIK in rats. Acute oral toxicity of HIK was assessed by administering a single dose of 2000 mg/kg bw and observed for signs & symptoms of toxicity and lethality for 14 days post-treatment. No treatment related gross pathological abnormalities were observed. The repeated dose toxicity was assessed by administering 400, 800 and 1200 mg/kg bw/day of HIK.

The study findings have not shown any toxicologically significant alteration in terms of survival, behaviour pattern, body weight, feed intake, urine examination, haematology, clinical chemistry and relative organ weight in any HIK treated group as compared to vehicle control. Therefore, based on the present findings HIK can be considered safe. The conclusive statement regarding safety of HIK could possibly be made based on histopathological findings.

Evaluation of Antidepressant and Anxiolytic Activity of *Habb-e-Ikhtelaj*

The antidepressant activity of HIK was evaluated using the Forced Swim Test (FST) in male Wistar rats and the Tail Suspension Test (TST) in male Swiss Albino mice. Anxiolytic activity was assessed using the Elevated Plus Maze (EPM) and Open Field Exploration tests in rats. In the FST, HIK at doses of 400 mg/kg and 800 mg/kg did not produce any statistically significant antidepressant effect in rats tested on Day 2 or Day 14. Similarly, in the TST, HIK at doses of 800 mg/kg and 1600 mg/kg did not significantly reduce immobility duration in mice on either Day 2 or Day 14, suggesting a lack of statistically significant antidepressant activity in this model. Furthermore, none of the tested doses of HIK demonstrated significant anxiolytic activity in the EPM or Open Field tests in rats.

Acute and repeated dose 28 day oral toxicity study of *Jawarish-e-Ood Mulaiyin* (JOM)

Jawarish-e-Ood Mulaiyan (JOM) is a semisolid preparation well known for its digestive properties and is commonly used in the management of gastrointestinal issues such as constipation and loss of appetite. An acute oral toxicity study was conducted in rats following OECD Guideline 425. A single oral dose of JOM at 2000 mg/kg body weight (bw) was administered to assess acute toxicity. For subacute toxicity evaluation, JOM was administered orally at a dose of 1000 mg/kg bw/day for 28 consecutive days. The results indicated no mortality or observable behavioral changes in either the acute or the 28-day repeated dose toxicity studies. No toxicologically significant changes were

observed in body weight, feed intake, hematological parameters, clinical biochemistry, or relative organ weights in JOM-treated rats. Based on these findings, JOM can be considered safe for its intended therapeutic use.

Acute and repeated dose 28 day oral toxicity study of *Itrifal khabsul Hadeed* (IKH)

Itrifal Khabsul Hadeed is a semi-solid Unani formulation which is commonly used in managing digestive and liver diseases as well as anemia. An acute oral toxicity study was conducted in Wistar albino rats following OECD Guidelines 425. A single oral dose of IKH at 2000 mg/kg body weight (bw) was administered to assess acute toxicity. Subsequently, IKH was administered orally at a dose of 1000 mg/kg bw/day for 28 consecutive days to evaluate subacute (28-day repeated dose) oral toxicity. The findings revealed no mortality or behavioral changes in either the acute or the 28-day repeated dose toxicity assessments. No toxicologically significant changes were observed in body weight, feed intake, hematological parameters, clinical biochemistry, or relative organ weights in either IKH-treated groups or control animals. Based on these observations, IKH may be considered safe for oral administration at the tested dose levels.

Clinical Studies

The Clinical Research Programme of the Council deals with the methods of diagnosis and treatment of diseases and aims at critical appraisal of the theory of pathogenesis, symptomatology, clinical methods of diagnosis, principles and methods of treatment, and the drug and diet therapies peculiar to Unani Medicine. Under this programme, clinical studies on different diseases were undertaken with a view to develop safe and effective Unani treatments. Besides, clinical validation of safety and efficacy of Unani pharmacopoeial formulations was conducted. Clinical validation of Unani pharmacopoeial fast-acting drugs in different diseases was also undertaken. The programme continued at the following centres:

- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
- Central Research Institute of Unani Medicine (CRIUM), Lucknow
- Regional Research Institute of Unani Medicine (RRIUM), Chennai
- Regional Research Institute of Unani Medicine (RRIUM), Bhadrak
- Regional Research Institute of Unani Medicine (RRIUM), Patna
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Regional Research Institute of Unani Medicine (RRIUM), Mumbai
- Regional Research Institute of Unani Medicine (RRIUM), Srinagar
- Regional Research Institute of Unani Medicine (RRIUM), Kolkata

- Regional Research Institute of Unani Medicine (RRIUM), New Delhi
- Regional Research Institute of Unani Medicine (RRIUM), Silchar
- Regional Research Centre (RRC), Allahabad
- Clinical Research Unit (CRU), Bengaluru
- Clinical Research Unit (CRU), Meerut
- Clinical Research Unit (CRU), Bhopal
- Clinical Research Unit (CRU), Burhanpur
- Clinical Research Unit (CRU), Edathala
- Clinical Research Unit (CRU), Imphal
- Clinical Research Unit (CRU), Kurnool
- Clinical Research Unit (CRU), Goa

CENTRE-WISE ALLOCATION OF DISEASES FOR CLINICAL STUDIES ON SAFETY AND EFFICACY OF UNANI DRUGS

Centre	Diseases
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad	<i>Hisat-ul-Kuliya</i> (nephrolithiasis), <i>Zofe-ul-Meda</i> (functional dyspepsia), <i>Kasrat-ul-Tams</i> (heavy menstrual bleeding), <i>Zeeq-un-Nafas</i> (bronchial asthma), <i>Malikhuliya</i> (mixed anxiety depressive disorder), <i>Su-ul-Qinya</i> (anaemia), <i>Humma</i> (fever), <i>Kasrat-ul-Bawl</i> (overactive bladder), <i>Amraz-i-Jild</i> (skin eruptions) and <i>Qooba</i> (dermatophytosis) <i>Bawaseer Amya</i> (Non-Bleeding piles), <i>Falij</i> (Hemiplegia), <i>Sual-e-Muzmin</i> (Chronic cough), <i>Tahajjur-e-Mafassil</i> (Osteoarthritis)
Central Research Institute of Unani Medicine (CRIUM), Lucknow	<i>Su-ul-Qinya</i> (anaemia), <i>Kasrat-ul-Tams</i> (heavy menstrual bleeding), <i>Sailan-ur-Rahem</i> (leucorrhoea), <i>Su-ul-Hazm</i> (dyspepsia), <i>Waja-ul-Mafasil</i> (rheumatoid arthritis), <i>Zofe-ul-Dimagh</i> (cerebrasthenia), <i>Zeeq-un-Nafas</i> (bronchial asthma), <i>Zofe-ul-Meda</i> (dyspepsia), <i>Melankhuliya</i> (mixed anxiety depressive disorder) and <i>Hisat-ul-Kuliya</i> (nephrolithiasis), <i>Warm-e-Kabid Barid</i> (Non Alcoholic Fatty Liver Disease-NASH), <i>Tahajjur-e-Mafassil</i> (Osteoarthritis)
Regional Research Institute of Unani Medicine (RRIUM), Chennai	<i>Hisat-ul-Kuliya</i> (nephrolithiasis), <i>Zeeq-un-Nafas</i> (bronchial asthma), <i>Zofe-ul-Dimagh</i> (cerebrasthenia), <i>Malikhuliya</i> (mixed anxiety depressive disorder), <i>Sahar</i> (insomnia), <i>Waja-ul-Mafasil</i> (rheumatoid arthritis), <i>Falij</i> (hemiplegia) and <i>Sailan-ur-Rahem</i> (leucorrhoea), <i>Qarha Asir-al-Indimal</i> (Non-Healing ulcers), <i>Waja-ul Qutn</i> (Non-Specific Low Backache), <i>Marham Khal-e-Khumri</i> in <i>Da-us-Salab</i> (Diffuse Alopecia), <i>Zof-e-Asab</i> (Neurasthenia)

Regional of Unani Bhadrak	Research Institute of Unani Medicine (RRIUM), Patna	<i>Busur-ul-Jild</i> (macules / pustules), <i>Surat-e-Inzal</i> (premature ejaculation), <i>Zofe-ul-Meda</i> (functional dyspepsia), <i>Zeeq-un-Nafas</i> (bronchial asthma), <i>Khafqan</i> (palpitation), <i>Jarab</i> (scabies), <i>Waja-ul-Mafasil</i> (rheumatoid arthritis) and <i>Bahaq Abyaz/ Aswad</i> (Pityriasis alba / nigra), <i>Malikhuliya</i> (Mixed Anxiety Depressive Disorder)
Regional of Unani Aligarh	Research Institute of Unani Medicine (RRIUM), Mumbai	<i>Su-ul-Qinya</i> (anaemia), <i>Nazla Muzmin</i> (chronic <i>rhino-sinusitis</i>), <i>Zeeq-un-Nafas</i> (bronchial asthma), <i>Niqris</i> (gout), <i>Waja-ul-Mafasil</i> (rheumatoid arthritis), <i>Zofe-ul-Dimagh</i> (Cerebroasthenia), <i>Zofe-ul-Meda</i> (dyspepsia), <i>Qooba</i> (dermatophytosis), <i>Bawasir Damiya</i> (bleeding piles), <i>Sahar</i> (insomnia), <i>Taqteer-ul-Baul</i> (Post Micturition Dribble -PMD), <i>Zof-e-Meda</i> (Functional Dyspepsia)
Regional of Unani	Research Institute of Unani Medicine (RRIUM), Mumbai	<i>Zeeq-un-Nafas</i> (bronchial asthma), <i>Zofe-ul-Dimagh</i> (cerebrasthenia), <i>Qula</i> (stomatitis), <i>Niqris</i> (Gout), <i>Humuzatal-Meda</i> (hyperacidity), <i>Jildi Quruh</i> (cutaneous ulcers), <i>Su-ul-Hazm</i> (functional dyspepsia), <i>Zofe-ul-Ishtiha</i> (anorexia) and <i>Waram al-Hanjara</i> (laryngitis), <i>Sual-e-Muzmin</i> (Chronic cough), <i>Shaqqeqa</i> (Migraine)
Regional of Unani	Research Institute of Unani Medicine (RRIUM), Mumbai	<i>Hisat-ul-Kuliya</i> (nephrolithiasis), <i>Ihtibas al-Tams</i> (amenorrhoea), <i>Quba</i> (dermatophytosis), <i>Sailan-ur-Rahem</i> (leucorrhoea), <i>Malikhuliya</i> (mixed anxiety depressive disorder), <i>Khafqan</i> (palpitation), <i>Nisyan</i> (amnesia), <i>Salasal Bawl</i> (stress urinary incontinence), <i>Zeeq-un-Nafas</i> (bronchial asthma) and <i>Quruh</i> (healing ulcers), <i>Warm-e-Kabid Barid</i> (Non Alcoholic Fatty Liver Disease –NASH), <i>Waj-ul-Mafasil</i> (Rheumatoid Arthritis)

Regional Research Institute of Unani Medicine (RRIUM), Srinagar	<i>Sailan-ur-Rahem</i> (leucorrhoea), <i>Malikhuliya</i> (mixed anxiety depressive disorder), <i>Kasrat-ul-Tams</i> (heavy menstrual bleeding), <i>Ihtibas al-Tams</i> (amenorrhoea) and <i>Niqris</i> (gout), <i>Taqteer-ul-Baul</i> (Post Micturition Dribble - PMD), <i>Da-us-Salab</i> (Diffuse Alopecia), <i>Qarha Asir-al-Indimal</i> (Non-Healing ulcers), <i>Ihtibas e Tams</i> (Amenorrhoea), <i>Busoor</i> (Skin eruptions)
Regional Research Institute of Unani Medicine (RRIUM), Kolkata	<i>Su-ul-Qinya</i> (anaemia) <i>Sual-e-Muzmin</i> (Chronic cough)
Regional Research Institute of Unani Medicine (RRIUM), New Delhi	<i>Su-ul-Hazm</i> (dyspepsia), <i>Khafqan</i> (palpitation), <i>Sailan-ur-Rahem</i> (leucorrhoea), <i>Irqal-Nasa</i> (sciatica), <i>Nisyan</i> (amnesia) and <i>Zofe-ul-Asab</i> (neurasthenia), <i>Zeeq un Nafas</i> (Bronchial Asthma), <i>Waram-e-Halaq</i> (Pharyngitis)
Regional Research Centre (RRC), Allahabad	<i>Waja-ul-Mafasil</i> (rheumatoid arthritis), <i>Su-ul-Qinya</i> (anaemia), <i>Su-ul-Yabis</i> (dry cough), <i>Sahar</i> (insomnia) and <i>Zeeq un Nafas</i> (bronchial asthma), <i>Bawaseer Amya</i> (Non-Bleeding piles)
Regional Research Institute of Unani Medicine (RRIUM), Silchar	<i>Su-ul-Qinya</i> (anaemia), <i>Sahar</i> (insomnia) and <i>Bahaq Abyaz/ Aswad</i> (pityriasis alba / nigra), <i>Zof-e-Ishteha</i> (Anorexia)
Clinical Research Unit (CRU), Bengaluru	<i>Busoor</i> (Skin eruptions)
Clinical Research Unit (CRU), Meerut	<i>Khafqan</i> (palpitation), <i>Waj-ul Qutn</i> (Non-Specific Low Backache), <i>Kunduri</i> in <i>Salasal-Bawl</i> (Stress Urinary Incontinence) <i>Zof-e-Dimagh</i> (Cerebrasthenia)
Clinical Research Unit (CRU), Bhopal	<i>Zof-e-Ishteha</i> (anorexia), <i>Sailan-ur-Rahem</i> (leucorrhoea) and <i>Malikhuliya</i> (mixed anxiety depressive disorder)
Clinical Research Unit (CRU), Burhanpur	<i>Su-ul-Hazm</i> (functional dyspepsia), <i>Busoor</i> (Skin eruptions), <i>Zof-e-Meda</i> (Functional Dyspepsia)

Clinical Research Unit (CRU), Kerala	<i>Sahar</i> (Insomnia), <i>Waram-e-Halaq</i> (Pharyngitis)
Clinical Research Unit (CRU), Kurnool	<i>Shaqeeqa</i> (Migraine), <i>Qula</i> (Stomatitis)

Randomized Controlled Trials

The following studies under Randomized Controlled Trials were allotted / initiated during the reporting period:

[A Single Centric, Single Blind, Randomized, Parallel group Study to compare efficacy and safety of coded Unani formulation *Qurs-i-Mafasil* with Diacerein-50 mg in patients with *Tahajjar-ul-Mafasil* \(Osteoarthritis\)](#)

A randomised controlled clinical study of a Unani formulation *Qurs-i-Mafasil* with Diacerein-50 mg in the patients of *Tahajjar-ul-Mafasil* (Osteoarthritis) was carried out at NRIUMSD, Hyderabad. The patients were divided into two groups. The test group received *Qurs-i-Mafasil* in a dose of two tablets (500 mg each) twice a day whereas the control group received Diacerein one tablet (50mg) twice a day for eight weeks.

During the reporting period, 17 patients were registered in the study. Out of 12 cases who completed the study, 03 (25.00%) were relieved and 09 (75.00%) were partially relieved. There were 04 dropouts and 01 case under the study. The test drug was found well-tolerated and no adverse effect was observed.

[A randomized, parallel group, open label, standard controlled clinical study to compare the efficacy and safety of Unani pharmacopoeial formulation *Jawarish Kundur* with Oxybutanin in cases of *Kathra al-Bawl* \(Overactive Bladder\)](#)

A study on Unani pharmacopoeial formulation *Jawarish Kundur* was conducted in the patients of in *Kasrat e Bol* (Overactive bladder) at NRIUMSD, Hyderabad. The test group received *Jawarish Kundur* in the dose of 5 gm twice a day whereas control group received tab Oxybutanin 2.5 mg twice a day for 12 weeks.

During the reporting period, 25 patients were studied, of which 14 completed the study. Out of the completed cases, 07 (50.00%) patients were relieved and 7 (50.00%) patients were partially relieved. A total of 11 cases under study. So far, 36 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

[A single blind, randomized, parallel group study to compare efficacy and safety of Unani formulation *Safoof-i-Dama Haldi wala* with Salbutamol in patients with *Zeeq-un-Nafas* \(Bronchial Asthma\)](#)

A randomised controlled clinical study of a Unani formulation *Safoof-i-Dama Haldi wala* with Salbutamol in the patients of *Zeeq-un-Nafas* (Bronchial Asthma) was carried out at NRIUMSD, Hyderabad. The patients were divided into two groups. The

test group received *Safoof-i-Dama Haldi wala* in powder form in a dose of 5 gm once daily whereas the control group received Salbutamol 2 mg once a day for 51 days.

During the reporting period, 38 patients were registered in the study. Out of which 15 completed the study. Out of the completed cases, 09 (60.00%) were relieved, 04 (26.67%) partially relieved and 02 (13.33%) were not relieved. There were 17 dropouts and 06 cases were under study. So far, 17 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

[A Single blind, Randomized, Parallel group study to evaluate anti-pyretic effect of Unani Medicine Kit formulation– *Cap Mubarak* with Paracetamol in patients with *Humma* \(Fever\)](#)

A randomised controlled clinical study of a Unani Medicine Kit formulation– *Cap Mubarak* with Paracetamol in patients with *Humma* (Fever) was carried out at RRIUM, Patna. The patients were divided into two groups. The test group received 02 *Cap Mubarak* (500 mg) twice daily whereas the control group received 01 tab Paracetamol (500 mg) twice a day for 03 days.

During the reporting period, 72 patients were registered in the study. Out of which 56 completed the study. Out of the completed cases, 09 (16.07%) were relieved, 32 (57.14%) partially relieved and 15 (26.79%) were not relieved. There were 15 dropouts and 01 case were under study. So far, 56 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

[A single blind, randomized, parallel group study to compare efficacy and safety of Unani formulation *Cap. Shaqiqa* with Divalproate in patients of *Shaqiqa* \(Migraine\)](#)

A randomised controlled clinical study of a coded Unani formulation, *Cap. Shaqiqa* with Divalproate, in the patients of *Shaqiqa* (Migraine) was carried out at RRIUM, Chennai. The patients were divided into two groups. The test group received *Cap. Shaqiqa* in a dose of two capsules (500 mg each) twice a day, whereas the control group received 250 mg (body weight < 30 kg) or 850 mg (body weight >80kg) once at night, for twelve weeks.

During the reporting period, 22 patients were registered in the study. Out of which, 13 completed the study. Out of the completed cases, 11 (84.62%) cases were relieved and 2 (15.38%) partially relieved. There were 07 dropouts and 02 cases were under study. So far, 61 cases have been completed the study and no adverse effect was observed.

[A Single blind, Randomized, Parallel group study to compare efficacy and safety of Unani Medicine Kit formulation– *Qurs Mulaiyin* with Dulcolax in patients with *Daimi Qabz* \(Chronic Constipation\)](#)

A single-blind randomised controlled clinical study of a Unani Medicine Kit formulation– *Qurs Mulaiyin* with Dulcolax – in patients with *Daimi Qabz* (Chronic Constipation) was carried out at RRIUM, Chennai. The patients were divided into two

groups. The test group received *Qurs Mulaiyin* in a dose of 02 tabs (500 mg) at bedtime, whereas the control group received 01 tab of Dulcolax (10 mg) at bedtime for 07 days.

During the reporting period, 54 patients were studied, of which 48 completed the study. Out of the completed cases, 06 (12.50%) patients were relieved, 32 (66.67%) partially relieved and 10 (20.83%) were not relieved. A total of 06 cases dropped out of the study. So far, 62 cases have been completed in the study. The test drug was found well-tolerated, and no adverse effect was observed.

A single blind, randomized, parallel group study to compare efficacy and safety of Unani formulation *Qurs-i-Mafasil* with Paracetamol in patients with *Tahajjar-ul-Mafasil* (Osteoarthritis)

A randomised controlled clinical study of a Unani formulation, *Qurs-i-Mafasil*, with Paracetamol in the patients of *Tahajjar-ul-Mafasil* (Osteoarthritis) was carried out at CRIUM, Lucknow. The patients were divided into two groups. The test group received *Qurs-i-Mafasil* in a dose of two tablets (500 mg each), whereas the control group received Paracetamol 01 (500 mg) once a day for 08 weeks.

During the reporting period, 37 patients were registered in the study. Out of which, 29 completed the study. Out of the completed cases, 22 (75.86%) were relieved, 02 (6.90%) partially relieved and 05 (17.24%) were not relieved. There were 08 dropouts. So far, 60 cases have completed the study, and no adverse effect was observed. The test and control drugs were found well tolerated, and no adverse effect was observed.

Comparative Clinical Validation of Unani pharmacopeial formulation *Majoon-e-Masihi* vs *Habbe Suranjan* in *Waj-ul Qutn* (Non-Specific Low Backache)

A study on validation of a Unani pharmacopoeial formulation *Majoon-e-Masihi* vs *Habb e suranjan* in the patients of *Waj-ul Qutn* (Non-Specific Low Backache) was carried out at RRIUM, Chennai and CRU, Meerut. The test group received *Majoon-e-Masihi* 5 gm twice daily, whereas the control group received *Habb-e-Suranjan* 02 pills twice daily for 04 weeks.

During the reporting period, 90 patients were studied, of which 63 completed the study. Out of the completed cases, 28 (44.44%) patients were relieved, 28 (44.44%) partially relieved and 07 (11.11%) patients were not relieved. A total of 04 cases dropped out of the study and 23 cases under the study. So far, 63 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

New Studies initiated

The following studies under validation of Unani pharmacopoeial drugs were initiated during the reporting period:

- RCT entitled “A Muticentric, Single blind, Randomized, Parallel group study to compare efficacy and safety of coded Unani formulation UNIM D 2000 with Metformin in patients with *Ziabetus Sukkari Qism-e-Sani* (Diabetes Mellitus Type II)
- Comparative Clinical Validation of Unani pharmacopoeial formulation *Habb-e-Gul-e-Aak* and *Roghan-e-Hina* vs *Majoon e Jograj Goggul* and *Roghan e Malkangani* in *Waj-ul-Mafasil* (Rheumatoid Arthritis)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Majoon-e-Mughalliz* vs *Majoon Piyaz* in *Surat-e-Inzaal* (Premature ejaculation)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Habb-e-Ikhtilaj* vs *Majoon e Najah* in *Malankholiya* (Mixed anxiety depressive disorder)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Itrifal-e-Muqil Mulaiyin* and *Roghan e Babuna Qawivs Habb e Suranjan* and *Roghan e Suranjan* in *Waja-ul-Mafasil* (Rheumatoid Arthritis)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Habb-e-Baqla* vs *Sharbat e Ejaz* in *Sual* (Cough)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Majun Brahmi* vs *Majoon e Nisyan* in *Zof-e-Dimagh wa Hafiza* (Cerebroasthenia)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Sharbat Murakkab Musaffi Khoon* and *Roghan Kamela* vs *Qurs e Asfar* and *Roghan e Narjeel* in *Qooba* (Dermatophytosis)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Qulai* vs *Zarur Kath* in *Qulaa* (Stomatitis)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Qurs-e-Foh* vs *Habb e Mudir* in *Ehtebas-e-Tams* (Amenorrhoea)
- Comparative Clinical validation of Unani pharmacopoeial formulation *Jawarish-e-Tamarhindi* vs *Jawarish e Shahi* in *Khafqan* (palpitation)

Validation of Unani Pharmacopoeial Formulations

Clinical validation of a Unani pharmacopoeial formulation *Majoon-Hajr-ul-Yahud* in *Hisat-ul-Kuliya* (nephrolithiasis)

A study on validation of a Unani pharmacopoeial formulation *Majoon-Hajr-ul-Yahud* in the patients of *Hisat-ul-Kuliya* (nephrolithiasis) was carried out at NRIUMSD, Hyderabad; and RRIUMs, Mumbai and Chennai. The patients received *Majoon-Hajr-ul-Yahud* 05 gm twice daily for 08 weeks.

During the reporting period, 78 patients were studied, of which 49 completed the study. Out of the completed cases, 12 (24.49%) were relieved, 17 (34.69%) partially relieved and 20 (40.82%) were not relieved. A total of 25 cases dropped out of the

study and 04 were under study. So far, 190 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Majoon-i-Suhag Sonth* in *Sailan-ur-Rahem* (excessive abnormal vaginal discharge)

A study on validation of a Unani pharmacopoeial formulation *Majoon-i-Suhag Sonth* in the patients of *Sailan-ur-Rahem* (excessive abnormal vaginal discharge) was carried out at CRIUM, Lucknow; RRIUM, Srinagar; and CRU, Meerut. The patients received *Majoon-i-Suhag Sonth* 5 gm twice daily for four weeks.

During the reporting period, 96 patients were studied, of which 75 completed the study. Out of the completed cases, 44 (58.67%) patients were relieved, 26 (34.67%) partially relieved and 05 (6.67%) were not relieved. A total of 17 cases dropped out of the study and 04 were under study. So far, 200 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Khamira Gaozaban Sada* in *Khafqan* (palpitation)

A study on validation of a Unani pharmacopoeial formulation *Khamira Gaozaban Sada* in the patients of *Khafqan* (palpitation) was carried out at RRIUMs, New Delhi, Mumbai and Bhadrak. The patients received *Khamira Gaozaban Sada* 5 gm twice daily for 04 weeks.

During the reporting period, 20 patients were studied, of which 18 completed the study. Out of the completed cases, 14 (77.78%) patients were relieved, 3 (16.67%) partially relieved and 01 (5.56%) were not relieved. A total of 02 cases dropped out of the study and no one was under study. So far, 197 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Majoon Khabath al-Hadid* in *Su-ul-Qinya* (anaemia)

A study on validation of a Unani pharmacopoeial formulation *Majoon Khabath al-Hadid* in the patients of *Su-ul-Qinya* (anaemia) was carried out at CRIUM, Lucknow; RRIUMs, Patna, Kolkata, Silchar ; RRC, Allahabad and CRU, Burhanpur. The patients received *Majoon Khabath al-Hadid* 5 gm twice daily for 12 weeks.

During the reporting period, 12 patients were studied, of which 08 completed the study. Out of the completed cases, none (0%) patients were relieved, 08 (100%) partially relieved and none (0%) were not relieved. A total of 04 cases dropped out of the study. So far, 198 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Itrifal Kabir* in *Zofe-ul-Dimagh* (cerebrasthenia)

A study on validation of a Unani pharmacopoeial formulation *Itrifal Kabir* in the patients of *Zofe-ul-Dimagh* (cerebrasthenia) was carried out at CRIUM, Lucknow; RRIUMs, Chennai, Aligarh and Patna. The patients received *Itrifal Kabir* 5 gm twice daily for 06 weeks.

During the reporting period, 177 patients were studied, of which 140 completed the study. Out of the completed cases, 33 (23.57%) patients were relieved, 84 (60.00%) partially relieved and 23 (16.43%) were not relieved. A total of 37 cases dropped out of the study and none were under study. So far, 311 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Majoon-i-Zanjabil* in *Kasrat-ul-Tams* (Menorrhagia)

A study on validation of a Unani pharmacopoeial formulation *Majoon-i-Zanjabil* was conducted in the patients of in *Kasrat-ul-Tams* (Menorrhagia) at RRIUM, Srinagar. The patients received *Majoon-i-Zanjabil* in the dose of 05 gm twice a day for 84 days.

During the reporting period, 28 patients were studied, of which 28 completed the study. Out of the completed cases, 17 (60.71%) patients were relieved and 11 (39.29%) partially relieved. So far, 110 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Qurs-i-Atash* in *Humuzat al-Mida* (Hyperacidity)

A study on validation of a Unani pharmacopoeial formulation *Qurs-i-Atash* was conducted in the patients of *Humuzat al-Mida* (Hyperacidity) at RRIUM, Aligarh. The patients received *Qurs-i-Atash* in the dose of one tablet (850mg) thrice a days for 42 days.

During the reporting period, 56 patients were studied, of which 45 completed the study. Out of the completed cases, 20 (44.44%) patients were relieved and 25 (55.56%) partially relieved. A total of 07 cases dropped out of the study and 04 were under the study. So far, 91 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Habb Irq al-Nasa* in *Irq al-Nasa* (Sciatica)

A study on validation of a Unani pharmacopoeial formulation *Habb Irq al-Nasa* was conducted in the patients of *Irq al-Nasa* (Sciatica) at RRIUM, New Delhi. The patients received *Habb Irq al-Nasa* in the dose of 02 tablets (800mg) thrice a day for 84 days.

During the reporting period, 76 patients were studied, of which 56 completed the study. Out of the completed cases, 43 (76.79%) patients were relieved, 09 (16.07%) partially relieved and 04 (7.14%) were not relieved. A total of 12 cases dropped out of the study and 08 cases were under study. So far, 99 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulations *Itrifal Mundi* and *Marham-i-Raskapur* in *Jarab* (scabies)

A study on validation of a Unani pharmacopoeial formulation *Itrifal Mundi* and *Marham-i-Raskapūr* was conducted in the patients of *Jarab* (scabies) at RRIUM, Bhadrak. The patients received *Itrifal Mundi* in the dose of 10 gm twice a day and *Marham-i-Raskapur* was applied locally on the affected area for 14 days.

During the reporting period, 19 patients were studied, of which 10 completed the study. Out of the completed cases 10 (100%) were partially relieved. A total of 06 cases dropped out of the study and 03 cases were under study. So far, 72 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Majoon-e-Falasifa* in *Nisyan* (Amnesia)

A study on validation of a Unani pharmacopoeial formulation *Majoon-e-Falasifa* in the patients of *Nisyan* (Amnesia) was carried out at RRIUM, Mumbai. The patients received *Majoon-e-Falasifa* in the doses of 5 grams twice daily.

During the reporting period, 74 patients were studied, of which 53 completed the study. Out of the completed cases, none (0%) of the patients were relieved and 53 (100%) partially relieved. No cases dropped out of the study and 21 cases under the study. So far, 56 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Qurs-e-Asfar* and *Roghan-e-Narjeel* in *Quba* (Dermatophytosis)

A study on validation of Unani pharmacopoeial formulation *Qurs-e-Asfar* and *Roghan-e-Narjeel* in the patients of *Quba* (Dermatophytosis) was carried out at RRIUM, Patna. The patients received *Qurs-e-Asfar* one tablets twice daily and *Roghan-e-Narjeel* locally.

During the reporting period, 54 patients were studied, of which 51 completed the study. Out of the completed cases, 17 (33.33%) patients were relieved, 27 (52.94%) partially relieved and 07 (13.73%) patients were not relieved. A total of 03 cases dropped out of the study and none cases under the study. So far, 51 cases have

been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Rawghan-i-Banafsha* in *Sahar* (Insomnia)

A study on validation of a Unani pharmacopoeial formulation *Rawghan-i-Banafsha* was conducted in the patients of *Sahar* (Insomnia) at RRIUM, Silchar, RRIUM, Chennai and RRC, Allahabad. The patients received *Rawghan-i-Banafsha* was applied locally on the scalp for 14 days.

During the reporting period, 98 patients were studied, of which 90 completed the study. Out of the completed cases, 64 (71.11%) patients were relieved, 25 (27.78%) partially relieved and 01 (1.11%) were not relieved. A total of 08 cases dropped out of the study. So far, 253 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Kushta Bayza-i-Murgh* in *Sailan-ur-Rahem* (Leucorrhoea)

A study on validation of a Unani pharmacopoeial formulation *Kushta Bayza-i-Murgh* was conducted in the patients of *Sailan-ur-Rahem* (leucorrhoea) at RRIUM, New Delhi and CRU, Bhopal. The patients received *Kushta Bayza-i-Murgh* in the dose of one tablet (50mg) twice a day for 28 days.

During the reporting period, 62 patients were studied, of which 53 completed the study. Out of the completed cases, 33 (62.26%) patients were relieved, 17 (32.08%) partially relieved and 03 (5.66%) were not relieved. A total of 06 cases dropped out of the study and 03 case was under study. So far, 181 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Kunduri* in *Salasal-Bawl* (Stress Urinary Incontinence)

A study on validation of a Unani pharmacopoeial formulation *Kunduri* was conducted in the patients of *Salasal-Bawl* (Stress Urinary Incontinence) at RRIUM, Mumbai and CRU, Meerut. The patients received *Kunduri* in the dose of 6 gm twice a day for 84 days.

During the reporting period, 38 patients were studied, of which 31 completed the study. Out of the completed cases 04 (12.90%) patients were relieved, 26 (83.87%) partially relieved and 01 (3.23%) were not relieved. A total of 07 cases dropped out of the study and none patients were under study. So far, 174 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Qurs-i-Zarishk* in *Su-ul-Qinya* (anaemia)

A study on validation of a Unani pharmacopoeial formulation *Qurs-i-Zarishk* was conducted in the patients of *Su-ul-Qinya* (Anaemia) at NRIUMSD, Hyderabad. The patients received *Qurs-i-Zarishk* in the dose of one tablet (850mg) thrice a day for 84 days.

During the reporting period, 25 patients were studied, of which 23 completed the study. Out of the completed cases, 11 (47.83%) patients were relieved and 12 (52.17%) partially relieved. A total of 12 cases dropped out of the study and none cases were under study. So far, 111 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulations *Majoon-i-Azaraq* and *Roghan Surkh* in *Waja-ul-Mafasil* (Rheumatoid Arthritis)

A study on validation of a Unani pharmacopoeial formulation *Majoon-i-Azaraq* and *Roghan Surkh* was conducted in the patients of *Waja-ul-Mafasil* (Rheumatoid Arthritis) at RRIUM, Chennai. The patients received *Majoon-i-Azaraq* in a dose of 03 gm twice a day and *Rawghan Surkh* was applied locally on the affected area for 84 days.

During the reporting period, 08 patients were studied, of which 04 completed the study. Out of the completed cases, 01 (25.00%) patient was relieved, 02 (50.00%) were partially relieved and 01 (25.00%) were not relieved. A total of 04 cases dropped out of the study and none patients were under study. So far, 111 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Habb-i-Banafsha* in *Zeeq-un-Nafas Riwi* (Bronchial Asthma)

A study on validation of a Unani pharmacopoeial formulation *Habb-i-Banafsha* was conducted in the patients of *Zeeq-un-Nafas Riwi* (Bronchial Asthma) at CRIUM, Lucknow and CRU, Meerut. The patients received *Habb-i-Banafsha* in the dose of two tablet (200mg each) twice a day for 84 days.

During the reporting period, 125 patients were studied, of which 94 completed the study. Out of the completed cases, 58 (61.70%) patients were relieved, 31 (32.98%) partially relieved and 05 (5.32%) were not relieved. A total of 20 cases dropped out of the study and 11 cases were under study. So far, 212 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Laoq-e-Hulba* in *Zeeq-un-Nafas* (Bronchial Asthma)

A study on validation of a Unani pharmacopoeial formulation *Laoq-e-Hulba* in the patients of *Zeeq-un-Nafas* (Bronchial Asthma) was carried out at RRIUM, Bhadrak. The patients received *Laoq-e-Hulba* 5 gm twice daily.

During the reporting period, 06 patients were studied, of which 01 completed the study. Out of the completed cases, none (0%) patients were relieved, 01 (100%) partially relieved. A total of 05 cases dropped out of the study and none cases under the study. So far, 01 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Jawarish-i-Darchini Qawi* in *Zofe-ul-Meda* (Dyspepsia)

A study on validation of a Unani pharmacopoeial formulation *Jawarish-i-Darchini Qawi* was conducted in the patients of *Zofe-ul-Meda* (Dyspepsia) at CRIUM, Lucknow and RRIUM, Patna. The patients received *Jawarish-i-Darchini Qawi* in the dose of 05 gm twice a day for 14 days.

During the reporting period, 80 patients were studied, of which 60 completed the study. Out of the completed cases, 23 (38.33%) patients were relieved and 30 (50.00%) partially relieved and 07 (11.67%) were not relieved. A total of 13 cases dropped out of the study and 07 case under study. So far, 128 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Arq Chiraita* in *Amraz e Jild* (Skin eruptions)

A study on validation of a Unani pharmacopoeial formulation *Arq Chiraita* was conducted in the patients of *Amraz e Jild* (Skin eruptions) at NRIUMSD, Hyderabad and CRU, Kurnool. The patients received *Arq Chiraita* 125 ml once a day for 14 days.

During the reporting period, 17 patients were studied, of which 09 completed the study. Out of the completed cases, 04 (44.44%) patients were relieved and 05 (55.56%) partially relieved. A total of 04 cases dropped out of the study and 04 cases were under study. So far, 42 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed. A total of two cases were under study.

Clinical validation of Unani pharmacopoeial formulation *Majoon Teewaj* in *Bawaseer Damiya* (Bleeding piles)

A study on validation of a Unani pharmacopoeial formulation *Majoon Teewaj* was conducted in the patients of *Bawaseer Damiya* (Bleeding piles) at RRIUM, Patna and CRU, Meerut. The patients received *Majoon Teewaj* in the dose of 05 gm twice a day for 42 days.

During the reporting period, 67 patients were studied, of which 52 completed the study. Out of the completed cases, 17 (32.69%) patients were relieved and 28 (53.85%) partially relieved and 07 (13.46%) patients were not relieved. A total of 15 cases dropped out of the study and none cases were under study. So far, 187 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Laoq Falij* and *Roghan-e-Mom* in *Falij* (Hemiplegia)

A study on validation of a Unani pharmacopoeial formulation *Laoq Falij* and *Roghan e Mom* was conducted in the patients of *Falij* (Hemiplegia) at RRIUM, Chennai and CRU, Bengaluru. The patients received *Laoq Falij* 5gm twice a day and *Roghan e Mom* 10ml/ Q.S. locally applied twice a day for 12 weeks.

During the reporting period, 28 patients were studied, of which 15 completed the study. Out of the completed cases, 04 (26.67%) patients were relieved, 09 (60%) patients were partially relieved and 02 (13.33%) patients were not relieved. A total of 10 cases dropped out of the study and 03 case under study. So far, 31 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Jawarish Zarooni Sada* in *Hasate Kulliya* (Nephrolithiasis)

A study on validation of a Unani pharmacopoeial formulation *Jawarish Zarooni Sada* was conducted in the patients of *Hasate Kulliya* (Nephrolithiasis) at CRIUM, Lucknow. The patients received *Jawarish Zarooni Sada* in the dose of 5 gm twice a day for 56 days.

During the reporting period, 52 patients were studied, of which 32 completed the study. Out of the completed cases, 11 (34.38%) patients were relieved, 15 (46.88%) patients were partially relieved and 06 (18.75%) patients were not relieved. A total of 13 cases dropped out of the study and 07 cases were under study. So far, 60 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Itrifal Aftimoon* in *Malikhuliya* (Mixed Anxiety Depressive Disorder)

A study on validation of a Unani pharmacopoeial formulation *Itrifal Aftimoon* was conducted in the patients of *Malikhuliya* (Mixed Anxiety Depressive Disorder) at CRIUM, Lucknow and CRU, Bhopal. The patients received *Itrifal Aftimoon* in the dose of 05 gm twice a day for 6 weeks

During the reporting period, 93 patients were studied, of which 69 completed the study. Out of the completed cases, 23 (33.33%) patients were relieved, 32 (46.38%) partially relieved and 14 (20.29%) patients were not relieved. A total of 18 cases dropped out of the study and 06 cases under study. So far, 95 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Majoon Baladur* in *Nisyan* (Amnesia)

A study on validation of a Unani pharmacopoeial formulation *Majoon Baladur* was conducted in the patients of *Nisyan* (Amnesia) at RRIUM, Delhi. The patients received *Majoon Baladur* in the dose of 5 gm twice a day for 12 weeks.

During the reporting period, 89 patients were studied, of which 61 completed the study. Out of the completed cases, 41 (67.21%) patients were relieved, 14 (22.95%) partially relieved 06 (9.84%) patients were not relieved . A total of 18 cases dropped out of the study and 10 cases under study. So far, 67 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Habbe Kibreeth Sagheer* in *Quba* (Dermatophytosis)

A study on validation of a Unani pharmacopoeial formulation *Habbe Kibreeth Sagheer* was conducted in the patients of *Quba* (Dermatophytosis) at NRIUMSD, Hyderabad. The patients received *Habbe Kibreeth Sagheer* in the dose of 1 pill (250mg each) twice a day for 35 days.

During the reporting period, 140 patients were studied, of which 55 completed the study. Out of the completed cases, 21 (38.18%) patients were relieved, 32 (58.18%) partially relieved and 02 (3.64%) were not relieved. A total of 58 cases dropped out of the study and 27 cases under study. So far, 73 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Roghan kaddu shireen* in *Sahar* (Insomnia)

A study on validation of a Unani pharmacopoeial formulation *Roghan kaddu shireen* was conducted in the patients of *Sahar* (Insomnia) at RRIUM, Patna and CRU, Kerala. The patients received *Roghan kaddu shireen* in the dose of 2 ml at night a day for 14 days.

During the reporting period, 70 patients were studied, of which 43 completed the study. Out of the completed cases, 25 (58.14%) patients were relieved, 17 (39.53%) partially relieved and 01 (2.33%) patients were not relieved. A total of 26 cases dropped out of the study and 01 cases under study. So far, 95 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Habb-e-Pachlona* in *Sue Hazm* (Functional dyspepsia)

A study on validation of a Unani pharmacopoeial formulation *Habbe-e- Pachlona* was conducted in the patients of *Sue Hazm* (Functional dyspepsia) at RRIUM, Aligarh and CRU, Burhanpur. The patients received *Habbe Pachlona* in the dose of 1 pill (500mg each) twice a day for 14 days.

During the reporting period, 95 patients were studied, of which 90 completed the study. Out of the completed cases, 20 (22.22%) patients were relieved, 59 (65.56%) partially relieved and 11 (12.22%) patients were not relieved. A total of 05 cases dropped out of the study and none cases under study. So far, 140 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeal formulation *Habb e Mafasil* and *Zamad-e-Muhallil* in *Wajaul Mafasil* (Rheumatoid arthritis)

A study on validation of a Unani pharmacopoeial formulation *Habb e Mafasil* and *Zamad e Muhallil* was conducted in the patients of *Wajaul Mafasil* (Rheumatoid arthritis) at RRIUM, Bhadrak. The patients received *Habb e Mafasil* and 2 pills (800mg) thrice in a day *Zamad-e-Muhallil* (10gm/ Q.S.) locally applied once in a day for 12 weeks.

During the reporting period, 14 patients were studied, of which 5 completed the study. Out of the completed cases, 05 (100.00%) patients were partially relieved. A total of 09 cases dropped out of the study. So far, 12 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Habb-e-Khunaq* in *Waram e Hanjara* (Laryngitis)

A study on validation of a Unani pharmacopoeial formulation *Habb-e-Khunaq* was conducted in the patients of *Waram-e-Hanjara* (Laryngitis) at RRIUM, Aligarh and CRU, Meerut. The patients received *Habb e Khunaq* in the dose of 3 pills (1gm each) chewed thrice a day for 14 days.

During the reporting period, 66 patients were studied, of which 56 completed the study. Out of the completed cases, 28 (50.00%) patients were relieved, 23 (41.07%) partially relieved and 05 (8.93%) patients were not relieved. A total of 07 cases dropped out of the study and 03 cases were under study. So far, 142 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Laoq Zeequn Nafas Balghami* in *Zeequn Nafas* (Bronchial asthma)

A study on validation of a Unani pharmacopoeial formulation *Laoq Zeequn Nafas Balghami* was conducted in the patients of *Zeequn Nafas* (Bronchial asthma) at RRIUM, Mumbai and RRC, Allahabad. The patients received *Laoq Zeequn Nafas Balghami* in the dose in the dose of 05 gm twice a day for 28 days.

During the reporting period, 56 patients were studied, of which 51 completed the study. Out of the completed cases, none (0%) patients were relieved, 51 (100.00%) partially relieved and none (0%) patients were not relieved. A total of 05 cases dropped out of the study. So far, 59 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Majoon Lana* in *Zofe Asab* (Neurasthenia)

A study on validation of a Unani pharmacopoeial formulation *Majoon Lana* was conducted in the patients of *Zofe Asab* (Neurasthenia) at RRIUM, New Delhi. The patients received *Majoon Lana* in the dose of 05 gm twice a day for 6 weeks.

During the reporting period, 81 patients were studied, of which 31 completed the study. Out of the completed cases, 27 (87.10%) patients were relieved, 03 (9.68%) partially relieved and 01 (3.23%) patients were not relieved. A total of 20 cases dropped out of the study and 30 cases under the study. So far, 42 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of *Habb-e-Aab-e-Gandana* and *Marham-e-Bawaseer* in *Bawaseer Amya* (Non-Bleeding piles)

A study on validation of a Unani pharmacopoeial formulation *Habb-e-Aab-e-Gandana* and *Marham-e-Bawaseer* in the patients of *Bawaseer Amya* (Non-Bleeding piles) was carried out at NRIUMSD, Hyderabad, and RRC, Allahabad. The patients received *Habb-e-Aab-e-Gandana* 2 pills (500mg) twice daily and *Marham-e-Bawaseer* locally applied 1g/QS twice daily for 6 weeks.

During the reporting period, 80 patients were studied, of which 60 completed the study. Out of the completed cases, 47 (78.33%) patients were relieved, 13 (21.67%) partially relieved. A total of 05 cases dropped out of the study and 15 cases under the study. So far, 60 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Majun Musaffi-e-Azam* in *Busoor* (Skin eruptions)

A study on validation of a Unani pharmacopoeial formulation *Majun Musaffi-e-Azam* in the patients of *Busoor* (Skin eruptions) was carried out at RRIUM, Srinagar and CRU, Bengaluru and Burhanpur. The patients received *Majun Musaffi-e-Azam* 7 gm twice daily for 4 weeks.

During the reporting period, 24 patients were studied, of which 14 completed the study. Out of the completed cases, 10 (71.43%) patients were relieved, 14 (28.57%) patients were partially relieved. A total 10 cases were under study. So far, 14 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of *Habb-e-Kotwali* and *Marham Khal-e-Khumri* in *Da-us-Salab* (Diffuse Alopecia)

A study on validation of a Unani pharmacopoeial formulation *Habb-e-Kotwali* and *Marham Khal-e-Khumri* in the patients of *Da-us-Salab* (Alopecia) was carried out at RRIUM, Chennai and Srinagar and CRU, Bengaluru. The patients received *Habb-e-Kotwali* 1 pill (250 mg) twice daily and *Marham Khal-e-Khumri* QS locally applied twice daily for 12 weeks. During the reporting period, none of the patients was studied.

Clinical Validation of Unani pharmacopoeial formulation *Laoq-e-Anjeer Qawi* and *Roghan-e-Haft Barg* in *Falij* (Hemiplegia)

A study on validation of a Unani pharmacopoeial formulation *Laoq-e-Anjeer Qawi* and *Roghan-e-Haft Barg* in the patients of *Falij* (Hemiplegia) was carried out at NRIUMSD, Hyderabad and CRU, Bengaluru. The patients received *Laoq-e-Anjeer*

Qawi 5 gm twice daily & *Roghan-e-Haft Barg* 10 ml/QS locally applied twice daily for 8 weeks.

During the reporting period, 19 patients were studied, of which 03 completed the study. Out of the completed cases, 02 (66.67%) patients were relieved, 01 (33.33%) partially relieved. A total of 04 cases were dropped out of the study and 12 cases were under the study. So far, 03 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of *Mufarrah Sheikh ur Rais* in *Khafqan* (Palpitation)

A study on validation of a Unani pharmacopoeial formulation *Mufarrah Sheikh ur Rais* in the patients of *Khafqan* (Palpitation) was carried out at CRU, Meerut. The patients received *Mufarrah Sheikh ur Rais* 5 gm daily for 4 weeks.

During the reporting period, 40 patients were studied, of which 34 completed the study. Out of the completed cases, 21 (61.76%) patients were relieved, 12 (35.29%) partially relieved and 01 (2.94%) patients were not relieved. A total of 04 cases were dropped out of the study and 02 cases were under the study. So far, 34 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of *Itrifal Zamani* and *Roghan Kahu* in *Malikhuliya* (Mixed Anxiety Depressive Disorder)

A study on validation of a Unani pharmacopoeial formulation *Itrifal Zamani* and *Roghan Kahu* in the patients of *Malikhuliya* (Mixed Anxiety Depressive Disorder) was carried out at RRIUM Bhadrak and Srinagar. The patients received *Itrifal Zamani* 5 gm twice daily and *Roghan Kahu* 10 ml/QS locally applied at bed time daily for 6 weeks.

During the reporting period, 51 patients were studied, of which 14 completed the study. Out of the completed cases, 14 (100.00%) patients were relieved, none (0%) partially relieved. A total of 04 cases dropped out of the study and 33 cases were under the study. So far, 14 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Safoof Makhana* in *Sailan ur Reham* (Leucorrhoea)

A study on validation of a Unani pharmacopoeial formulation *Safoof Makhana* in the patients of *Sailan ur Reham* (Leucorrhoea) was carried out at CRIUM, Lucknow. The patients received *Safoof Makhana* 6 gm daily for 4 weeks.

During the reporting period, 68 patients were studied, of which 48 completed the study. Out of the completed cases, 17 (35.42%) patients were relieved, 23 (47.92%)

partially relieved and 08 (16.67%) patients were not relieved. A total of 10 cases dropped out of the study and 10 cases were under the study. So far, 48 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Habb-e-Mujarrib* in *Shaqeeqa* (Migraine)

A study on validation of a Unani pharmacopoeial formulation *Habb-e-Mujarrib* in the patients of *Shaqeeqa* (Migraine) was carried out at RRIUM, Aligarh and CRU, Kurnool. The patients received *Habb-e-Mujarrib* 1 pill (1 gm each) twice daily for 12 weeks.

During the reporting period, 20 patients were studied, of which 09 completed the study. Out of the completed cases, 04 (44.44%) patients were relieved, 05 (55.56%) partially relieved. None cases dropped out of the study and 11 cases were under the study. So far, 09 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Laoq-e-Unsul* in *Sual-e-Muzmin* (Chronic cough)

A study on validation of a Unani pharmacopoeial formulation *Laoq-e-Unsul* in the patients of *Sual-e-Muzmin* (Chronic cough) was carried out at NRIUMSD, Hyderabad and RRIUMs, Aligarh, and Kolkata. The patients received *Laoq-e-Unsul* 05 gm twice daily for 4 weeks.

During the reporting period, 10 patients were studied, of which 07 completed the study. Out of the completed cases, 16 (85.71%) patients were relieved, none (0%) partially relieved and 01 (14.29%) patient was not relieved. A total of 03 cases dropped out of the study and none of the cases were under the study. So far, 07 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of *Habb-e-Khardal* in *Waram-e-Halaq* (Pharyngitis)

A study on validation of a Unani pharmacopoeial formulation *Habb-e-Khardal* in the patients of *Waram-e-Halaq* (Pharyngitis) was carried out at RRIUM New Delhi and CRU, Kerala. The patients received *Habb-e-Khardal* 2 pills (250 mg each) twice daily for 2 weeks.

During the reporting period, 44 patients were studied, of which 40 completed the study. Out of the completed cases, 39 (97.50%) patients were relieved, 1 (2.50%) partially relieved. A total of 04 cases dropped out of the study and none of the cases

under the study. So far, 40 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of *Qurs-e-Sumbul-ut-Teeb* in *Warm-e-Kabid Barid* (Non Alcoholic Fatty Liver Disease-NASH)

A study on validation of a Unani pharmacopoeial formulation *Qurs-e-Sumbul-ut-Teeb* in the patients of *Warm-e-Kabid* (Steatohepatitis) was carried out at CRIUM, Lucknow and RRIUM, Mumbai. The patients received *Qurs-e-Sumbul-ut-Teeb* 2 tablet (1 gm each) twice daily for 12 weeks.

During the reporting period, 74 patients were studied, of which 35 completed the study. Out of the completed cases, 09 (25.71%) patients were relieved, 26 (74.29%) patients were partially relieved. A total of 08 cases were dropped out of the study and 31 cases were under the study. So far, 35 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Majun Azaraqi* in *Zof-e-Aasab* (Neurasthenia)

A study on validation of a Unani pharmacopoeial formulation *Majun Azaraqi* in the patients of *Zof-e Aasab* (Neurasthenia) was carried out at RRIUM, Chennai. The patients received *Majun Azaraqi* 3 gm twice daily for 4 weeks.

During the reporting period, 68 patients were studied, of which 37 completed the study. Out of the completed cases, 16 (43.24%) patients were relieved, 16 (43.24%) partially relieved and 05 (13.51%) patients were not relieved. A total of 19 cases were dropped out of the study and 12 cases were under the study. So far, 37 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical Validation of Unani pharmacopoeial formulation *Jawarish-e-Muqawwi-e-Meda* in *Zof-e-Meda* (Functional Dyspepsia)

A study on validation of a Unani pharmacopoeial formulation *Jawarish-e-Muqawwi-e-Meda* in the patients of *Zof-e-Meda* (Functional Dyspepsia) was carried out at RRIUM, Patna and CRU, Burhanpur. The patients received *Jawarish-e-Muqawwi-e-Meda* 5 gm twice daily for 4 weeks.

During the reporting period, 24 patients were studied, of which 20 completed the study. Out of the completed cases, 11 (55.00%) patients were relieved, 08 (40.00%) patients were partially relieved and 01 (5.00%) patients were not relieved. None of the cases were dropped out of the study and 4 cases were under the study. So far, 20 cases have been completed in the study. The test drug was found well-tolerated and no adverse effect was observed.

New Studies initiated

The following studies under validation of Unani pharmacopoeial formulations were initiated during the reporting period:

- Clinical validation of *Roghan Nafa-i-Waram-i-Niqris* and *Majoon-i-Yahyabin Khalid* in *Niqris* (gout)
- Clinical validation of *Marham Gulabi* in *Jild Quroh* (Cutaneous Ulcer)
- Clinical Validation of *Safoof Hazim Kalan* in *Zofe Ishteha* (Anorexia)
- Clinical Validation of *Habb-e-Sadrin Zeeq un Nafas* (Bronchial Asthma)
- Clinical Validation of *Jawarish-e-Ood Mulaiyin* in *Zof e Ishteha* (Anorexia)
- Clinical Validation of *Habbe musaffi-e-khoon* and *Marham Kafoor* in *Qarha Asir-al-Indimal* (Non-Healing ulcers)
- Clinical Validation of *Itrifal-e-Khabs-ul Hadeed* and *Habbe Mudir* in *Ihtibas e Tams* (Amenorrhoea)
- Clinical Validation of *Majoon-e-Rashidi* in *Taqteer-ul-Baul* (Post Micturition Dribble -PMD)
- Clinical validation of *Qurs-e-Tabasheer Mulaiyin* in *Khushunat-e-Halq* (Dryness of Throat)
- Clinical validation of *Kushta-e-Sadaf* in *Sailan-ur-Reham* (Leucorrhoea)
- Clinical validation of *Jawarish-e-Javed* in *Zof-e-Meda* (Functional dyspepsia)
- Clinical validation of *Sharbat-e-AnarShireen* in *Ghasiyan* (Nausea)
- Clinical validation of *Habb-e-Kibreeth* in *Su-e-Hazm* (Dyspepsia)
- Clinical validation of *Habb-e-Anjeer* in *Bawaseer* (Hemorrhoids)
- Clinical validation of *Habb-e-Filfil* in *Zeequn-Nafas* (Bronchial asthma)
- Clinical validation of *Qurs e Gulnar* in *Ishal-e-Muzmin*
- Clinical validation of *Habb-e-Leemun* in *Niqris* (Gout)
- Clinical validation of *Lauq Nazli* in *Nazla-e-Har* (Common Cold)
- Clinical validation of *Habb-e-Suzak Haad* in *Hurqat-e-Baul* (Burning micturition)

New Studies allotted for RCT/Pharmacopoeial Validation

In addition to the above, the following studies under validation of Unani pharmacopoeial drugs were allotted during the reporting period:

- Clinical validation of *Habb-e-Shibyar* in *Suda* (Headache)
- Clinical validation of *Habb-e-Raal* in *Qurooh-e-Meda* (peptic Ulcer)
- Clinical validation of *Qurs Kaknaj* in *Hurqat e Baul* (Burning Micturition)
- Clinical validation of *Itrifal Sagheer* in *Nisyan* (Amnesia)

- Clinical validation of *Jawarish Utraj* in *Zofe-ul-Meda* (Functional Dyspepsia)
- Clinical validation of *Khamira Gaozaban Sada* in *Malikhuliya* (Mixed Anxiety Depressive Disorder)
- Clinical validation of *Laooq-e-Abhal* in *Zeeq-un-Nafas* (Bronchial Asthma)
- Clinical validation of *Laooq-e-khayar Shambar* in *Sual* (Cough)
- Clinical validation of *Majoon-e-Chob chini* and *Roghan-e-Surkh* in *Waja-ul-Mafasil* (Rheumatoid Arthritis)
- Clinical validation of *Majun-e-Dabeedul ward* in *So ul qiniya* (Anaemia)
- Clinical validation of *Majoon-e-Jograaj Goggul* in *Bawaseer Damiya* (Bleeding Piles)
- Clinical validation of *Majoon-e-Muqawwi e Reham* in *Kasrat-e-tams* (Heavy Menstrual Bleeding)
- Clinical validation of *Majoon-e-Talkh deedani* in *Ehtebas-e-Tams* (Amenorrhoea)
- Clinical validation of *Sufoof-e-chobchini* in *Irqun Nisa* (Sciatica)
- Clinical validation of *Sufoof-e-kishneez* in *Khafaqan* (Palpitation)
- Clinical validation of *Sufoof-e-Tabkheer* in *Nafakh e shikam* (Hyperacidity)
- Clinical validation of *Halwa-e-Khasta-e-Tamarhindi* in *Waja ul qutn* (Low Backache)
- Clinical validation of *Halwa-e-Khasta-e-Tamarhindi* in *Waja ul qutn* (Low Backache)
- Clinical validation of *Halwa-e-Malkangani* in *Zof-e-Asab* (Neurasthenia)
- Clinical validation of *Halwa-e-Badam* in *Zof-e-Dimagh* (Cerebroasthenia)

Validation of Regimenal Therapies

Besides pharmaco therapy, Unani Medicine offers *Ilajbil-Tadbeer* (Regimen Therapy), such as *Hijama* (Cupping), *Taleeq al-Alaq* (Leeching), *Dalk* (Massage), *Hammam Yabis* (Sauna), *Hammam al-Bukhar* (Steam bath) etc. for certain disease conditions. During the reporting period, various regimen therapy procedures were performed in a total of 44,024 patients with different diseases. These patients showed significant therapeutic effects in subsiding the signs and symptoms of the diseases.

Hijama bila-Shart (Dry cupping) was performed on 4,888 patients with different diseases including *Tahajjur-e-Mafassil* (osteoarthritis), *Irqal-Nasa* (sciatica), *Tahajjur Mafassilal-Unuq* (cervical spondylosis), *Tahajjur Mafassil al-Zahr* (lumbar spondylosis), *Katif Mujammad* (frozen shoulder), *Waja al-Zahr* (backache), *Waja al-Katif* (shoulder pain), *Wajaal-Unuq* (neckpain), *Wajaal-Rukba* (kneepain), *Wajaal-Aqib* (achillodynia), *Dawali* (varicose veins), *Kasrat-ul-Tams* (menorrhagia),

Usral-Tams (dysmenorrhoea), *Suda* (headache), *Sala* (baldness), *Huzn* (depression), etc. at NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUMs, Chennai, Bhadrak, Patna, Mumbai, Srinagar, New Delhi and Silchar; Co-Location Centre, AIIA, New Delhi, Safdarjung Hospital, New Delhi, Ram Manohar Lohia Hospital, New Delhi and CRU, Goa.

Hijama bil-Shart (Wetcupping) was performed on 3,104 patients with different diseases including *Nar Farsi* (eczema), *Busur Labaniyya* (acne vulgaris), *Da al-Salab* (alopecia), *Bawasir* (haemorrhoid), *Zaghtal-Dam Qawi* (hypertension), *Uqr* (infertility), *Waja-ul-Mafasil* (rheumatoid arthritis), *Tahajjur-e-Mafassil* (osteoarthritis), *Irqal-Nasa* (sciatica) and other musculo-skeletal disorder satat NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUMs, Chennai, Bhadrak, Patna, Srinagar, Mumbai, New Delhi and Silchar; Co-Location Centre, AIIA, New Delhi; CRU, Goa and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hijama bil-Nar (Fire cupping) was performed on 1,150 patients with different diseases including *Waja-ul-Mafasil* (rheumatoid arthritis), *Tahajjural-Mafasil* (osteoarthritis), *Irqal-Nasa* (sciatica), *Wajaal-Zahr* (backache), *Katif Mujammad* (frozen shoulder), *Wajaal-Katif* (shoulder pain) and *Wajaal-Rukba* (kneepain) at CRIUM, Lucknow; RRIUMs, Chennai & Srinagar; CRU, Goa and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hijama Muzliqa (Moving cupping) was performed on 6,830 patients with different diseases including *Waja al-Zahr* (backache) and *Katif Mujammad* (frozen shoulder) at CRIUM, Lucknow; RRIUMs, Srinagar, Chennai, New Delhi; Co-Location Centre, AIIA, New Delhi and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hammam al-Bukhar (Steam bath) was performed on 1,986 patients with diseases including *Wajaal-Katif* (shoulder pain), *Quba* (dermatophytosis) and *Siman Mufrit* (obesity) at CRIUM, Lucknow; RRIUM, Chennai, Srinagar and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Dalk Mutadil (moderate massage) was performed on 1,609 patients with different diseases including *Waja-ul-Mafasil* (rheumatoid arthritis), *Tahajjur-e-Mafassil* (osteoarthritis), *Tahajjur Mafasil al-Unuq* (cervical spondylosis), *Katif Mujammad* (frozen shoulder), *Wajaal-Zahr* (backache), *Waja al-Katif* (shoulder pain) and *Waja al-Aqib* (achillodynia) at CRIUM, Lucknow, RRIUMs, Chennai, Bhadrak, Patna, New Delhi, Silchar; CRU, Goa and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi

Hammam Yabis (Sauna) was performed on 21 patients with different diseases including *Waja al-Katif* (shoulder pain), *Tahajjur-e-Mafassil* (osteoarthritis), *Siman Mufrit* (obesity) at RRIUM's, Chennai and New Delhi.

Natool (Irrigation) was performed on 329 patient of *Waja-ul-Mafasil* (rheumatoid arthritis) at RRIUM's Srinagar and Chennai.

Inkibāb (vaporisation) was performed in 4,328 patients of *Waja-ul-Mafasil* (rheumatoid arthritis) and *Wajaal-Katif* (shoulder pain) at RRIUMs, Chennai and Srinagar.

Mundij-Mushil therapy was performed in 70 patients of *Baras* (vitiligo) at RRIUMs, Chennai and New Delhi.

Taleeq (leeching) was performed in 213 patients of *Dawali* (varicose veins) and *Takhaththural-Dam* (deep vein thrombosis) at RRIUMs, Chennai, Bhadrak, Patna Mumbai, Srinagar and Silchar.

Takmid (fomentation) was performed in 1,628 patients of *Waja-ul-Mafasil* (rheumatoid arthritis), *Tahajjur-e-Mafassil* (osteoarthritis), *Siman Mufrit* (obesity) and *Katif Mujammad* (frozen shoulder) at CRIUM, Lucknow; and RRIUMs, Chennai, and Srinagar.

Fasad (Venesection) was performed on 23 patients of *Humma-e-Aajaamia* (Malaria) and Splenic disorders, *Bawaser-e-Damvi* (haemorrhoid), *Jarb-o-Hikka* (Scabies and Pruritus), *Khuraj* (boils), *Iltehab-e-Kabid* (Hepatitis) at RRIUMs, Chennai, Patna and Srinagar.

Others *Aml-e-Kai* (Cauterization), Cleaning & Dressing, and Mechanical Massage Chair) was performed in 2,058 patients at RRIUM's Chennai Srinagar, New Delhi, Silchar and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Validation of Fundamentals

Theory of *Akhlat wa Mizaj* (humours and temperament)

The CCRUM has been conducting studies to validate the fundamentals of Unani Medicine at NRIUMSD, Hyderabad. The objective is to scientifically examine the concepts of *Akhlat* (humours) and *Mizaj* (temperament) and their relevance to health and disease states. This project at NRIUMSD, Hyderabad, aims to explore the Clinical, Genetic, Physiological, Pathological, and Biochemical parameters of participants across various temperaments, conduct clinical assessments of *Mizaj* (temperament) in different diseases, and establish scientific correlations among different factors.

Genetic Studies on the Theory of Humours

Genetic studies on humours, with a focus on conditions such as Diabetes Mellitus, Essential Hypertension, Vitiligo, Gastritis, and Psoriasis, were conducted, with healthy volunteers serving as a control group. Pharmacogenomics studies of Unani formulations in Vitiligo, Liver metabolism genes and Temperament susceptibility genes were also completed and technical reports have been published and released during the Unani day 2025.

During the 2024–2025 period, 235 healthy volunteers and 194 patients were enrolled. A total of 2,634 healthy volunteers have been enrolled so far. This project consists of an observational study to analyze dominant temperament according to *Ajnās 'Ashara*, followed by genetic, biochemical, physiological, pathological, and pulse wave analysis studies in healthy volunteers and patients.

Ongoing studies

A total number of 12 studies involving the following components continued during the reporting period:

- Determination of dominant temperament by *Ajnās Ashara*
- Determination of dominant temperament by special CRF on assessment of temperament
- Genetic marker studies in relation to temperament of each subject
- Study of Biochemical, Physiological and Pathological parameters and Pulse Wave Analysis in relation to temperament of each subject

Study-wise summary of the progress made during the reporting period is as under:

Project I: mi RNA 146a and Th1/17 Cells in Vitiligo Pathogenesis:

- 39 healthy volunteers (13 Damawi, 26 Balghami) and 44 vitiligo patients (21 Damawi and 23 Balghami) were enrolled during the reporting period. A Total of 55 Vitiligo patients and 80 healthy participants were enrolled since inception of the project.
- In 30 patients and 30 control samples, cDNA conversions were done.
- ELISA standardization was completed and CXCL-10, IL-17A, CCL20 and FOXP3 Serum Biomarkers analysis by ELISA was done in 50 patients, 30 follow-ups and 50 control samples.
- IL-17A and β -Actin standardization is completed. Expression studies are under process.
- CCR6, miRNA 146a and U6 snRNA primers standardization is under process.

Project II: In-vitro anti-psoriatic activity of UNIM formulation by multi-parametric analysis:

- Photochemical analysis, antioxidant assay and Cell proliferation assay of different extracts UNIM 401 was completed
- ELISA was performed for IL22 and IL-17 in RAW cell lines on three different extracts: aqueous, methanol, and hydro ethanol extracts.

- 33 healthy individuals and 22 patients were enrolled, among them 4 cases were completed. A Total of 22 psoriasis patients and 50 healthy participants were enrolled since inception of the project.
- ELISA IL-22, IL-17, IL-6, and TNF- α were performed in serum samples of 30 healthy controls and 15 patients.

Project III: Effect of Unani formulation on diabetes mellitus in in-vitro and clinical studies:

- Antioxidant assay, cell cytotoxicity assay, DNA fragmentation assay, Wound Healing assay, Glucose consumption assay was estimated by treating with different extract of UNIM-221 formulation.
- cDNA conversion and Real time PCR experiments were performed for different extracts of drug treated Hep G2 cell line with Hexokinase and PEPCK genes.
- 55 Diabetic patients were screened, 39 patients were enrolled, 19 clinical trial cases were completed and 16 Controls of Damawi temperament were registered during year 2024-2025. A Total of 34 Diabetic patients and 52 healthy participants were enrolled so far in the project.
- RNA was extracted from 51 patient blood Samples which includes 36 Baseline, 15 end of follow-ups along with 20 healthy controls of Damawi temperament.
- cDNA conversion and Real time-PCR was performed on 05 completed clinical cases (05 Baseline & 05 end of follow-up) and 05 Healthy controls with Hexokinase gene.

Project IV: Gene expression analysis in type-2 diabetes pathogenesis:

- 15 patients were enrolled for the study out of 32 screened and 02 patient's study was completed. 20 *Damawi* temperament healthy participants' samples were collected and preserved in -20° for further analysis during year 2024-25. A Total of 15 diabetic patients and 52 healthy participants were enrolled since inception of the project.
- RNA was isolated from previously preserved 10 patient samples and 25 control samples.
- IL-6, TNF- α IL-1 β and Fetuin-A ELISA were standardized and carried out for 30 control samples and 12 patient samples.
- IL-1 β , IL-6 and TNF- α primers standardization is under process.

Project V: Gene expression and polymorphism in rheumatoid arthritis:

- 63 Rheumatoid arthritis patients were screened, 52 patients were enrolled, 13 patients were completed & 31 healthy controls of *Safrawi* temperament were registered.

- RNA was extracted from the blood samples collected from 55 patients which includes 43 at Baseline, 12 at the end of follow-ups along with 30 from healthy controls of Safrawi temperament.
- DNA was isolated from 55 patient's samples which includes 45 baselines, 10 at the end of follow-ups along with 30 healthy controls.
- cDNA conversion and RT PCR were performed with β -actin, IL-1 β , TNF- α and miR-146a for 10 completed cases (10 Baseline & 10 end of follow-up) and 10 healthy controls.
- Serum IL-1 β , TNF- α , IL-6 and MMP-1 concentrations were quantified by standard ELISA kits for 10 completed cases (10 Baseline & 10 end of follow -up) and 16 healthy controls.
- Analysis of Disease activity score (DAS-28) was calculated for 12 completed cases.

Project VI: Leptin gene expression in psoriasis:

- 21 patients and 33 healthy controls were enrolled; among them, 4 cases were completed.
- RNA was extracted for 20 blood samples (10 healthy controls and 10 patient samples).
- cDNA conversion was performed on the blood samples of the 05 healthy individuals and 5 patients.
- Primers were standardized for the Leptin Gene.
- ELISA has been performed for the Leptin gene in 30 healthy controls and 15 patient samples.

Project VII: Vitamin D enzymatic markers in Psoriasis: 20 healthy controls were enrolled in the study.

Project VIII: Cytokines expression in Bronchial Asthma: 17 healthy controls were enrolled in the study.

Project IX: GSTP1 gene expression Gastritis: 01 patient and 26 healthy participants were enrolled in the study.

Project X-XII: The study was initiated with a focus on molecular markers related to Vitiligo, Rheumatoid Arthritis and Diabetes.

Clinical Assessment of Mizaj (Temperament)

During the reporting period, temperament assessment of 300 patients attending the Research OPD of NRIUMSD, Hyderabad was done. The temperaments assessed were *Damawi*, *Balghami*, *Safrawi* and *Sawdawi*. These included patients of *Zeeq-un-*

Nafas (bronchial asthma), *Quba* (dermatophytosis), *Kasrat-ul-Bawl* (overactive bladder), *Su-ul-Qinya* (anaemia), *Tahajjur-e-Mafasil* (osteoarthritis) and *Bawasir Amya* (Non-bleeding piles).

Out of 75 patients of *Zeeq-un-Nafas* (bronchial asthma), 19 were *Damawi*, 46 *Balghami* and 10 were *Safrawi*. In *Quba* (dermatophytosis), 130 patients were registered with 93 patients were classified as *Damawi*, 10 as *Safrawi* 20 as *Balghami* and 07 as *Sawdawi*. In *Kasrat-ul-Bawl* (overactive bladder), 22 cases were registered, with 16 identified as *Balghami*, 04 as *Damawi*, and 02 as *Safrawi*. In *Su-ul-Qinya* (anaemia), 25 patients were registered, of which 11 were *Balghami*, 12 were *Safrawi*, and 02 were *Damawi*. In *Tahajjur-e-Mafassil* (osteoarthritis), 32 patients were registered, of whom 13 were *Balghami*, 15 *Safrawi* and 04 were *Sawdawi*. In *Bawasir Amya* (Non-bleeding piles), 16 patents were registered, of which 10 patients *Damawi*, 04 *Balghami*, and 02 *Safrawi*.

In these patients, susceptibility for acquiring diseases in relation to different temperaments was also studied. An interim analysis of data revealed that individuals of *Balghami* temperament were more susceptible to conditions such as *Kasrat-ul-Bawl* (overactive bladder) and *Zeeq-un-Nafas* (bronchial asthma). Similarly, individuals of *Damawi* temperament showed a higher susceptibility to *Quba* (dermatophytosis) and *Bawasir Amya* (Non bleeding piles). Individuals of *Safrawi* temperament showed a higher susceptibility to *Su-ul-Qinya* (anaemia) and *Tahajjur-e-Mafassil* (osteoarthritis). This suggests a potential correlation between specific temperaments and the likelihood of developing certain health conditions.

Research-oriented Healthcare

General Outpatient Department (GOPD) Programme

The CCRUM undertakes GOPD Programme which also includes Geriatric OPD and RCH / MCH OPD. It is aimed at promoting, protecting, and preserving public health through Unani Medicine. Besides, OPDs for Post-trial Treatment Access (PTA) is also conducted in order to provide treatment facility to the research patients after completing the trial.

During the reporting period, this programme continued at National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad; Central Research Institute of Unani Medicine (CRIUM), Lucknow; Regional Research Institutes of Unani Medicine (RRIUMs), Chennai, Bhadrak, Patna, Aligarh, Mumbai, Srinagar, Kolkata, New Delhi and Silchar; Regional Research Centre (RRC), Prayagraj; Clinical Research Units (CRUs), Bengaluru, Bhopal, Burhanpur, Meerut, Kurnool, Edathala, Goa and Imphal; Hakim Ajmal Khan Institute for Literary and Historical Research in Unani Medicine, New Delhi; AYUSH Wellness Centre, President's Estate, New Delhi; and Co-location centres at RML Hospital, Deen Dayal Upadhyay Hospital, Safdarjung Hospital, All India Institute of Ayurveda, New Delhi, JJ Hospital

Mumbai. A total of 9,91,450 beneficiaries comprising 6,19,006, in GOPDs, 1,29,120 in Geriatric OPDs, 28,852 in RCH / MCH OPDs, 1,49,585 in NCD's OPDs and 64,887 in OPDs for Post-trial Treatment Access (PTA) were treated at different centres. These beneficiaries were also assessed for their temperaments and various other factors responsible for occurrence of the disease, thus generating data for research feedback and Unani treatment was prescribed accordingly. They were treated with Unani pharmacopoeial formulations.

In-patient Department (IPD) Programme

The CCRUM also has IPD facilities at its select research institutes. During the reporting period, IPD programme continued at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUM, Chennai, Bhadrak, Patna, Srinagar and New Delhi. A total of 14,500 beneficiaries were treated with Unani pharmacopoeial formulations at these facilities.

Mobile Clinical Research Programme

The Mobile Clinical Research Programme is aimed at providing healthcare to the population residing in rural areas, urban slums, scheduled caste and scheduled tribe pockets, besides reducing the disease burden in the society by creating health awareness among them. Under this programme, rural areas, urban slums, and pockets predominantly inhabited by Scheduled Caste (SC) / Scheduled Tribe (ST) population with limited medical facilities are covered. The Council's researchers visit the adopted pockets at regular intervals and provide free Unani treatment to the patients at their door steps, and thus serve as a potential source of healthcare delivery to the masses. Patients are also referred to CCRUM institutes / units and other hospitals for treatment of specific diseases or clinical research. Besides, health awareness is created among the population under coverage particularly women and senior citizens through health lectures and group meetings on the preventive, promotive and curative health aspects based on the principles of Unani Medicine. They are also made aware of the therapeutic uses of medicinal plants growing in their vicinity in the management of different common / seasonal ailments.

During the reporting period, this programme continued at NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUMs, Chennai, Bhadrak, Patna, Mumbai, Aligarh and Srinagar; RRC, Prayagraj. During the reporting period, 32 rural pockets / urban slums covering over 7.96 lakh population were covered. A total of 37,138 patients were treated in 435 mobile visits made to these pockets. Predominant diseases as observed were rheumatoid arthritis, cough, fever, skin infections, joint pain, constipation, headache, dysentery, leucorrhoea, piles, etc.

3.1.2.4 Literary Research

The Council's Literary Research Programme was continued at Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine (HAKILHRUM), New Delhi. Under the programme, the Council published an Urdu translation of the Arabic book *Man La Yahzuruhu al-Tabib* (The Book for One Who is not attended by a Physician) written by the famous medieval physician Muhammad b. Zakariyya Razi (d. 926 AD). This book contains 37 chapters. The Council also published the Urdu translation of the Persian book *Kitab al-AbniyaanHaqaiq al-Adwiya* (Book of Fundamentals on True Nature of Drugs) which was authored by *Muwaffaq al-Din Abu Mansir Ali al-Harawi*, an Iranian physician of the 4th century AH and has been regarded as the oldest available medical book in the Persian language. Besides being the oldest Persian medical book, it is the first Unani materia medica authored originally in the Persian language, providing an insight into materia medica prevailing in that region, and is a milestone in the history of Unani materia medica of the Persian era.

The Council has also published Hindi translation of the fourth edition of 'A Handbook of Common Remedies in Unani Medicine' with the titles *Unani Chikitsa mein Saadhaaran Upchaar ki Pustika*.

The Council also compiled Standard Treatment Guidelines on Management of Common Musculoskeletal Disorders in Unani system of medicine that was published by Ayush Vertical, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. The document covers descriptions of osteoarthritis, rheumatoid arthritis, cervical spondylosis, lumbar spondylosis, fibromyalgia, and adhesive capsulitis.

The Council has developed Standard Unani Treatment Guidelines for 125 diseases for the Insurance Regulatory Development Authority, Ministry of Finance, Government of India, for bringing Ayush treatments under health insurance cover.

Continuing the momentum of developing SOPs on different procedures of *Ilaj bil Tadbir*, the Council has initiated work on SOPs on *Taleeq al-Alaq*, *Dalk*, *Natul*, *Bakhur*, *Munzij-Mushil*, and *Inkibab* with the involvement of research officers of the HAKILHRUM.

During the reporting period, CCRUM's quarterly peer-reviewed English journal, Hippocratic Journal of Unani Medicine, has gone online and was published by Wolters Kluwer India Pvt Ltd (Med Know). The work on revision and updating of NUMC Version 1.0 continued, and numerous new codes were developed for adding them in NAMASTE Portal and AHMIS. Besides, retrieval and compilation of NUMC data from NAMATE-P was also carried out.

3.2. Studies under IMR Policy

To utilize full potentials of the researchers working in the different centres and to conduct studies based on region-specific needs, the CCRUM has an Intramural Research (IMR) Policy. The policy aims to conduct studies in a time-bound manner. During the reporting period, the following studies under the IMR policy were conducted:

A Clinical Study to evaluate the efficacy of the *Munzij*, *Mushil* therapy along with Coded Unani Drugs UNIM-318 & UNIM-319 and dry fomentation in patients of Primary *Tahajjur-e-mafasil* (Osteo Arthritis Grade I & II)

Evaluation of the efficacy of the *Munzij*, *Mushil* therapy along with Coded Unani Drugs UNIM-318 and UNIM-319 and dry fomentation in patients of Primary *Tahajjur-e-mafasil* (Osteo Arthritis Grade I & II) a was carried out at CRIUM Lucknow.

During the reporting period, a total of 07 patients were screened and all were dropout.

To study the effect of coded Unani formulations (UNIM-004-oral and UNIM-005-Topical) on certain biomarkers in vitiligo patients

A study to evaluate the effect of coded Unani formulations (UNIM-004-oral and UNIM-005-Topical) on certain biomarkers in vitiligo patients was carried out at NRIUMSD, Hyderabad. The study patients received 2 tabs UNIM-004 (500 mg) twice daily, and UNIM-005 locally applied one time on every alternate day for 8 months.

During the reporting period, 14 new patients were enrolled, and 10 old patients were continued from the previous year. 09 patients completed the study, 07 patients dropped out and 08 patients were under follow-up. 16 samples from healthy participants were collected. The study drug was found well tolerated, and no adverse effect was reported in patients.

To evaluate the effect of UNIM-301 on selected inflammatory molecules associated with *Waja-ul-mafasil* (Rheumatoid arthritis) pathogenesis

Evaluation of the efficacy of UNIM-301 on selected inflammatory molecules associated with *Waja-ul-mafasil* (Rheumatoid arthritis) pathogenesis was carried out at RRIUM Srinagar. The study patients received 2 capsules of UNIM-301 (500 mg each) thrice daily for 6 weeks.

During the reporting period, 32 patients were enrolled in the study. Out of them, 20 patients completed the study. There were 12 cases were under study. A total number of 20 cases have completed the study so far. The study drug was found well tolerated and no adverse effect was reported in patients.

Clinical evaluation of efficacy of *Hijamah Bila Shart* (Dry Cupping) in *Waja al Rakba* (Knee Osteoarthritis) and its relation to frequency of *Hijamah Bila Shart* (Dry Cupping) for formation of SOPs

A study to evaluate the efficacy of *Hijamah Bila Shart* (Dry Cupping) in *Waja al Rakba* (Knee Osteoarthritis) and its relation to frequency of *Hijamah Bila Shart* (Dry Cupping) for formation of SOPs was carried out at RRIUM, New Delhi.

During the reporting period, a total of 57 patients were screened, out of which 53 patients were enrolled in the study. 48 patients completed the study. There were 05 dropouts. So far sample size of 48 cases has been achieved in the study.

Shelf-life study on five commonly used Unani Paharmacopoeial formulations

The study was initiated at RRIUM, Chennai, on 06.11.2023 to determine the real-time stability of five commonly used Unani formulations, i.e., *Habb-e-Suranjan*, *Habb-e-Hilteet*, *Habb-e-Bawaseer Damiya*, *Qurs Zibetus Khas*, and *Zarur-e-Qula*.

During the reporting period, Organoleptic studies to determine Appearance, Colour, Taste & Odour, Solubility, TLC/HPTLC profile, Hardness; Friability; Disintegration and Moisture content were studied for Hab / Qurs were carried out.

In case of Powder formulations, Organoleptic parameters like Appearance, Colour, Taste & Odour; pH (5%); Solubility in alcohol & water; TLC/HPTLC profile; Assay (i.e., label claim ingredients); Moisture Content; Particle size; Sieve size; Volatile oil content were studied. The quality control parameters like microbial load, heavy metal analysis, and estimations of aflatoxin and pesticide residues was analysed by standard procedure (AOAC, 2005) were also determined.

Microbiological studies e.g. Detection of Total bacterial count, Total fungal content, Specific pathogens like Enterobacteriaceae, Escherichia coli, Salmonella species, Staphylococcus aureus & Pseudomonas aeruginosa were also carried out. The estimation of aflatoxin (B1, B2, G1 & G2) was carried out using Vicam Aflatest Fluorometer (WHO, 2018). The Heavy metal analysis (Lead, Cadmium, Arsenic & Mercury) was carried out by Atomic Absorption Spectroscopy (WHO, 1998; AOAC, 2005). Pesticide residues (Organochlorine & organophosphorus) were analysed using GC-MS Agilent instrument as per the method of AOAC (2005).

A randomized controlled clinical trial of the effectiveness of Asbi and Pregabalin in *Zof al-Asab* (Peripheral Neuropathy)

A study to evaluate the effect of *Asbi* and Pregabalin in *Zof al-Asab* (Peripheral Neuropathy) was carried out at RRIUM, Chennai. The test group received tab *Asbi* (500 mg) twice daily, and the control group received tab Pregabalin (150 mg) twice daily for 45 days.

During the reporting period, a total of 36 patients were screened, 30 patients enrolled in the study. Out of them, 05 patients completed the study. There were 03 dropouts

and 22 cases are under study at present. So far sample size of 5 cases has been achieved in the study.

Development of Unani treatment protocol comprising oral medication (*Itrifal Mushil*) and regimental procedures (*Natul* (Irrigation) and *Dalak* (Massage) by Roghan banafsha in *Shaqiq* (Migraine without aura) (NUMC: A-2): An open-label single-arm clinical trial.

A study to evaluate the effect of oral medication (*Itrifal Mushil*) and regimental procedures *Natul* (Irrigation) and *Dalak* (Massage) by Roghan banafsha in *Shaqiq* (Migraine without aura) was carried out at RRIUM, Chennai. The patients received regimental procedures including *Natul* (Irrigation) therapy once in a day for 14 days, *Roghan banafsha* locally applied once in a day for 28 days, and *Itrifal Mushil* (10 g) twice daily orally for 28 days.

During the reporting period, a total of 70 patients were screened, 50 patients were enrolled. 26 patients completed the study, 17 patients were dropped out, 07 patients were under follow up. So far sample size of 26 cases has been achieved in the study. The study drug was found well tolerated and no adverse effect was reported in patients.

A Phased Study on the Development, Characterization and Therapeutic Potential of Unani Elixir (*Ma al-Shair*): Evidence-Based Nutraceutical

The initial phase, focusing on development of flavored electrolyte enriched Unani Elixir (*Ma al-Shair*) has been completed and the developed *Ma al-Shair* (Barley water) fortified with electrolytes was launched on Unani Day 2025.

Modernizing Talbeena: Development of Barley-Based Functional Foods

This project, supported by the Central Council for Research in Unani Medicine (CCRUM), aimed to develop innovative, ready-to-consume barley-based foods derived from *Talbeena*, a traditional Unani preparation known for its digestive, cardiovascular, and neurological health benefits. Given the time-intensive preparation of traditional *Talbeena*, this study sought to modernize it into four convenient formats—Elaichi Barley Flakes, Chocolate Barley Flakes, Barley Cookies and Instant Barley Dalia. Each product was formulated with a blend of barley flour, sattu, and functional ingredients such as jaggery, cocoa, spices, or vegetables to enhance nutritional value and consumer appeal. The formulations underwent thorough physico-chemical, microbiological, sensory, and shelf-life evaluations under various storage conditions. Nutritional analysis highlighted their high dietary fibre content, low fat, minimal added sugars, and absence of trans fats and cholesterol, making them suitable for heart and digestive health. Microbiological results confirmed product safety, with all parameters within permissible limits.

Among the four products, refrigerated storage was found most effective for maintaining sensory and nutritional quality over a 28-day period. The study successfully bridges traditional Unani principles with contemporary food technology, offering consumer-friendly, health-oriented food solutions that align with modern dietary preferences. These products hold significant commercial potential in the functional foods segment and exemplify how ancient wisdom can be transformed into evidence-based, market-ready innovations.

The following IMR projects have also been initiated at the various institutes of the Council:

1. Effect of UNIM 401 and UNIM 402 on PASI, Serum Uric Acid and C-reactive protein with reference to metabolic syndrome and its components.
2. Clinical evaluation of *Hijama bil Shurt* (Wet Cupping) and *Majoon Ushba* in the management of persistent non-specific *Wajaul Zahar* (Low Back Pain)".
3. A single blind pilot study to evaluate the efficacy and safety of coded Unani formulations UNIM-001 + UNIM-003 with NB UVB therapy in cases of *Baras* (Vitiligo).
4. Establishing shelf life of commonly used Unani formulations (*Arq Mako*, *Majoon Chobchini*, *Marham Raal*, *Sharbat Unnab*, *Roghan Suranjan*).
5. Exploring the molecular mechanism underlying the therapeutic potency of UNIM-301 against rheumatoid arthritis.
6. Open label pilot study to evaluate the effect of Topical Unani formulation in the management of Cervical Low-Grade Squamous Intraepithelial Lesion (LSIL).
7. Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to compare the Efficacy of *Qurs-e-Asfar* (O) and *Marham-e-Dad* (L) with Itraconazole (O) and *Terbinafine* (L) in the Management of *Quba* (Dermatophytosis) along with Gene expression and Biomarkers Analysis.
8. Quality control evaluation, phytochemical profiling and in-vitro anti-inflammatory activity of compound Unani formulation- *Habb-e-Gul-e-Aak*
9. Effect of two polyherbal Unani formulations used for *Waja-ul-Mafasil* (Rheumatoid Arthritis) on serum biomarkers, inflammasomes activation, pyroptosis and endothelial dysfunction - A clinical and in-vitro study to understand their mechanism of action.
10. Macro-microscopy and chromatography studies: important tools for identification of adulterants in market samples of Unani drugs.
11. Assessment of Neurological Soft Signs and Efficacy of Unani Regime to alleviate the burden of neurological soft signs in ADHD: A Non-randomized open label clinical trial.

12. Efficacy of *Habb-e-Chobchini* (Oral administration) and *Zimad Muhallil* (topical application) in *Niqris* (Gout) (NUMC: L-7; ICD: M10): A randomised single blind double dummy placebo controlled comparative clinical trial.
13. A Randomized, controlled, parallel-group study to compare efficacy and safety of a Compound Unani formulation with Metformin in patients with *ZiyabitusHarr* (Diabetes mellitus-Type-II (G-2))
14. Establishment of germplasm of some rare and threatened high altitude medicinal plants of Kashmir Himalayas under temperate climatic conditions of Srinagar.
15. A Hybrid Dose-Escalation Randomized Controlled Trial Comparing Unani Drugs and Standard Treatment for Glycaemic Control in Type 2 Diabetes Mellitus (ICD-E11/NUMC-G2).
16. Evaluating the Efficacy and Safety of the Oral Polyherbal Drug UNIM-301 as an Add-On Therapy to Standard Care in Rheumatoid Arthritis: A Randomized Controlled Trial
17. A Single-Arm, Open-Label, Interventional Pilot Study to investigate the Efficacy and Modulatory Impact of *Hijama bil Shart* (Wet Cupping Therapy) on Biomarkers in *Waja-ul-Mafasil* (Knee Osteoarthritis).

3.3 Collaborative Research

Under the collaborative research scheme, several interdisciplinary studies were undertaken in reputed scientific institutions to validate and explore the therapeutic potential of Unani formulations using modern scientific tools and techniques. These studies focused on critical health areas such as liver disorders, cancer, cardiovascular health, neurological diseases, dermatological infections and metabolic diseases. These are described as follows:

Comparison of clinical efficacy and safety of Unani therapy in the form of systemic UNIM-004 and topical UNIM-005 and conventional allopathic therapy in the form of PUVASOL and topical Mometasone cream in the treatment of clinically stable vitiligo.

A randomized, parallel-group, active-controlled, outcome-assessor-blinded clinical trial jointly at AIIMS, New Delhi and NRIUMSD, Hyderabad to compare the clinical efficacy and safety of Unani therapy, a combination of oral UNIM-004 and topical UNIM-005 with conventional allopathic treatment comprising PUVA sol (oral 8-methoxypsoralen followed by sun exposure) and topical mometasone/tacrolimus in the management of clinically stable vitiligo. The primary objectives were to assess the reduction in Vitiligo Area Scoring Index (VASI), improvement in quality of life using VIS-22 and DLQI scales and the rapidity of clinical response between the two treatment arms over 36 weeks. Results showed that Unani therapy achieved comparable efficacy to PUVA sol therapy in terms of VASI score reduction and quality of life improvement with both groups demonstrating significant clinical benefit.

Reverse Pharmacology of Asrin and Dawa UI Shifa to evaluate their anti-hypertensive efficacy, safety and mechanism of Action.

A study conducted at Division of Pharmacology, CSIR- Central Drug Research Institute, Lucknow on reverse Pharmacology of Asrin and Dawa UI Shifa to evaluate their antihypertensive efficacy, safety and mechanism of action. Over a 60-day oral administration period, both Asrin and Dawa UI Shifa at doses of 100 and 200 mg/kg body weight significantly reduced systolic and diastolic blood pressure and mean arterial pressure in SHR. These effects were comparable to standard antihypertensive drugs like Telmisartan and Reserpine. The formulations also showed beneficial effects on left ventricular hypertrophy (LVH), improved cardiac function and reduced structural damage, as confirmed by 2D echocardiography and histological analysis. Additionally, both formulations exhibited anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-1 β , IL-6, TNF- α) and increasing IL-10 levels in heart tissues.

Phytochemical standardization and evaluation of anti-cancer and immunomodulatory activity of Unani formulation, *Itrifal ghudadi*

A study conducted at Cell and translational Research Division, Interactive Research School for Health Affairs (IRSHA), Bharati Vidya Peeth University, Pune on the phytochemical standardization and evaluation of anticancer and immunomodulatory activity. Phytochemical standardization of the aqueous extracts of individual ingredients and the whole formulation of *Itrifal Ghudadi* using LC-MS analysis revealed the presence of compounds with various pharmacologically significant properties including antioxidant, anti-inflammatory, anti-diabetic and anticancer activities. The extract of Majoon IG showed a higher content of sugar derivatives and a lower concentration of bioactive compounds compared to the aqueous extract (IGaq). Majoon IG did not exhibit any effect on cell viability whereas IGAq significantly reduced cell viability in cervical, breast and oral cancer cell lines without affecting the viability of normal oral keratinocyte cells.

Elucidating the therapeutic potential of Unani formulation in Glaucoma

A study conducted at Department of Ocular Biochemistry, All India Institute of Medical Sciences, New Delhi on elucidating the therapeutic potential of an Unani formulation in glaucoma. This study investigated the therapeutic efficacy of a Unani formulation composed of *Mameeran*, *Zanjabeel*, *Filfil*, *Dar Filfil* and *Badyan* in the treatment of glaucoma with a focus on its antioxidant and neuroprotective effects on trabecular meshwork (TM) and retinal ganglion cells (RGCs), the two anatomical sites most affected in glaucoma. The Unani formulation exhibited significant antioxidant activity confirmed through SOD, GPx, and LPO assays. It also mitigated oxidative stress by reducing intracellular ROS levels and stabilized mitochondrial membrane

potential in both TM and RGCs under oxidative stress conditions. Gene expression analysis by real-time PCR showed that the formulation significantly upregulated neuroprotective markers Thy1, Brn3b, BDNF and downregulated the pro-apoptotic gene Caspase-3. These findings were further validated by Western blot analysis, affirming the formulation molecular impact on preserving neuronal integrity.

Evaluation of Aftimoon (*Cuscuta Reflexa* Roxb.) Plant and its Seeds on Different Human Cancer (Sartan) Cell Lines

A study in progress at Department of Chemistry, Jamia Millia Islamia, New Delhi on Aftimoon (*Cuscuta Reflexa* Roxb.) Plant and its Seeds on Different Human Cancer (Sartan) Cell Lines. The study demonstrated that all tested plant extracts obtained using various solvents exhibited significant DNA-binding ability and induced structural damage to DNA suggesting potential anticancer effects through inhibition of cancer cell proliferation. Among the extracts, those derived from the stem showed stronger DNA interactions compared to seed extracts. The plant extracts displayed concentration-dependent cytotoxicity against both lung (H1299) and breast (MCF) cancer cell lines with higher efficacy observed in breast cancer models. Ethyl acetate and acetone extracts showed remarkable anticancer activity and strong antioxidant properties with no associated toxicity.

Effect of Unani preparations on macrophage polarization and its role in Increased Browning of fat leading to amelioration of insulin resistance

A study in progress at Department of Biochemistry, Jamia Hamdard, New Delhi on effect of Unani preparations on macrophage polarization and its role in increased browning of fat leading to amelioration of insulin resistance. The study demonstrates the therapeutic potential of Unani formulations Araq-e-Mako (AEM), Araq-e-Kasni (AEK) and Luk Magshool (LM) in alleviating obesity-induced insulin resistance and chronic inflammation. In a high-fat diet (HFD) mouse model, oral administration of these Araqs significantly improved metabolic parameters including body weight, fat pad mass, adiposity index, blood glucose, insulin, triglycerides and cholesterol levels. The findings confirmed the role of AEM, AEK, and LM in skewing macrophage polarization from the M1 (pro-inflammatory) to M2 (anti-inflammatory) state, thereby enhancing insulin sensitivity and contributing to improved immune and metabolic balance. These results support the potential application of these Unani remedies in managing obesity-related metabolic disorders through immunomodulation and fat browning.

Identification of Anti-dengue Viral Compounds from Unani Medicinal Plants and formulations

A study in progress at Institute of Molecular Medicine, School of Interdisciplinary Sciences, Jamia Hamdard, New Delhi. The study aims to scientifically validate the anti-dengue potential of Unani medicinal plants and formulations addressing the lack of licensed treatments for dengue. Aqueous, methanolic, and hydro-methanolic extracts were prepared as per Unani Pharmacopoeia and cytotoxicity was assessed via MTT assay. Extracts with IC₅₀ values ranging from 300–1448 µg/ml were tested for antiviral activity at 2, 20, and 200 µg/ml. Remarkably, aqueous extracts of Asl-us-soos, Balchar, Habb-e-Bukhar, and Habb-e-Tap-e-Balgami showed >90% DENV inhibition, confirmed via RT-PCR and plaque assay.

Pharmacokinetics, stability and quality control studies on Itrifal's of the Unani Pharmacopoeia of India (Part 2 Vol.1 & Vol.2) using Chromatographic Analysis by HPTLC and LC-MS

A study in progress at Department of Pharmacognosy & Phytochemistry, Jamia Hamdard, New Delhi on pharmacokinetics, stability and quality control studies on Itrifal's of Unani Pharmacopoeia of India (Part 2 Vol.1 & Vol.2) using Chromatographic analysis by HPTLC and LC-MS. This comprehensive study on nine traditional Unani formulations of Itrifal provides robust scientific validation for their traditional use through modern analytical, pharmacokinetic and network pharmacology approaches. All formulations were prepared as per NFUM and UPI standards and authenticated through powder microscopy while HPTLC, UPLC-MS and LC-MS/MS analyses confirmed the presence of major bioactive constituents, particularly polyphenols. Stability studies showed that the formulations remained organoleptically stable over time and pharmacokinetic evaluations in Wistar rats revealed the ADME profile and bioavailability of active metabolites. Furthermore network pharmacology analysis revealed potential therapeutic targets supporting their multifaceted action in disease management.

In vitro Evaluation of Antiviral activity of Unani Drugs and their Green Nano-particles against Dengue Virus.

A study in progress at Centre for Interdisciplinary Research in Basic Sciences Jamia Millia Islamia, New Delhi on in-vitro evaluation of antiviral activity of Unani Drugs and their Green Nano-particles against Dengue Virus. The present study demonstrates the promising antiviral potential of selected Unani formulations against Dengue virus (DENV) in *in-vitro* cell culture models. Treatment of DENV-infected Vero cells with Sharbat Anjbar, Habb-e-Papita, and Khamira Marwareed resulted in a significant reduction in cytopathic effects (CPE), with Sharbat Anjbar showing the highest inhibitory activity at CC₅₀ of 2 µl/mL. These findings were further supported by in silico

docking and biophysical interaction studies which revealed a strong binding affinity of the test drugs with the NS3 protein of DENV suggesting a potential mechanism of antiviral action.

Preclinical evaluation of UNIM-401 and UNIM-403 against experimentally induced psoriasis and UNIM-004 and UNIM-005 for their efficacy against experimentally induced vitiligo in mice

The ongoing preclinical study at NIPER, Hyderabad provides compelling evidence for the therapeutic potential of Unani formulations UNIM-401, UNIM-402, and UNIM-403 in psoriasis and UNIM-004, UNIM-005 in vitiligo. In murine models, these formulations demonstrated significant efficacy in reducing disease severity evident from improvements in PASI and VASI scores, histopathological restoration, reduction of inflammatory cytokines (TNF- α , IL-17A, IL-6) and normalization of oxidative stress markers (MDA, GSH). The topical Carbopol-based gels and anionic emulsifying creams were found to be physicochemically stable, well-tolerated and effective in both models. These findings validate the anti-inflammatory and immunomodulatory potential of these Unani formulations. Furthermore, ongoing mechanistic investigations involving key biomarkers like Loricrin, Involucrin, Keratin 17, pSTAT3, NF- κ B, Tyrosinase, MITF, TRP-1, and TRP-2 are expected to provide deeper insights into the molecular mechanisms underlying their therapeutic actions.

Targeting Alzheimer's disease by a mixture of Unani plant extract via modulation of human kinase

A study in progress at Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi on targeting Alzheimer's disease by a mixture of Unani plants (*Bacopa monnieri*, *Terminalia chebula*, *Withania somnifera* and *Boswellia serrata*) extracts via modulation of human kinase, focusing on MARK-4 and PDK-3. The extracts were validated through enzyme inhibition assays and cytotoxicity tests (MTT assay) to ensure efficacy and safety. Findings indicate potent kinase inhibition and minimal toxicity forming the basis for mechanistic studies and in vivo validation in an Alzheimer's disease rat model.

Drug proving studies, mechanistic insight and development of novel drug delivery systems of UNIM-H and UNIM-R used in the treatment of Arthritis in the Unani system of Medicine

An ongoing study at the Department of Life Sciences, University of Mumbai focuses on the development of novel drug delivery systems for UNIM-H and UNIM-R, Unani formulations used in the treatment of arthritis. In the Carrageenan-Induced Rat Paw Edema model, higher doses of the test substances demonstrated greater anti-inflammatory activity compared to both lower doses and the standard drug,

Indomethacin. In the sub-acute oral toxicity study, no histopathological abnormalities were observed, indicating a favourable safety profile. However in the chronic toxicity study (male rats) mild signs of hepatocyte degeneration and increased sinusoidal space were noted, suggesting potential liver toxicity though not severe. In contrast, the chronic toxicity study (female rats) did not exhibit any significant histopathological changes.

Pharmacological studies on the probable mechanism of action of *Khamira Gaozaban Sada* (KGS) in the management of Hypertension, involving Quality Control and formulation optimization studies for this age old Unani preparation.

A study at the Department of Pharmaceutical Technology, Jadavpur University, Kolkata, focuses on the management of cardiovascular diseases using *Khamira Gozaban Sada* (KGS). Among the tested formulations, KGS has shown the most promising results in antihypertensive models. Preclinical evaluations employing advanced in vivo and in vitro techniques have validated its traditional Unani use. Furthermore, sodium alginate-loaded, chitosan-coated KGS beads have been developed and pharmaceutically characterized. Quality control studies, including metabolite profiling and phytomarker quantification were conducted using LC-qTOF and LC-MS/MS techniques.

Investigating and validation of the molecular mechanism of Unani medicines in vitro and in vivo for the treatment of Atopic Dermatitis.

A study currently underway at the Faculty of Life Sciences and Technology, South Asian University, New Delhi aim to investigate the therapeutic potential of Unani medicinal plants *Barg-e-Shahtra*, *Babchi*, *Badaam Sheerin*, *Tukhme Khurfa*, and *Halela Siyah* in the treatment of Atopic Dermatitis. Based on preliminary screening, *Barg-e-Shahtra* and *Halela Siyah* were shortlisted for detailed mechanistic studies. The research highlights the anti-inflammatory properties of these herbs primarily through inhibition of the MAPK/JAK/STAT signaling pathways. Initial experimental results support their traditional Unani use in managing skin inflammation.

Evaluation of Anti-oxidant and Anticancer Effect of Unani medicine against the Liver cancer.

A study in progress at School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi on evaluation of antioxidant and anticancer effects of Unani medicine against hepatocellular carcinoma (HCC). Eighteen traditionally used herbs were selected based on classical Unani texts and scientific literature and categorized into three groups: anticancer (*Sarṭān*), hepatoprotective (*Muqawwi-i-Jigar*) and antioxidant-rich plants. Aqueous extracts of these herbs were prepared, standardized through phytochemical analysis and evaluated using in-vitro (HepG2

cell line) and in-vivo (DEN+TAA-induced HCC rat model) methods. The in-vitro cytotoxicity assessment revealed that *Nigella sativa*, *Cuscuta reflexa*, and *Chicorium intybus* exhibited promising inhibitory effects on cancer cell proliferation with IC_{50} values comparable to the standard drug Sorafenib.

Evaluation of anti tubercular and immune-modulatory activities of Unani Pharmacopoeial formulations (UPF) *Qurs Tabasheer Sartani* and *Arq e Hara Bhara* through in vitro and in vivo studies.

A study in progress at ICMR- National Institute for Research in Tuberculosis on anti-tubercular, safety and immunomodulatory activities of Unani pharmacopoeial formulations (UPF) *Qurs-e-Tabasheer Sartani* and *Arq-e-Hara Bhara* through in-vitro and in-vivo studies. The in-vitro analysis using the Broth Microdilution Method demonstrated that AHB exhibited promising anti-mycobacterial activity against both standard (*Mtb*-H37Rv) and multi-drug resistant (MDR) strains of *Mycobacterium tuberculosis* with minimum inhibitory concentrations (MICs) ranging between 5 to 10 mg/ml. In contrast, QTS showed no inhibition up to 10 mg/ml. Further assays revealed that AHB when combined with first-line anti-TB drugs such as Rifampicin and Isoniazid produced synergistic effects with fractional inhibitory concentration (FIC) values of 0.25 and 0.05 respectively. These results highlight the potential of AHB as an adjunct therapy alongside standard TB treatment without showing any antagonistic interactions. In the in-vivo phase, guinea pigs were infected with *Mtb* and divided into nine groups each receiving different treatments including various doses of the UPFs alone and in combination with standard anti-TB drugs (ATT). The animals were monitored for pharmacokinetics, clinical biochemistry, hematological parameters and bacterial load through colony-forming unit (CFU) counts. Preliminary data confirmed the successful establishment of infection and the tolerability of the formulations at all tested doses.

Pharmacological activities and pre clinical screening of the promising Unani medicines against hepatic diseases.

A study entitled *Pharmacological Activities and Preclinical Screening of the Promising Unani Medicines Against Hepatic Diseases* has been initiated at the Department of Pharmaceutics, NIPER, Hyderabad focusing on the development of therapeutic interventions for Non-Alcoholic Steatohepatitis (NASH) and its progression to liver cirrhosis. The project aims to formulate and evaluate *Saad Koofi* (*Cyperus rotundus*) and *Mastagi* (*Pistacia lentiscus*) extracts in HFD and CCl_4 -induced NASH models emphasizing cost-effective extraction, isolation and characterization with potential for commercial viability and patient compliance. The expected deliverables include targeted therapeutic strategies against NASH using Unani formulations.

Determination of anti-aging and antioxidant potential of a Unani formulation

A study on anti-aging and antioxidant potential of an Unani formulation (Habb-e-Asgandh) was carried out at Department of Geriatrics, All India Institute of Medical Sciences, New Delhi Habb-e-Asgandh composed of authenticated ingredients like Asgand (*Withania somnifera*), Ajwain Desi (*Trachyspermum ammi*), Zanjabeel (*Zingiber officinale*), Peepla Mool (*Piper longum*), Bidhara (*Argyrea nervosa*), Peepal Kalan (*Piper longum*), Satawar (*Asparagus racemosus*), Musli Siyah (*Curculigo orchioides*) was extracted using Soxhlet apparatus in distilled water. Enzyme inhibition assays revealed significant anti-aging potential as Habb-e-Asgandh showed 58.5% inhibition of elastase, 67.4% inhibition of collagenase and 63.5% inhibition of hyaluronidase, all key enzymes involved in the degradation of skin structure and aging processes. The formulation enhanced lymphocyte proliferation in a dose-dependent manner with the highest proliferation observed at 100 µg/ml alongside a notable increase in CD45 expression indicating robust T-cell activation. Habb-e-Asgandh significantly reduced intracellular reactive oxygen species and demonstrated strong free radical scavenging activity with IC₅₀ values of 5.7 mg/ml (DPPH) and 2.34 mg/ml (ABTS+). Moreover, it contained a high flavonoid content (430.43 µg QE/g) and phenolic content (189.96 µg GAE/g) affirming its antioxidant richness.

Evaluation of immune modulatory and antioxidant potential of an Unani formulation

The ongoing study at the Department of Ocular Biochemistry (RPC), AIIMS New Delhi, highlights the immunomodulatory and antioxidant potential of the Unani formulation Tiryaq-e-Samaniya. Using in vitro models of humoral and cell-mediated immunity, the aqueous extract was found to stimulate immune cell proliferation, particularly enhancing CD3⁺ and CD8⁺ T cell populations, and increasing intracellular IL-2 and IL-6 expression, key cytokines in T cell function and development. Furthermore, the extract modulated Th1 and Th2 responses by reducing TNF-α, IFN-γ, and IL-4 levels suggesting both anti-inflammatory and immune-regulatory effects. The formulation also exhibited significant antioxidant activity shown by increased SOD and GPX enzyme levels along with stabilization of red blood cell membranes indicating anti-haemolytic properties. These findings collectively support Tiryaq-e-Samaniya traditional use as an antidote and emphasize its therapeutic potential in managing immune-related disorders.

Evaluation of neuro protective potential of Majun Nisyan: A mechanistic study.

A study in progress at Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai on evaluation of neuro-protective potential of Majun Nisyan. This study investigated the neuroprotective and anti-Alzheimer potential of Unani formulation Majoon-e-Nisyan, traditionally prescribed for Zof-e-Dimagh (weakness of the brain) and Zof-e-Hafiza (memory impairment). The

study encompassed standardization, chemical characterization and preclinical efficacy evaluation in two animal models of Alzheimer's disease (AD) i.e aluminum chloride-induced and amyloid-beta ($A\beta$ 1–42)-induced models. Physicochemical characterization, HPTLC profiling and LC-MS/MS analysis validated the presence of key phytoconstituents including ($\alpha+\beta$) boswellic acid, β -asarone, luteolin, 6-gingerol and piperine in the formulation. Behavioral tests such as the Morris water maze and passive avoidance test showed that Majoon-e-Nisyan significantly improved memory performance, reduced escape latency and increased entries in the target quadrant in AD-induced rats. Biochemical assays demonstrated that the formulation restored antioxidant levels (GSH), reduced oxidative stress markers (MDA) and inhibited acetylcholinesterase (AChE) activity, a hallmark of cognitive decline in AD. Furthermore, brain-derived neurotrophic factor (BDNF) expression was enhanced indicating improved neuroplasticity. The study concludes that Majoon-e-Nisyan exerts its beneficial effects in AD through modulation of the GSK-3 β /NF- κ B signaling pathway.

Investigation of hepatoprotective activity of Unani Formulations with emphasis on alleviation of antitubercular drugs induced hepatotoxicity: Elucidation of molecular mechanism

A study conducted at the Department of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard evaluated the hepatoprotective properties of several Unani drugs, including *Artemisia absinthium* (Afsanteen), *Apium graveolens* (Tukhm Karafs), *Valeriana wallichii* (Asaroon), *Prunus amygdalus* (Badam), *Saussurea lappa* (Qust-e-Talkh), *Rosa damascena* (Gul-e-Surkh), *Nardostachys jatamansi* (Sumbul-ul-Teeb), and *Rheum emodi* (Rewand Chini). Results from preliminary experiments demonstrated that these formulations attenuated liver cell damage, reduced inflammatory infiltration and improved hepatic function by inhibiting oxidative stress. These protective effects were attributed to the antioxidant, immunomodulatory and possibly enzyme-regulating properties of their bioactive constituents, including flavonoids, phenolic acids, and sesquiterpene lactones. The findings provide a scientific basis for integrating these formulations as adjunct therapies in TB management to prevent drug-induced liver injury and set the stage for further mechanistic and clinical studies

Redesigning and pharmacological evaluation of some classical Unani formulations with specific reference to immune-modulatory activity, safety profile and stability studies

A study in progress at Dept of Pharmacognosy and Phyto-chemistry, Jamia Hamdard, New Delhi on Unani formulations Dawa-ul Kurkum, Itrifal Ustukhuddus, and Halwa Gheekwar were prepared and standardized following WHO and Ayush protocols. Phytochemical screening and quantification of total phenolic and flavonoid contents

were conducted using advanced techniques. Sugar-free capsule of these formulations were developed and evaluated through pharmacopoeial methods including physicochemical analysis and HPTLC profiling which were compared with classical formulations. Safety and stability studies of sugar free capsules were also completed.

Development of Sugar Free Dosage Forms, Quality Control and Pharmacological Evaluation of Khamira Banafsha, Khamira Aabresham, Laooq-e-Katan, Sharbat Toot Siyah, Laooq Sapistan and Sharbat Zoofa against Covid -19 related disorders

A study in progress at Department of Pharmacognosy & Phyto-chemistry, Jamia Hamdard, New Delhi. The study aimed to evaluate and compare sugar-based and sugar-free Unani formulations for their antioxidant, immunomodulatory, anti-allergic and anti-inflammatory properties. A series of in-vitro screenings and phytochemical analyses were performed revealing that Khamira Abresham (sugar-based) exhibited the highest phenolic content (29.75 mg GAE/g), while Laooq Sapistan (sugar-free) showed the highest flavonoid content (32.93 mg Rutin/g). Importantly, comparative studies indicated no significant difference in biological efficacy between sugar-based and sugar-free variants, confirming their therapeutic equivalence. Among all tested, Khamira Abresham and Laooq-e-Sapistan emerged as the most potent formulations based on antioxidant and immunomodulatory activity.

Chemotherapeutic effect of a selected Unani Medicine in xenograft mouse model of lung cancer

A study carried out at Department of Pharmacology AIIMS, New Delhi. A lung cancer model was successfully standardized in C57BL/6 mice using LLC-1 (Lewis Lung Carcinoma) cells to evaluate the chemotherapeutic potential of the Unani formulation Joshanda-i-Aftimoon as an adjuvant to cisplatin. Subcutaneous injection of 5×10^6 LLC-1 cells led to visible tumor formation in most mice within 7–11 days. Tumor progression was monitored bi-weekly with caliper measurements and the volume increased steadily to over 6200 mm³ by day 21 in some animals accompanied by severe physical symptoms such as reduced mobility, weight loss, fur loss and ulceration. Western blot analysis was performed to assess the expression of apoptotic markers including BAX, BCL2 and Caspase-3 in tumor tissues. Protein extraction and quantification were carried out using homogenization, BCA estimation and electrophoretic transfer onto membranes for detection.

Evaluation of hepatoprotective efficacy and underlying molecular mechanism of CCRUM formulations, in experimental animal models of Anti-tuberculosis drug-induced liver injury (ATDILI): A pre-clinical study

A study is currently in progress at the Department of Molecular & Cellular Medicine, Institute of Liver and Biliary Sciences (ILBS), Vasant Kunj, New Delhi, focusing on the hepatoprotective efficacy and underlying molecular mechanisms of Unani formulations. The Unani formulation Sharbat-e-Deenar was found to be non-toxic at concentrations of 75 µg/mL and 100 µg/mL with an IC₅₀ value of 1600 µg/mL. To establish the anti-tuberculosis drug-induced liver injury (AT-DILI) model, various physiological and molecular parameters were assessed. While no significant changes were noted in anthropometric measurements across groups, a decrease in body weight was observed in the AT-DILI group by the end of the study. Real-time PCR analysis revealed a significant upregulation in the mRNA expression of cell death markers: CD68 (apoptosis), RIPK1 (necrosis) and PGAM5 (necroptosis) in the AT-DILI group. Analysis of drug-metabolizing enzyme expression confirmed that the liver damage was due to anti-tubercular drugs, validating the AT-DILI model. The study concludes that AT-DILI primarily induces oxidative stress as demonstrated by altered levels of GPx, MDA and related oxidative stress markers.

[Assessment on the modulation of Anticancer activity of Standard Cancer Drugs by Nutraceuticals and Unani drug in colorectal cancer](#)

A study in progress at Dept. of Biosciences, Jamia Millia Islamia, New Delhi to evaluate the synergistic effects of the Unani formulation Majoon Sangdana Murgh, along with nutraceutical extracts, in combination with standard chemotherapeutic agents (5-Fluorouracil and Oxaliplatin) against colorectal cancer using HCT116 and SW480 cell lines. The objectives include assessing antioxidant activity, cell viability, and the impact on apoptotic signaling pathways involving key molecular markers such as Bax, Bcl2, Caspase-3, Caspase-9, and p53. Initial milestones have been achieved successfully, including MTT assay-based cell viability testing of standard drugs and procurement and maintenance of cancer cell lines. Phytochemical extraction from *Coriandrum sativum* and *Trachyspermum ammi* using solvents of increasing polarity is in progress. Upcoming phases will focus on evaluating the combination treatments, expression analysis of signaling molecules and in silico docking studies to understand molecular interactions and mechanisms of action.

[Unravelling the cardioprotective mechanism of Khamira Abresham Hakim Arshad Wala using in-silico, in-vitro and in-vivo \(New Zealand Rabbit\) system: A step towards planning a clinical trial with Unani formulation for cardioprotection](#)

A study in progress at Dept. of Cardio-Thoracic & Vascular Surgery, PGIMER, Chandigarh on Preliminary in-vitro findings from MTT assays demonstrated that UNIM CP-1 promoted exponential growth in THP-1, AC16 cardiomyocytes, and PBMCs, with EC50 values comparable to Atorvastatin, indicating its safety and

efficacy. Cardiac biomarkers (myoglobin, Troponin I, BNP, and D-Dimer) remained stable in rabbit models.

Redesigning & Evaluation of Antifungal potential and Mechanism of action of *Marham Hina*, a Unani pharmacopoeial formulation against Resistant *Candida* stains and Dermatophytes

A study entitled *Redesigning & Evaluation of Antifungal Potential and Mechanism of Action of Marham Hina, a Unani Pharmacopoeial Formulation against Resistant Candida Strains and Dermatophytes* is currently in progress at the Department of Biosciences, Jamia Millia Islamia, New Delhi. The research evaluates the antifungal efficacy of Marham Hina and its individual bioactive components Hina essential oil, camphor, menthol and thymol against resistant fungal strains such as *Candida albicans*, *Candida auris*, and *Trichophyton* spp. using standard susceptibility assays (MIC, MFC, disc diffusion). While Marham and camphor alone showed limited activity, a combination of the active constituents (excluding wax and paraffin) exhibited potent synergistic antifungal effects. A redesigned cream formulation using the same actives demonstrated enhanced antifungal efficacy, including inhibition of virulence factors like enzyme secretion, adhesion and biofilm formation.

Preparation of sugar-free *Khamira-e-Gaozaban Sada* (sf KGS) and it's comparison with the Unani drug (KGS) for their immunomodulatory potential against the in vivo model of maniac phase of bipolar disorder (BD)

A study carried out at Amity Institute of Pharmacy, Amity University Noida UP. A sugar-free formulation of *Khamira-e-Gaozaban Sada* (sf-KGS) was successfully developed using authenticated herbal ingredients. The extracts were prepared using optimized maceration, soxhlation, boiling techniques and their yields ranged between 1.6% to 10.6%. Antioxidant activity assessed by DPPH and PFRAP assays revealed that sf-KGS possesses strong radical scavenging and ferric-reducing power comparable to Gallic acid at higher concentrations. The total phenolic content was quantified at 12.87 ± 0.29 mg GAE/g indicating a rich presence of bioactive compounds. Phytochemical analysis confirmed the presence of key constituents such as flavonoids, phenols, terpenoids, and steroids, while alkaloids and saponins were absent. The organoleptic evaluation described the formulation as semi-solid, dark green, slightly sticky with a characteristic odor and bitter taste. The in-vitro MTT assay on SHSY5Y neuroblastoma cells demonstrated that sf-KGS has significant cytotoxic activity with an IC_{50} value of 1.44 ± 0.19 μ g/mL, which is lower (and hence more potent) than the standard drug Lithium carbonate ($IC_{50} = 2.328 \pm 0.29$ μ M).

Effect of Unani Formulations against Mitochondrial Mediated Cellular Mechanisms: A strategy to combat Alzheimer's Disease

A study currently in progress at the Department of Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi focused on the repurposing of traditional Unani formulations for therapeutic application in Alzheimer's disease. The research evaluates the neuroprotective potential of *Bacopa monnieri* (Brahmi) and Majun Falasfa through a combination of in vitro, in vivo, and *Drosophila* model studies. Brahmi demonstrated significant protective effects against scopolamine-induced cytotoxicity, enhancing cell viability and preserving mitochondrial function, as confirmed by MTT assay. In transgenic *Drosophila melanogaster* expressing amyloid-beta peptide, Brahmi restored locomotor function, while in Wistar rats, it significantly improved cognitive performance and anxiety behavior in behavioral tests such as NOR, Barnes Maze, and EPM. Similarly, Majun Falasfa showed efficacy in reducing amyloid-beta-induced cytotoxicity, pro-inflammatory cytokine expression (IL-1 β , IL-6), and motor impairments. Collectively, the findings suggest that both formulations offer neuroprotection via modulation of oxidative stress, mitochondrial health, inflammation, and synaptic function.

Formulation, Development and Preclinical evaluation of novel Unani dispersible tablets for Immunomodulatory activity and as adjuvant to Anticancer therapy

A study is currently underway at the Amity Institute of Pharmacy, Amity University, Noida focusing on the formulation, development and preclinical evaluation of novel Unani dispersible tablets of Habb-e-Shifa for their immunomodulatory activity and potential as adjuvants to anticancer therapy. The project involves standardization of the Habb-e-Shifa pill using HPLC/UV analytical techniques with proposed phytochemical markers including 6-Gingerol, 8-Gingerol, 10-Gingerol, Shogaol, Atropine, Scopolamine, Hyoscyamine and Zingiberene. The extracts alcoholic, hydroalcoholic and aqueous will be compared against these standards to ensure consistency and quality of the formulation. Additionally, the antiviral efficacy of Habb-e-Shifa will be evaluated using Vero-E6 cell lines, known for their high expression of receptors for Corona and Influenza viruses, assessing cellular uptake, toxicity and viral inhibition potential.

Evaluation of Unani formulation Harira for improving mental retardation and exploration of underlying molecular mechanisms using animal model

A study in progress at CSIR Indian Institute of Chemical Technology, Hyderabad on therapeutic potential and safety evaluation of the Unani formulation Harira. Project focusses on development of a validated Prenatal Stress (PNS) mouse model to replicate neurodevelopmental deficits. Comprehensive behavioral and molecular assessments confirmed stress-induced cognitive and affective impairments in both male and female mice. High mortality was observed in PNS mice treated with Harira at 1000 mg/kg, raising significant safety concerns. This led to the initiation and completion of acute and sub-acute toxicity studies in C57BL/6 mice and in vivo

genotoxicity assays in Swiss albino mice. Based on these findings, a revised dose of 200 mg/kg has been selected for the next phase, where the efficacy of Harira will be evaluated in a dose- and duration-dependent manner in juvenile PNS mice.

Development and Evaluation of New Intranasal Nano formulation of Anti-epileptic Unani Medicinal Herbs

A study in progress at Dept. of Pharmaceutics, DPSRU, New Delhi on development and evaluation of new intranasal Nanoformulation of Anti-epileptic Unani Medicinal Herbs. In the study, three Unani herbs i.e Ustukhuddus (*Lavandula stoechas*), Ood Saleeb (*Paeonia emodi*), and Habb-e-Balsan (*Commiphora opobalsamum*) were selected, authenticated and standardized based on WHO guidelines. Detailed pharmacognostic evaluation including morphology, microscopy, swelling index, foaming index, ash values, moisture content and microbial load was conducted. Phytochemical screening confirmed the presence of key bioactive constituents such as flavonoids, glycosides, tannins, phenols and sterols. Multiple extraction techniques were explored including maceration, ultrasonic-assisted extraction (UAE), reflux and Soxhlet extraction. Among these, UAE yielded the highest extractive values 19.5% for LS, 52.4% for PE and 22.8% for CO. Optimization using Design of Experiments (DoE) further improved yield efficiency. Standardization of extracts included pH measurement and TLC profiling, confirming chemical consistency. A triple-extract formulation (1:1:1 ratio) was prepared using LS, PE, and CO followed by preliminary dose titration using the PTZ-induced seizure model in rats. Intranasal administration of the triple extract at 60 mg/kg showed significantly prolonged latency to myoclonic jerks and generalized seizures compared to both oral extract and lower intranasal doses indicating better antiepileptic efficacy. Safety studies were performed following OECD guidelines (425 & 412) through both acute and sub-acute toxicity tests showing no observable toxicity at the tested doses via intranasal or oral routes.

To Perform Shelf Life studies and Animal safety Studies of selected Unani Formulations as per ICH/OECD Guidelines

A comprehensive research study was conducted at Department of Pharmaceutical Sciences, Jamia Hamdard to evaluate the shelf-life and animal safety of selected Unani formulations following ICH and OECD guidelines. The primary objectives were twofold i.e to perform animal safety studies and to conduct accelerated and real-time stability testing of five traditional Unani formulations i.e Majoon Supari Paak, Majoon Suranjan, Majoon Chobchini, Khamira-e-Abresham Saada and Khamira Gaozaban Ambari Jadwar Ood Saleeb Wala. In the first phase, physicochemical analyses such as total ash, acid insoluble ash, water soluble ash, moisture content, pH, alcohol and water-soluble matter, reducing and non-reducing sugar content and TLC profiling were carried out. All formulations met the standards laid down in the Unani Pharmacopoeia of India and parameters remained within acceptable limits across

three tested batches. The formulations were also subjected to stability testing under room temperature, refrigeration, and accelerated stability chamber conditions ($40^{\circ}\text{C} \pm 5^{\circ}\text{C}$, RH $75\% \pm 5\%$) for 3 to 6 months. The observations confirmed that the products remained stable in terms of physical and chemical properties over time.

Pharmacological Evaluation and Comparison of Anti-diabetic Activity of *Novel Unani Formulation (NUF)* with Metformin in Experimental model of Diabetes

A study in progress at Dept. of Pharmacology, DPSRU, New Delhi on development and pharmacological evaluation of a Novel Unani Formulation (NUF) composed of hydro-ethanolic extracts of Jamun, Methi, Karela, and Black Pepper for the management of diabetes and its complications. Key milestones achieved include raw material procurement, authentication and extraction followed by phytochemical screening and LC-MS/MS analysis for secondary metabolite profiling. NUF tablets have been successfully designed and developed.

Preclinical and clinical studies to evaluate the safety and efficacy of topical Unani formulation in Dermatophytosis

A study in progress at Dept. of Amraze Jild wa Zohrawiya, Faculty of Unani Medicine, AMU on Preclinical and Clinical studies to evaluate the safety and efficacy of Unani Topical Formulation for Dermatophytosis. A comprehensive evaluation of a Unani topical formulation for dermatophytosis was conducted including authentication, detoxification, extraction, in vitro and in vivo testing. The formulation was prepared using authenticated ingredients such as Gandhak (Sulphur), Suhaga (Borax), Naushadar (Ammonium chloride), Chuna (Calcium carbonate), Mazu (*Quercus infectoria*), Lehsan (Garlic) and Tukhme Kunjud Aswad (Black Sesame). The formulation exhibited potent antifungal activity with a maximum zone of inhibition observed at 100 mg/ml concentration against all tested fungal strains. Physicochemical standardization of the ointment confirmed desirable properties including pH stability (pH 7.02 for 1% and 8.39 for 10% solutions), uniform consistency, good spreadability, no irritation and thermal stability. The formulation was categorized as a stiff ointment and demonstrated no phase separation after 24 hours. In vivo studies conducted on Sprague Dawley rats infected with dermatophytes revealed that the Unani ointment promoted faster wound healing compared to the standard terbinafine 10% ointment. Clinical scores and mycological findings showed significant recovery within 4–7 days in the Unani-treated group compared to approximately 10 days in the standard drug group and 20 days in the untreated group.

Local application of *Zuroor Asqoolan* for medical management of Oral submucous fibrosis (OSF): A randomized controlled clinical trial

A randomized controlled clinical trial is currently in progress at the Department of Otolaryngology, All India Institute of Medical Sciences (AIIMS), New Delhi evaluating the efficacy and safety of the Unani formulation Zurūn Asqoolan for the medical management of Oral Submucous Fibrosis (OSF). The trial aims to assess the primary efficacy in terms of inter-incisor distance (in mm) after 6 months of local application. Secondary objectives include evaluation of burning sensation, cheek flexibility, mucosal tightness, and the adverse drug reaction (ADR) profile. Additionally, biomarker analysis (including α -SMA, TGF- β 1, IL-1 β , and TNF- α) and collagen density assessments are being conducted to understand the anti-fibrotic potential of the formulation. The study is progressing as per protocol and data collection is ongoing.

Pharmacokinetic and pharmacodynamics studies of Habb e Asgand- a clinically used anti-arthritic Unani formulation

A study in progress at Dept. of Pharmaceutical Sciences, University of Kashmir, Jammu & Kashmir focusing on the pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of the Unani formulation Habbe Asgand, known for its anti-arthritic potential. The objectives include developing a pharmacokinetic profile of Habbe Asgand based on its active markers (Withaferin-A, gingerol, thymol, and piperine), correlating this with pharmacodynamic effects, and exploring its immunomodulatory role in arthritis. Significant progress has been made with the development and quantification of an HPLC method for these active constituents. Additionally, a bioanalytical method has been established to facilitate pharmacokinetic studies. The methanol soluble extractive value of the formulation was recorded at $37.6 \pm 1.01\%$, while the dichloromethane (DCM) fraction yielded $5.1 \pm 0.8\%$ on a dry weight basis.

Exploring the Anti-inflammatory Mechanism of Action of Unani Formulation Tiryag-e-Wabai

A study in progress at Dept. of Biochemistry, Islamiah College, Newtown, Vaniyambadi, Tamil Nadu on exploring the anti-inflammatory mechanism of action of a specific Unani formulation- Tiryag-e-Wabai using both in vivo and in vitro approaches. Lipopolysaccharide (LPS)-induced systemic and lung inflammation models were developed in SD rats to assess the formulation effects. Rats pre-treated with TW showed significant attenuation of LPS-induced pathological changes. Biochemical, hematological, histological and immunohistochemical analyses revealed that TW significantly reduced levels of inflammatory mediators such as TNF- α , IL-1 β , IL-17A, and iNOS in serum. Masson's trichrome staining demonstrated that TW prevented collagen deposition in lung tissues, while toluidine blue staining confirmed its protective role against mast cell infiltration. Immunofluorescence analysis indicated

that TW reduced nuclear translocation of NF- κ B, suggesting a mechanism involving the suppression of this key inflammatory pathway.

Preclinical and Immunotherapeutic assessment of Majoon Najah an Unani Formulation in Cervical Carcinoma

A comprehensive study is currently underway at the Amity Institute of Biotechnology, Amity University, Uttar Pradesh to evaluate the anticancer potential of the Unani formulation Majoon Najah (MN) with a focus on cervical cancer. Extensive phytochemical screening confirmed the presence of bioactive compounds such as alkaloids, flavonoids, tannins, quercetin, rutin, curcumin, and β -eudesmol known for their antioxidant, anti-inflammatory and anticancer properties. GC-MS profiling and TLC revealed potent phytoconstituents with detoxifying and pro-apoptotic effects. MTT assays demonstrated dose-dependent cytotoxicity of the MN ethyl acetate extract against HeLa, SiHa, and C33A cervical cancer cell lines, with the strongest effect observed in C33A cells (IC_{50} : 22.91 μ g/mL). Importantly, the extract showed selective cytotoxicity with low toxicity in normal L929 fibroblast cells, highlighting its safety and specificity. Flow cytometry confirmed significant apoptosis induction, while IL-6 inhibition assays supported its anti-inflammatory and immunomodulatory effects.

Study and validation of the anticancer potential of prominent Unani medicines Arq Makoh and Arq Kasni and their nano formulations against liver carcinoma

A study in progress at D/o Bioengineering, Integral University, Dasauli, Kursi Road, Lucknow focusing on the development and evaluation of nanoformulations of Unani formulations Arq Makoh and Arq Kasni for their anticancer potential against liver carcinoma. The nanoemulsions were successfully formulated using the aqueous titration method, and oil-in-water nanoemulsions were optimized with the aid of a ternary phase diagram to determine the ideal proportions of oil, water, and surfactant mix (Smix). Several nanoemulsion formulations were prepared and subjected to thermostability testing and physicochemical characterization, including droplet size, polydispersity index (PDI), surface potential, and TEM-based morphology. Among them, NE12 emerged as the most promising, displaying the smallest and uniformly distributed nanodroplets with a neutral surface charge, indicating good stability. The NE12 formulation was separately loaded with Arq Makoh and Arq Kasni, and further studies are being conducted to evaluate their cytotoxic and anticancer activities in vitro on liver carcinoma cell lines, both individually and in combination.

A randomised Controlled trial comparing Unani medicine plus standard of care vs Standard of care in reducing exacerbations in COPD patients

A study in progress at Dept. of Pulmonary and sleep medicine, VMMC & Safdarjung Hospital, New Delhi. On The study entitled "To evaluate the toxicological profile of

Safoof Kakrasingi- a preclinical study" at Department of Pharmacology, VMMC & Safdarjung Hospital, New Delhi aims to assess the safety profile of the traditional Unani formulation *Safoof Kakrasingi* through standardized preclinical protocols. The research involves sub-chronic toxicity testing in Wistar rats administered oral doses of 250, 500, and 1000 mg/kg for 90 days. Observations include mortality, body weight, food and water intake, along with hematological, biochemical, and histopathological assessments. Preliminary findings indicate good tolerance at all tested doses. The study conducted in compliance with CCSEA and OECD guidelines will be followed by acute and subacute toxicity phases.

Development of DNA Barcodes for Medicinal Plants used in Unani System of India

A study in progress at Shivaji College, Delhi University, New Delhi on the application of DNA barcoding for the identification and biodiversity assessment of medicinal plant species, with a particular emphasis on Delhi-based flora. DNA barcoding, which uses specific genetic markers to distinguish species, offers a rapid, accurate, and reliable method for species identification by comparing intra- and inter-species genetic variation. As part of the current progress, a herbarium of 16 medicinal plant species has been successfully prepared. DNA was isolated from the leaves of 27 species, and PCR amplification was carried out for various barcode markers. Amplicons were obtained for the rbcL 375 marker in species such as *Justicia adhatoda* L., *Bombax ceiba* L., *Momordica charantia* L., *Curcuma longa* L., *Phyllanthus emblica* L., *Aloe vera* (L.) Burm.f., *Mimosa elengi* L., and *Acacia nilotica* L.; for rbcLaF marker in *Asparagus racemosus* Willd., *Tinospora cordifolia* (Willd.), and *Cuscuta reflexa* Roxb.; and for the ITS marker in *Justicia adhatoda* L., *Tinospora cordifolia* (Willd.), and *Curcuma longa* L..

Evaluation of Unani Polyherbal formulations, acting as Muqawwi Dimagh fo their potential to inhibit Acetylcholinesterase and ameliorate Beta-amyloid toxicity

A study in progress at Dept. of Clinical Biochemistry, School of Biological Sciences, University of Kashmir on cell line studies with human neuroblastoma (Neuro2A) cells demonstrated a concentration-dependent protection of the poly Unani herbal formulations against β - amyloid-induced cytotoxicity, with Majoon-e-Falasifa showing the highest recovery of cell viability. Animal studies using an A β 42-induced Alzheimer's rat model further substantiated the neuroprotective efficacy of Majoon-e-Bolas, which significantly improved memory performance, reduced anxiety-like behavior, and enhanced exploratory activity in behavioural assays including NOR, EPM, and OFT. Parallel in vitro investigations confirmed that all three formulations Majoon-e-Bolas, Majoon-e- Baladur, and Majoon-e-Falasifa exhibit potent inhibitory effects on AChE-induced A β aggregation. This was further supported by biophysical studies including ThT fluorescence, CD spectroscopy, Congo Red, ANS, and Nile Red assays, all of which indicated reduced β -sheet content and fibrillar

hydrophobicity. GC-MS profiling revealed the presence of several bioactive metabolites with antioxidant, neuroprotective, and anti-aggregative properties. Collectively, the findings support a multifaceted mechanism of action for these formulations in modulating key pathways of Alzheimer's pathology.

Evaluation of safety and efficacy of Unani Pharmacopoeial formulations(s) as a therapeutic adjuvant to antiepileptic drugs in drug resistant epilepsy

A study is currently in progress at the Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi focused on the safety assessment, efficacy, and pharmacokinetic evaluation of two Unani Pharmacopoeial formulations Majoon-e-Zabeb and Majoon-e-Najah through a repeated dose (90-day) toxicity study in experimental animals, following OECD guidelines. The formulations are being tested at four dose levels: 310 mg/kg (low), 620 mg/kg (intermediate), 900 mg/kg (high), and 2000 mg/kg (ultra-high) for both Unani drugs. Key parameters such as body weight (monitored weekly) and physical signs and symptoms (monitored daily) are being closely observed.

Design, Development and Evaluation of Novel Immunodulatory RTD (Ready to Dispense) formulations UNIM 2020A and UNIM 2020B

A study in progress at Department of Pharmaceutics, SPER, Jamia Hamdard, New Delhi on two Unani herbs *Ocimum sanctum* and *Cinnamomum zeylanicum* with the aim of developing three consumer-friendly dosage forms: tea bags (UNIM 2020A), effervescent sachets (UNIM 2020B), and edible jelly (UNIM 2020C). Tea bags were evaluated for moisture content, pH, particle size, tensile strength, permeance and brewing parameters. Effervescent powders were optimized for effervescence efficiency, disintegration time and flavor, with the 1:1 ratio of citric acid to sodium bicarbonate and orange-lemon flavor performing best. For edible jelly, comparative analysis of gelatin, agar, and pectin was done, and optimal concentrations were identified based on setting time, pH, and firmness.

Development of chemical profile and identification of bioactive & chemical markers for authentication and elite identification of the selected Unani herbal drugs

A study in progress at School of Chemical and Life Sciences, Jamia Hamdard, New Delhi to evaluate the chemical profiles and therapeutic potential of selected Unani medicinal plants with a particular focus on their antioxidant and anticancer activities. The research involved phytochemical screening, chromatographic fingerprinting and bioactive compound identification in plants such as *Ziziphus jujube* (Unnab), *Cordia dichotoma* (Sapistan), and *Cydonia oblonga* (Behidana). Standardized extraction techniques were followed and advanced analytical tools such as TLC, HPTLC, HPLC, GC-MS and LC-MS were employed to isolate and characterize bioactive constituents

like oleanolic acid, rosmarinic acid, caffeic acid and flavonoids. These analyses provided a chemical basis for quality control and authentication of the herbal drugs. The results demonstrated that each plant possessed a rich diversity of secondary metabolites with notable antioxidant, anti-inflammatory and hepatoprotective properties. *Ziziphus jujube* was particularly rich in triterpenoids and flavonoids showing potential in liver protection and inflammation modulation. *Cordia dichotoma* and *Cydonia oblonga* also showed the presence of polyphenols and phenolic acids, confirmed through both HPTLC and GC-MS profiling.

Evaluation of Unani Drug on FoxP3 expressing regulatory T Cells in the modulation of rheumatoid arthritis

A study is currently in progress at the Central University of South Bihar, Gaya, aimed at evaluating the immunomodulatory effects of traditional Unani formulations Majun Suranjan (MS), Majun Jograj Gugal (MJG), and Majun Chobchini Banuskha Kalan (MCBK) on regulatory T cells (FoxP3⁺) and associated cytokine markers in the context of rheumatoid arthritis (RA). Initial toxicity assessments (MTT assay, trypan blue dye exclusion, and phase-contrast microscopy) were completed on lymphocytes and SW-982 arthritis-specific cell lines, revealing a dose- and time-dependent cytotoxicity, with consistent LC₅₀ values determined for each formulation. The ELISA protocol has been optimized for cytokine analysis, and RT-PCR-based gene expression studies targeting FOXP3 and RORγt are proceeding.

Evaluation of a Unani Polyherbal formulation, acting as a brain tonic, and its constituents for potential Anti-Alzheimer activity.

A study in progress at Neuropharmacology Laboratory, Indian Institute of Integrative Medicine–CSIR, Sanat Nagar Srinagar on proposed formulations (*Delphinium denudatum*, *Viola odorata*, *Crocus sativus*, *Bacopa monnieri*, and *Nardostachys jatamansi*) have been collected, dried, powdered, and subjected to sequential extraction based on polarity of different solvent systems. Furthermore, a suitable in vitro cell line model relevant to Alzheimer's Disease (AD) has been established. Preliminary assessments to evaluate the role of the formulation in AD pathology including cell viability assays, Biochemical analyses such as ROS estimation, TBARS, thiol detection, AChE activity and BDNF quantification are ongoing.

Effects and Molecular mechanisms of Cardioprotective Unani drugs Khamira Abresham on Nitric Oxide (NO) production, uncoupling and reactive oxygen species (ROS)

A multidisciplinary study is currently ongoing at the Department of Biotechnology, Jamia Millia Islamia, New Delhi, aimed at investigating the mechanistic and therapeutic potential of Khamira Abresham in modulating eNOS (endothelial nitric

oxide synthase) function and its relevance to cardiovascular diseases, including atherosclerosis. Cloning and site-directed mutagenesis of eNOS into the pcDNA3.1 vector has been successfully completed, and transfection protocols in HEK and COS-7 cells have been optimized. Preliminary data on NO synthesis and ROS production from wild-type eNOS have been obtained, and experimental work with Khamira Abresham is currently underway. Preclinical animal studies were initiated and Cloning, purification of wild-type and phosphomimetic eNOS in pCWori vector for bacterial expression has been completed. A series of functional assays have been carried out, including NO production, cytochrome c reductase activity, eNOS uncoupling, and ROS generation.

Exploring the therapeutic potential of Majoon Ushba, and Unani Medicine against psoriasis (Dau-S-Sadaf) with reference to IL-17 acytokine signalling

A study in progress at School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu on the ongoing research aims to assess the anti-psoriatic potential of Unani formulations Majoon Ushba and Arq Murakkab Musaffi Khoon using an IMQ-induced psoriasis model in mice. Histopathological evaluations confirmed reductions in skin thickness, acanthosis, and parakeratosis. Immunohistochemical analyses validated the formulations ability to regulate key psoriasis mediators Cyr61, HMGB1 and VEGF along with modulation of the STAT3 signaling pathway. Currently, in-vitro experiments are underway to standardize treatment timelines using epidermal keratinocytes.

Investigate the Therapeutic and Chemo-Sensitizing Efficacy of Unani Pharmacopoeial formulation Dawa-ul-Kurkum on Head and Neck Squamous Cell Carcinoma

A study is currently in progress at the Islamic University of Science & Technology, Avantipora, Jammu & Kashmir focused on evaluating the therapeutic and chemosensitizing potential of the Unani Pharmacopoeial formulation Dawa-ul-Kurkum (DuK) in Head and Neck Squamous Cell Carcinoma (HNSCC). The central hypothesis is that DuK, either alone or in combination with standard chemotherapeutics (Cisplatin and/or 5-Fluorouracil), may synergistically inhibit HNSCC growth, enhance therapy response, and mitigate the development of therapeutic resistance.

Colon targeting of Unani Medicine via gum (polysaccharide) based oral formulations for effective treatment of irritable bowel syndrome: Clinical Intervention by Gamma Scintigraphy

A study is currently underway at the Amity Institute of Pharmacy, Amity University, Noida, focused on the development of a colon-specific oral tablet formulation of the Unani medicine Jawarish Shahi. To achieve targeted drug delivery to the colon,

polysaccharides extracted from *Abelmoschus esculentus* and *Hibiscus rosa-sinensis* were initially evaluated for yield, viscosity, and pH-dependent swelling behavior. The polysaccharide from *A. esculentus* was found to exhibit superior characteristics, making it more suitable for colon-targeted applications. To enhance its functionality, chemical modification through polyacrylamide grafting was carried out, improving its pH-sensitive swelling capacity under simulated colonic conditions. The success of the grafting reaction was preliminarily confirmed using Fourier Transform Infrared Spectroscopy (FTIR), while Scanning Electron Microscopy (SEM) and pulsatile pH-swelling studies further validated its improved responsiveness compared to the unmodified polysaccharide.

To investigate the Pharmacological effect of certain Unani formulations in a Preclinical animal model of Polycystic Ovary Syndrome

A study in progress at SVKM Institute of Pharmacy, Mumbai (Maharashtra) on the project investigates the therapeutic efficacy of Unani formulations in a preclinical letrozole-induced polycystic ovary syndrome (PCOS) rat model. The model was successfully standardized, and PCOS induction was confirmed through detailed biochemical and histological analyses. Majoon-Dabidul-Ward was evaluated at three oral doses (250, 500, and 1000 mg/kg), with the highest dose showing significant improvement in hormonal balance, lipid profile, antioxidant levels, cytokine regulation, and ovarian structure. Currently, the study is extending its focus to Ark-e-Kasni and Ark-e-Mako within the same model.

Design and Development of Sharbat Ahmad Shahi in to Tablet alongwith its Physico-pharmaceutical and Pharmacological evaluation

A study is currently in progress at the Department of Saidla (Pharmacy), Faculty of Unani Medicine, Aligarh Muslim University, Aligarh focusing on the formulation, standardization, and pharmacological evaluation of the Unani preparation Sharbat Ahmad Shahi. Work has also commenced on formulation development, standardization protocols and project documentation marking a steady progression in the early phase of the study.

Preclinical and clinical validation of safety and efficacy of traditional Unani formulation Sharbat Mundi pertaining to its hepatoprotective effect

A study in progress at Sathyabama Institute of Science & Technology, Chennai on preclinical and clinical validation of Unani formulation Sharbat Mundi, aimed at evaluating its hepatoprotective potential with a focus on developing a sugar-free alternative using Stevia. In the initial phase, Mundi flowers (*Sphaeranthus indicus*) were collected, stalks removed, and the inflorescence powdered to prepare an aqueous decoction. Simultaneously, Stevia leaves were shade-dried, powdered, and

processed to obtain an infusion as a 0-calorie sugar substitute in place of jaggery. Different concentrations of Mundi decoction and Stevia infusion were combined to prepare sugar-free Sharbat Mundi, followed by rotary evaporation and drying for phytocomponent screening. The formulations underwent standardization, which included microbial testing, especially critical due to the replacement of jaggery with Stevia. Microbial culture tests showed no growth initially, but minimal contamination appeared after Day 4, prompting further investigation into natural and permissible preservatives to maintain formulation safety and integrity. The prepared samples have been submitted for LC-MS analysis for detailed phytochemical profiling, and annotation of LC-MS data is currently ongoing.

Phytochemical Profiling, Assessment of Safety, and Validation of Anti-amnestic Effect of the Majoon Boolis: a Preclinical Investigation

A study is currently underway at the Department of Pharmaceutical Sciences, Dibrugarh University, Assam, focusing on the scientific evaluation of the Unani formulation Majoon Boolis for its neuroprotective potential in dementia. To investigate the molecular basis of Majoon Boolis action in dementia, in-silico computational techniques such as network pharmacology, molecular docking, and molecular dynamics simulations were employed. These studies identified possible mechanisms of action and molecular targets, supporting the formulation's traditional neurotherapeutic use.

Anti-diabetic and Immune-modulatory effect of Unani formulation “Safuf-i-Dhayabitus’

A study in progress at Department of Biotechnology School of Bioengineering SRM Institute of Science and Technology, Kattankulathur on the Unani formulation Safūf-i-Dhayābītus, aimed at investigating its molecular mechanisms of immunomodulation and potential interactions with conventional antidiabetic drugs. The powdered formulation underwent sequential Soxhlet extraction using solvents of increasing polarity (hexane to water). Among all, the methanolic extract demonstrated the highest antioxidant and immunomodulatory activity and was selected for further detailed investigation. LC-MS/MS-based metabolite profiling of the methanolic extract identified a range of bioactive compounds including Naringenin, Kaempferol, Luteolin, Myricetin, Ellagic acid, Ferulic acid, Gingerol, Quercetin, and β -sitosterol, all of which are associated with antioxidant and anti-inflammatory effects. Using a network pharmacology approach, the study predicted strong interactions between these phytochemicals and molecular targets relevant to Type 2 diabetes and immune regulation, such as NF- κ B, MAPK, Nrf2, STAT3, Akt, IGF-1R, and TLR4. These interactions were further validated in the MIN6 pancreatic β -cell line using real-time PCR, supporting the involvement of these pathways in the formulation action.

Studies on Evaluating the Anti-Fibrotic Potential of a Unani Formulation (Majusi Formula)

A study is currently in progress at (MHS) SRM MCH & RC, Kattankulathur to evaluate the antifibrotic potential of a traditional Unani Majūsī formulation in the context of aggressive, fibrosis-associated cancers with a focus on inducing mesenchymal-to-epithelial transition (MET) as a therapeutic strategy. In the initial phase, multi-solvent extraction of the formulation was carried out followed by standardization and in silico bioinformatics analysis, which identified GPR35 and TEK as key molecular targets linked to fibrosis and vascular signaling. Cytotoxicity assays (MTT and Annexin V/PI) indicated that the aqueous extract was the most effective and exhibited the lowest toxicity among all tested fractions. The study has now advanced to the isolation and culture of primary cancer-associated fibroblasts (CAFs) and the development of 3D tumour models, aiming to mimic the in vivo tumour microenvironment more accurately.

Effect of Unani drugs on the transgenic drosophila flies model of Parkinson's disease

A study is in progress at the Department of Zoology, Aligarh Muslim University, Aligarh to evaluate the neuroprotective potential of the Unani polyherbal formulation Khamira Gawzaban Ambari Jadwar Ood Saleeb Wala in a Parkinson's Disease (PD) Drosophila model. The drug was incorporated into the Drosophila diet at four graded doses (0.00018 to 0.0014g per 20g diet) and administered to PD model flies. Key behavioral assays revealed a dose-dependent delay in the loss of climbing ability, a functional indicator of neurodegeneration in flies. Additionally, the treatment resulted in a significant dose-dependent extension of lifespan in PD flies compared to untreated controls.

Structural characterization, pharmacokinetics, pharmacodynamic and herb-drug interactions of major constituents of compound Unani formulation for diabetes

A study is currently underway at the Department of Pharmaceutical Analysis, NIPER, Hyderabad, focusing on the development and validation of an HPLC method to support pharmacokinetic and pharmacodynamic studies of a traditional formulation in the context of diabetes management and herb-drug interactions, particularly with glimepiride. In the initial phase, an HPLC method was successfully developed for the separation and quantification of key phytoconstituents using three reference standards: quercetin, kaempferol, and gallic acid. The method demonstrated acceptable resolution, retention times, and peak symmetry, and optimization of chromatographic parameters was achieved.

3.4. Publications

3.4.1. Books, Monographs, Reports, etc.

During the reporting period, the CCRUM brought out the following books, monographs, reports, journals, etc:

S.No.	Title	Language	Category
1.	<i>Man La Yahzuruahu al-Tabib</i> (The Book for one who is not attended by a Physician)	Urdu	Book
2.	<i>Kitab al-Abniya an Haqaiq al-Adwiya</i> (Book of Fundamentals on True Nature of Drugs)	Urdu	Book
3.	Manual on Geriatric Health Care in Unani Medicine	English	Book
4.	Training Module for Geriatric Health Care in Unani Medicine	English	Book
5.	A Handbook of Common Remedies in Unani Medicine (यूनानी चिकित्सा में सामान्य उपचार – एकपुस्तिका)	Hindi	Book
6.	The National Formulary of Unani Medicine, Part – I (Revised)	English	Book
7.	Research on Fundamentals of Unani Medicine – A Technical Report	English	Technical Report
8.	CCRUM Research Policy 2025	English	Book
9.	Hippocratic Journal of Unani Medicine, Volume-16, Number-4	English	Journal
10.	CCRUM Annual Report – 2023-24	English	Annual Report
11.	CCRUM Annual Report – 2023-24	Hindi	Annual Report
12.	Unani Day 2025 and International Conference on “Innovations in Unani Medicine for Integrative Health Solutions - A Way Forward”	English	Souvenir
13.	Central Council for Research in Unani Medicine – At a Glance	English	IEC Brochure
14.	Central Council for Research in Unani Medicine – At a Glance	Hindi	IEC Brochure
15.	Prevention and Control of Anaemia through Unani Medicine	English	IEC Pamphlets

S.No.	Title	Language	Category
16.	Prevention and Control of Cancer through Unani Medicine	English	IEC Pamphlets
17.	Prevention and Control of Cancer through Unani Medicine	Hindi	IEC Pamphlets
18.	Cupping Therapy	English	IEC Pamphlets
19.	Prevention and Control of Deficient Lactation through Unani Medicine	English	IEC Pamphlets
20.	Prevention and Control of Diabetes Mellitus through Unani Medicine	English	IEC Pamphlets
21.	Prevention and Control of Diabetes Mellitus through Unani Medicine	Hindi	IEC Pamphlets
22.	Healthy Ageing through Unani Medicine	English	IEC Pamphlets
23.	Prevention and Control of Hyperlipidaemia through Unani Medicine	English	IEC Pamphlets
24.	Prevention and Control of Hyperlipidaemia through Unani Medicine	Hindi	IEC Pamphlets
25.	Prevention and Control of Hypertension through Unani Medicine	English	IEC Pamphlets
26.	Prevention and Control of Hypertension through Unani Medicine	Hindi	IEC Pamphlets
27.	Prevention and Control of Lifestyle Diseases through Unani Medicine	English	IEC Pamphlets
28.	Prevention and Control of Obesity through Unani Medicine	English	IEC Pamphlets
29.	Oral Hygiene through Unani Medicine	English	IEC Pamphlets
30.	Prevention and Control of Palpitation through Unani Medicine	English	IEC Pamphlets
31.	Principles of Healthy Living	English	IEC Pamphlets
32.	Ahaar	English and Hindi	IEC Pamphlets

3.4.2. Research Paper

1. Ahmed W, Ansari AP, Ahmed NZ, Ahmed KK, Ahmad F; An Observational Study on Prevalence and Risk Factors for OA Knee Joint Among Adult Population Attending the SCSP Camps in Chennai, Tamil Nadu, India; Journal of Unani, Siddha and Homeopathy; 12; 9-17; 2394-1960;2025
2. Khan JA, Khan PJ; A brief Guide to Statistical Quality Control SQC; Journal of Emerging Technologies and Innovative Research; 11(7); b279-b291; 2349-5162;2024
3. Sheeraz M, Nazmeen; A Clinical Comparative Study on therapeutic Formulation of (Ajwain, Tukhme-e-Suddab, Zeera) Versus Tariq (Diphoresis) in the Management of Siman-e-Mufrit (Obesity); Unimed-Kulliyat; 14(1:50); 45664; 2249-5703;2024
4. Sheeraz M, Alam MT; A clinical study of Unani formulation in the management of chronic sinusitis: A Open randomised, controlled study; International journal of Unani and Integrative Medicine; 8(1); 34-42; 2616-454X;2024
5. Kumar A, Singh G, Pengoria R, Yadav C, Tiwari N, Gupta LK, Sharma M; A Clinico-Epidemiological study on dengue among Children in Firozabad, Uttar Pradesh; International Journal of Academic Medicine and Pharmacology; 6(5);141-145; 2687-5365;2024
6. Bhardwaj K, Parashar R, Gupta A, Yadav C; A Comparative Analysis of Established Versus Newer Standard Anatomical Parameters for Fetal Age Determination-An Ultrasound Study; Physical Therapy Issues; 54(4); 6332-6337; 1135-8599;2025
7. Bhardwaj K, Parashar R, Kumar S, Yadav C; A Comparative Analysis on 3rd Trimester Using Different Fetal Biometric Parameters- An Ultrasound Study; Journal of Neonatal Surgery; 14(5);270-274; 2226-0439;2025
8. Falak, Hussain Z; A Complete Review of Taqashur-Al-Jild (Psoriasis) with special reference to Unani Medicine; Journal of Emerging Technologies and Innovative Research; 11(6);724-731; 2349-5162;2024
9. Nameera S, Nasim M, Sehjad S, Ahmed M Farooqui S, Ahmad I, Sharif N; A comprehensive investigation of trombiculid mite larvae of chiggers; International Journal of Entomology Research; 9(9); 118-120; 2455-4758;2024
10. Rasool A, Hussain Z; A Comprehensive review and recent Highlights of Nar-e-Farsi (Eczema) in the aspect of Unani conception; Journal of Emerging Technologies and Innovative Research; 11(5); 520-526; 2349-5162;2024
11. Bibi C, Husain S; A comprehensive review on medicinal properties, phytochemistry, and pharmacology of Hordeum vulgare linn: An important plant origin Unani drug; Journal of Pharmacognosy and Phytochemistry; 13;132-139; 3;2024

12. Ahmed R, Ahmed WM, Khan AS, Sagar PK, Ansari SA; A concise review on pharmacological applications of potent Unani drug: *Mesua ferrea* L. (Nagkesar); *Journal of Pharmacognosy and Phytochemistry*; 13(1); 412-416;2024
13. Sumeena, Hussain Z; A Critical review of QABD (Constipation in Unani Medicine); *Journal of Drug Delivery and Therapeutics*; 14 (12); 206-213; 2250-1177;2024
14. Husain S, Khan AM Sherwani, Bibi C, Wasim M; A cross-sectional study to assess the prevalence and contributing factors of anaemia in private school children in Bengaluru; *International Journal of Community Medicine and Public Health*; 11; 3167-3174;2024
15. Khan S, Devi N, Rehman Z, Yadav P; A Cross-Sectional Study to Determine the Sociodemographic Profile, Water and Energy Resource in Rural Area of Navi Mumbai; *International Journal of Health Sciences and Research*; 15(3);25-31; 2249-9571;2025
16. Afza S, Khan P, Rehman S, Ayub S, Singh R, Verma SR, Akhtar J, Khan AA; A preliminary study on the safety and efficacy of the compound Unani medicine *Jawarish-e-Shahi* in the treatment of palpitation; *Indian Journal of Traditional Knowledge*; 23(7); 687-693; 0975-1068;2024
17. Abdullha M, Qurashi MA, Ali SA, Khan AM; A Review on Donkey Milk as Adjuvant Dieto therapy with Anti-Tuberculosis Treatment; *Journal of Biological & Scientific Opinion*; 12(3); 001-006; 2321-6328;2024
18. Habib A, Kalam MA, Riyaz, Aziz A, Avid M, Belal A; A Review on *Khubbāzī* (*Malva sylvestris* L.): Phytochemical, Pharmacological Properties and Therapeutic Applications; *Journal of complementary and alternative medicine*; 25; 28-36; 2456-6276;2024
19. Sheeraz M, Ayyub M; A Review on Pharmacological Action and Therapeutic uses of *Balchar* (*Nardostachys jatamansi* DC): Unani Perspective; *Journal of Complementary and Alternative Medical Research*; 25(8); 47-56; 2456-6276.;2024
20. Jan U, Kalam MA, Barjes, Shagufta, Hizaifa; A review on therapeutic potential of *Digitalis purpurea* L. in perspective of Unani medicine; *Journal of Pharmacognosy and Phytochemistry*; 13(4); 296-299; 2278-4136;2024
21. Husain S, khan N, Raheem A, Urooj S, Siddiqui ZH; A study of clinical validation of Unani Pharmacopoeial formulation *Habb-e-Hilteet* in *Zu'f al-Ishtihā'* (anorexia)"at RRIUM, New Delhi: an open prospective clinical trial; *International Journal of Community Medicine and Public Health*; 12(2); 755-761;2024
22. Shamshad M, Ramesh M, Haq J & Tabassum S; A study on Health Profile of 3 ITDA Spots of Kurnool District, Andhra Pradesh; *Indian Journal of Health Care, Medical & Pharmacy Practice*; 5(1);20-28; 2583-2069;2024

23. Alam MM, Ahmad MI, Jamali MAH, Imam H, Yasir M; A Systematic Review of COPD from the Perspectives of Greco-Arabic and Modern Medicine; Alternative Therapy in Health and Medicine; 30;27-31; 1078-6791;2024
24. Ahmed W, Siddiqui JI, Naikodi MAR, Usmani QI; A time tested polyherbal formulation for the management of Premature ejaculation, A comprehensive review; Journal of drug delivery and Therapeutics; 14 (6);191-199; 2250-1177;2024
25. Hasan I; Abzan (Sitz Bath) therapy in Unani Medicine: historical roots, Therapeutic benefits, and contemporary applications; World Journal of Pharmaceutical and Medical Research; 4; 10; 2455-3301;2024
26. Sheikh WM, Jadhav I, Shafi M, Bashir SM, Kalam MA; Acute and sub-acute Toxicity Profiles of *Anchusa strigosa* and *Zataria multiflora*; Toxicon; 249;108051; 0041-0101;2024
27. Kalam MA, Khan S, Ashraf B, Uvais M, Ibrahim T, Naqqash N; Aftīmūn (*Cuscuta Reflexa* Roxb): Identification, Therapeutic Applications and Scientific Exploration - A Review; Journal of Advance research in Ayurveda, Yoga, Unani, Sidha & Homeopathy.; 12(1&2);19-25; 2394-6547;2025
28. Mehraj M; *Agrimonia eupatoria*): An In-depth Review of its Historical Context, Therapeutic properties, Ethnopharmacological applications, and Scientific research; International Journal of Medical Sciences and Pharma Research; 10;35-38; 2394-8973;2024
29. Sagar PK, Mageswari S, Ahmed MW; An Conscious review validation biodiversity, pharmacognostical, pharmacological, toxicological research studies and therapeutic potential of ASU herbal drugs - seed part of Baphali / Duku / Duqu (*Peucedanum grande* C.B. Clarke); Journal of Pharmacognosy and Phytochemistry; 13; 396-404; 4;2024
30. Ahmed F, Singh VB, Fahima A, Khatoon A, Sehar NU; An over view of depression and its management by Unani system of medicine; International Journal of Unani and Integrative Medicine; 8 (3); 85 - 88; 2616-4558;2024
31. Akram W, Christopher MSJ, Jameel M, Saquib M, Kumar TS, Anwar N, Asif M, Ahmed K; Antimicrobial and antioxidant study of combined essential oils of *Anethum sowa* Kurz. And *Trachyspermum ammi* (L.) along with quality determination with comparative histo- anatomical features, GC–MS and HPTLC Chemometrics; Scientific Report; 14;27010; 2045-2322;2024
32. Rifat I, Kalam MA, Khanday S, Salati H; Anti-Oxidant Activity of an Aquatic Plant *Jar-UI-Nahr* (*Potamogeton Natans* Linn): An Unani Drug; Indian Journal of Unani Medicine; 17(2); 115-121; 2249- 5746;2024
33. Khanam S, Zakir M, Husain GM, Husain MK, Kazmi MH, Urooj M; Antipyretic and Analgesic Activity of Polyherbal Unani Formulation in Experimental Animals;

- Research Journal of Pharmacy and Technology; 17(7);3089-3096; 0974-3618;2024
34. Mehfooz S, Iqbal A, Kalam A; Arthritis (Waja-al-Mafasil) in Scheduled Tribe dominant areas of Srinagar and Ganderbal Districts of J and K - An observational Study under TSP; International Journal of Research and Analytical Reviews; 11(3);957-962; 2348-1269;2024
 35. Raghubanshi, Amir, Alam MT, Idris M, Bushra Sabir B, Khan MN; Asfanj (*Spongia Officinalis*) An Origins Drug, Historical Zoological, Description, Chemical Constituters and Pharmacological Studies : A Review; International Journal Current Research; 16 (3); 27438-27442;2024
 36. Arsha Noor A, Ahmed S; Assessment of the Therapeutic Efficacy of a Unani Formulation in Alleviating Pain, Dysuria, and Pruritus Associated with Leucorrhoea (*Sayalānal-Raḥīm*); International Journal of Life Sciences, Biotechnology and Pharma Research; 13;327-332; 2977-0122;2024
 37. Kalam MA, Ashraf B, Khan S, Bhat A, Ansar Ahmad A, Jan U; Aynul Hirra (Cat's Eye): Introduction And Therapeutic Benefits of a Precious Gemstone In the Perspective of Unani Medicine.; Indian Journal of Unani Medicine; 17(2);537-544; 0974-6065;2025
 38. Raghuvasnshi, Sabir B, Siddaqui ZH, Khan N; Baize-Murg, an important food product of animal organ and its uses as Ghiza-e--dawai; International Journal of Unani and Integrative Medicine; 8 (2); 1-6; 2616-454X, 2616-4558;2024
 39. Fatima Y, Khan AM, Qaiser A, Abdullha M; Baladur (*Semecarpus anacardium* Linn): An overlooked unani medicine having potential health benefits with broad spectrum of pharmacological activities; International Journal of Unani & Traditional Medicine; 1 (1);003-013; 2616-454X, 2616-4558;2024
 40. Haque SU, Javed A, Avid M, Kalam MA, Shahid S, Rehman R, Zahoor U; BARAŞ (*Vitiligo*): Introduction, etiology, and its managements through Unani Medicine; International Journal of Pharmacognosy and Life Science; 5;87-92; 2707-2835;2024
 41. Jalal B, Kalam MA, Hamid S, Zahoor U; Bijband (*Sida cordifolia* L.): A vital medicinal plant in Unani medicine, its uses, and pharmacological insights; International Journal of Unani and Integrative Medicine; 8(3);74-79; 2348-1269;2024
 42. Ahmed T, Vinay E, Naikodi MAR, Siddiqui JI, Dwivedi DK., Munshi YI, Viqar U, Husain GM; Blood Glucose-Lowering Activity of Compound Herbo-Mineral Unani Formulation Qurs-e-Ziabetus in Nicotinamide-Streptozotocin-induced Diabetic Rats; Natural Resources for Human Health; 5 (1);156-170; 2583-1194;2025
 43. Akhlaq S, Akhlaq S, Khan M, Mohammad Fazil M, Akram U, Haque MU, Bilal Ahmad B, Sayeed A, Quddusi N; Characterization of bioactive components, ethnomedicinal uses, nutraceutical potential, and pharmacological aspect of

- juglansregia I in Unani Medicine: a narrative review; Indian Journal of Unani Medicine; 17(1);40-49; 0974-6065;2024
44. Jan J, Bashir SM, Sheikh WM, Bhat OM, Rafeeqi TA, Shah SA, Dar AH, Zargar MA, Wani NA; Chlorpyrifos and dimethoate exposure impairs female fertility by deregulating WNT signaling pathway & uterine receptivity; Reprod Toxicol; 130; 1-10; 0890-6238;2024
45. Sheeraz M, Alie Jan A, Jan I; Clinical Efficacy of Safuf -i-Baras in the management of Fasad Al- Lawn (Hypopigmentation): A Case Study; International Journal of Ayush Case Reports; 8(4); 523-530; 2457-0443;2024
46. Rauf E, Siddiqui ZH, Jahan N, M. Khan N, Khan AA; Clinical evaluation of Dawaul Shifa, lifestyle modifications and yoga in hypertension patients under NPCDCS (Unani) Projects; Hippocratic Journal in Unani Medicine; 17(2);:p 56-61;Apr–Jun 2022 published in 2025
47. Muzaffer M, Qamar U, Minhajuddin A, Jabeen J; Clinical Potency of Unani Regimen in Management of Vitiligo: A Case Report; Journal of Biological & Scientific Opinion; 12 (4); 50-53;2024
48. Siddiqui ZH, Arshad M, Ahmad F, Naime M, Amir, Akhtar J, Khan MN; Clinical study for validation of safety and efficacy of Laooq Khayar Shambar for symptomatic relief in Nazla (Common cold); International Journal of Unani and Integrative Medicine; 8(1); 45819;2024
49. Raghubanshi, Alam MT, Amir, Sabir B, Siddiqui ZH, Khatoon A, Idris M, Khan MN, Akhtar J; Clinical study for validation of safety and efficacy of Laooq Sapistan for symptomatic relief in Nazla (Common Cold); International Journal of Unani and Integrative Medicine; 8(1); 26-33;2024
50. Rasheed A, Khan H, Kumar K, Singh N, Zakir M, Jamali AH, Siddiqui ZH, Saifi M; Clinical Study for Validation of Safety and Efficacy of Sharbat Zufa Murakkab in Su'al-i-Ratb (Productive Cough) in Eastern India; Hippocratic Journal of Unani Medicine; 17(1);15-19; 0975-1293;Jan–Mar 2022 Published in 2025
51. Josee A, Islam, Naquibul I, Rafeeqi, Amin T; Clinical study to Evaluate Safety and Efficacy of Boozidaan (Pyrethrum indicum) in the management of Nigris Muzmin (Chronic Gout).; Journal of Drug Delivery & Therapeutics; 14(3); 8; 2250-1177;2024
52. Afreen S, Bari B, Bari H, Ahmed F, Ziddiqui ZH, Sehar NS; Clinical validation of Unani Pharmacopial formulation Habbe-e-Irq-un-Nisa in Waja-al-Mafasil (Rhematoid Arthirits); International Journal of Unani and Integrative Medicine; 8 (2); 104-110; 2616-4558;2024
53. Khan MT, Parveen S, Ahmad F, Naseem M; Clinical Validation to evaluate the safety and efficacy of Unani Pharmacopeial formulation Habb-e-Banafsha in the Management of Dīq al- Nafas (Bronchial Asthma); African Journal of Biological Sciences; 6 (4); 1354-1362; 2663-2187;2024

54. Sumaiya S, Begum W, Bano S, Husain N; Comparative Efficacy of Aristolochia rotunda L. (Zarawand Mudaharaj) and Saussurea lappa C.B. Clarke (Qust) in Primary Dysmenorrhea—A Single-Blind Randomized Clinical Study; Alternative Therapies in Health and Medicine; 30(12);1-9; 1078-6791;2024
55. Ahangar AY, Wani SA, Ara I, Kalam MA, Rafeeqi TA; Comparative preliminary study on using a manual and electrical suction Comparative preliminary study on using a manual and electrical suction pump for Hijama bil shart (Wet Cupping) in healthy participants; Afr.J.Bio.Sc.; 7(2): ;750-761; 2663-2187;2025
56. Rajaram M, Komala M, Ashok M, Nazeer M, Swathi M; Comprehensive description of massage and its applications in Unani medicine - an updated review; International Journal of Research and Review; 11(12);625-630; 2454-2237;2024
57. Mubeen S, Hussain Z; Concept and Management of Sara (Epilepsy) in Unani System of Medicine: An Overview; International Journal of Novel Research and Development; 9(6) ;482-491; 2456-4184;2024
58. Ansari Y, Raheem; Concept of BMR in Unani System of Medicine: An Overview.; Paripex - Indian Journal of Research; 14(2); 58-60;2025
59. Singh VB, Tauseef Alam T, Amir, Dr.Fayaz Ahmed F, Sehar N; Controversies of herbal Unani drugs, Navigating and unveiling the Identities of Unani Medicinal plant. A comprehensive Unani review; International Journal of Unani and Integrative Medicine; 8 (3) ;93 - 100; 2616-4558;2024
60. Ansari AP, Anwar N, Ahmed KK; Current status of Unani medicine in India; Journal of Ayurvedic and Herbal Medicine; 10; 3; 2454-5023;2024
61. Bilal A, Ansari MM, Munshi YI, Khannum F, Firdous N; Demographic survey of prevalence of diseases in Chandpur area of district 24 Pargana (WB); International journal of Unani and Integrative Medicine; 8(1); 90-95; 2616-4558/ 2616-454X;2024
62. Ahmad I, Kumar M, Udmale A, Naznin SI, Shaikh M, Aatif S, Ansari R, Ahmed AY, Khan R, Khairnar N; Diagnosis of Cancer Using Artificial Intelligence Modeling tools: A Comprehensive Review; Nanotechnology Perceptions; 15; 1660-6795;2024
63. Ahmad F, Khatoon A, Naime M, Salam M, Rauf, Sehar N; Digital Pathology – A Review; World Journal of Pharmacy and Pharmaceutical Sciences; 13(9); 1008-1014; 2278-4357;2024
64. Sagar PK, Ahmed MW, S Kashyap, S Mageswari, Meera P, Sri D; Drug standardization, HPTLC fingerprinting, toxicological research studies of ASU herbal drug fruit seeds part of Peucedanum Grande CB Clarke; International Journal of Herbal Medicine; 12(6); 15-23; 6;2024
65. Shahid A, Khanum A, Khan JA, Riyazuddin M, Siddiqui MA; Effect of a polyherbal Unani formulation on left ventricular diastolic dysfunction in

- hypertensive patients - a randomized single blind placebo controlled clinical trial; Drug Metabolism & Personalized Therapies; 39(3); 137-144; 2363-8915;2024
66. Fatma B, Nomani AN, Anwar M, Mustafa S, Zeenat F; Effect of Ğimād of Barg-i-Nīm and Roghan-i-Nārjīl in the Management of Diabetic Foot Ulcer: A Case Report; International Journal of AYUSH Case Reports; 8;3; 2457-0443;2024
67. Sheeraz M, Barjees; Effect of Hammam (Steam Bath) With Herbal Decoction of Burg-l-Nim and Burg-l-Hina-A Case Study; World Journal of Pharmacy and Pharmaceutical Research; 01(2); 82-90; 2278-4357;2024
68. Kalam, Barjes, Shugufta; Effect of Hījāma bilā Shart (Dry cupping) and Unani Formulation on Waja'-i-Mafṣal-i-Katif (Frozen Shoulder) - A Case Study; International Journal of Ayush Case report; 8(3); 351-356; 2457-0443;2024
69. Tanveer Y, Ahmad Z, Azhar M; Effect of Syrup Antox-e-Qooba powder and Roghan-e-Shaar oil in a case of Qooba-Al-Rass (Tinea capitis); Unani Medicine; 6 (1); 11-14; 2230-8083;2024
70. Sheeraz M, Ahtesham, Sahiba; Effectiveness of Habb-l-Musaffi Khun in Managing Buthur-l-Labaniyya (Acne Vulgaris): A Case Study; Indian Journal of Unani Medicine; 17(2); 135-140; 0974-6065;2024
71. Sheeraz M, Shagufta; Effects of Aftimoon vilayati (Cuscuta europaea) in the management of Izterab-i-Nafsani (Anxiety): A Case Report; International Journal of Unani and Integrative Medicine; 8(3); 166-168; 2616-454X;2024
72. Sheeraz M, Sadiya; Effects of Araq l- llaichi in the management of Kathra Al-Jushā' (Eructus/Belching): A Case Report; World Journal of Pharmaceutical Research; 14(3); 735-741; 2277-7105;2025
73. Arsha Noor A, Ahmed S; Efficacy and Safety of Unani Formulation in the Management of Sayalān al-Raḥīm (Leucorrhoea): A Comprehensive Prospective Clinical Study; African Journal of Biological Sciences; 6; 7696-7714; 2663-2187;2024
74. Afzal A, Ahmad S, Bhat SA, Zahoor S, Iqbal A; Efficacy and safety of wet cupping in the management of Gout: An open labeled, randomized standard control study; Advances in Integrative Medicine; 11; 149-154;2024
75. Sheeraz M, Adnan; Efficacy of A Topical Dimad in the Management of Waja' Al - Rakba (Knee Osteoarthritis): A Case Report; Indian Journal of Unani Medicine; 17(2); 160-164; 0974-6065;2024
76. Shahid A, Zakir N, Riyazuddin M, Itrat M; Efficacy of Bozidan (Tanacetum umbelliferum Boiss.) in pain management associated with hyperuricemia: a randomized controlled trial; Advances in Integrative Medicine; 2212-9588/2212-9596;2024
77. Sheeraz M, Adnan; Efficacy of Fire Cupping (Hījāma Nāriyya) In Alleviating Symptoms of Waja-ul-Mafasil-l-Katif (Frozen Shoulder): Case Report; World

- Journal of Pharmacy and Pharmaceutical Research; 2(8); 173-180; 2278-4357;2024
78. Sheeraz M, Sahiba; Efficacy of Roghan-I-Chameli (Jasmine Oil) In the management of Intithar Al-Sha'r (Diffuse Hair Loss): A Case Report; World Journal of Pharmaceutical Research; 13(23); 983-988; 2277-7105;2024
79. Parveen FS, Horti A, Abbas SN, Fathima S, Razzaq MS, Mistry AP, Husain N; Efficacy of topical Raphanus sativus seed powder mixed with honey versus hydroquinone 4% cream in the treatment of odelli-A randomized controlled trial; Journal of Dermatologic Science and cosmetic technology; 1; 4; 2950-306X;2024
80. Mastan A, Fazil M; Efficacy of Unani Treatment Regimen in the Management of Psoriasis; Hippocratic Journal of Unani Medicine; 17(1);123-127; 0974-1291; Jan–Mar 2022 Published in 2025
81. Ahmad P, Alam M, Asif M, Venkatesan K, Ahmed NZ; Ethnobotanical survey of medicinal plants of Haridwar Forest Division, Uttarakhand, India; Trends in Horticulture; 7;2; 2578-1812;2024
82. Alam MM, Bano S, Rehman S, Imam MH, Jamali MAH, Alam MI, Noman M; Ethno-Pharmacological and Phytochemical Study of Rauwolfia Serpentina (Asrol) - An Extensive Review; Advances in Bioresearch; 15(2); 59-68; 2277-1573;2024
83. Mehraj N; Evaluating the therapeutic of Habb-e-Ghafis in Non-Alcoholic fatty liver disease, a randomised, single blind, standard controlled trial; Journal of Herbal Medicine; 50; 100986; 2210-8033;2025
84. Mehraj N, Hussain Z; Evaluating the therapeutic safety and efficacy of Habb-e-Ghafis in Non- alcoholic fatty liver disease, a randomized, single blind, standard controlled trial; Journal of Herbal Medicine; 25;100986; 2210-8033;2025
85. Subathra T, Shanmugapriya P, Rajalakshmi K, Arokiarajan MS, Ramamurthy M, Meena R; Evaluation of antimicrobial activity and time-kill kinetics of chithiramoola kuligai against microbial pathogens; International Journal of Research in Ayurveda and Pharmacy; 15; 3; 2229-3566;2024
86. Ashraf A, Ahmad S, Mehraj M; Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver Disease: A Randomized, single-blind, controlled trial; Arab Journal of Gastroenterology; 26; 112-119;2025
87. Khan MT, Ahmad F, Hashimi A, Naseem M; Evaluation of Demographic and socioeconomic profile of SC villages of Meerut under SCSP Mobile Health Care Programme; Frontiers in Health Informatics; 13 (18);2291 to 2302; 2676-7104;2024
88. Sheeraz M, Farooq F; Evaluation of effects of a polyherbal Unani formulation in the management of Baras (vitiligo): A single -case report; International Journal of Unani and Integrative Medicine; 8(3); 127-131; 2616-454X;2024

89. Parveen FS, Horti A, Abbas SN, Allapat MR, Razzaq MS, Husain N; Evaluation of the efficacy of topical *Nigella sativa* L. with vinegar in the treatment of acne vulgaris: A randomized controlled trial; *Journal of Dermatologic Science and Cosmetic Technology*; 2 (1);1; 2950-306X;2025
90. Kumar TS, Shamy SM, Christopher J, Mageswari S, Akram W, Jameel M, Ansari AP, Gopal S, Meena RP, Ahmed NZ, Mandal AK; Evaluation of Turmeric – Based Unani Formulation for Respiratory Tract Infection: Physicochemical Analysis, HPTLC Fingerprint Screening and Microbiological Studies; *Journal of Medicine and Health Research*; 10;1; 2456 –9178;2025
91. Fatima SH, Lahari K, Chakraborty A, Ahmad T, Jabeen A, Javed G, Yadav PK, Munshi YI, Ahmed NZ; Exploring apolipoprotein E Gene Polymorphism and Serum Lipid Profile in psoriasis patients with reference to Unani temperament; *Indian Journal of Clinical Biochemistry*; 39;2024
92. Salim S, Khanday S, Kalam MA, Yousuf A, Rifat I; Exploring Morphological and Phytochemical Differences in *Iris ensata* (Sosan asmanjuni) and Market Varieties; *Traditional Medicine*; 6(1); 32; 2413-3973;2025
93. Tahseen Z, Sofi G, Heyat B, Jahan MB, Rashid A; Exploring Obstruction and Deobstruent Drugs in Unani Medicine: A Comprehensive Survey and Future Directions.; *Alternative therapies in health and medicine*; 30(7);20-27; 1078-6791;2024
94. Ara SA, Ahmad B, n Akhlaq S, Haque M, Fazil M, Akram U, Sayeed A, Quddusi N, Khan AA; Exploring Scientific validation of anti-inflammatory drugs used in Unani medicine for contemporary healthcare: A critical appraisal with special reference of Dioscorides *De Materia Medica*; Apple Academic Press, Florida, USA; 2(2);2025
95. Sheeraz M, Tooba S; Exploring the Effects of Local Steaming in the Management of Primary Frozen Shoulder: A Case Report; *International Journal of Ayush Case Reports*; 9(1); 845-550; 2457-0443;2025
96. Sabir B Usmani S, Raghubanshi, Sehar N; Exploring the Medicinal Applications of Mint (*Mentha arvensis*) in Traditional and Modern Medicine; *Goya Journal*; 18 (3); 45962; 0017 - 2715;2025
97. Habib A, Arzoo KS, Kalam MA, Aziz A, Ahmad B; Exploring the Medicinal Benefits of *Filfil Darāz* (*Piper longum* L.): Insights from Unani Medicine and Modern Perspectives; *Journal of Complementary and Alternative Medical Research*; 25(12);133-145; 2456-6276;2024
98. Rasheed A, Tariq M, Siddiqui U; Exploring the therapeutic potential of *Nigella sativa* (Kalonji): an overview; *International Journal of Unani and Integrative Medicine*; 8;117-120; 2616-4558;2024
99. Jameel M, Ali A, Ali M, Ashraf K, Meena RP; Extraction of α glucosidase inhibitory phyto-compounds from the roots of traditional medicinal plant;

- Clerodendrum phlomidis L.; Journal of Pharmacognosy and Phytochemistry; 10;3; 2278-4136;2024
100. Jan U, Kalam MA, Wani NN, Ayoub M, a Farooq SF, Yaqoob F; Filfil Siyāh (Piper nigrum): Medicinal importance in perspective of Unani medicine and pharmacological studies; Journal of Pharmacognosy and Phytochemistry; 13; 652-656; 2278-4136;2024
101. Hussain Z, Kalam MA; Genitourinary Complications in Diabetes mellitus: A review; International Journal of Creative Research Thoughts; 12(4);512-519; 2320-2882;2024
102. Afzal A, Ahmad S, Bhat SA; Gouty Arthritis and Its Appraisal in Greco-Arab (Unani) Medicine; International Journal of Research and Review; 11; 818-827; 2454-2237;2024
103. Naikodi MAR, Nagaiah K, Chaithra D, Gopal S, Lingaraju A, Munshi YI; Green biosynthesis and characterization of silver nanoparticles using wheatgrass extract and its potential applications: A review; Phytonanotechnology and Pharmaceutical Sciences; 4(3); 011-017;2024
104. Kalam MA, Jalal B, Zahoor U, Ahmed A; Gurhal (Hibiscus Rosa-Sinensis): Medicinal Importance In Perspective of Unani Medicine and Pharmacological Studies; European Journal of Pharmaceutical and Medical Research; 11;322-329; 2394-3211;2024
105. Ansari Y, Raheem A; Health benefits of Ajwain (Tracyspermum Ammi L.); Global Journal of Medical Research; 24; 35-38; 1;2024
106. Qazi RA., Masroor A. Qureshi MA, Chandni K; Hemorrhoids Through the Ages: From Ancient Remedies to Modern Therapies; World Journal of Pharmaceutical Research; 13;1055-1061; 2277-7105;2024
107. Jaculine A. Mageswari S, Selvarani R. Ahmed KK, Meena RP, Ahmed NZ; HPTLC Finger Print Analysis and Evaluation of Heavy Metals for Citrullus Colocynthis Root; Journal of Emerging Technologies and Innovative Research; 11;8; 2349-5162;2024
108. Ansari Y, Raheem A; Hypertension and its Management Through Alternative Regimes of Unani Medicine; "Paripex - Indian Journal of Research; 10; 45-56; 2;2025
109. Sahar N, Husain GM, Ahmed T, Urooj M, Viqar U, Zakir M; Hypoglycemic Activity of Safuf-i-Dhayabitus in Nicotinamide Streptozotocin-induced Diabetic Rats; Research J. Pharm. and Tech; 17(7);3019-6; 0974-360X;2024
110. Samal M, Siddiqui A, Dar M I, Srivastava V, Khan M, Parveen R, Ansari SH and Ahmed S.; Identification of Anticholinesterase Active Compounds from the Ethylacetate Fraction of Hydroalcoholic Extract of Itrifal Sana Using TLC–bioautography–MS and Its Validation Using an In Silico Molecular Approach; Journal of AOAC International; 108(2);189-198;2024

111. Kumar A, Khan MS, Siddiqui ZH, Rai A, Fazil M, Rabbani G; Immunomodulatory effect of Unani polyherbal formulation - Tiryag Wabai in mild to moderate COVID-19 patients - A randomized placebo-controlled clinical trial; Journal of Ayurveda and Integrative Medicine; 15;100903; 0976-2809;2024
112. Ahmed MW, Ahmed R, Husain S, Sajid M, Siddiqui ZA; Increased prevalence of anemia (Faqr-al-dam) among teenagers and related control programs in India; Journal of Research in Unani Medicine; 11;60-64; 1;2024
113. Rao V, Hasan I; Integrated approaches to obesity management: Synergizing yoga practices and Unani therapeutics; International Journal of Advance Research in Community Health Nursing; 1; 7; 2664-1666;2025
114. Shah AJ, Dar MY, Adnan M, Varma TK, Agarwal D, Garg P, Mir RH, Meena RP, Masoodi MH; Integration of phytochemical profiling and computational approaches to evaluate the neuroprotective potential of Nardostachys jatamansi in Alzheimer's disease.; Biotechnology Reports; 45; e00881.; 2215-017X. ; 2025
115. Ansari Y, Raheem A; integrative approaches to managing Dysmenorrhoea: a comprehensive review of unani medicine; Paripex - Indian Journal of Research; 13; 45-58; 3;2024
116. Ansari AP, MS Arokiarajan, Akbar SWA, Ahmed NZ, Anwar N; Investigating the Quality Control, Antimicrobial, and Antioxidant Evaluation of the Ointment "Marham-i-Raal" Used in the Unani System of Medicine; Pharmaceutical and Biomedical Research; 10;1; 2949-8244;2024
117. Raghubanshi, Saleem M, Alam MT, Khatoon A, Idrees M, Sahar N; Jast (Zinc) an Essential Inorganic Element for Biological Function and Human Health Studies: A Review; International Journal of Current Microbiology and Applied Sciences; 14(1); 184 - 192; 2319-7706;2025
118. Ibrahim T, I Kalam MA; Kabābchīnī (Piper cubeba L.F.): A comprehensive review of its medicinal and therapeutic Applications in Unani Medicine; Journal of Medicinal Plants Studies; 12(4);429-434; 2320-3862;2024
119. Sheeraz M, Sahiba, Ali A, Jalal B; KĀBŪS: The Incubus Phenomenon in Unani Medicine -Evolution Contemporary Insights, And Effective Therapeutic Approaches: A Comprehensive Review; International Journal of Creative Research Thoughts; 12 (9); 37-45; 2320-2882;2024
120. Arshi, Kalam MA, Zahoor U; Kibrit (Sulphur): Medicinal Importance in Perspective of Unani Medicine and Pharmacological Studies; Indian Journal of Unani Medicine; 17(2);165-173; 0974-6065;2024
121. Bhaktiari SS; Kitab –Al-Mia fit Tibb "Hundred Chapters on Medicine" a Lexicon of Greecoarabic tibb pathology; International Journal of Innovative Research in Technology; 11;8; 2349-6002;2025
122. Salati HA, Kalam MA, Wani TB, Zahoor U, Jan U, Bhat AA; Kundur (Boswellia Serrata): Medicinal Importance in Perspective of Unani Medicine and

- Pharmacological Studies; International Journal of Ayurvedic and Herbal Medicine; 14(6);4646-4657; 2249- 5746;2024
123. Akhlaq S, Akhlaq S, Khan M, Fazil M, Akram U, Haque M, Ahmad B, Sayeed A, Quddusi N; *Lawsonia inermis* L.: an updated review of the ethnobotanical phytochemical, pharmacological, and toxicological aspects in Unani Medicine; Indian Journal of Unani Medicine; 17(1); 20-31; 0974-6065;2024
124. Khatoon A, Ahmad F, Rauf E, Khan MN; Leucorrhoea-A Review; World Journal of Pharmacy and Pharmaceutical Sciences; 13(6);1406-1411; 2278-4357;2024
125. Salam M, Alam MT, Khan N, Azeem MA; Limb Girdle Muscular Dystrophy (LGMD) and its Management through Unani System of Medicine: A Case Study; International Journal of AYUSH Case Reports; 8(2);234-241; 2457-0443;2024
126. Kalam MA, Bilal, Riyaz, Chand; Lokāt (*Eriobotrya japonica*; family: Rosaceae): Nutritional and Medicinal Properties, in the Light of Unani Medicine and Scientific Studies; European Journal of Medicinal Plant; 35(6);94-104; 2231-0894;2024
127. Rafeeqi TA, Shah A, Ara N, Ahmed NZ, Raheem, Kumar P, Akbar S; Long-term Safety of Coded Unani Formulation and PUVASOL in Patients with Vitiligo - A Randomized Comparative Controlled Clinical Trial; Hippocratic Journal of Unani Medicine; 17 (1); 20-24; 0974-1291; Jan–Mar 2022 Published in 2025
128. Mahajan HD, Ahmad I, Salunke P, Shirsat P, Manyar A, Sayyed G, Khan S, Kinjal VD; Mahajan H. Formulation and evaluation of mucoadhesive buccal film of azilsartan medoxomil by solvent casting method; Cuestiones De Fisioterapia; 54(4);414-427; 1135-8599;2025
129. Sahar N, Khan N, Sabir, Bushra; Majoon suparipak: A Remarkable Unani drug for Women; Indian Journal of Medical Research; 6(3); 1-7;2024
130. Rahman Z, Alam S, Ahmad I, Shaikh N, Adil M, Devi MKN, Hussain N, Javed G; Management of Bawl fi'l Farāsh Ibtidayi (Primary Nocturnal enuresis) through Unani medicine: A Case Report; International Journal of Health Sciences and Research; 14(7); 192-197; 2249-9571;2024
131. Rahman Z, Alam S, Ahmad I, Shaikh N, Adil M, Devi MKN, Hussain N, Yadav P; Management of Dubayla al-Kabid (Liver abscess) in Unani medicine: A review; Journal of Drug Delivery & Therapeutics; 14(5);191-193; 2250-1177;2024
132. Shahid A, Quamri MA; Riyazuddin M; Management of Tinea incognito with Unani medicine: A case report; Journal of Ayurveda Case Reports; 7(2); 109-113; 2321-0435/ 2582-7693;2024
133. Zaidi SS; Managing Diabetes through Selfcare, key strategies for better health, Souviner; A Publication by Unani Doctors Association, Barbabanki, third edition 2025-26; ;62-63;2025
134. Rashid Q, Qureshi MA, Fatima Y; Marham Ahmar: A comprehensive Analysis of it's therapeutic efficacy and composition"; World Journal of Pharmaceutical Research; 13(11);497-502; 2277-7105;2024

135. Prakash R, Waseem A, Siddiqui AJ, Naime M, Khan MA, Robertson AA, Boltze J, Raza SS; MCC950 mitigates SIRT3-NLRP3-driven inflammation and rescues post-stroke neurogenesis.; *Biomedicine & Pharmacotherapy*; 183;2025
136. Husain N, Jamali MAH, Akhtar J, Akram U, Ahmed NZ; Medicinal leech therapy and grated unripe papaya bandage for the treatment of chronic leg ulcer: A case report; *Chinese Journal of Plastic and Reconstructive Surgery*; 01-04;2025
137. Waheed MA, Zaigham M, Hamiduddin, Ali; Modification and physicochemical Evaluation of Naque Nazla a Unani Infusion preparation for cold and flu into soluble granules; *Pharmacognosy Research*; 16(4);837-853; 0974-8490;2024
138. Naikodi MAR, Chaithra D; Murraya koenigii (L.) Spreng; *Medicinal and Aromatic Plants of India, Vol. 3. Medicinal and Aromatic Plants of the World*; 11;245-256; 978-3-031-75660-3;2024
139. Alam MM, Mustehasan, Akram U, Ahmad M, Ahmed NZ; Nanotechnology in the Unani System of Medicine: A Comprehensive Review and Hypothesis; *Advances in Integrative Medicine*; 8(1);2025
140. Fazil M, Nikhat S; Neuropharmacological profile of Ḥabb-e-Ṣar': A Unani pharmacopeial formulation for epilepsy; *Phytomedicine Plus*; 5;100769; 2667-0313;2025
141. Sheeraz M, Ahmad SA, Hamid S; Neuroprotective strategies in Unani medicine for managing autism spectrum disorders: A holistic approach; *International Journal of Unani and Integrative Medicine*; 8(3);8-13; 2616-454X;2024
142. Husain S, Bibi C, Arish, Sherwani MK; Nutritional and Therapeutic Values of Cow Milk: A Comprehensive Review; *Journal of Drug Delivery and Therapeutics*; 14; 180-184; 5;2024
143. Ajaz AB, Kalam MA, Nasir NW, Jaweriya M, Aaqib A, Avid M, Riyaz A; Pān (Piper betle L.): An assessment on medicinal profitability in outlook of Unani medicine; *International Journal of Unani and Integrative Medicine*; 8(3);14-19; 2616-4558;2024
144. Rashid Q, Qureshi MA, Fatima Y; Pathophysiology and Management of Haemorrhoids in Unani Medical Practice; *World Journal of Pharmaceutical Research*; 13(11);534 to 543; 2277-7105;2024
145. Ansari AP, Arokiarajan MS, Christopher J, Anwar N, Ahmed NZ, Shazia F, Ahmed KK; Pharmaceutico-analytical standardization and in vitro anti-diabetic potential of Qurṣ Dhayābītus Khāṣ (Unani formulation)- A preliminary scientific appraisal; *Next Research*; 2;1; 3050-4759;2024
146. Devi U, Ansari SA, Khan AS, Ahmad A, Ahmed MW, Meena RP; Pharmacognostic evaluation and development of quality control parameters for Fufal (Areca nut); *The Journal of Phytopharmacology*; 13;13; 3;2024
147. Fathima AF, Shamsi S, Irfhan M, Ahmed NZ, Raiza J, Mageswari S, Anwar N; Pharmacognostical standardization, phytochemical evaluation and contaminants

- determination of *Ustukhudūs* (*Lavandula stoechas* Linn) – A potent Unani drug; *Research Journal of Pharmacy and Technology*; 017(11);5499-5508; 0974-360X;2024
148. Rifat I, Kalam MA, Khanday S, Yousuf A, Salim S; Pharmacognostical Study of *Jar-UI-Nahr* (*Potamogeton Natans* Linn.) (Whole Plant) Found in Dal-Lake Kashmir; *Indian Journal of Unani Medicine*; 17(2);97-109; 2249- 5746;2024
149. Kancherla M, Dr. Mageswari S, Ahmed KK, R Murugeswaran, Ahmed NZ, Meena RP, Kumar P; Pharmacognostical, Physicochemical Properties and HPTLC Analysis of *Asteracantha Longifolia* nees.–seed; *World Journal of Pharmaceutical Sciences*; 13;1; 2321-3310;2025
150. Sheeraz M, Uzma H, Zahoor U; Pharmacological Role of *Habb-I-Shifa* in Ameliorating Addiction of opioids: A Review; *World Journal of Pharmacy and Pharmaceutical Research*; 2(1); 14-23;2025
151. Ahmed MW, Asif M, Ahmed R, Khan AS, Raza R; Pharmacology, nutrition value and therapeutic potential of honey: A review; *Journal of Pharmacognosy and Phytochemistry*; 13; 40-47; 1;2024
152. Chaithra D, Naikodi M.A.R., Shaik G, Nimmanapalli Y, Nazeer M, Siddiqui J I, Siddiqui A, Munshi YI; Phenological and propagation studies of *Curcuma neilgherrensis* Wt, a wild medicinal plant; *Annals of Phytomedicines*; 13(1);1069-1083;2024
153. Mustafa A, Siddiqui Z A, Alvi A I, Akhter G, Javed G; Physico and phyto-chemical evaluation of seeds and their extracted crude oil's characteristic of a nutritionally important plant *Daucus carota* linn; *Research Journal of Pharmacognosy and Phytochemistry*; 16;17-22; 1;2024
154. Alam RMT, Amir, Sabir B, Idrees M, Khan M; Physicochemical and Atomic Absorption Spectroscopic (AAS) Study of *Taus* (*PavoChristatis*) Feather *Sokhta* (Moharraq); *World Journal of Pharmacy and Pharmaceutical Sciences*; 13(6);1681-1688; 2278-4357;2024
155. Ashraf N, Naikodi M A R, Kumar G S, Ahmed T, Munshi Y I, Zakir M.; Physicochemical standardization, evaluation of antioxidant and antimicrobial activity of a polyherbal formulation; *Annals of Phytomedicine*; 13(2);726-733;2024
156. Shamy A M, Christopher J, Wasim A SA, Ahmed N Z, Meena R P, Ahmed KK; Phyto-chemical, analytical evaluation and biological attributes of rare medicinal species of flowering shrub *Bauhinia racemosa* L.; *Advances in Traditional Medicine*; 24;1181–1203; 2662-4060;2024
157. Ansari A P, Habib A, Arzoo K S, Mariyam Z, Asif M, Anwar N; Phytochemistry, Pharmacology and Therapeutic Potential of *Su'ad Kūfī* (*Cyperus rotundus* L.): An Insight; *European Journal of Medicinal Plants*; 35;6; 2231-0894;2024

158. Pratap G P, Husain M K, Prasad S B, Gurav a M, Alam M, Prasad G P, and Munshi YI; Phyto-Pharmacognostical Standardization on Three Morpho-Variants of *Cissus quadrangularis* L.; *Pharmacognosy Research*; 16 (3);518-530; ISSN: Print -0976-4836, Online - 0974-8490;2024
159. Padgilwar S, Pokale P, Kote P, Sayyed G, Garje S, Shinde S, Ahmad I, Naznin S I; Plants' Potential for Radioprotection against the Effects of Ionising Radiation; *Cuestiones De Fisioterapia*; 53(3);260-272; 1135-8599;2025
160. Sheeraz M; Possibilities and Opportunities of Unani Medicine in Arctic countries: A Review; *Indian Journal of Unani Medicine*; 17(1);50-61; 0974-6065;2024
161. Habib A, Arzoo A S, Kalam M A, Aziz A, Ahmad B; Post-I-Halela Zard (*Terminalia Chebula* Retz.): An Overview of theKey Medicinal Plant and Therapeutic Uses in the Unani System ofMedicine; *International Journal of Ayurvedic and Herbal Medicine*; 14(5);4492-4502; 2249- 5746;2024
162. Abdullha M, Khan A M, Qurashi M A, Ali S A; Prevalence of Functional Gastrointestinal Disorders in Schedule Cast Dominant Rural Population of Bhopal M.P.; *International Journal of Pharmacy and Medical Sciences*; 8(2);001-005; 2581-3277;2025
163. Amir B M, Ansari A H; Prevalence of Wajs 'al-Mafasil in the patients of Dhayabitus, attending NIUM, hospital: A cross-sectional study; *International Journal of Community Medicine and Public Health*; 12;1; 2394-6032;2025
164. Husain M T, Husain S, Khan N, Siddiqui Z A, Siddiqui Z H; Prevention and Management of Skin Aging in Unani System of Medicine: A Narrative Review; *Alternative therapies in health and medicine*; 12;34-35; 3;2025
165. Ansari Y, Raheem; Prevention and Management of Sahar (Insomnia) Through Unani System of Medicine: An Overview; "Paripex - Indian Journal of Research; 13;41-43; 10;2024
166. Ansari A P, Ahmed N Z, Anwar N, Ahmed KK; Protective and therapeutic role of Itrifal (Unani dosage form) in neuro behavior, neurodegeneration, and immunomodulation: an appraisal; *Brain Behaviour and Immunity Integrative*; 7;(1-15); 2949-8341;2024
167. Uvais MA, Khan S, Ashraf B, Naqqash N and Ibrahim T; Pukhraj (Topaz): A Review on Medicinal Utility in Perspective of Unani Medicine; *Indian Journal of Unani Medicine*; 17 (2);110-114; 0974-6065;2024
168. Raghubanshi, Amir, Akam M T, Bari B, Sehar N, Siddiqui Z H, Khatoon A, Idris M, Khan M N F, Akhtar J; Qalae (Stannum) metallic origin element, its chemical compound action therapeutic uses adverse effect and pharmacological activity studies: A Review; *Journal of Drug Delivery and therapeutics*; 14(7);136-141; 2250 -1177;2024
169. Kotagasti M N, Manumula K, Begum M, Kotagasti T, Raza A; Qillat-e-Darqiyya (Hypothyroidism): A Comparative Approach Between Conventional Medicine

- and Unani System of Medicine; Journal of Infertility and Reproductive Biology; 12(1);001-005;2024
170. Jabeen J, Qamar U, Kazmi MH; Qillat-i-Darqiyyat Aşlî (Primary Hypothyroidism) and its management in Unani system of medicine; Hippocratic Journal of Unani Medicine; 16 (4);001-012;Oct-Dec-2021 Published in 2024
171. Sagar P K, Kashyap S, Kurele R and Ahmed MW; Quality assurance, shelf life, stability studies of ASU herbal, medicinal plants-Syzygium aromaticum (Linn.) Merr LM Perry and W. fruticosa (Linn.) Kurz; Journal of Pharmacognosy and Phytochemistry; 13; 323-333; 4;2024
172. Qayoom I, Ansari A P, Huzaifa A, Bhat M M, Reshi B M, Goswami P, Anwar N; Quality Control and Acute Toxicity Study of Habb-i-Hayat (Unani Formulation) in Albino Wistar Rats; Pharmacognosy Research; 16;1; 0976-4836;2024
173. Devi N MK, Adil M, Shaikh N, Ahmad I, Alam S, Yadav P, Javed G; Randomized Control Trial to Study the Effect of Coded Unani Formulation UNIM-904 and Amlodipine on Serum Lipid Profile and Electrolyte Level in Patients with Essential Hypertension; Indian Journal of Public Health Research and Development; 16(1); 312-318; 0976-5506;2024
174. Rajaram M, Ashok M, Swathi M; Rheumatoid Arthritis (Waja-ul-Mafasil) – It's Concept & Understanding in Unani Medicine - A Review; International Journal of Creative Research Thoughts; 12 (3); a798-a805; 2320-2882;2024
175. Ahmad T, Priyanka P, Chakraborty A, Fatima SH, Jabeen A, Javed G, Yadav PK, Munshi YI, Ahmed NZ; Role of IFN- γ Gene expression and its variants in vitiligo pathogenesis among South Indian population; Indian Journal of Clinical Biochemistry; 39;2024
176. Bibi C, Husain S; Role of Jawarish Amla as an adjunct to anti-tuberculosis drugs in the symptomatic relief of pulmonary tuberculosis; International Journal of Community Medicine and Public Health; 11;3976-3982; 10;2025
177. Kalam MA, Sahiba, Ahtesham A; Role of Unani Medicine in Dumbal (Furuncles) Management: An Evidence-Based Case Report; International Journal of AYUSH Case Reports; 8(3);364-371; 2457-0443;2024
178. Siddiqui Z H, Arshad M, Sehar N U, Ahmad F, Naime M, Bari B, Amir, Akhtar J and Mohd Khan N; Role of Unani Medicine in Stress Management: An Integrative Approach; Paripex - Indian Journal of Research; 12;67-68;2;2024
179. Ahmed K, Ahmed NZ, Ahmed W, Parvez A, Anwar N; Safety and efficacy evaluation of Unani pharmacopoeial formulation La'uq Badam in patients with Khushuna al-Halaq (Sore throat) (NUMC: C-119): An open-label single- arm study; Hippocratic Journal of Unani Medicine; 16; 4; 0974-1291; Oct-Dec-2021 Published in 2024
180. Rashid R, Rather S A, Shabir; Safety and efficacy of decoction obtained from Asparagus officinalis and Cucumis melo in the management of nephrolithiasis:

- single blind, randomized, active controlled parallel arm study; International Journal of Community Medicine and Public health.; vol.11;3883-3891; 2394-6040;2024
181. Ansari M, Khan N A, Munshi YI; Safety Evaluation of a Unani Pharmacopeial Formulation Qurş Mafāşil Jadīd on the World Health Organization Parameters; Hippocratic Journal of Unani Medicine; 17(2);62-66; 0974-1291;Apr-Jun-2022 Published in 2025;
182. Ansari Y; Sanitary Conditions of Few Urban Slums in New Delhi: A Cross-Sectional Study; International Journal of Research in Medical Sciences; 12;4193-4197; 11;2025
183. Urzeeba Z. Kalam MA, Berjes, Huzaifa S, Uzma Lone, Avid M.; Sarakhs (Dryopteris fihlix-mass): Medicinal importance in perspective of Unani Medicine and Pharmacological studies; Indian Journal of Unani Medicine; 17;45444; 0974-6065;2024
184. Ansari Y; Satawar (Asparagus Racemosus): Astounding Medical Benefit; Global Journal for Research Analysis; 13;35-37; 3 2025
185. Sagar P K, Sajwan S, Mageswari S, Ahmed MW, Kashyapand S, Venkatesan K; Scientific assessment, research studies of botanical, pharmacognostical, biodiversity and toxicological of ASU herbal drug Kaladana/Habb-ul-Neel (Ipomoea nil (Linn.) Roth.) seeds; Journal of Pharmacognosy and Phytochemistry; 13;112-123; 5;2024
186. Tahseen Z, Yadav C; Serological insights and clinical patterns of dengue fever in a tertiary care hospital: a survey-based study; Journal of Ideas in Health; 8(1);1240-1246; 2645-9248;2025
187. Rafeeqi T A, Pandith R A, Humma A, Shah A, Zakir M, Anjum N, Ara I, Ahmed NZ; Serum biomarkers in rheumatoid arthritis patients and effect of Unani herbal formulation Qurs-e-Hudar on these biomarkers suggesting the anti-IL-6 effect; Journal of Herbal Medicine; 100999;45839; 2210-8033; 2025
188. Nikhat S, Fazil M; Shortening the long-COVID: An exploratory review on the potential of Unani medicines in mitigating post-Covid-19 sequelae; Phytomedicine Plus; 4;100570; 2667-0313;2024
189. Duhan L., Kumari D., Naime M., Parmar VS., Chhillar AK., Dangi M., Pasrija R; Single-cell transcriptomics: background, technologies, applications and challenges. Molecular Biology Reports; Molecular Biology Reports; 51 (60); 1-16; 0301-4851/ 1573-4978;2024
190. Tabassum S, Haq J, Ramesh M & Shamshad M; Socio Demographic and Health Profile of Scheduled Tribes of Six ITDA in Kurnool District - A Survey Report; Indian Journal of Health Care, Medical & Pharmacy Practice; 5(1);29-36; 2583-2070;2024

191. Kalam MA, Jan U, Yaqoob F, Ayoub M, Wani TB and Salati HA; So'd Kūfi (Cyperus rotundus): A Review on Pharmacological Actions and Therapeutic Uses of a Unani Drug; Alternative Medicine & Chiropractic Open Access Journal; 5(1);18-31; 2642-0171;2025
192. Ali S, Rasool I, Sidra, Sadakattullah S; Somatotype difference in sanguine and choleric temperament: A comparative study based on Unani literature and health-carter anthropometric method; African Journal of Biological Sciences; 2;15; 2663-2187;2024
193. Fazil M, Sayeed A, Ahmad B, Haque M, Quddusi N; Standard Operating Procedures for Hijama (Cupping Therapy); Published by Central Council for Research in Unani Medicine, New Delhi; 978-93-94347-82-3;2024
194. Tanveer F J, Naikodi M A R, Viquar U, Zakir M, UrooJ M, Husain M K, Munshi Y I and Husain G M; Standardization and evaluation of the antiulcer potential of a traditional polyherbal formulation in experimental animals; Annals of Phytomedicine: An International Journal; 13(1); 656-666;2024
195. Devi N MK, Adil M, Shaikh N; The Effects of Unani Formulation Jawarish Bisbasain Dyslipidaemia and Anthropometric Parameters Associated with Central Obesity: An Open-Label Clinical Trial; Indian Journal of Public Health Research and Development; 15; 346-353; 0976-0245;2024
196. Amir M, Parvez A, Anwar N, Shazia F, Ahmed K; The origin, philosophy, core concepts and current practices of Unani system of medicine in South Asia. THITTAM (YOJANA –TAMIL); Published by Ministry of Informatics and Broadcasting, Govt. of India, Chennai Division; 1;(50-54); 0971-8362;2025
197. Akhlaq S, Ahmad B, Haque M, Fazil M, Akram U, Sayeed A and Khan AA; The Perpetual Impact of COVID-19 on the Geriatric Population's Quality of Life and Potential Preventive and Therapeutic Measures in Unani Medicine: An Evidence-based Review; Current Traditional Medicine; 10 (3); 61-74; 2215-0838;2024
198. Horti A, Husain N, Shaikh S, Imran S, Abbas SNA, Khan KAK; The Perspective of Unani Medicine in Understanding Melasma – A Review; Current Cosmetic Science; 3(1); 45627;2024
199. Christopher J, Akram A W, Shamyia M A, Jameel M, Kumar TS, Ahmed VM, Anwar N, Ahmed KK; The Qualitative and histo- anatomical validation of Daucus carota L., fruit along with in vitro cytotoxic, antioxidants and antimicrobial analysis; Food and Humanity; 3; 2949-8244;2024
200. Fatma B, Nomani AN, Khan SN, Mustafa S; The Role of Oxidative Stress in Gestational Diabetes Mellitus; International Journal of Health Sciences and Research; 14; 10; 2249-9571;2024

201. Hasan I, Mehraj N; The role of Unani medicine in enhancing sleep quality: Traditional approaches for modern lifestyle disorders; International Journal of Advance Research in Community Health Nursing; 1; 7; 2664-1666;2025
202. Ara SA, Itrat M, Jamal A, Siddiqui A, Akhlaq S; The Sequelae of Sleeping Issues and their Management in Post COVID-19: A Unani and Contemporary Narrative Review; Current Traditional Medicine; 10; 25-34; 7;2024
203. Rahman ZU, Adil M, Mudassir M, Salahuddin, Khan A; Therapeutic approach and management of Marz-e-Shayb (Premature greying of hair) in the perspective of Unani medicine: A case study; International Journal of Herbal Medicine; 13(1); 13-15; 2321-2187;2025
204. Sabir B, Usmani S, Raghubanshi, Sehar N; Therapeutic effect of polyherbal Unani formulation in case of hepatitis C: A case report; International Journal of Unani and Integrative Medicine; 9 (1);35 -36;2025
205. Sheeraz M, Rizwan A; Therapeutic Efficacy of Unani Medicine in the Management of Warne Ghudda -I-Madhī Sulb (Benign Prostatic Hyperplasia): A Case Report; International Journal of Ayush Case Reports; 135-140; 2457-0443;2025
206. Ansari Y, Raheem; Therapeutic Potential Health Benefits of Ashwagandha (Withania Somnifera); International Journal of Scientific Research; 13(3); 58-60; 3;2024
207. Kumar K, Tariq M, Rasheed A; Therapeutic profile of Fermented Ginseng: future prospective in India; International Journal of Herbal Medicine; 2;86-90; 2321-2187; 2024
208. Fida Z, Hussain Z; Therapeutic safety and efficacy of oral administration of Joshanda (Decoction) of Parsiaoshan (Adiantumcapillus veneris linn) in the management of Hasah-al- Kulya (Nephrolithiasis): A single blind randomized controlled study; African Journal of Biological Sciences; 06(12); 3978-3990; 2663-2187;2024
209. Chand K; Tinospora Cordila falia (Guduchi) An over view and its role in unani system of medicine; A Publication by Unani Doctors Association, Barabanki, third edition 2025-26; 64; 2025
210. Sheeraz M, Tooba; Topical Application of Herbal Unani formulation in the chronic Relapsing Dermatophytosis related Erythoderma: A Case Report; International Journal of Ayush Case Reports; 8(4);845-550; 2457-0443;2024
211. Siddiqui NA, Ansari MZ; Treatment Outcomes of Single-Dose Liposomal Amphotericin B-Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India; American Journal of Tropical Medicine and Hygiene; ;1-8; 0002-9637;2024
212. Kalam MA, Habib A, Babu C, Riyaz A, Nasir N, Ajaz A; Tukhm-i-Katān (Linum usitatissimum Linn.): An Important Medicinal Plant and its Uses in Unani System

- of Medicine; International Journal of pharmacy and pharmaceutical research; 30(4);268-282; 2349-7203;2024
213. Anurag Gupta A, Gayathri SL, Bhakat M, Mohanty TK, Chaturvedi KK, Kumar RR, & Kumar, S; Udder thermogram-based deep learning approach for mastitis detection in Murrah buffaloes.; Computers and Electronics in Agriculture; 220;2024; 1872-7107;2024
214. Shahid A, Tahseen Z. A, Sofi G, Sofia, Aazam S; Unani Approach to Graded Management of Thrombosis in COVID-19 Patients; Current Traditional Medicine; 11 (1); 2215-0838/ 2215-0846;2025
215. Abbas M, Hussain Z; Unani concept and management of Qarha Humudi (Peptic Ulcer): A Review; International Journal of Research and Analytical Reviews; 11(3);64-71; 2349-5138;2024
216. Sheeraz M, Akhtar F; Unani Concept and Management of Humma E Danaj (Dengue Fever): A Review; Journal of Emerging Technologies and Innovative Research; 11(4); 2349-5162;2024
217. Rao V, Hasan I, Boligarla A; Unani Dietotherapy (Ilaj Bilghiza) and Yogic Diet: A Comparative Analysis and Integration for Optimal Health; International Journal of AYUSH; 9; 13; 2349-7025;2024
218. Aamir BM, Shehilla, Meher AS; Understanding and Managing Waja'al-Mafāsil: Insights from the Unani Medicine System; Indian Journal of Modern Research and Reviews; 3;2; 2584-184X;2025
219. Gani R, Sheikh BA, Mir RA, Bhat BA, Dar PA, Mohany M, Dar MY, Bhat ZA; Unravelling the antianxiety activity of various fractions of aerial parts of *Salvia moorcroftiana* Wall. Ex Benth., by in vivo implicated through computational studies.; Natural Product Research; 38;01 to 12; 240 306;2024
220. Ahmed T, Viqar U, Munshi YI, Sultana N, Islam MF; Unveiling the healing properties of Khurfa (*Portulaca*); International journal of Creative research thoughts; 12(6); G34-g40; 23202882;2024
221. Anwar N, Ahmed KK, N. Ahmed NZ, Ansari AP, Shazia F; Validating ethnomedicinal claims of Itrifal Mulayyin 'a Unani Pharmacopoeial formulation' in patients with Şudā' (NUMC: A-36; IUMT-5.1.1) (headache disorders) – an open prospective clinical trial; Journal of Natural Remedies; 24;12; 2320-3358;2024
222. Asif M, Fatima S, Khan F, Shariq M, Alam M, Aslam A, Khan A, Siddiqui MA, Elnour R, Hashem M, Ahmad F; Weeds-derived compounds and their interaction assessment with *Meloidogyne javanica* using homology-built protein modelling; Physiological and Molecular Plant Pathology; 138;(5)102641; 0885-5765;2025
223. Khan S, Kalam MA, Bisma Ashraf B, Uvais M, Ibrahim T, Naqqash N; Zircon (Red Oxide of Lead): A Valuable Gemstone from Jawaharat-I-Tis'a Having Medicinal Potential in Perspective of Unani Medicine; Indian Journal of Unani Medicine; 17(2);127-130; 0974-6065;2024

224. Ahmed MW, Ahmed R, Husain S, Sajid M, Siddiqui ZA; यूनानी चिकित्सा के आधारभूत सिद्धांत; National Journal of Multidisciplinary Research; 9; 6-8; 3;2024
225. Shah A, Hanga AH, Iqbal A, Rafiq H, Ara I, Nighat, Bashrat; A Novel Treatment for Scabies with Herbal Formulation: A Clinical Safety Assessment Study; Journal of Drug Delivery and Therapeutics; 15(1); 59-66; 2250-1177;2025
226. Zaidi ZK, Allaqaband SM, Alam S, Nasir A; A pilot study to evaluate the efficacy of local application of Unani compound formulation in geriatric knee joint oa patients; Annals of Geriatric Education and Medical Sciences; 11(1); 15-18;2024
227. Ahmed R, Ahmed MW, Khan AS, Ansari SA; A Review on Anti-Cancerous Property of Single Unani Drugs; World Journal of Pharmaceutical Research; 13(8); 182-203;2024
228. Maqbool M, Geer MI, Ganie MA, Irfat Ara; An Investigation on the Therapeutic Synergy of Metformin and Qurs-e-Ziabetes in the Treatment of Type 2 Diabetes Mellitus; African Journal of Biomedical Research; 27(4); 10185-10193;2024
229. Akhtar S, Mudassir M, Faiz A, Khan P, Afza S, Ahmad F, Ahmed NZ.; Assessment of demographic attributes and health profile of schedule caste of 5 villages of Aligarh District, Uttar Pradesh, India.; International Journal Community Med Public Health; 11(6); 2373-9; 2394-6040;2024
230. Ansari AP, Ahmed NZ, Anwar N; Chapter 11. Role of common spices in prevention and management of neurodegenerative diseases. Medicinal plants for the management of neurodegenerative diseases.; USA: CRC Press, Taylor & Francis Group;2024
231. Anwar N, Ahmed NZ, Ansari AP; Chapter 16. Role of Delphinium denudatum (Jadwar) and Carthamus tinctorius (Safflower) their traditional knowledge, chemical derivatives, and potential benefits in the management of neurodegenerative diseases in the elderly. Medicinal plants for the management of neurodegenerative diseases.; USA: CRC Press, Taylor & Francis Group;2024
232. Ara SA, Ahmad B, Akhlaq S, Haque M, Fazil M, Akram U, Sayeed A, Quddusi N, Khan AA; Chapter 7: Exploring scientific validation of anti-inflammatory drugs used in Unani medicine for complementary health care: A critical appraisal with special reference of Dioscorides De Materia Medica.; Apple Academy Press. CRC Press, a Taylor & Francis Group; 1;2024
233. Ansari AP, Anwar N, Ahmed NZ; Chapter 8: Phytochemistry and Pharmacology of aquatic plants used in the Unani System of Medicine. In. Phytochemistry and Pharmacology of Aquatic plants and Pharmacovigilance. Crude Drugs of Unani Medicine; Apple Academy Press. CRC Press, a Taylor & Francis Group; 1;2024
234. Khan AS, Ahmed R; Chromatographical Authentication and Standardisation of Unani Herbal Formulation Habb-e-Suranjan; World Journal of Pharmaceutical Research; 13 (7); 363-648; 2277-7105;2024

235. Husain N, Jamali MAH, Abdullah, Khan SA; Chronic anal fissure treated with Unani formulation – A series of case reports; Gastroenterology & Endoscopy.2(1):52-55;2024
236. Khan MT, Anjum N, Parveen S, Naseem M; Clinical Validation of Unani Pharmacopeial Formulation Jawarish Pudina Wilayati in the management Of Sū' Al-Hazm (Dyspepsia); International Journal of Ayush; 13 (2); 16-25;2024
237. Mustafa A, Alvi AI, Zaki Siddiqui A, Chandra M, Javed G; Comparative Chemical Study of Three Different Market Samples of an Important Clay Mineral Drug "Gil-E-Makhtum" with A Brief Ancient Description of Earth's Natural Resources; Asian Journal of Research in Pharmaceutical Sciences. 14(3); 2024
238. Kalam MA, Ara I, Rafeeqi TA; Dalk or malish (Massage therapy): Application and benefits in the perspective of Unani Regimenal therapy; Futuristic Trends in Medical Sciences; 3(23); 90-108; 2024
239. Ammara U, Ansari MA, Qamaruddin, Husain N, Ahmad T, Fatima SH, Minhajuddin A; Evaluation of the efficacy and safety of a herbal formulation for rheumatoid arthritis – A non-inferiority randomized controlled trial; Journal of Ethnopharmacology; 325; 2024
240. Ahmed R, Ahmed I, Azharuddin M, Kharat AR, Ingole S, Sayyed G, Garje S, Chopade S, Kharat KR; Exploring the anticancer potential of crude extract containing bioactive secondary metabolites isolated from endophytic fungi of the host plant *Physalis angulata* L.; Cuestiones De Fisioterapia; 54(4); 4994-5002; 2024
241. Khan N, Zulkifile M, Wasim Ahmad W, Itrat M, Nilophar; Functional Abstract explanation of reproductive organs in perspective of Unani Medicine; Hippocratic Journal of Unani Medicine; 16(4);41-48;Oct-Dec-2021 published in 2024
242. Urooj S, Bhattacharyya A, Rej A, Jahangir U; Identification of the vulnerable section among the service class and the modes-adopted for the resilience; Hippocratic Journal of Unani Medicine; 16(4);63-78; Oct-Dec-2021 published in 2024
243. Ahmed F, Javed G, Mirza A; Khirni [*Manilkara hexandra* (Roxb.)]-A Review of its Uses in Unani Medicine, Phytochemistry and Pharmacology; Asian Journal of Dairy and Food Research; 0971-4456/ 0976-0563;2024
244. Bashir F, Parveen S, Ahmad F; Management of Neuropathic pain through Unani system of medicine; Frontiers in Health Informatics; 13(4);1253-63;2024
245. Alam S, Devi NMK, Akhtar J, Anjum N, Adil M; Management of Substance use disorders in Unani Medicine: An Insight; Acta Scientific Medical Sciences; 9(2); 90-99; 2582-0931;2025
246. Salam M, Sabir B, Iqra Hashmi I, Sehar N, Akhtar J; Management of Uterine Fibroid (Sal'An Al-Rahim) In the Unani Medicine Perspective - A Case Study; International Ayurvedic Medical Journal;2025

247. Abdullah, Khan SA, Siddiqui U & Sami M; Medicinal properties of Darchini (Cinnamomum zeylanicum): A review; International Journal of Herbal Medicine 12(2): 05-09;2024
248. Mustehasan, Azhar M; Momiyā'ī or Silājīt (pissasphalt), a unique healing drug of Unani Medicine: A review; Hippocratic Journal of Unani Medicine ; 16(4);13-29;Oct-Dec 2021 Published in 2024
249. Rahman Z, Shaikh N, Abdurrahman, Akram U, Akhtar J, Ahmed NZ; Natural Agents Used for the Management of Obesity in the Traditional Unani System of Medicine: A Comprehensive Review; Acta Scientific Medical Sciences; 9(2); 144-126; 2582-0931;2025
250. Devi U, Khan AS, Ansari S, Ahmed R, Meena RP; Pharmacognostic Evaluation and HPTLC Fingerprinting of Itrifal Mulayyan-A Unani Polyherbal Formulation; World Journal of Pharmaceutical Research; 13(6) ;544-562; 2277–7105;2024
251. Fazil M, Ahmad S, Ahmad B, Quddusi N, Haque M; Potential role of Khamīrah-i-Banafsha in outbreaks of respiratory illnesses: A critical review; Hippocratic Journal of Unani Medicine; 16(4); 31-40;Oct-Dec 2021 Published in 2024
252. Dar MA, Maqbool M, Qadrie Z, Ara I, Qadir A; Unravelling PCOS: Exploring its causes and diagnostic challenges; Open Health; 5; 20230026;2024
253. Jeelani SM, Ansari AH, Amir M; Unveiling the concept of Nisyan (Amnesia) in Unani Medicine- A systematic review; International Journal of Contemporary Research in Multidisciplinary; 3(6); 34;2024
254. Adil M, Devi NMK, Shaikh N, Alam S, Rahman Z, Yadav P; Variation of Haematological profile in Postmenopausal Women – A preliminary study; International Journal of Pharmaceutical Research and Applications; 9(2); 415-424; 2249-7781;2024
255. Khan MN, Jabeen A, Begum M, Rajaram M; Zeequn Nafs (Bronchial Asthma): Non-Communicable Disease - A Systematic Review Analysis; EC Clinical and Medical Case Reports; 7(11); 45298;2024

3.5. Extension of Healthcare Services

3.5.1. School Health Programme

The School Health Programme is aimed at improving the health and hygiene status of school children and to reduce morbidity rate among them through healthcare and health education. Under this programme, the Council's researchers visit selected Primary and Secondary Schools, particularly those in rural areas and urban slums. A baseline health check-up of school children is conducted and those found suffering from any ailment are treated with Unani medicines. Thereafter, health education is provided to them through lectures on different preventive, promotive, and curative health aspects, and health related literature is distributed. The children are also

educated about the potentialities of the commonly available plants in their vicinity for the management of different diseases. Specific lectures are given on oral hygiene, cleanliness of body and environment, safe drinking water, nutrition, balanced diet, etc.

During the reporting period, this programme continued at NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUMs, Aligarh, Srinagar, Chennai Patna, Mumbai and Bhadrak. The Council's physicians visited 26 schools that were adopted under the School Health Programme particularly those falling in the pockets adopted under Mobile Clinical Research Programme. A total of 4,249 school children were covered under this programme during 114 visits made to these schools. Out of them, 3,293 children were found suffering from different ailments and they were treated with Unani Pharmacopoeial Formulations. With a view to educate the children on healthy living, 119 lectures were delivered on preventive and promotive health aspects. The most common diseases found among them included cold & cough, dental cavities, tonsillitis, helminthiasis, skin infections, otorrhoea and conjunctivitis.

3.5.2. Unani Medical Centres in Allopathic Hospitals

Under the scheme of collocation of AYUSH centres in Allopathic hospitals in Delhi, a Unani Medical Centre was established at Dr. Ram Manohar Lohia (RML) Hospital on 14 January 1998 with a view to provide Unani treatment facility to the patients desirous of taking treatment of this system. On public demand, another Unani Specialty Centre started functioning at Deen Dayal Upadhyay (DDU) Hospital, New Delhi on 01 November 2010. Another Unani Medical Centre was established at VMMC & Safdarjung Hospital, New Delhi on September 13, 2020 One extension centre of RRIUM, Mumbai is also functioning at J J Hospital, Mumbai. These centres are run by the Council. Besides the General Outpatient Department (GOPD) facilities, these centres provide specialized Unani treatment for some selected disorders like vitiligo, eczema, psoriasis, rheumatoid arthritis, bronchial asthma, sinusitis, infective hepatitis, diabetes mellitus, etc.

During the reporting period, 34,171 patients were treated at Unani Medical Centre in Dr. RML Hospital, 26,821 patients at Unani Speciality Centre in DDU Hospital, New Delhi; 27,065 patients at Unani Medical Centre at Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi and 29,870 patients at J J Hospital, Mumbai. Patients visiting the centres were suffering from chronic diseases. Counselling of patients, particularly the senior citizens, was also done to improve their physical activities and mental health.

3.5.3. Health Melas / Camps

The Council organized health camps through its Institutes/Units with a view to create health awareness among the masses and to provide treatment through Unani

system of medicine. During the reporting period, 240 health camps were organized and 19,197 patients were treated in these camps. Lectures on preventive and promotive health aspects were also delivered by the physicians of the Council. Referral of the patients to the Council's centres as well as other hospitals was also done.

3.5.4. Activities under Gender Component Plan for Women

The Council continued research and treatment facilities for women under Gender Component Plan. Treatment facilities were made available to women at all clinical centres of the Council. Besides, female patients in the pockets adopted under Mobile Clinical Research Programme were treated by the physicians in the Mobile OPDs. During the reporting period, 5,25,513 female patients in different OPDs were treated. Efficacy of Unani pharmacopoeial formulations was also validated under this component. Health lectures / group meetings on preventive and promotive health aspects were also organized in the pockets adopted under Mobile Clinical Research Programme. Published literature on preventive, promotive, and curative health aspects was also distributed among the masses. Clinical studies on the diseases specific to female such as Ihtibas al- Tamth (amenorrhoea), Kathrat al-Tamth (Menorrhagia) Sayalan al-Rahim (leucorrhoea) and Su-ul-Qinya (Anaemia) also continued.

3.5.5. Activities in the North-Eastern Region

The two centres of the Council in the North-Eastern Region – Regional Research Institute of Unani Medicine Silchar and Clinical Research Unit, Imphal – continued Research/GOPD Programmes/Regimin Therapy activities.

During the reporting period, RRIUM, Silchar and CRU, Imphal continued Research/GOPD Programmes/ Regimenal therapy to the patients. A total of 74,305 beneficiaries were treated. The most commonly occurring diseases were Waja-ul-Mafasil (rheumatoid arthritis), Ishal (diarrhoea), Humma (fever), Sayalan al-Rahim (leucorrhoea), Su-ul-Hazm (dyspepsia), Hummā Ajāmiyya (malaria) and Zahir (dysentery). The patients were treated with Unani pharmacopoeial drugs and 1,124 patients were treated through Regimenal Therapy.

3.5.6. Ayush Wellness Centre - President Estate

Ayush Wellness Clinic was established in President Estate, in the year 2015 with a view to provide medical care through various streams of Ayush (viz. Ayurveda, Yoga and Naturopathy, Unani, Siddha & Homeopathy) to the officials of President's Secretariat and residents of the President's Estate.

During the reporting period, health care services were provided through OPD and Regimenal therapy to the patients. A total of 3,327 patients were treated in Unani Out Patient Department and 2,862 were treated in Regimenal Therapy.

3.5.7. All India Institute of Ayurveda, New Delhi

Unani Speciality Clinic was established in All India Ayurveda Institute, New Delhi, in the year 2015 with a view to provide medical care through unani streams.

During the reporting period, health care services were provided through OPD and Regimenal therapy to the patients. At All India Institute of Ayurveda, New Delhi, 3,391 patients were treated in Unani OPD and 2,707 patients were given Regimenal Therapies for different chronic ailments.

3.5.8. Mobile Healthcare Program under Scheduled Caste Sub plan

The CCRUM conducts a Mobile Healthcare Program under the Scheduled Caste Sub Plan (SCSP) at 12 peripheral institutes namely NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUMs- New Delhi, Chennai, Mumbai, Aligarh, Patna, and Kolkata; RRC, Prayagraj; and CRUs- Bhopal, Meerut and Bengaluru. This program aims to extend healthcare services to the Scheduled Caste (SC) population at their doorstep.

The objectives include screening and examining the health status of SC population through Mobile OPDs and health camps, and providing Unani treatment to patients suffering from various diseases. The program also seeks to raise awareness among the masses regarding preventive, promotive, and curative health aspects through lectures, health camps, and distribution of educational literature. Five villages with a predominantly SC population are identified for conducting the program at each center.

During the reporting period, a total of about 13.74 lakh individuals were covered, including approximately 8.63 lakh from the SC population, with 1,68,247 individuals benefitting from the program.

3.5.9. Mobile Healthcare Program under Tribal Sub plan

Similar to the Mobile Healthcare Programme under the Scheduled Caste Sub-Plan, the CCRUM operates a Mobile Healthcare Programme under the Tribal Sub-Plan (TSP) at RRIUMs- Bhadrak and Srinagar, and CRUs- Burhanpur and Kurnool. This Program extends healthcare services to the Scheduled Tribe (ST) population at their doorstep.

The program aims to screen and examine the health status of the ST population in Mobile OPDs and health camps, providing Unani treatment to patients suffering from various diseases. Additionally, it strives to create awareness among the masses on preventive, promotive, and curative health aspects through lectures, health camps, and distribution of literature. Five villages with a predominantly ST population are identified for conducting the program at each centre.

During the reporting period, a total population of about 93,000 was covered, including approximately 69,000 from the ST population, with 60,955 individuals benefitting from the program. Activities related to Janjatiya Gaurav Diwas were also organized during the year.

3.6. Linking Education with Research

With a view to link education with research and utilize the comprehensive facilities available at its institutes, the CCRUM is conducting postgraduate (MD) programmes in Unani Medicine at National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad and Regional Research Institute of Unani Medicine (RRIUM), Srinagar in affiliation with Kaloji Narayana Rao University of Health Sciences, Warangal (Telangana) and University of Kashmir, Srinagar respectively. During the reporting period, 33 students were admitted, with an intake of 09 students in each discipline of *Moalijat* (medicine) and *Ilm al-Adwiya* (pharmacology) at NRIUMSD, Hyderabad, 09 students in *Moalijat*, and 06 students in *Ilm al-Adwiya* at RRIUM, Srinagar.

The students were trained through a structured academic schedule comprising theory classes, hands-on practical classes, bedside teaching and dissertation projects. The institutes also organized monthly meeting for postgraduate training that included clinical and research skills, development of protocols, case presentations and discussions. Students were posted in various OPDs as well as IPD wards for clinical training on rotation basis. The academic activities also included seminars, journal club and tutorials. The faculty members conducted classes as per prescribed syllabus. The students were also engaged in their theses work, in addition to attending classes. During the reporting period, several meetings of Departmental Research Committee, Board of Studies and Institutional Ethics Committee were organized to deliberate, evaluate and approve the research proposals for thesis work.

3.7. Studentship Programme for Unani Research (SPUR)

The Studentship Programme for Unani Research was introduced by the CCRUM with 25 studentships after getting approval from the Ministry of Ayush in July 2024. The program is envisioned to promote research aptitude among undergraduate students of Unani medicine. Through this program, the Council aims to give an opportunity to the undergraduate BUMS students (3rd professional and final professional students) to explore the research technologies and methods at an early stage, which may serve as an incentive to choose a career in research.

This program is also a part of the activities under the MoU signed between CCRUM and NCISM to take forward the areas of cooperation. A separate website for SPUR, <https://ccrum-spur.org/>, was launched in August 2024 by the chairman of NCISM, Ministry of Ayush, Government of India. The timelines for different activities—

notification, registration and submission of proposal, evaluation, result announcement, receipt of acceptance, issuance of award letter, completion of project, submission of report, review of report, sanction of the stipend, and award of certificate—were fixed between September 2024 and July 2025. The Council has been able to successfully follow the timelines. Out of the 108 SPUR proposals received, 25 were selected, and the work on the approved studies is continuing.

3.8. Pharmacovigilance program of ASU & H drugs

Pharmacovigilance refers to the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug- or vaccine-related problems. While all medicines and vaccines undergo extensive clinical trials to assess their safety and efficacy before reaching consumers, post-marketing surveillance remains crucial to ensure continued patient safety. Over recent decades, the global use of Ayush systems has grown significantly due to their perceived efficacy, cost-effectiveness and relatively lowers risk of side effects. However, the widespread belief that Ayush medicines are entirely free from adverse effects is a misconception. Certain herbal ingredients have the potential to cause undesirable effects, especially when used irrationally or without proper guidance. This misplaced confidence often leads to self-medication and over-the-counter usage, limiting the understanding of potential adverse drug reactions (ADRs). Recognizing the importance of drug safety and public health, the Ministry of Ayush, Government of India launched a Central Sector Scheme for Promoting Pharmacovigilance of ASU&H Drugs in November 2017. The primary objectives of this initiative are to encourage the culture of reporting ADRs related to ASU&H drugs, monitor and report misleading advertisements and create awareness among AYUSH practitioners, pharmacists, health workers, patients and other stakeholders.

Drug safety has always been the major area of concern in Unani medicine, long before the Pharmacovigilance program came into existence. It encourages the rational and safe use of medication. CCRUM has been associated with the pharmacovigilance program of ASU&H Drugs from the very beginning. CCRUM, with its eight peripheral pharmacovigilance centres across the country is actively engaged in monitoring, assessing, understanding, preventing, and reporting adverse drug reactions (ADRs), scrutinizing misleading or objectionable advertisements appearing in print and electronic media, and reporting them to state drug licensing authorities. Further, it conducts awareness lectures, workshops, seminars and other IEC activities aiming to create awareness and foster a reporting culture among stakeholders including practitioners, pharmacists, health workers, and patients. During the reporting period, the Council has reported 119 ADRs, 1845 misleading advertisements, and conducted nearly 147 awareness programs.

The CCRUM advocates the consumers of Ayush drugs to consume these medications under the supervision of registered medical practitioner of concern

system of Ayush. They are advised to ignore misleading advertisements and avoid self-medication. They are also encouraged to report, if any adverse reactions they experienced after using these medications to the designated peripheral pharmacovigilance centres spread across the country.

3.9. Transfer of Technology for Commercialization

The CCRUM has undertaken several initiatives to commercialize its research-based drugs. These efforts aim to translate laboratory innovations into widely accessible Unani medicines that can benefit the public across the globe.

CCRUM's research and development activities are focused on formulating effective Unani remedies that can be adopted by pharmaceutical companies and other stakeholders. To facilitate commercialization, CCRUM signed a Memorandum of Understanding (MoU) with the National Research Development Corporation (NRDC) for the promotion and licensing of its research products, particularly those that are patented.

Below are some success stories of CCRUM's commercialization efforts:

Unani Toothpaste for Dental Care

This Unani toothpaste is a herbo-mineral formulation developed to promote oral hygiene, strengthen teeth, and support the prevention and management of periodontal diseases. In February 2025, NRDC, on behalf of CCRUM, licensed this formulation to the Unani company Dehlvi Naturals for commercial production and marketing.

Unani Regimen for Vitiligo

The Unani regimen for vitiligo consists of a herbal capsule (UNIM-001) and a herbo-mineral topical powder (UNIM-003). It has undergone clinical testing and has been found to be safe and effective in treating vitiligo. The regimen works by arresting the spread of the disease, preventing remission, and promoting re-pigmentation of the affected areas. In February 2025, NRDC licensed this treatment to Hamdard Laboratories for commercial use on behalf of CCRUM.

3.10 Strategic MoUs for Advancing Research and Development

Collaborative partnerships are essential for advancing research, fostering innovation, and building capacity across various disciplines. For the CCRUM, these partnerships enable access to diverse expertise, support interdisciplinary research, and promote Unani medicine nationally and globally. Through well-structured Memorandums of Understanding (MoUs) with leading research institutions, universities, and scientific organizations, the CCRUM facilitates knowledge exchange, skill enhancement, and

joint initiatives in critical areas such as drug discovery, safety and efficacy studies, standardization, and molecular research. By leveraging the collective resources and expertise of its partners, the CCRUM strengthens its research impact, addresses contemporary healthcare challenges, and integrates Unani principles into modern healthcare, reinforcing its role in public health and policy.

During the reporting period, the CCRUM forged collaboration with the following 09 imminent institutions and signed MoUs for different purposes:

S.No.	Name of the Institute	Date	Purpose
1.	Aligarh Muslim University (AMU), Aligarh	30 th April 2024	The purpose is to collaborate in any mutually agreeable field of research and education through different regional institutes which will encourage collaboration in research areas of mutual interest such as new drug development, preclinical safety and efficacy studies, pharmaceutical analysis, quality control (QC) and microbiological studies of Unani formulations.
2.	Amity University, Noida	27 th May 2024	A collaborative effort between CCRUM and Amity University, Noida will help in solving challenges associated with classical as well as new formulations of USM, its standardization and pharmacological evaluation.
3.	Government Unani Medical College, Chennai	19 th June 2024	The MoU is aimed at fostering collaboration in the fields of clinical research, patient evaluation, and the promotion of Unani medicine in the healthcare sector. The MoU encompasses the following objectives- Clinical Research, Patient Evaluation, Education and Training, Promotion and Dissemination of Research etc.

4.	Anna University, Chennai	19 th June 2024	The purpose of this MoU is to foster collaboration between CCRUM and AU and to provide mutual beneficial working opportunity to develop and validate the Unani formulation(s).
5.	Sher-e-Kashmir Institute of Medical Sciences (SKIMS), Srinagar	18 th July 2024	The MoU is focused on exploring several key aspects of integrating Unani medicine with modern medical practices, particularly in the context of clinical intervention, adjuvant therapy, and herb-drug interactions. The primary aim is to explore the role of Unani medicine as an adjuvant therapy to complement conventional medical treatments. This could involve integrating Unani medicines such as herbal formulations, dietary plans, and lifestyle regimens alongside modern medical protocols. One of the critical objectives of the MoU is to investigate herb-drug interactions between Unani herbal remedies and conventional pharmaceuticals. Both CCRUM and SKIMS aim to work together to generate robust scientific evidence on the clinical efficacy of Unani therapies. This could involve conducting randomized controlled trials (RCTs), observational studies, and laboratory investigations to validate the safety, efficacy, and mechanisms of action of Unani medicines when used in clinical settings.
6.	ICMR- National Institute of	13 th November	The MoU between CCRUM and the ICMR- NITM, Belagavi focuses

	Traditional Medicine (NITM), Belgavi	2024	on addressing critical public health challenges such as Antimicrobial Resistance (AMR) and Viral Hepatitis, with particular attention to research and development through the use of BCL-1 and BCL-2 laboratories (biosafety level labs). The collaboration aims to combine traditional medicine (specifically Unani medicine) with modern biomedical research to develop innovative solutions and contribute to scientific understanding. One of the primary aims of the MoU is to investigate the potential of Unani medicine as a source of novel antimicrobial agents to combat the growing issue of AMR. Traditional systems like Unani have a long history of using herbal and natural remedies for infections, and these could be studied for their ability to target drug-resistant pathogens.
7.	State Takmil-ut-Tib College and Hospital, Lucknow	16 th Dec 2024	The MoU between CCRUM and the State Takmil-ut-Tib College and Hospital, Lucknow is aimed at fostering collaboration in the fields of clinical research, patient evaluation, and the promotion of Unani medicine in the healthcare sector. Specifically, the purpose of the MoU is to encompass the following objectives- Clinical Research, Patient Evaluation, Education and Training, Promotion and Dissemination of Research etc.
8.	Bhaskaracharya College of Applied Sciences	18 th Dec 2024	The purpose is to collaborate in standardization and development of cookies, flakes and instant dalia

	(BCAS), Delhi University		from barley.
9.	CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu	22 nd Feb 2025	The purpose of this MoU is to foster collaboration between CCRUM and CSIR-IIIM and to provide mutual beneficial working opportunity to develop and validate the Unani formulation(s) and to initiate research in the areas of mutual interest including high altitude studies.

- An MoU was signed between CCRUM and School of Persian Medicine, Tehran University of Medical Sciences, Iran for cooperation in the field of Unani and Persian medicine during the visit of DG CCRUM to Tehran University of Medical Sciences (TUMS) for participation in the International Symposium on "Policy, Legal and Regulatory Landscape of Traditional and Complementary Medicine" during November 20-23, 2024

4. INFORMATION, EDUCATION & COMMUNICATION

4.1. Library Services

The CCRUM has a Library and Information Centre (LIC) at the Headquarters which aims to collect and preserve scattered literature on Unani Medicine, and to disseminate information to the researchers, academicians and practitioners of Unani Medicine.

During the reporting period, services of the LIC remained fully automated through Wide Area Network (WAN). The Centre provided its services to the readers through e-Granthalaya 4.0 Library Software that controls the Web Online Public Access Catalogue (Web-OPAC), circulation of books, etc. A total of 177 books were acquired and accessioned, out of which 48 books purchased and 129 books were received on complimentary basis. The acquired books were catalogued in e-Granthalaya 4.0 NIC software.

A total number of 2,405 books were in circulation including 54 books that were circulated through Inter-Library Loan Service to the Athens Academy Library and DELNET's member libraries. The library subscribed 3,543 issues of daily newspapers and 107 issues of popular magazines. In addition, 115 issues of journals were also received, out of which 29 were in Hindi language and 86 issues of Unani & Allied Medicines in Urdu & English, besides, the on-line journals.

The LIC carried out physical processing and barcoding of 84 books received after binding. The LIC provided spiral binding and photocopying, and reference services to the readers. Comb spiral binding of 237 documents and photocopying of 2,20,043 pages were carried out. Besides, long and short range reference service was provided through WhatsApp and e-mail to the researchers and allied staff members of the Council. A Facebook page was also maintained during the year with an objective of facilitating the researchers with reference services and recent updates.

The Library continued digital publication and circulation of Medical News Update Service among 780 subscribers on daily basis. The Selective Dissemination of Information (SDI) service also continued at the LIC. Under this service, 240 news clippings were collected, out of which important ones were sent to the Director General and also displayed on the library notice board.

To provide access of library resources to researchers, LIC is developing Digital Repository & Digital Archive of CCRUM publications. The library has also a digital archive of Medical News Update & CCRUM News to preserve them for future reference. The centre continued institutional membership of Developing Library Network (DELNET) during the year.

During the reporting period, 266 member and guest researchers visited the LIC to access its resources.

4.2. Organization of Conferences, Seminars, Workshops, etc.

4.2.1. Unani Day 2025 and International conference on Unani Medicine

The Central Council for Research in Unani Medicine (CCRUM) organized two-day International conference on Unani Day 2025 on the "Innovations in Unani Medicine for Integrative Health Solutions – A Way Forward" at the Vigyan Bhawan, New Delhi during 11-12 February, 2025.

Smt. Droupadi Murmu, the Hon'ble President of India inaugurated the International Conference on the occasion of Unani Day in the august presence of Dr. Jitendra Singh, Minister of State (Independent Charge), Ministry of Science and Technology, Ministry of Earth Sciences, Minister of State, Prime Minister's Office, Ministry of Personnel, Public Grievances and Pensions, Department of Atomic Energy & Department of Space, Government of India; Shri Prataprao Jadhav, Minister of State (Independent Charge), Ministry of Ayush & Minister of State for Health Family Welfare; Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush; Ms. Monalisa Dash, Joint Secretary, Ministry of Ayush; Dr. M. A Qasmi, Advisor (Unani), Ministry of Ayush; Dr. N. Zaheer Ahmed, Director General, CCRUM, Government of India and international delegates from nine countries and national delegates from reputed institutions attended the event.

Addressing the gathering, the President of India paid tribute to Hakim Ajmal Khan, a freedom fighter, educationist and eminent Unani Physician and congratulated CCRUM on the remarkable contributions to human health and well-being through Unani Medicine. She said that Unani Medicine, a system rooted in ancient wisdom, enriched over centuries, exemplifies the synergy between tradition and innovation. She added that innovation is the key to ensuring that this ancient system continues to serve humanity. The theme of this International Conference "Innovations in Unani Medicine for Integrative Health Solutions – A Way Forward" is quite relevant in this rapidly changing world. She emphasized that Innovations in Unani Medicine for Integrative Health Solutions will play a vital role in expanding the acceptability and recognition of Unani Medicine across the globe. She further said the Government of India, through the Ministry of Ayush, has taken significant steps to support and promote Unani Medicine. India has the widest network of educational, research, healthcare and pharmaceutical institutions of Unani Medicine. The Central Council for Research in Unani Medicine, with its network of 24 peripheral institutes, conducts high-quality research and plays a key role in the promotion and development of Unani Medicine.

Addressing the conference, Dr. Jitendra Singh, Minister of State (Independent Charge) highlighted the need to modernize Unani medicine through molecular biology, Artificial Intelligence, and advanced research to enhance its evidence-based credibility and

global reach. Shri Prataprao Jadhav, Union Minister of State (Independent Charge), Ministry of Ayush said that there is a need for integrating traditional knowledge with modern science to redefine Unani medicine's role in building a healthier, sustainable world. Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush, highlighted India's expanding global partnerships in the AYUSH sector, including collaborations with over 50 countries and a key agreement with the WHO for standardization.

During the valedictory session, in her address, Ms. Monalisa Dash, Joint secretary, Ministry of Ayush extended her warm greetings on the occasion and emphasized that Unani medicine, with its rich heritage and holistic approach, has immense potential to address contemporary health challenges. Encouraging stakeholders to actively engage, she urged them to leverage this platform for knowledge exchange, interdisciplinary partnerships, and efforts to enhance the scientific validation and accessibility of Unani medicine. The Ministry of Ayush is offering significant support for the development and promotion of Unani medicine.

On the occasion, Dr. N. Zaheer Ahmad, Director General, CCRUM, Ministry of Ayush expressed his gratitude to the dignitaries, academicians, researchers, industry leaders and CCRUM officials for their valuable contributions to the conference. He stated that the presence of Hon'ble President of India was a historic and overwhelming occasion. He summed up the proceedings of the conference which include the launch of books, videos, barley based Unani Ahaar, and proudly shared that the transfer of technology was done for the first time in the history of CCRUM. He further stressed CCRUM's pivotal role in pioneering advanced research, establishing state-of-the-art laboratories, and promoting evidence-based practices to elevate the global recognition of Unani medicine. By fostering innovation, upholding quality standards, and strengthening collaborations, Unani medicine can continue to thrive as a vital component of integrative healthcare, contributing to a healthier and more sustainable future.

Prof. Mohammad Afshar Alam, Vice Chancellor, Jamia Hamdard stated that Unani medicine has been the cornerstone for healthcare systems. It is relatively safe and has the ability to address contemporary health issues. He stated that no single system can address all health issues and so we need better collaboration and integration. Integrating health solution is not only for treating disease but also for promotion and improvement of lifestyle. Dr. M.A. Qasmi, Advisor (Unani), Ministry of Ayush, acknowledged the significance of the international conference in promoting Unani medicine. He emphasized the strength of diversity in Ayush systems and described Unani medicine as balanced and aligned with nature. He also highlighted Ayush as both a heritage and a living science, reinforcing the conference's commitment to research, innovation, and global collaboration.

The International conference had nine scientific sessions which includes - Harnessing Artificial Intelligence and Machine learning for Ayush/Traditional Medicine: Prospects

and Challenges, Unani Medicine for Globalized Health-Unlocking New Opportunities, Moving towards Sustainable Development Goal-3: Good Health and Well Being, Integrating Traditional Medicine into Healthcare Systems, Unani Perspectives on Mental Health and Well-Being, Development of Unani Ahar (Diet): through Scientific Approach, Evidence based recent research trends in Unani Medicine, Advancements in Regimenal therapies (Ilaj biltadbir) and Translational Research in Unani/traditional systems of medicine.

In the conference, national and international experts from health sciences shared their knowledge and expertise. Delegates from the United States of America, South Africa, Iran, Malaysia, United Arab Emirates, Tajikistan, Uzbekistan, Sri Lanka and Bangladesh participated in the conference. Stakeholders from industry, academia, and research organizations involved in Unani Medicine also attended the event. The conference witnessed strong participation both in person and online.

The conference also witnessed the transfer of patented technology, developed by CCRUM. The technology was transferred by NRDC on behalf of CCRUM to industry. The technology for Unani toothpaste for dental care was transferred to Dehlvi Naturals while the technology for Unani Regimen for Vitiligo was transferred to Hamdard Laboratories.

On this occasion, various publications of CCRUM and conference souvenir were released. Also NABL and NABH certificates were given to CCRUM institutes. A short video showcasing the Council's recent initiatives was launched. Furthermore, Certificates of Appreciation was given for the best research papers, outstanding contributions to Unani medicine, and the best-performing institutions. The conference offered a dynamic platform for meaningful dialogue, knowledge exchange, and networking among stakeholders, while highlighting the vital role of Unani Medicine in promoting global health.

4.2.2. National Seminar on *Ilaj-bit-Tadbeer* (Regimenal Therapy)

The CCRUM's Regional Research Institute of Unani Medicine (RRIUM), Srinagar organized two days national seminar on "Innovations in Regimenal Therapy: Combining Traditional Methods with Contemporary Research" during 18-19 July, 2024 at Gandhi Bhawan, University of Kashmir Srinagar. The seminar was aimed to enhance awareness about regimenal therapy, a core component of Unani Medicine that emphasizes life style modifications and physical therapies for Holistic health.

During the inaugural session, Prof. Nilofer Khan, Vice Chancellor of the University of Kashmir, was the Special Guest of Honour. In her address, she congratulated the organizers for arranging such a seminar. She spoke about the activities of RRIUM and expressed her satisfaction with the institute's academic and patient care initiatives. Prof. Shakeel Ahmed Ramshoo, Vice Chancellor, Islamic University of Science and

Technology (IUST), Awantipora highlighted the ongoing collaborations between the two institutes and discussed the research proposals currently under process between IUST and RRIUM Srinagar. During the inaugural function, Prof. M. Ashraf Ganie, Director of Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar emphasized the need for integrating different systems of medicine for the betterment of humanity and expressed his willingness to collaborate with RRIUM, Srinagar.

Smt. Bhavana Saxena, Joint Secretary, Ministry of Ayush, Government of India presided over the function. Dr. Mushtaq Ahmad Rather, Director, Health Services, Kashmir graced the occasion as the Chief Guest and Department of Indian Systems of Medicine (ISM), Ayush, Jammu and Kashmir was Guest of Honour of the valedictory function.

In his welcome and introductory remarks, Dr. N. Zaheer Ahmed, Director General, CCRUM, highlighted the development of SOPs on Hijamah, an important regimenal therapy in Unani medicine, emphasized the significance of organizing the seminar on regimental therapy, and encouraged all participants to adopt the latest technologies and innovations in this field.

The occasion also marked signing of MoUs between the CCRUM and CSIR-Indian Institute of Integrative Medicine, Jammu and Kashmir as well as the Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar. On this occasion, hands-on training was also provided to the participants, which proved beneficial in enhancing the practical skills of approximately 250 attendees, thereby improving the efficacy of the procedures and ensuring patient safety.

The programme concluded with a vote of thanks by Dr. Ghazala Javed, Assistant Director (Unani) and Technical Head, CCRUM to the dignitaries and participants of the seminar.

4.2.3. Orientation cum Induction Workshop on Core Research Programmes of CCRUM, Research Methodology and HRD for Research Officers (Unani)/Scientist Level-1

The CCRUM's National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad organized two-day "Orientation cum Induction Workshop on Core Research Programmes of CCRUM, Research Methodology and HRD for Research Officers (Unani)/Scientist Level-1" on 26-27 September, 2024 in hybrid mode.

Smt. Bhavana Saxena, Joint Secretary, Ministry of Ayush, Government of India graced the workshop as the Chief Guest. She congratulated CCRUM on organizing the workshop, emphasizing that it would play a significant role in enhancing the skills and competencies of the newly inducted Research Officers, thereby ensuring they are well-prepared to contribute meaningfully to scientific research in Unani Medicine.

Dr. S. Glory Swarupa, Director General, NI-MSME, Hyderabad appreciated the efforts of CCRUM and motivated new research officers to excel and perform well in all facets of life.

Dr. N. Zaheer Ahmed, Director General of CCRUM, highlighted the functioning of the Council and its achievements in the field of Unani medical research. He also encouraged the officers by sharing his own experiences and urged them to give their best while making the most of the various opportunities available within the Council. Prof. Asim Ali Khan, Former Director General, CCRUM and Dr. M.A. Waheed, Former Director, CRIUM, Hyderabad were also present in the event. Dr. Younis Iftikhar Munshi, Director Incharge, NRIUMSD, Hyderabad shed the light on the activities of the institute.

About 150 delegates, including Research Officers (Unani) and scientists from various states across the country, participated in the workshop. The participants also shared their feedback on the program.

4.2.4. National Seminar on "Harnessing Artificial Intelligence and Machine learning for Ayush: Prospects and Challenges"

The Central Research Institute of Unani Medicine (CRIUM), Lucknow organized a one-day national seminar on "Harnessing Artificial Intelligence & Machine Learning in Ayush - Prospects and Challenges" on 16th December, 2024.

Dr. N. Zaheer Ahmad, Director General, CCRUM, in his welcome address gave a brief overview of the functioning of CCRUM and highlighted the integrated in the area of Artificial Intelligence (AI) and Machine Learning for AYUSH Prospects and Challenges. Prof. Javed Mussarat, Vice Chancellor of Integral University, Lucknow, stated that traditional medical procedures like cupping therapy can be automated with the help of Artificial Intelligence (AI), particularly through advancements in Artificial Intelligence and Machine Learning. Dr. Radha Rangarajan, Director of CSIR-Central Drug Research Institute (CDRI), Lucknow, focused on the application of Artificial Intelligence (AI) and Machine Learning in AYUSH

Dr. Najmus Sahar, Deputy Director Incharge, CRIUM, Lucknow proposed the vote of thanks. She shed light on various activities of the Institute and assured to take forward the Institute to greater heights with continuous collaboration and support with the other research organization.

The seminar aimed to provide a platform for exploring the potential of Artificial Intelligence (AI) and Machine Learning (ML) in advancing AYUSH systems, with a particular focus on Unani medicine, while also addressing the challenges and opportunities these emerging technologies present in the field.

On this occasion a MoU was also signed between CCRUM and State Takmil-ut-Tib College and Hospital, Lucknow.

4.2.5. Workshop cum Hands on Training on “Preventive and Therapeutic approaches for Musculo-skeletal disorders through *Ilaj-bit-Tadbeer* (Regimenal Therapy) - Recent Initiatives”

The Regional Research Institute of Unani Medicine (RRIUM), Chennai organized a two day workshop cum hands on training on "Preventive and Therapeutic Approaches for Musculoskeletal Disorders through *Ilaj-bit-Tadbeer* (Regimenal Therapy) – Recent Initiatives" on 23-24 December, 2024.

In his address, Dr. N. Zaheer Ahmed, Director General, CCRUM emphasized the importance of integrating regimenal therapy into mainstream healthcare for the management of musculoskeletal disorders. He lauded the contributions of all the speakers and participants, reiterating CCRUM's commitment to fostering innovation and excellence in Unani Medicine.

Prof. Dr. N. J. Muthukumar, Director General, Central Council for Research in Siddha (CCRS), Chennai attended the event as the Chief Guest stressed that *Ilaj-bit-Tadbeer* offers a holistic preventive and therapeutic approach for musculoskeletal disorders by focusing on natural detoxification, tailored exercises, and lifestyle modifications. He emphasized that this approach not only alleviates symptoms but also enhances overall musculoskeletal health and well-being.

The technical sessions featured insightful deliberations by a distinguished panel of speakers, including Prof. Mohd Aleemuddin Quamri, National Institute of Unani Medicine (NIUM), Bengaluru; Dr. Hepzibah Rubella D, Physiotherapist, Chennai; Prof. Mohd Anwar, Ajmal Khan Tibbiya Collage (AKTC), Aligarh Muslim University (AMU), Aligarh; Dr. Syed Abbas Zaidi, HSZH Unani Medical College and Hospital, Bhopal; Dr. S. Nizamuddin, Government Unani Medical Collage (GUMC), Chennai; Dr. Abdul Azeez Faris, National Institute of Unani Medicine (NIUM), Bengaluru; Dr. Shaikh Nikhat, Research Officer (Unani), RRIUM, Mumbai; Dr. Arisha Shahid, Research Officer (Unani), CRU, Bengaluru; Dr. Athar Parvez Ansari Research officer (Unani); Dr. Noman Anwar, Research Officer (Unani), RRIUM, Chennai and Dr. Farooqui Shazia Parveen, Research Officer (Unani), RRIUM, Chennai. The session included participant feedback, which highlighted the comprehensive and practical nature of the workshop.

On this occasion, hands-on-training in various regimenal therapies like *Hijama bil Shart* (wet cupping), *Hijama bila Shart* (dry cupping), *Hijama bil Nar* (fire cupping), *Hijama Mutharrika* (moving cupping), *Dalk* (massage), *Pashoya* (foot bath), *Dastshoya* (arm bath), *Aml-i-Kayi* (cauterization), *Fasd* (venesection), *Irsal-i-Alaq* (leech therapy), *Inkibab* (vapour therapy), *Natul* (irrigation), Full body steam, Physiotherapy modalities, Sauna bath, Hip bath, Jacuzzi bath, etc., was also given to the participants by experts. The workshop witnessed enthusiastic participation from 170 attendees, including Unani scholars, researchers, and practitioners from different parts of the country.

The event was concluded with a vote of thanks proposed by Dr. Shaheen Akhlaq, Research Officer (Unani) acknowledging the efforts of the organizing team, speakers, and participants in making the workshop a grand success.

4.2.6. National Seminar on “Collaborative Activities – A Means to Integrate Ayush Systems into Mainstream Healthcare”

The Regional Research Institute of Unani Medicine (RRIUM), Chennai organized a one-day national seminar on “Collaborative Activities – A Means to Integrate Ayush Systems into Mainstream Healthcare” on 04 February 2025. The programme was held as part of pre-activities for the 9th Unani Day 2025.

The Inaugural session of the seminar began with the recitation of the invocation of Tamil Thaaivazhthu. Dr. Athar Parvez Ansari, Research Officer (Unani), RRIUM, Chennai delivered the welcome address and introductory remarks. Dr. G Nandhini Devi, Director, Centre for Technology in Traditional Medicine (CTTM), Anna University, Chennai graced the event as the chief guest and addressed the gathering. Prof. Hakim Sayed Imamuddin Ahmed, Former Principal, Government Unani Medical College, Chennai was the guest of honour at the event and shared this valuable insights.

Dr. N. Zaheer Ahmed, Director General, CCRUM presided over the session virtually and delivered the presidential address on the importance of collaborative activities for successfully integrating AYUSH systems into mainstream healthcare. He emphasized that through joint efforts in research, education and clinical practice, we can unlock the full potential of traditional medicine to complement and strengthen modern healthcare for the benefit of all.

Two technical sessions were conducted wherein eminent speakers articulated the theme. Eminent speakers of the event include, Prof. Ghulamuddin Sofi, Head, Department of Ilmul Advia, Bengluru; Dr. R.C. Satish Kumar, SRM Institute of Science and Technology, Cehnnai; Dr. Syed Hissar, Scientist- E, ICMR-National Institute for Research in Tuberculosis, Chennai; Prof. S. Senthilkumar, Department of Information Science & Technology, Anna University, Chennai; Prof. V. Habibullah, Head, Department of Ilmul Advia, Government Unani Medical College, Chennai; Dr. Athar Parvez Ansari, Research Officer (Unani) and Dr. Farooqui Shazia Parveen, Research Officer (Unani), RRIUM, Chennai.

More than 200 delegates, including Ayush professionals, researchers, academicians, practitioners, and UG & PG students enthusiastically participated in the seminar.

The seminar was extremely fruitful and lucrative in terms of content and deliberations. Eminent experts shared valuable insights on AI, bioinformatics, and collaborative research models.

The event concluded with a valedictory address acknowledging the dignitaries, speakers, participants and organizing committee by Dr. Noman Anwar, Research officer (Unani).

4.2.7. National Webinar on Biomedical Ethics

The CCRUM organized a national webinar on “Biomedical Ethics with Emphasis on GCP Guidelines” (a Reorientation Training Program for IEC members) in virtual mode on 27th April, 2024.

Dr. Nandini K. Kumar, Former Deputy Director General, ICMR, and Vice President of the Forum for Ethics Review Committees in India graced the event as the Chief Guest and addressed the gathering on the importance of biomedical ethics, emphasizing that adherence to Good Clinical Practice (GCP) guidelines ensures the protection of human rights, safety, and dignity in clinical research while promoting ethical conduct and scientific integrity in line with international standards.

In his presidential address, Dr. N. Zaheer Ahmed, Director General of the Central Council for Research in Unani Medicine (CCRUM), highlighted the importance of biomedical ethics in medical research. He placed particular emphasis on the GCP guidelines which ensure ethical and scientific integrity in clinical trials.

The inaugural session of the webinar commenced with a welcome address by Dr. Ghazala Javed, Assistant Director (Unani), CCRUM Headquarters, New Delhi.

The webinar provided engaging discussions on complex medical dilemmas. Experts from ICMR, JNMC, AMU, Aligarh presented diverse topics, fostering interactive exchanges and practical insights for navigating ethical challenges in healthcare. Overall, it left participants with a deeper understanding and renewed commitment to ethical principles. About 190 delegates participated in this webinar.

4.2.8. Orientation cum Induction Program for Investigators on "Statistics related work of CCRUM"

The CCRUM organized an “Orientation cum induction program for Investigators on "Statistics related work of CCRUM" in virtual mode on May 01, 2024. The program was intended mainly for recently recruited Investigators (Statistics) in particular and all existing Investigator (Statistics) of the council in general.

In his introductory remarks, Dr. N. Zaheer Ahmed, Director General, CCRUM encouraged the participants to give their best efforts to enhance the quality of clinical research work.

The presentation was presented by Shri Anirban Rej, Investigator (Statistics), CCRUM. He presented the organization profile of the CCRUM in detail focusing over the research and development activities and role and responsibilities of the Investigator

(Statistics) in CCRUM. Shri Harender Singh Thapa, Research Officer (Statistics), highlighted the challenges faced by Investigators (Statistics) at the institute/unit level.

Dr. Naheed Parveen, Deputy Director General, CCRUM along with Nodal Officers from the Headquarters, Investigators (Statistics), In-charges of peripheral institutes, and staff working in related fields were also present.

The concluding remarks were delivered by Dr. Ghazala Javed, Assistant Director (Unani), CCRUM, New Delhi.

4.2.9. Awareness Program on Pharmaco-vigilance

The Regional Research Institute of Unani Medicine (RRIUM), New Delhi as the Peripheral Pharmaco-vigilance Centre (PPvC) organized an 'Awareness Programme on Pharmaco-vigilance on April 03, 2024 at Unani Medical Center, Safdarjung Hospital, New Delhi. Dr. Zaki Ahmad Siddiqui welcomed the guests and participants, providing a brief overview of Pharmaco-vigilance, the role of the Peripheral Pharmaco-vigilance Centre (PPvC) at RRIUM, New Delhi, and a summary of its achievements to date. The event was conducted by the Dr. Talib, JRF, PPvC, RRIUM, New Delhi. Dr. Syed Ahmad Khan, Former Deputy Director, CCRUM and Dr. B. Akila, Coordinator, PPvC and In-charge, Siddha Clinical Unit, Safdarjung Hospital, New Delhi were the guest speaker of the programme and they delivered insightful lectures on various aspects of pharmaco-vigilance. The program concluded with a vote of thanks delivered by Dr. Tamanna Nazli, Research Officer (Unani), Unani Medical Centre, Safdarjung Hospital, New Delhi.

4.2.10. Training on "Public Procurement Principles and GeM Portal"

The CCRUM organized a training programme on "Public Procurement Principles and GeM Portal" on June 12, 2024 at its headquarters in hybrid mode for all technical and administrative staff of CCRUM and Peripheral institutes.

In his inaugural remarks, Dr. N. Zaheer Ahmed, Director General, CCRUM, emphasized the importance of transparency, fairness, competition, and value for money in government procurement. Smt. Geeta Bansal, Trainer, GeM portal highlighted the procurement process, L1 purchase, bid creation and service procurement and payment methods in her presentations. The full-day training program concluded with a vote of thanks delivered by Dr. Ghazala Javed, Assistant Director (Unani), CCRUM. Over 100 technical and administrative staff from CCRUM and its peripheral institutes, particularly those involved in procurement, participated in and benefited from the program.

4.2.11. Awareness and Orientation Programme on the Prevention of Sexual Harassment (POSH) Act

The CCRUM organized an Awareness and Orientation Programme on the Prevention of Sexual Harassment (POSH) Act for Ayush professionals on 10th September, 2024.

In his introductory remarks, Dr. N. Zaheer Ahmed, Director General, CCRUM reaffirmed the organization's commitment to fostering a healthy and inclusive work environment, free from prejudice, gender bias, and harassment. He also highlighted that the Council has established Internal Complaints Committees in each of its peripheral institutes to ensure a harassment-free workplace for all employees, regardless of race, caste, religion, marital status, gender, age, or disability.

In her inaugural address, Mrs. Meenakshi Negi, Member Secretary, National Commission for Women, emphasized the importance of gender equality and highlighted the significance of the POSH Act. She described it as a comprehensive legislation aimed at preventing, prohibiting, and addressing sexual harassment in workplaces across India. She noted that the Act, enacted in 2013, has played a pivotal role in safeguarding women in workplaces nationwide.

Shri Manmohan Verma, Law Officer, National Commission for Women and Ms. Tunika Sharma, Counsellor, National Commission for Women were the keynote speakers. The sessions were marked by insightful deliberations and expert presentations. The programme featured two key sessions focusing on Gender Sensitization and the POSH Act. Around 300 staff participated from all Research Councils in the program organised in hybrid mode. The programme concluded with a vote of thanks of Dr. Ghazala Javed, Assistant Director (Unani), CCRUM.

4.2.12. National Webinar on e-Granthalaya 4.0

The CCRUM organized a national webinar on e-Granthalaya 4.0 in collaboration with the National Informatics Centre (NIC) for the training of Library professionals of CCRUM,

New Delhi on 12 September 2024. The webinar aimed to educate library professionals on how to effectively implement and utilize the updated features of e-Granthalaya 4.0. On the occasion, Dr. Ghazala Javed, Assistant Director (Unani), CCRUM highlighted the importance of staying updated with technological advancements in the field of library management. Mohd. Azhar Khan ALIO, Library & Information Centre, CCRUM delivered introductory remarks. The session provided valuable knowledge to library professionals looking to optimize their use of e-Granthayala 4.0.

4.2.13. A Pharmacovigilance Awareness Program

The NRIUMSD's Peripheral Pharmacovigilance Centre (PPvC), Hyderabad, organized a 'Pharmacovigilance Awareness Program' on March 18, 2025, at MIMS Paramedical College, Hyderabad, with the aim of enhancing awareness about the importance of pharmacovigilance, particularly in the context of Ayurveda, Siddha, Unani and Homeopathy (ASUH) drugs.

The program was a great success and received an enthusiastic response, making a significant contribution to raising awareness about pharmacovigilance and reinforcing safety practices for ASU&H drugs. The program highlighted the drug safety, encouraging responsible use of medications, and protecting public health.

4.2.14. Other Events

S.No.	Name of the event	Place	Duration
1.	Hands on training on SOP's related to admission of patients	RRIUM, Chennai	Apr 03, 2024
2.	An awareness program on pharmacovigilance of ASU drugs for visiting patients and general public	RRIUM, Chennai	May 09, 2024
3.	An Advocacy programme on Competition Law for Procurement	NRIUMSD, Hyderabad	May 15, 2024
4.	Pre-activities commemorating World Environment Day	CCRUM, New Delhi	May 27-June 05, 2024
5.	World No Tobacco Day	CCRUM, New Delhi	May 31, 2024
6.	World Environment Day	CCRUM, New Delhi	Jun 05, 2024
7.	World Blood Donor Day 2024	CCRUM, New Delhi	Jun 07, 2024
8.	A Brainstorming Workshop on Development of Mizaj Assessment Tool	CCRUM, New Delhi	Jun 13, 2024
9.	International Day of Yoga 2024	CCRUM, New Delhi	Jun 21, 2024
10.	An awareness program on the pharma-covigilance of ASU drugs for visiting patients and the general public	RRIUM, Chennai	Jun 27, 2024
11.	International Conference on Ayurveda, Unani, Siddha and Traditional Medicine (ICAUST 2024) and 1 st International Research Symposium	University of Colombo, Sri Lanka	Aug 9–10, 2024
12.	Nasha Mukta Bharat Abhiyaan	CCRUM, New Delhi	Aug 12, 2024
13.	Participation of Council in Har	CCRUM, New Delhi	Aug13-15, 2024

	Ghar Tiranga Campaign 2024		
14.	A programme on "Importance of Preventive vigilance in the establishment of transparency in the system"	RRIUM, Srinagar	Aug 31, 2024
15.	Seminar on Overview of Quality Management System and its Implementation	Connaught Place, New Delhi	Sept 4, 2024
16.	Participation of Council in Ek Ped Maa Ke Naam Campaign	CCRUM, New Delhi	Sept 13, 2024
17.	Conference commemorating 75 years of Hindi as the Official Language by Department of Official Language, MHA, Gol	Bharat Mandapam, New Delhi	Sept 14–15, 2024
18.	Participation of Council in Rashtriya Poshan Maah 2024 initiative	CCRUM, New Delhi	Sept 2024
19.	National Webinar on the occasion of Rashtriya Poshan Maah	RRIUM, Mumbai	Sept 20, 2024
20.	Participation of Council in Swachhata Hi Seva Campaign 2024 (SHS)	CCRUM, New Delhi	Sep 14-Oct 01, 2024
21.	An awareness program focusing on crucial themes such as anaemia, growth monitoring, complementary feeding, and the integration of education and nutrition	CRU Kurnool	Sept 23, 2024
22.	A sensitization / awareness program on pharmacovigilance of ASU & H drugs	Organized by RRIUM, Chennai at Sri Sairam Ayurveda Medical College and Research Centre, West Tambaram, Chennai	Sept 26, 2024
23.	A Pharma-covigilance awareness program	Organized by NRIUMSD, Hyderabad at MNR Homeopathic Medical College and Hospital, Sangareddy, Telangana	Sept 28, 2024
24.	National Voluntary Blood Donation Day	CCRUM, New Delhi	Oct 01, 2024
25.	Webinar on Awareness of	NRIUMSD,	Oct 15, 2024

	Studentship Program for Unani Research (SPUR)	Hyderabad	
26.	Vigilance Awareness week	CCRUM, New Delhi	Oct 28-Nov 3, 2024
27.	Rashtriya Ekta Diwas- 2024 (National Unity Day)	CCRUM, New Delhi	Oct 30, 2024
28.	Awareness programme on Cyber hygiene and security	RRIUM, Bhadrak	Oct 30, 2024
29.	International Conference on Communication and Dissemination of Traditional Knowledge (CDTK-2024)	Gurugram University, Haryana	Nov 13-14, 2024
30.	An awareness lecture on SPUR organized by RRIUM, New Delhi	Ayurvedic & Unani Tibbia College, New Delhi	Nov 14, 2024
31.	International Symposium on Policy, Legal & Regulatory Landscape of Traditional and Complementary Medicine	Tehran University of Medical Sciences, School of Persian Medicine, Iran	Nov 21-23, 2024
32.	PG Orientation Programme 2024-25, mandated by NCISM	NRIUMSD Hyderabad	Dec 04, 2024
33.	Annual Conference of the Association of Clinical Biochemists of India (ACBICON 2024)	PGIMER, Chandigarh	Dec 04-07, 2024
34.	Six-Day CME Program for Unani Medical Officers	Eram Unani Medical College & Hospital, Lucknow	Dec 05, 2024
35.	100-day campaign for TB elimination	CCRUM, New Delhi	Dec 07, 2024
36.	Traditional, Complementary, and Alternative Medicine (TCAM) & 3rd Edition of Sheikh Zayed International Awards	Abu Dhabi	Dec 10-12, 2024
37.	Three-day workshop on Scientific writing, Research integrity & Publication ethics, a capacity-building program for PG Guides	NRIUMSD Hyderabad	Dec 19-21, 2024

38.	National Conference on "Advances in Biological Sciences: Molecules to Organisms"	Aligarh Muslim University, Aligarh	Dec 28–29, 2024
39.	International Conference "Millet Fusion: Cultivating Sustainability, Nourishing Nations"	Amity University, Noida	Jan 22, 2025
40.	Round Table on "India-Indonesia Cooperation on Traditional Herbal Medicines: Relevance of Sustainable Bioresource Management"	New Delhi	Jan 23, 2025
41.	National seminar on emerging trends in Unani fundamental Research	NRIUMSD, Hyderabad	Feb 03, 2025
42.	International Conference on "Advances in Medicinal & Aromatic Plant Research in Context to Indian Ocean Region (Ensuring Trade, Sustainability and Global Transformation)"	CSIR-CIMAP, Lucknow	Feb 4–6, 2025
43.	Unani Day Pre-Activity by the Unani section of the Ayush Wellness Centre at AWC, President's Estate	Rashtrapati Bhavan, New Delhi	Feb 07, 2025
44.	CME Programme	Government Unani Medical Collage, Chennai	Feb 10–15, 2025
45.	Unani Day 2025 celebrations	Rashtrapati Bhavan	Feb 15, 2025
46.	5 th Official Language Conference organized by Indian Institute of Mass Communication and CCRUM in collaboration with 6 other partner offices	National Health and Family Welfare Institute	Feb 15, 2025
47.	A workshop titled "NABH for Unani Hospitals - Enhancing Quality Standards in Healthcare" organized by Govt. Tibbi College Hospital (GTCH), Patna, in collaboration with RRIUM, Patna	Govt. Tibbi College Hospital, Patna	Feb 27, 2025
48.	Fit India Mission, a Fit India Cycle Drive initiated by Sports Authority	Dhyanchand Stadium, New Delhi	Mar 02, 2025

	of India with the inspiring slogan Fitness Ki Dose, Aadha Ghanta Roz		
49.	International Women's Day	CCRUM, New Delhi	Mar 07, 2025
50.	World Oral Health Day	CCRUM, New Delhi and its peripheral centers	Mar 20, 2025

4.3. Participation in Training and Capacity Building Programmes

The CCRUM places a high priority on continuous learning and skills enhancement for its workforce to advance research and ensure the highest standards in Unani Medicine. Throughout the reporting year, CCRUM staff actively participated in various training sessions, workshops, and capacity-building programmes organized at both national and international levels. These initiatives aimed to deepen knowledge in specialized fields, enhance research methodologies, and foster collaborative skills. The Council's officers attended the following workshops, training and capacity-building programmes.

1. A one-day online training programme on 'Core Competencies – Conduct, Misconduct, Ethics, Noting, Drafting, Letter Writing, Records Management, and Prevention of Sexual Harassment' was conducted on May 13, 2024, under the guidance of subject-matter experts."
2. Training Programme on "Cultivation and Primary Processing of Economically Important Medicinal and Aromatic Plants" was attended at Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow from May 14–16, 2024.
3. Modular Training Programme on Musculoskeletal Disorders for Unani Master Trainers was organized by the AYUSH Vertical, Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare at the Central Health Education Bureau on May 16, 2024.
4. DOE-Sponsored Training Programme on Public Procurement Principles in Hyderabad from May 27–31, 2024.
5. Capacity Building Programme on "Entrepreneurship Development" at National Institute for Micro Small and Medium Enterprises (NI-MSME), Hyderabad from June 10–14, 2024.
6. National Conference 'PRANA' organized by National Commission for Indian System of Medicine (NCISM) in collaboration with AICTE and MIC at AICTE, Vasant Kunj, New Delhi on June 11–12, 2024.
7. National Consultative Meet on Research Priority Settings for Traditional Medicine organized by CCRAS in collaboration with WHO-SEARO on June 24, 2024.

8. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” conducted at State Unani Medical College, Prayagraj on June 25, 2024.
9. A 5-day Training Programme on Herbal Medicine, Functional Food based on Ayurveda Ahara & Regulatory Aspects at Dept. of Food Technology, Jamia Hamdard, New Delhi on July 8, 2024.
10. One-Day Workshop on Intellectual Property Rights (IPR) was organized by CCRAS at Auditorium Hall, CCRAS on July 18, 2024.
11. Expert Group Meeting on Integrative Medicine Research – Ethical Aspects at ICMR Headquarters, New Delhi on July 19, 2024
12. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” organized by National Commission for Indian System of Medicine (NCISM) conducted at Shri Ayurveda Mahavidyalaya, Nagpur from August 6–8, 2024.
13. 4-Day Training Programme on Laboratory Quality Management System and Internal Audit was held at NITS, BIS from August 6–9, 2024.
14. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” organized by National Commission for Indian System of Medicine (NCISM) conducted at Mansoor Campus, Malegaon from August 20–22, 2024.
15. National Conference on OMICS in Redefining Healthcare, organized by the Jubilee Centre for Medical Research at Thrissur, Kerala from August 23–24, 2024.
16. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” organized by National Commission for Indian System of Medicine (NCISM) at National Institute of Siddha, Chennai from August 26–28, 2024.
17. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” organized by National Commission for Indian System of Medicine (NCISM) at Pt. Khushilal Sharma Govt. Ayurved College, Bhopal from August 29–31, 2024.
18. One-Day Workshop on Improved Financial Management in Autonomous Bodies/Subordinate Offices/Statutory Bodies under Ministry of AYUSH at National Institute of Ayurveda, Jaipur on September 2, 2024.
19. Three-Day Training Course on Active Ageing and Wellbeing for Healthcare Professionals at National Institute of Health and Family Welfare (NIHFW), New Delhi from September 9–11, 2024.
20. DOE-Sponsored Training Programme on Public Procurement Principles at Hyderabad from September 23–27, 2024.
21. Workshop for Framing of Competency-Based Curriculum and Syllabus for Third Professional BUMS at Hyderabad from November 4–6, 2024.
22. Sensitization Programme for Empanelment of AYUSH Hospitals with General Insurance Companies at NIS, Chennai on November 8, 2024.
23. Master Trainer in the Workshop on Scientific Writing, Research Integrity & Publication Ethics organized by National Commission for Indian System of

- Medicine (NCISM) at Bharteya Sanskrit Prabodhini, Goa from November 13–15, 2024.
24. Training Course on “Holistic Health and Well-being of the Elderly for Health Professionals” organized by the Department of Social Sciences, National Institute of Health and Family Welfare (NIHFW), New Delhi from November 18–22, 2024.
 25. DOE-Sponsored Training Programme on Public Procurement Principles held at Hyderabad from November 25–29, 2024.
 26. 6-Day CME Training Programme on “Current Trends in R&D, Modern Scientific Advances & Technology for Scientific Understanding and Promotion of AYUSH Teachers/Scientists” at Captain Srinivasa murthy Central Ayurveda Research Institute (CSMCARI) Chennai from November 25–30, 2024.
 27. WHO ICD-11 TM Chapter Technical Meeting at NIH, Setia Alam, Malaysia on November 26, 2024.
 28. Science Odyssey of North East India: Focused S&T for North East organized during IISF at IIT, Guwahati on December 2, 2024.
 29. DST-Sponsored Training Programme on Innovation Management Tools (for Women) held at ASCI, Hyderabad from December 2–6, 2024.
 30. Training Course on Building Nursing and Midwifery Leadership in the Context of UHC/SDG at NIHFW, New Delhi from December 2–6, 2024.
 31. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” conducted by NCISM at NIUM, Bengaluru from December 3–5, 2024.
 32. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” conducted by National Commission for Indian system of Medicine (NCISM) at NIUM, Bengaluru on December 4, 2024.
 33. DST-Sponsored Training Programme on Science Administration and Research Management held at Administrative Staff College of India (ASCI), Hyderabad from December 9–20, 2024.
 34. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” organized by NCISM at State Takmeel-ut-Tib, Lucknow on December 10, 2024.
 35. Workshop on “Gathering Technical Inputs for Country Implementation of ICD-11 TM2 and Adoption of WHO International Terminologies of Ayurveda in India” at Dehradun, Uttarakhand from December 13–14, 2024.
 36. Workshop on “Scientific Writing, Research Integrity & Publication Ethics” conducted by National Commission for Indian system of Medicine (NCISM) under its "Empowering PG Guide" mission at Government Ayurveda College, Kerala from December 16–18, 2024.
 37. DOE-Sponsored Training Programme on Public Procurement Principles at Hyderabad from December 16–20, 2024.

38. Two-Day Training Programme on Intellectual Property Rights (IPR) organized by Rashtriya Ayurveda Vidyapeeth (RAV) at All India Institute of Medical Sciences (AIIMS), New Delhi from December 17–18, 2024.
39. Two-Day Offline Training Programme (Blended Mode) for Group A and Group B Officers on “Emerging Technology and Dashboard (WETD-05)” at Institute of Secretariat Training & Management, New Delhi from December 30–31, 2024.
40. DST-Sponsored Training Programme on “Artificial Intelligence Tools for Scientific Project Management” at ASCI, Hyderabad from January 20–31, 2025.
41. National Workshop (DISHA–2025) organized by the Bureau of Indian Standards (BIS) at Hyderabad on January 30, 2025.
42. Workshop on “Biostatistics and Research Methodology: We Must Know for Successful Research Protocols” at Chandigarh from February 7–8, 2025.
43. Joint Regional Official Language Conference of Central West and Northern Region at Jaipur from February 17–18, 2025.
44. 5-Day Hands-on Training Programme on “Toxicological Studies in Zebrafish Model” at Chennai from February 17–21, 2025.
45. The Capacity Building Programme on Pharmacovigilance at NIUM, Bengaluru from February 24–25, 2025.
46. Pharmacovigilance Awareness Programme organized by Siddha Clinical Research Unit (SCRU), Safdarjung Hospital at Dr. B.R. Sur Homoeopathic Medical College & Hospital, New Delhi on February 27, 2025.
47. Training of Trainers on Entrepreneurship Development (ToT-ED) at National Institute for Micro Small and Medium Enterprises (ni-msme), Hyderabad from March 3–7, 2025.
48. 5-Day Capacity Building Training Programme on “Quality Control and Standardization of ASU&H Drugs” held at PCIM&H, Ghaziabad from March 3–7, 2025.
49. Two-Day National Conference on Complementary and Alternative Therapies (NC CAT–2025) organized by Amity University, Lucknow from March 6–7, 2025.

4.4. Participation in Arogya Fairs/Health Melas/Exhibitions/Expos

The Ministry of Ayush, Government of India, in collaboration with state governments and other stakeholders, organizes and participates in Arogya fairs, expos, and similar events to promote Indian systems of medicine, highlight the activities and achievements of its research councils, provide free-of-cost diagnosis and treatment to visitors, and impart awareness about health, hygiene, and the curative aspects of ill-health. The CCRM and its institutes, following the directives of the Ministry of Ayush, participated in national and state-level Arogya fairs and similar events held during the reporting period.

During these events, the CCRUM showcased its progress in clinical research, drug standardization, the survey and cultivation of medicinal plants, and literary research. It displayed posters and charts highlighting various concepts of Unani Medicine. Additionally, significant publications from the CCRUM, such as the Unani Pharmacopoeia of India, National Formulary of Unani Medicine, Hippocratic Journal of Unani Medicine, Standard Unani Medical Terminology, and Standard Unani Treatment Guidelines for Common Diseases, were made available for viewing. To create awareness about healthy living and the role of Unani Medicine in disease prevention and health promotion, free literature on Unani Medicine and success stories regarding the treatment of chronic and common diseases were distributed among visitors. The CCRUM also deployed its physicians to provide free consultations and treatments to visitors seeking Unani remedies, while lectures on various health issues were delivered by CCRUM researchers.

Health Camp in Buldana District, Maharashtra

The RRIUM, Mumbai intervened to a sudden and alarming outbreak of hair loss affecting multiple villages in Shegao Taluka of Buldana District, Maharashtra. The outbreak, reported in early January 2025, involved widespread complaints of rapid hair fall, alopecia patches, and associated scalp symptoms. Suspected factors included contaminated water sources, expired or chemically harsh hair products, nutritional deficiencies, and poor hygiene practices.

To address this health crisis, CCRUM promptly deputed a series of Unani medical teams from the Regional Research Institute of Unani Medicine (RRIUM), Mumbai to conduct field investigations, provide therapeutic intervention through Unani Medicine and coordinate with local authorities for a multi-system response. The teams were deployed to the most affected villages — Matergaon, Nimbi, Jalam, and Pahunjira. Initial meetings were held with District Health Officers, PHC staff, and AYUSH representatives to streamline the intervention process. Across different phases, over 260 individuals received Unani treatment. 140 cases were diagnosed while the rest were treated preventively.

The symptoms ranged from sudden onset hair loss to dry, itchy scalp with visible bald patches. Medical management was executed using three Unani combinations tailored to symptom severity, consisting of formulations such as Habbe Musaffi Khoon, Majoon Dabedul Ward, Roghan Kamila, Khamira Marwareed, and Itrifal Shahatra, along with decoctions and topical applications. Coordination with ICMR and District Health Authorities ensured a holistic investigation into the outbreak. A high-level meeting led by the District Collector emphasized joint action among Unani, Ayurveda, and Homeopathy systems. AYUSH medicines were approved for distribution in PHCs with monthly follow-up protocols.

The Hon'ble Labour Minister of Maharashtra, Shri Akash Pandurang Fundkar, visited the affected site, engaged with the medical team, and appreciated the efforts of CCRUM. Environmental and nutritional factors continue to be investigated to identify root causes, with ongoing support from ICMR. Under the leadership of Dr. Najeebullah Hasan, Deputy Director Incharge, RRIUM Mumbai has committed to sustaining intervention through medicine supply, regular follow-ups, and technical support. Early signs of hair regrowth and symptomatic relief were observed in follow-up assessments. Additionally, public health education on hygiene, safe hair care practices, and Unani lifestyle recommendations (Asbāb-e-Sitta Zarūriyya) was imparted.

The Council participated in approximately 28 Arogya fairs, exhibitions, and melas during the reporting period. The list of events is as follows:

S.No.	Name of Event	Place	Duration
1.	Free Unani Medicine Awareness Camp	Heartfulnesss Meditation Centre, Shri Ram Chandra Mission New Panvel, Navi Mumbai	May 13, 2024
2.	Free Unani Medical Camp	Pulimamidi village of Kandukur mandal of Ranga Reddy District of Telangana	May 26, 2024
3.	State Level Arogya Fair	Nashik, Maharashtra	Jun 12-14, 2024
4.	Arogya Fair 2024	Raipur, Chattisgarh	Jun 28-30, 2024
5.	Free Eye check-up camp	Chennai	Jul 03, 2024
6.	Special Geriatric Health Camp	RRC, Prayagraj CRU, Kurnool	July 29, 2024
7.	Special Geriatric Health Camp	Sri Matha old age home, Kukutpally, Hyderabad	Jul 31, 2024
8.	Ayurveda Parv	ASCI campus, Hyderabad	Aug 01-03, 2024
9.	Special Geriatric Health Camp	Sahrudaya old age home, Boduppal, Hyderabad	Aug 21, 2024
10.	3 rd Edition of World Food India	Pragati Maidan, New Delhi	Sept 19-22, 2024
11.	Exhibition on "Heritage Healing"	Chennai	Sept 27-28, 2024
12.	Special Free Unani Medical camp	Chanchalguda, Hyderabad	Sept 29, 2024

13.	Mega Exhibition “Health Expo 2024”	Abu Road, District Sirohi-Rajasthan	Oct 16-18, 2024
14.	Ayurveda Parv	Amritsar, Punjab	Oct 18-20, 2024
15.	Free Mega Health Camp	Guidance Public School, Malakpet, Hyderabad	Nov 14, 2024
16.	43rd India International Trade Fair (IITF)	Bharat Mandapam, New Delhi	Nov 14-27, 2024
17.	Ayurveda Parv	Puri, Odisha	Dec 04-06, 2024
18.	Ayush Health Mela on the occasion of 7 th UDMA Day	Atal Bihari Vajpayee Convention Centre in Lucknow	Dec 06-08, 2024
19.	State Level Arogya Fair	Mon, Nagaland	Dec 13-15, 2024
20.	Mahakumbh at Prayagraj	Prayagraj, U.P	Jan 13-Feb 26, 2025
21.	Ayurveda Parv	Bhopal	Jan 20-22, 2025
22.	Exhibition in the International Conference on Millet	Amity University, Noida	Jan 22-24, 2025
23.	Bharat Parv 2025	Red Fort, New Delhi	Jan 26-31, 2025
24.	38 th Surajkund International Crafts Mela	Surajkund, Faridabad, Haryana	Feb 07-23, 2025
25.	Health Tech India	Bharat Mandapam, New Delhi	Feb 20-22, 2025
26.	Rise in India	Ghaziabad	Feb 20-22, 2025
27.	Free Unani Medicine Camp on Vitiligo and Skin Disorders	Shri Krishna Ayush University, Kurukshetra	Feb 27, 2025
28.	Exhibition during the World Medicine Day	Era Medical University, Lucknow	Mar 06, 2025

4.5. Participation in Promotion of Official Language

In accordance with the annual programme issued by the Ministry of Home Affairs, Government of India, for the year 2024–25, the Central Council for Research in Unani Medicine, New Delhi, is making every possible effort regularly to achieve the prescribed targets with the objective for use of the Official Language and the promotion of Hindi.

Organising Hindi Pakhwada

During the reporting period, Hindi Pakhwada was organised in the Central Council for Research in Unani Medicine and its subordinate institutes, centres and units under the

session 2024-25 with the objective of promoting the use of the official language and Hindi. During this program, apart from various competitions, the work done in Hindi by various sections of the Council in the session 2024-25 was reviewed. At the Council headquarters, Hindi Pakhwada was organized from 14 September to 30 September 2024.

From 17 September 2024, during the Hindi Pakhwada programme, various competitions such as Hindi dictation, Hindi translation, Hindi noting and drafting, debate, Hindi poetry recitation, vocabulary, and essay writing were organized at the Council headquarter in which the winning participants were honored with various awards. To promote the use of Hindi in government work, Hindi Pakhwada was also observed at the subordinate institutes/centres/units of the Council such as NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUM Mumbai, Chennai, Kolkata, Bhadrak, New Delhi, Aligarh, Patna, Srinagar and Silchar, Drug Standardization Research Institute, Ghaziabad, Regional Research Centre, Prayagraj; Clinical Research Units, Meerut, Burhanpur, Bhopal and Kurnool; the Drug Standardization Research Unit, New Delhi; and the Hakim Ajmal Khan Institute for Literary and Historical Research in Unani Medicine, New Delhi.

On 30 September 2024, the closing/award distribution ceremony was organized at the CCRUM headquarters, in which Shri Ranvijay, Indian Railway Electrical Engineering Service, General Manager (Electrical) and Chief Official Language Officer, Dedicated Front Corridor Corporation Limited, New Delhi, was invited.

[Inspection of the Council's subordinate institutes/centres/units by the headquarter](#)

As directed by the Department of Official Language, Ministry of Home Affairs, Government of India, it is mandatory to inspect 25 percent of institutes/centres/units each year. In the year 2024–25, inspections were conducted for RRIUM; Chennai, Silchar, Kolkata, the Drug Standardization Research Institute, Ghaziabad, and the Clinical Research Unit, Meerut, Bengaluru. During the inspection, discussions were held with the in-charges of all the institutions/units regarding the works related to the official language and the deficiencies found during the inspection were also discussed and instructions were given to take action on some points. The inspection questionnaire was filled and submitted by the in-charges of all the institutions/units, which was reviewed by the Council Headquarters and the institutions/centres/units in-charges were informed about the errors found in it.

[Official Language inspection of the Council's subordinate institutes/units/centres by the Third Sub-Committee of the Parliamentary Official Language Committee:](#)

The third sub-committee of the Parliamentary Official Language Committee conducted official language inspections of two institutions under the Council: Hakim Ajmal Khan Unani Medical Literary and Historical Research Institute, New Delhi, on 21 November 2024 and the Regional Unani Medical Research Institute, New Delhi, on 26 December 2024. The parliamentary official language inspections of both institutions were successful.

[Regarding the workshops organized at the Council headquarters and its subordinate offices:](#)

As per the instructions of the Department of Official Language Ministry of Home Affairs, Government of India, four workshops are expected to be held each year. During the year 2024–25, three workshops were organized at the Council headquarters on 29.08.2024,

31.12.2024, and 26.03.2025 under the chairmanship of the Director General, CCRUM, in which several distinguished speakers were invited as chief guests. The main objective of these workshops is to promote the Official Language, train all attending officers/employees, and raise awareness about Hindi.

Additionally, during the reporting period, workshops were organized from time to time at several institutes/units/centres under the Council headquarters as per the rules, and reports of these workshops are sent periodically.

Official Language Conference and Ceremony

(a) On 13.09.2024, the Ministry of Ayush, Government of India, organized an Official Language ceremony, in which Shri Mayank Tiwari, Administrative Officer/Official Language Officer, and Smt. Purna Kathuria, Junior Hindi Translator, from the Council headquarter participated.

(b) Hindi Diwas and All India Official Language Conference was organized on 14th and 15th September, 2024 at Bharat Mandapam, New Delhi, which was presided over by the Honorable Minister of Home Affairs and Cooperation, Shri Amit Shah. The conference was attended by the Council Headquarters and its subordinate offices, along with their heads and several officers/employees concerned with the official language.

(c) Apart from this, on 14.02.2025, the Official Language Conference was organized by the Council Headquarters as co-organizer along with five other member offices including the office of the Chairman of NARAKAS, Indian Institute of Mass Communication, New Delhi, under the aegis of NARAKAS South Delhi-03. Several distinguished speakers and eminent personalities were invited to the Official Language Conference, which included multiple sessions aimed at promoting Hindi and enhancing the knowledge and interest of the attendees in the language. The co-chairmanship of the NARAKAS session was held by the Director General, CCRUM, New Delhi, and it was coordinated by Shri Mayank Tiwari, Administrative Officer/Official Language Officer, CCRUM, New Delhi.

(d) The Department of Official Language, Ministry of Home Affairs, Govt. of India organized a "One Day Joint Regional Official Language Conference and Award Distribution Ceremony" for North-I & North-II and Central & West regions on 17th February 2025 at JECC (Jaipur Exhibition & Convention Centre, Sitapur Jaipur (Rajasthan) in which many officers/employees from the Council Headquarters and its related subordinate institutions participated.

Half-yearly meeting organized by NARAKAS South Delhi-03

The Council headquarters also participated in the half-yearly meeting organized by Narakas South Delhi-03 on 26.06.2024 and 22.11.2024.

Special initiatives undertaken by the Department of Official Language

(1) During Unani Day, Rajbhasha Section prepared invitation letter for Unani Day, the Programme Outline, Stage Plan, Concept Note, Address of Hon'ble President, Address and Message of Shri Prataprao Jadhav, Hon'ble Minister of State (Independent Charge) / Ministry of Ayush and Minister of State / Ministry of Health and Family Welfare, Address of Dr. Jitendra Singh, Hon'ble Minister of State (Independent Charge), Ministry of Science and Technology / Ministry of Earth Sciences, Address of Minister of State / Prime Minister's Office, Ministry of Personnel, Public Grievances and Pensions, Department

of Atomic Energy and Department of Space, Government of India, Address of Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush and many other documents in Hindi. Also, many documents like invitation cards, concept notes, agenda, programme outline, stage plan etc. were translated into Hindi during Unani Day.

(2) The Council headquarter provides the Hindi translation of the fortnightly report along with its details after every 15 days to Hon'ble Minister of State (Independent Charge), Ministry of Ayush, Govt. of India.

(3) During the Parliamentary session, the tasks assigned by the Ministry of Ayush were translated into Hindi.

(4) The Council headquarters' website has been made bilingual. Additionally, the main page of the Council's website provided with a pop-up option to select between Hindi and English.

(5) Translation work related to the annual report was carried out.

(6) Under the Hindi Teaching Scheme organized by the Department of Official Language, Ministry of Home Affairs, RK Puram, five officers/employees from the Council headquarter were nominated for the Advanced Training Course "Parangat".

(7) Several new books related to the Official Language are purchased for the Library Department of the Council headquarter.

(8) In the office, necessary steps has been taken for the proper bilingual working in order to maximize the use of Hindi in the e-Office.

4.6 Appointments

S.N.	Name	Designation	Institute where posted	Date of Joining
1.	Dr. Mohd Anis Ansari	Research Officer (Unani)	NRIUMSD, Hyderabad	15 July 2024
2.	Dr. Masood Ahmad	Research Officer (Unani)	NRIUMSD, Hyderabad	15 July 2024
3.	Dr. Reesha Ahmed	Research Officer (Unani)	RRIUM, Aligarh	16 July 2024
4.	Dr. Amir	Research Officer (Unani)	NRIUMSD, Hyderabad	16 July 2024
5.	Dr. Aaisha Ansari	Research Officer (Unani)	NRIUMSD, Hyderabad	18 July 2024
6.	Dr. Ansari Shabnam Mohd. Ashfaque	Research Officer (Unani)	RRIUM, Mumbai	18 July 2024
7.	Dr. Mir Idrees Hanief	Research Officer (Unani)	RRIUM, Patna	18 July 2024
8.	Dr. Sayeda Shifa Zaidi	Research Officer (Unani)	CRIUM, Lucknow	19 July 2024
9.	Dr. Mahd. Uzair Beg	Research Officer (Unani)	RRIUM, Bhadrak	20 July 2024

S.N.	Name	Designation	Institute where posted	Date of Joining
10.	Dr. Asia Khanam	Research Officer (Unani)	RRC, Prayagraj	22 July 2024
11.	Dr. Gazala Fatima	Research Officer (Unani)	HAKILHRUM, New Delhi	22 July 2024
12.	Dr. Abid Nadeem Nomani	Research Officer (Unani)	RRIUM, Mumbai	22 July 2024
13.	Dr. Syed Sadakathulla Bakhtiar	Research Officer (Unani)	RRIUM, Chennai	22 July 2024
14.	Dr. Suheena Khanday	Research Officer (Unani)	CCRUM Headquarters	22 July 2024
15.	Dr. Nida Mehraj	Research Officer (Unani)	AWC, Rashtrapati Bhawan	23 July 2024
16.	Dr. Mustaqeem Khan Munaf	Research Officer (Unani)	RRIUM, Chennai	26 July 2024
17.	Dr. Mohd. Mudassir	Research Officer (Unani)	RRIUM, Bhadrak	31 July 2024
18.	Dr. Usama	Research Officer (Unani)	RRIUM, Patna	01 August 2024
19.	Dr. Farhath Fathima	Research Officer (Unani)	CRU, Kerala	02 August 2024
20.	Dr. Mehnaz Qureshi	Research Officer (Unani)	RRIUM, New Delhi	05 August 2024
21.	Dr. Mohd. Azam	Research Officer (Unani)	NRIUMSD, Hyderabad	05 August 2024
22.	Dr. Amreen Zehra	Research Officer (Unani)	RRIUM, Bhadrak	06 August 2024
23.	Dr. Fatima Anjum	Research Officer (Unani)	RRIUM, Silchar	09 August 2024
24.	Dr. Sofia Naushin	Research Officer (Unani)	CRIUM, Lucknow	09 August 2024
25.	Dr. Abdul Aleem	Research Officer (Unani)	RRIUM, Silchar	09 August 2024
26.	Dr. Vandna Rajak	Research Officer (Unani)	CRU, Bhopal	10 October 2024
27.	Dr. Rameesa Rashid	Research Officer (Unani)	RRIUM, Aligarh	15 October 2024
28.	Dr. Shaheen Akhlag	Research Officer (Unani)	RRIUM, Chennai	11 Nov 2024
29.	Dr. Khem Chand	Research Officer (Unani)	CRIUM, Lucknow	22 Nov 2024
30.	Dr. Sayeed Adnan Mohammad	Research Officer (Unani)	RRIUM, Chennai	01 March 2025

4.7 Promotion

S.N.	Name	Designation	Institute where posted	Date of Promotion
1.	Dr. Najmus Sehar	Deputy Director (Unani)	CRIUM, Lucknow	14 June 2024
2.	Dr. Ziaul Haq Siddiqui	Deputy Director (Unani)	RRIUM, Delhi	22 July 2024
3.	Shri Subhashendra Singh	Research Officer (Botany)	RRIUM, Bhadrak	01 October 2024
4.	Dr. Kiran Negi	Research Officer (Botany)	DSRU, New Delhi	01 October 2024
5.	Dr. Sonali Sajwan	Research Officer (Botany)	DSRI, Ghaziabad	19 Feb 2025.

4.8 Retired

S.N.	Name	Designation	Institute where posted	Date of Retirement
1.	Smt. Ishrat Javed Khan	Laboratory Technician	RRIUM, Mumbai	30 April 2024
2.	Shri Peer Mohammad Ishaq	Compounder	RRIUM, Srinagar	30 April 2024
3.	Dr. Mohammad Arshad	Research Officer (Unani)	CRIUM, Lucknow	30 April 2024
4.	Shri S.A. Kirmani	Junior Administrative Officer	RRIUM, Chennai	31 May 2024
5.	Shri Yasin Ahmad Khan	Upper Division Clerk	CRIUM, Lucknow	31 May 2024
6.	Shri Mohammad Alauddin	Upper Division Clerk	RRIUM, Kolkata	31 May 2024
7.	Dr. Naheed Parveen	Deputy Director General	CCRM Headquarters	30 June 2024
8.	Dr. Mohammad Nafees Khan	Deputy Director (Unani)	CRIUM, Lucknow	30 June 2024
9.	Shri Syed Tayab Hashmi	Junior Administrative Officer	RRIUM, Mumbai	31 July 2024
10.	Dr. Shereen Afza	Deputy Director (Unani)	RRIUM, Aligarh	31 July 2024
11.	Dr. Rahat Raza	Deputy Director (Unani)	RRIUM, New Delhi	31 July 2024

S.N.	Name	Designation	Institute where posted	Date of Retirement
12.	Shri Rais Ahmed	Storekeeper	RRIUM, Kolkata	01 August 2024 <i>took voluntary retirement</i>
13.	Shri Sanjay,	Safaiwala	RRIUM, Aligarh	01 August 2024 <i>took voluntary retirement</i>
14.	Shri Rahmatullah	Assistant	RRIUM, New Delhi	31 August 2024
15.	Dr. Akhlaq Mustafa	Research Officer (Chemistry)	DSRU, New Delhi	30 Sept. 2024
16.	Dr. Mohammad Ehsan Ansari	Research Officer (Unani)	RRC, Prayagraj	30 Sept. 2024
17.	Dr. Shamsul Arfin	Research Officer (Unani)	CRIUM, Lucknow	30 Sept. 2024
18.	Shri Zafrul Islam	Compounder	CRIUM, Lucknow	30 Sept. 2024
19.	Shri Mahesh Chandra	Laboratory Technician	DSRU, New Delhi	31 October 2024
20.	Dr. Mokhtar Alam	Research Officer (Botany)	CCRUM Headquarters	31 January 2025
21.	Shri L. Bichya	Assistant	NRIUMSD Hyderabad	31 January 2025
22.	Shri Shakil Ahmed	Upper Division Clerk	DSRU, New Delhi	31 March 2025
23.	Smt. Shahnaz	Kitchen Servant	CRIUM, Lucknow	01 January 2025 <i>took voluntary retirement</i>
24.	Mohammad Qayyum Khan	MTS (Kitchen Servant)	CRIUM, Lucknow	01 Feb. 2025 <i>took voluntary retirement</i>

4.9 Deaths

S.N.	Name	Designation	Institute where posted	Date of Deaths
1.	Dr. Ravendra Singh	Investigator	CRIUM, Lucknow	23 June 2024 <i>passed away in harness</i>
2.	Dr. Azma	Research Officer (Unani)	RRIUM, New Delhi	17 Nov.2024 <i>passed away in harness</i>

5. FINANCIAL STATEMENT

5.1 Audit report

Opinion of the Comptroller & Auditor General of India on the Accounts of Central Council for Research in Unani Medicine (CCRUM) for the year ended 31st March 2025

Qualified Opinion

We have audited the financial statements of Central Council for Research in Unani Medicine (CCRUM) which comprise the statement of financial position as at 31st March 2025 and the Income & Expenditure Account/Receipts & Payment Account for the year then ended, and notes to the financial statements, including a summary of significant accounting policies under Section 20(1) of the Comptroller & Auditor General's (Duties, Powers & Conditions of Service) Act, 1971. The audit has been entrusted for the period upto 2028-29. These financial statements include the accounts of 11 regional offices of the CCRUM.

This Audit Report contains the comments of the Comptroller & Auditor General of India (CAG) on the accounting treatment only with regard to classification, conformity with the best accounting practices, accounting standards, disclosure norms, etc. Audit observations on financial transactions regarding compliance with the Law, Rules and Regulations (Propriety & Regularity) and efficiency cum performance aspects, etc., if any, are reported through inspection reports/ CAG's audit reports separately.

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements of CCRUM, read together with the accounting policies and Notes thereon and matters mentioned in the Separate Audit Report, which follows, give a true and fair view of the financial position of the autonomous body as at March 31, 2025, and (of) its financial performance and its cash flows for the year then ended in accordance with uniform format of accounts.

Basis for Qualified Opinion

CCRUM had awarded the construction work of Regional Research Institute of Unani Medicine (RRIUM) Silchar, Assam to M/s National Projects Construction Corporation Limited (NPCC) on 29-03-2017 and released advances of ₹49.62 crore. Out of this, CCRUM has depicted Capital Work-in-Progress of ₹26.12 crore and capital advances of ₹23.49 crore. The building was completed and handed over to RRIUM, Silchar on 30.4.2022 and was inaugurated on 20.11.2022 and was made functional immediately after the inauguration. However, CCRUM did not capitalize the amount of ₹49.62 crore (WIP & Capital advance) in the accounts as fixed assets (Building)

and charge the applicable depreciation of ₹4.96 crore (@ 10 per cent). This has resulted in understatement of fixed assets by ₹44.66 crore and depreciation by ₹4.96 crore and overstatement of Capital Work-in-Progress by ₹26.12 crore and Current Assets (Capital Advance) by ₹23.49 crore.

We conducted our audit in accordance with CAG's auditing regulations / standards / manuals / guidelines / guidance-notes / orders / circulars etc. Our responsibilities are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the autonomous body in accordance with ethical requirements that are relevant to our audit of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.


Responsibilities of Management for the financial statements

The Governing Body of CCRUM is responsible for the preparation and fair presentation of the financial statements in accordance with uniform format of accounts, and for internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion in accordance with CAG's auditing regulations/ standards/manuals / guidelines/guidance-notes/orders/circulars etc.

For and on behalf of C&AG of India



(Saurav Kumar Jaipuriyar)

Director General of Audit

(Central Expenditure)

Place: New Delhi

Date: 11.12.2025

SEPARATE AUDIT REPORT ON THE ANNUAL ACCOUNTS OF CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE (CCRUM) FOR THE PERIOD ENDING 31ST MARCH, 2025

A. Balance Sheet

A. 1 Assets ₹251.78 crore

A.1.1 Fixed Assets (Schedule - 8): ₹129.21 crore

A.1.1.1 CCRUM had awarded the construction work of Regional Research Institute of Unani Medicine (RRIUM) Silchar, Assam to M/S National Projects Construction Corporation Limited (NPCC) on 29-03-2017 and released advances of ₹49.62 crore. Out of this CCRUM has depicted Capital Work-in-Progress of ₹26.12 crore and capital advances of ₹23.49 crore.

As per records, the building was completed and handed over to RRIUM Silchar on 30.4.2022 and was inaugurated on 20.11.2022 and was made functional immediately after the inauguration. However, CCRUM did not capitalize the amount of ₹49.62 crore (WIP & Capital advance) in the accounts as fixed assets (Building) and charge the applicable depreciation of ₹4.96 crore (@ 10 per cent).

This has resulted in understatement of fixed assets by ₹44.66 crore and depreciation by ₹4.96 crore and overstatement of Capital Work-in-Progress by ₹26.12 crore and Current Assets by ₹23.49 crore and deficit is also understated by ₹4.96 crore

A.1.2 Current Assets (Schedule - 11) – ₹59.19 crore

A.1.2.1 CCRUM has released an advance of ₹4.35 Crore to National Projects Construction Corporation Ltd. (NPCC) for procurement of Computers, Air Conditioners, Furniture and Kitchen items etc. for RRIUM, Silchar, Assam. However, out of total advance, Assets of ₹2.92 crore supplied by M/S NPCC and taken over by RRIUM, Silchar were not capitalised in Annual Account. The Details are given below:

Sl.NO.	Items	Amount in Rs.
1	Kitchen items	79,37,612
2	Computer items	18,45,000
3	Furniture	1,94,02,195
	Total	2,91,84,807

This has resulted in overstatement of Current Assets (Advances) and understatement of Fixed Assets by ₹2.92 crore. Further, the item-wise details were not furnished to the Audit. In the absence of the same the Audit is not able to quantify the exact amount of depreciation thereon.

B. Income & Expenditure Account

B.1 Expenditure Rs.189.81 crore

B.1.I Schedule 21- Other Administrative Expenses- (₹76.50 crore)

B.1.1.1 CCRUM booked the 'salaries of consultant/contractual staff' amounting to ₹13.08 crore under sub- head wages of 'Schedule 21 - Other Administrative Expenses'. However, as per Uniform Format of Accounts, all salary and wages should be depicted under 'Schedule 20 Establishment Expenses'. This has resulted in Overstatement of 'Other Administrative Expenses' and understatement of 'Establishment Expenditure' by ₹13.08 crore.

C. Significant Accounting Policies

CCRUM did not incorporate Significant accounting policies and Contingent Liabilities in its Annual Accounts. Further, CCRUM did not clearly disclose the proper policy of Depreciation adopted. Also, CCRUM has not disclosed the details of income tax demand of ₹109.36 crore pertaining to the F.Y.2022-23.

D. General

D.1 CCRUM has depicted various outstanding advances of ₹41.81 crore (Capital advance of ₹30.80 crore, contingent advance of ₹10.99 crore, travelling advance of ₹2.32 Lakh) under Current Assets. These advances are pending for adjustment from 2000-01 to 2023-24. CCRUM may take necessary action to adjust these advances on urgent basis.

D.2 CCRUM has been depicting provision of ₹25.51 Crore since 2022-23 in Schedule-7 "Current Liability, Provisions etc" for retirement benefits viz. gratuity, pension and leave encashment. There has not been any adjustment to the provision. Further, the provision is not based on actuarial valuation as prescribed in AS-15. The disclosure in Notes to Accounts is also not appropriate as it states 'retirement benefits are treated as per GOI Rules'. Further, CCRUM made expense of ₹11.24 Crore on account of payment of Retirement Benefits and the same is incorporated under current year Income & Expenditure Account instead of adjusting through the provision. This defeats the purpose of creating the Provision. This issue raised in the previous years SARs as well, but no corrective action has been taken by CCRUM.

E. Management Letter

Deficiencies which have not been included in this Separate Audit Report have been brought to the notice of the Management through a Management Letter issued separately for remedial/corrective action.

F. Assessment of Internal Controls

1. Adequacy of internal audit system

The internal audit of the CCRUM was conducted upto 2024-25 by the Ministry of Health & Family Welfare. However, report is yet to be received.

2. Adequacy of internal control system

Internal control system was not adequate as 16 paras pertaining to the period 2015-16 to 2018-19 were outstanding for settlement. Further, Annual Accounts of CCRUM disclosed assets valued at 129.21 crore as on 31 March 2025. However, an Assets Register required to be maintained in Form GFR-22 under General Financial Rules 2017 has not been maintained by the CCRUM.

3. System of physical verification of fixed assets

The physical verification of fixed assets was conducted up to 2024-25 and no discrepancy was reported.

4. System of physical verification of inventory

The physical verification of Books and Publications was conducted up to 31.03.2025.

5. Regularity in payment of statutory dues

As per accounts, no payments for over six months in respect of statutory dues were outstanding as on 31.03.2025.

G. Grant in aid

(i) Health Account

CCRUM had received Grant in Aid of ₹190.05 crore during 2024-25 from Ministry of AYUSH. CCRUM had earned interest of ₹18.40 lakh on unspent GIA, which was not refunded to the Ministry. Out of total Grant-in-Aid of ₹190.05 crore, CCRUM utilized Rs.190.05 crore leaving only the earned interest of ₹18.40 lakh as on 31.03.2025.

(ii) Specific Project Account

CCRUM has not received any grant during 2024-25 under Pradhan Mantri Jan Vikas Karyakram (PMJVK) account and has unspent balance of ₹2.55 crore from previous year. CCRUM had other receipts of ₹10.45 lakhs. Thus out of available balance of ₹2.65 crore, CCRUM utilized ₹2.04 crore, leaving an unspent balance of ₹61.55 lakh as on 31.03.2025.



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Index of the Annual Accounts for the Year 2024-25

S. No.	Name of the accounts	Page No.	Schedules at Page No.
1.	Balance Sheet	195	202-210
2.	Income & Expenditure account	196	211-222
3.	Receipt & Payment a/c	197-201	223-239
4.	Notes on Accounts	240	-



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Balance Sheet as on 31st March 2025

CORPUS/CAPITAL FUND AND LIABILITIES	Schedule	Current Year	Previous Year
CORPUS/CAPITAL FUND	1	144,29,49,554.27	140,16,42,769.32
RESERVE AND SURPLUS	2	-	-
EARMARKED/ENDOWMENT FUNDS	3	61,54,794.48	2,55,03,391.15
SECURED LOANS AND BORROWINGS	4	-	-
UNSECURED LOANS AND BORROWINGS	5	-	-
DEFERRED CREDIT LIABILITIES	6	-	-
CURRENT LIABILITIES AND PROVISIONS	7	41,64,16,132.82	34,09,62,479.84
CURRENT LIABILITIES AND PROVISIONS (OTHER A/Cs)		65,22,94,320.88	85,43,81,504.42
Total		251,78,14,802.45	262,24,90,144.73
ASSETS			
FIXED ASSETS	8	129,21,19,390.00	127,54,71,881.00
INVESTMENTS-FROM EARMARKED/ENDOWMENT FUNDS	9	-	-
INVESTMENTS-OTHERS	10	63,37,34,058.51	64,52,61,916.62
CURRENT ASSETS, LOANS, ADVANCES ETC.	11	59,19,61,353.94	70,17,56,346.49
CURRENT ASSETS (OTHER A/Cs)			
Total		251,78,14,802.45	262,24,90,144.73

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Income and Expenditure account for the year ending 31st March 2025

	Schedule	Current Year	Previous Year
INCOME			
Income from Sales/Services	1	-	-
Grants	13	1,84,05,00,000.00	166,10,00,000.00
Fees	14	52,66,963.19	44,12,488.00
Income from Investments (Income on Invest from earmarked/endow. Funds transferred to Funds)	-	-	-
Income from Publication etc.	16	2,54,090.00	1,79,505.00
Interest earned	17	-	-
Other Income	18	3,33,46,430.75	5,23,73,291.37
Less:- Capitalized		(-)1,19,75,452.00	(-) 1,26,82,565.00
Total (A)		186,73,92,031.94	170,52,82,719.37
EXPENDITURE			
Establishment Expenses	20	111,17,42,779.00	109,99,64,509.00
Other Administrative Expenses etc.	21 (A- D)	76,49,73,459.99	62,42,08,984.18
Expenditure on Grants, Subsidies etc.	22		
Depreciation (Net Total at the year end – Corresponding to Schedule 8)	21 (E)	2,13,44,460.00	1,86,78,283.00
Total (B)		189,80,60,698.99	174,28,51,776.18
Balance being excess of Expense over Income (A-B)		(-)3,06,68,667.05	(-) 3,75,69,056.81
Balance BEING SURPLUS/ (DEFICIT) CARRIED TO CAPITAL FUND		(-)3,06,68,667.05	(-) 3,75,69,056.81

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Receipt & Payment a/c for the year ending 31st March 2025

RECEIPT SIDE: -

Current Year					Previous year				
I.	Opening balance	CCRUM A/c	Other specific a/c	GPF/GIS/Pension NPS a/cs	Total	CCRUM A/c	Other specific a/c	GPF/GIS/Pension NPS a/cs	Total
a.	Cash in Hand (Imprest)	4,51,987.15				5,83,336.22	-	-	5,83,336.22
b.	Cash at Bank	2,29,49,424.29	2,55,03,391.15	11,93,48,845.80	16,82,53,648.39	337,63,591.60	5,21,66,727.50	11,87,74,620.97	20,47,04,939.47
	Total (I)	2,34,01,411.44	2,55,03,391.15	11,93,48,845.80	16,82,53,648.39	3,43,46,927.22	5,21,66,727.50	11,87,74,620.97	20,52,88,275.69
II.	Grant in Aid					-	-	-	-
a.	Capital	6,00,00,000.00	-	-	600,00,000.00	8,00,00,000.00	-	-	8,00,00,000.00
b.	Revenue	184,05,00,000.00	-	-	184,05,00,000.00	1,66,10,00,000.00	42,50,378.00	-	166,52,50,378.00
	Total (II)	190,05,00,000.00	-	-	190,05,00,000.00	174,10,00,000.00	42,50,378.00	-	174,52,50,378.00
III.	Investments of GPF/GIS/Pension funds	-	-	21,40,21,998.00	21,40,21,998.00	-	-	3,19,68,640.00	3,19,68,640.00
	Total (III)	-	-	21,40,21,998.00	21,40,21,998.00	-	-	3,19,68,640.00	3,19,68,640.00
IV	Interest received								
a.	Bank interest	17,22,468.00	7,79,280.07	12,73,556.00	37,75,304.07	23,62,097.00	12,37,825.65	20,89,458.00	56,89,380.65
	Total (IV)	17,22,468.00	7,79,280.07	12,73,556.00	37,75,304.07	23,62,097.00	12,37,825.65	20,89,458.00	56,89,380.65

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

V. Other Income									
a. Interest on refundable advances	50,525.00	-	-	50,525.00	67,292.00	-	-	67,292.00	
b. Other misc income	3,29,29,672.05	2,66,200.00	-	3,31,95,872.05	2,83,50,275.00	-	1,14,116.00	2,84,64,391.00	
c. Sale of publications	2,54,090.00	-	-	2,54,090.00	1,79,505.00	-	-	1,79,505.00	
d. Unani Academic Courses fee etc.	52,66,963.19	-	-	52,66,963.19	44,12,488.00	-	-	44,12,488.00	
Total (V)	3,85,01,250.24	2,66,200.00	-	3,87,67,450.24	3,30,09,560.00	-	1,14,116.00	3,31,23,676.00	
VI Other receipts									
a. Refund against by adjustment of advances pertaining to previous year	8,81,596.00	-	-	8,81,596.00	23,06,314.00	-	-	23,06,314.00	
b. Recoveries of refundable advances to Govt Servants	10,04,217.00	-	-	10,04,217.00	-	-	-	-	
c. Recoveries for remittances	1,04,06,172.00	-	5,64,917.00	1,09,71,089.00	1,94,04,187.00	-	-	1,94,04,187.00	
d. Recoveries of subscription & advance	-	-	4,20,83,740.00	4,20,83,740.00	-	-	5,88,34,577.00	5,88,34,577.00	
e. Security deposit (CCRUM)	10,000.00	-	-	10,000.00	1,06,500.00	-	-	1,06,500.00	
f. Receivable amount received	13,67,939.00	-	-	13,67,939.00	26,93,960.00	-	-	26,93,960.00	
g In-transit amount received					-	-	-	-	
h. Unspent balance from Institutes/units	2,26,17,984.06	-	-	2,26,17,984.06	-	-	-	-	
i. Amount received but payable to other Institute/Unit	24,67,504.00	-	16,549.00	24,84,053.00	-	-	-	-	

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

j.	LIC amount received from LIC for disbursement	-	-	5,60,000.00	-	-	-	-	-
k.	Pension fund transfer from Health a/c received in pension fund a/c	-	-	20,79,33,285.00	-	-	-	28,14,96,741.00	28,14,96,741.00
l.	Unani Day Funds	-	-	-	-	39,98,912.00	-	-	39,98,912.00
m.	Receipts on closing Bank a/c	-	-	-	-	-	-	-	-
n.	NPS Trust	22,93,418.85	-	1,43,11,005.00	-	3,20,40,648.62	-	-	3,20,40,648.62
o.	Interest received from NPCC	2,33,76,872.00	-	-	-	-	-	-	-
p.	Unspent Balance (Current Year)	-	-	-	-	1,24,74,386.50	-	-	1,24,74,386.50
q.	Interest on FDRs	-	-	1,56,61,400.00	-	-	-	-	-
r.	Fund Transfer	-	-	-	-	-	-	-	-
	Total (VI)	6,44,25,702.91	-	28,11,30,896.00	-	7,30,24,908.12	-	34,03,31,318.00	41,33,56,226.12
	Grand Total (I to VI) of Receipt side	202,85,50,832.59	2,65,48,871.22	61,57,75,295.80	-	1,88,37,43,492.44	5,76,54,931.15	49,32,78,152.97	2,43,46,76,576.56

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Receipt & Payment a/c for the year ending 31st March 2025

Current Year					Previous year			
I. Expenses	CCRUM A/c	Other specific a/c	GPF/GIS/Pension NPS a/cs	Total	CCRUM A/c	Other specific a/c	GPF/GIS/Pension NPS a/cs	Total
a. Establishment Expense	105,81,65,559.00	-	5,29,84,667.00	111,11,50,226.00	108,42,69,917.00	-	-	108,42,69,917.00
Total I	105,81,65,559.00	-	5,29,84,667.00	111,11,50,226.00	108,42,69,917.00	-	-	108,42,69,917.00
II. Administrative Expense								
i. Admn. Expenses	54,21,49,846.07	76.74	1558.43	54,21,51,481.24	48,27,00,004.53	-	3897.17	48,27,03,901.70
ii. Material & Supplies	15,52,68,636.00	-	-	15,52,68,636.00	12,58,22,137.00	-	-	12,58,22,137.00
iii. Other charges	6,89,53,403.00	-	-	6,89,53,403.00	3,08,78,646.00	9,65,542.00	-	3,18,44,188.00
iv. Publication exps	-	-	-	-	-	-	-	-
Total (II)	76,63,71,885.07	76.74	1558.43	76,63,73,520.24	63,94,00,787.53	9,65,542.00	3897.17	64,03,70,226.7
III. Investment made out of GPF, GIS, Pension funds	-	-	10,68,10,000.00	10,68,10,000.00	-	-	-	-
Total (III)	-	-	10,68,10,000.00	10,68,10,000.00	-	-	-	-
IV. Capital advances	6,00,01,796.00	2,03,94,000.00	-	8,03,95,796.00	5,54,89,253.00	-	2,51,71,290.00	8,06,60,543.00
a. Purchase of fixed assets	1,19,75,452.00	-	-	1,19,75,452.00	1,54,73,843.00	-	-	1,54,73,843.00
b. Fund Transfer	11,51,065.00	-	-	11,51,065.00	-	-	-	-
c. IPR fund transfer					-	-	-	-
Total (IV)	7,31,28,313.00	2,03,94,000.00	-	9,35,22,313.00	7,09,63,096.00	-	2,51,71,290.00	9,61,34,386.00
V. Interest remitted to Ministry received by NPCC	2,33,76,872.00	-	-	2,33,76,872.00				
a. Total (V)	2,33,76,872.00	-	-	2,33,76,872.00	-	-	-	-
b. To the States Govt.	-	-	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

**Sd/-
(Mohammad Parvez)
Administrative Officer**

Sd/-
(Shakaib Hasan)
Consultant (IA)

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule of Balance Sheet for the year ending 31st March 2025

Schedule of Balance Sheet Schedule - 1-Capital Fund

S.No.		Current Year	Previous year
	Balance at the beginning of the year	140,16,42,769.32	134,62,46,983.13
	Addition during the year	1,19,75,452.00	1,29,64,843.00
	Add:- Capital Grant	6,00,00,000.00	8,00,00,000.00
	Total Rs.	147,36,18,221.32	143,92,11,826.13
	Add/Deduct Balance of net Income/Expenditure transferred from the Income and Expenditure a/c	(-) 3,06,68,667.05	(-) 3,75,69,056.81
	Total Rs.	144,29,49,554.27	140,16,42,769.32
	Net Balance	144,29,49,554.27	140,16,42,769.32

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule forming part of Balance Sheet as on 31st March 2025

(Schedule -3) Earmarked/Endowment funds

	Herb Garden a/c	Unani Day	IPR	PMJVK a/c	Current year	Total	Previous year
(a) Opening balance	2,64,252.00	5,45,529.50	26,519.00	2,46,67,090.65	2,55,03,391.15		35,03,727.50
Total (a)	2,64,252.00	5,45,529.50	26,519.00	2,46,67,090.65	2,55,03,391.15		35,03,727.50
(b) Additions:	-	-	-	-	-		5,26,61,912.00
• Grant-in-aid	-	-	-	-	-		
Other additions a/c of:	-	-	-	-	-		
• Bank interest	-	42,396.00	11,675.00	7,25,209.07	7,79,280.07		12,37,825.65
• From Health a/c	-	-	-	-	-		
• Recoveries for remittances	-	-	-	-	-		
• Receivable received	-	-	-	-	-		
• Misc receipts	-	2,66,000.00	-	200.00	2,66,200.00		2,51,466.00
Total (b)	-	-	-	-	-		
Total (a+b)	2,64,252.00	8,53,925.50	38,194.00	2,53,92,499.72	2,65,48,871.22		5,76,54,931.15
(c) Utilization/expenditure	-	-	-	-	-		-
i) Capital expenditure	-	-	-	2,03,94,000.00	2,03,94,000.00		2,51,71,290.00
• Assets	-	-	-	-	-		-
• Others	-	-	-	-	-		-
ii) Revenue expenditure	-	-	-	-	-		-
• Salaries/wages allowances	-	-	-	-	-		-
• Other administrative expenditure	-	-	76.74	-	76.74		96,5542.00
• Material & supplies	-	-	-	-	-		
• Remittance of recoveries	-	-	-	-	-		39,98,912.00
• Amount payable paid	-	-	-	-	-		20,15,796.00
• Unspent balance refunded	-	-	-	-	-		-
• Transfer to Health a/c on a/c of closure	-	-	-	-	-		-
Total (c)	-	-	76.74	2,03,94,000.00	2,03,94,076.74		3,21,51,540.00
Net balance (a+b (-) c)	2,64,252.00	8,53,925.50	38,117.26	49,98,499.72	61,54,794.48		2,55,03,391.15

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule -7- Current Liabilities & Provisions: -

S.No	Statutory Liabilities: - • Duties and taxes	Current Year	Previous Year
7(A)(5)		67,26,699.57	32,75,599.57
	Total 7 (A) (5)	67,26,699.57	32,75,599.57
7(A)(6)	Other Current Liabilities	-	-
➤	Secured Deposits (CCRUM)	14,44,945.00	14,84,945.00
➤	Short payments payable	23,798.00	23,798.00
➤	Undisbursed amounts (Decentralized Instt)	79,948.00	79,948.00
➤	Recoveries not received details	2,289.00	2,289.00
➤	FW a/c	17090.00	17090.00
➤	Advances from Vidya Peeth (Decentralized Instt Srinagar)	2,50,000.00	2,50,000.00
➤	Amount received but detail not received (Kol)	16,469.00	16,469.00
➤	Received from CCRAS for UPC	30,00,000.00	30,00,000.00
➤	Payable by RRI, New Delhi to Hqrs, ND	36.00	36.00
➤	Security deposit (CCCBG)	4,03,000.00	4,03,000.00
➤	Unspent balance payable to Min. of AYUSH	-	0.27
➤	Unspent balance of specific accounts	2,02,17,495.70	2,02,17,495.70
➤	Sundry Creditors	37,53,603.43	-
➤	Deduction from salaries	78,31,631.00	2708,655.00
➤	Salary payable	2,48,47,907.00	1,21,01,620.00
➤	Seminar Expense Payable	-	1,50,250.00
➤	I.T. Repair & Maintenance Payable	-	3,69,000.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

➤	Remittance to Ministry	20,14,662.00	26,55,151.00
➤	Imprest	24,974.00	24,974.00
➤	Unani Day Expense Payable	1,49,115.00	61,357.00
➤	Wages Payable	15,86,802.00	15,51,402.00
➤	Release payable (Branches)	8,54,46,468.97	3,74,73,171.00
➤	T.A. Expense Payable	38,768.00	(-) 33,796.00
➤	Misc Receipts	13,078.00	-
➤	Nps amount received from RRIUM, ND	1,28,004.00	-
➤	Nps corpus amt payable to subscribers	12,37,518.85	-
➤	Office Expenses payable	19,168.00	-
➤	Training programme exp payable	87,059.00	-
➤	Excess expenditure (pr yr)	19,25,568.00	-
➤	Hindi Workshop exp payable	10.00	-
	Total	15,45,59,407.95	8,25,56,854.97
7(B)	Provisions For Retirement Benefits	25,51,30,025.30	25,51,30,025.30
	Total 7 (B)	25,51,30,025.30	25,51,30,025.30
	Total 7 (A+B) c/f	41,64,16,132.82	34,09,62,479.84
7(D)	NPS a/c • NPS liability	-	1,42,43,150.31
7(E)	GPF a/c • GPF liability to GPF subscribers	42,77,07,742.16	44,77,55,692.39
7(F)	GIS a/c • GIS liability to GIS subscribers	2,30,69,990.19	2,52,58,527.19
7(G)	Pension Fund a/c • Pension funds bank interest and payment of pension, FP commutation of pension from	20,15,16,588.53	36,71,24,134.53
	Total 7(C) to 7(G) Rs.	65,22,94,320.88	85,43,81,504.42

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Shakaib Hasan)
Consultant (IA)

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE
Ministry of Ayush, Government of India

Annual Report
2024-2025

Consolidated Schedule of Fixed Assets as on 31st March 2025

Schedule (8)

SNo	Name of the Assets	Opening balance as on 01.04.23	Gross Block					Depreciation			Net Block		
			Addition	Deductions	Transferred to/from M/E a/c	Total	Rate of Depreciation	Opening balance as on 01.04.23	On addition	On deductions	Total	As on 31.03.2025	As on 31.03.2024
(A) 1.	Machinery Equipment	21,51,68,846.00	2,71,80,468.00	-	-	24,23,49,314.00	10%	11,04,19,101.00	1,19,17,899.00	-	12,23,37,000.00	12,00,12,314.00	10,47,49,745.00
2.	Furniture & Fixture	10,09,37,825.00	8,51,528.00	-	-	10,17,89,353.00	10%	7,22,90,383.00	29,24,214.00	-	7,52,14,597.00	2,65,74,756.00	2,86,47,442.00
3.	Computers	4,03,34,641.00	38,92,855.00	-	-	4,42,27,496.00	40%	3,60,50,557.00	27,57,969.00	-	3,88,08,526.00	54,18,970.00	42,84,084.00
4.	Land	27,85,336.00	-	-	-	27,85,336.00	-	-	-	-	-	27,85,336.00	27,85,336.00
5.	Books & Journals	3,63,23,732.00	-	-	-	3,63,23,732.00	40%	3,31,66,252.00	12,62,992.00	-	3,44,29,244.00	18,94,488.00	31,57,480.00
6.	Vehicles	86,22,166.00	19,45,966.00	-	-	1,05,68,132.00	15%	71,21,379.00	3,71,091.00	-	74,92,470.00	30,75,662.00	15,00,787.00
7	Building	13,43,46,873.00	41,21,152.00	-	-	1,384,68,025.00	10%	11,53,04,500.00	21,10,295.00	-	11,74,14,795.00	2,10,53,230.00	1,90,42,373.00
	TOTAL (A)	53,85,19,419.00	3,79,91,969.00	-	-	57,65,11,388.00	-	37,43,52,172.00	2,13,44,460.00	-	39,56,96,632.00	18,08,14,756.00	16,41,67,247.00
(B)		-	-	-	-	-	-	-	-	-	-	-	-
1.	Works in progress	111,13,04,634.00	-	-	-	111,13,04,634.00	-	-	-	-	-	111,13,04,634.00	111,13,04,634.00
	TOTAL (B)	111,13,04,634.00	-	-	-	111,13,04,634.00	-	-	-	-	-	111,13,04,634.00	111,13,04,634.00
	TOTAL (A+B)	164,98,24,053.00	3,79,91,969.00	-	-	168,78,16,022.00	-	37,43,52,172.00	2,13,44,460.00	-	39,56,96,632.00	129,21,19,390.00	127,54,71,881.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule of Investments out of the following funds as on 31.03.2025

Schedule S-10

		Current Year	Previous Year
1	GPF	40,93,08,825.66	37,02,54,780.77
2.	GIS	2,29,60,482.85	2,15,55,768.85
3.	Pension Fund	20,14,64,750.00	25,34,51,367.00
	Total S/5C	63,37,34,058.51	64,52,61,916.62

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule of Current Assets (S-11)

(A)	CCRUM A/Cs :-	Current year	Previous year
1.	Contingent advance	10,99,16,907.00	10,98,33,036.00
2.	Exhibitions advance	73,000.00	73,000.00
3.	T.A advance	2,32,466.00	2,40,620.00
4.	Excess paid to be recovered/adjusted	-	8,107.00
5.	LTC advance	5,78,657.90	4,73,903.00
6.	Advance for Seminar	31,60,907.00	26,83,717.00
7.	Capital advance	30,80,51,102.00	30,40,67,041.00
8.	Scooter advance	18,093.00	27,456.00
9.	Fan advance	768.00	768.00
10.	Car advance	103,049.07	1,16,449.07
11.	Computer advance	57,863.00	4,55,256.00
12.	House building advance	66,30,251.00	81,29,237.00
13.	In transit amount	18,200.15	18,200.15
14.	Security deposits	4,70,311.00	4,70,311.00
15.	Medical advance	3,28,264.85	3,28,265.00
16.	Receivable from IPR a/c	70,960.00	70,960.00
17.	Receivable from LIC	1351.50	1,351.50
18.	Excess TDS to be recovered/adjusted	19,706.00	19,706.00
19.	Training advance	4,75,225.00	3,78,552.00
20.	Ethics Committee Advance	1,95,307.00	1,46,524.00
21.	Share amount receivable from CCRYN, N. Delhi	2,62,992.00	2,62,992.00
22.	Advance for A-HMIS	1,34,200.00	1,34,200.00
23.	Receivable from F.W. a/c	17,090.00	17,090.00
24.	Swachhta Action Plan Advance	13,26,206.00	5,62,707.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

25.	Maintenance Advance	3,39,751.00	3,44,751.00
26.	Hindi workshop	3,46,230.00	2,67,650.00
27.	IT maintenance	77,561.00	95,674.00
28.	Machinery and equipment advance	88,47,512.00	88,47,512.00
29.	Material & supplies advance	2,92,082.00	-
30.	Office Expense advance	7,86,529.10	8,43,309.10
31.	Excess paid	-	-
32.	Bank Balance lying with RRI Kolkata to be received/adjustment s	19,323.00	19,323.00
33.	Hindi Pakhwada Advance	138,100.00	1,36,899.00
34.	Advance for Health Camp	1,89,928.00	1,59,928.00
35.	Arogya advance	1,76,482.00	1,67,765.00
36.	International Conference & Unani Day Advance	17,18,245.00	15,29,089.00
37.	Fuel advance	-	3,000.00
38.	Fuel Advance (NER)	2,00,000.00	2,00,000.00
39.	IT (Computer/Accessories) Advance	33,400.00	33,400.00
40.	Office Expense advance (SCSP)	35,000.00	15,000.00
41.	Office Expense advance (NER)	87,950.00	50,000.00
42.	Capital advance (NER)	3,25,00,000.00	25,00,000.00
43.	Expense paid	-	700.00
44.	Imprest Advance	-	49,943.00
45.	Hindi workshop advance SCSP	7500.00	-
46.	Computer printer advance	20,000.00	-
47.	Advance NER	10500.00	-
48.	Office expenses advance SAP	26000.00	-
(B)	A-Total (Rs.)	47,79,94,970.57	44,37,31,956.86
(C)	Family Welfare a/c :- (i) Current Assets	-	-
(D)	NPS a/c	-	-
(E)	GPF a/c (i) Current Assets	56,10,246.00	5,79,04,589.00
(F)	GIS a/c	-	12,72,336.00
(F)	Pension Fund a/c	-	3,05,93,817.00
	Total (B to F) Rs. C/f	56,10,246.00	8,97,70,742.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Closing balance as on 31.03.2025

Schedule-11

(G) Bank of India (A)	Imprest 16602		4,41,987.15	Health A/c
	Total (A)		8,88,09,339.37	
-do- (B)	16601		8,92,51,326.52	GPF A/c
-do-	16640		1,27,88,670.50	GIS A/c
Bank of Baroda	8477		1,09,507.34	Pension A/c
SBI	1088		51,838.53	NPS A/c
	Total (B)		-	
	Grand Total (A + B) Schedule S/5A		1,29,50,016.37	
-do- (C)	3988		10,22,01,342.89	IT A/c
-do-			Nil	CRISM A/c
-do-	11685		-	AIUM A/c
Bank of India	19612		-	UPS Aligarh
-do-	17450		2,64,252.00	Herb Garden A/c
-do-	17450		38,117.26	IPR a/c
-do-	2226		-	Publication of Text Books
-do-	25291		-	DSOP A/c
-do-	3654		-	International Events Conferences (DST)
-do-	6063		-	Unani Chair South African
-do-	190312		-	DST A/c
-do-	24656		-	WHO A/c
-do-			49,98,499.72	PMJVK
State Bank of India	7704		-	(i) Ph-co.vigilance a/c
			8,53,925.50	(ii) Unani Day Conferences a/c
	Total (C)		61,54,794.48	
		Total (A + B + C) of G	10,83,56,137.37	
		TOTAL (A+B TO F+G)	59,19,61,353.94	

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule of Grant in aid for the year ending 31st March 2025

Schedule of Income & Expenditure a/c
Schedule 13- Grants
Schedule of Income forming part of Income & Expenditure a/c for the year ending 31st March 2025

	Grant in aid	Current Year	Previous Year
A.	Central Government	1,84,05,00,000.00	166,10,00,000.00
	Total	1,84,05,00,000.00	166,10,00,000.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule 14- Fees/Subscription Schedule of Income forming part of Income & Expenditure a/c for the year ending 31st March 2025

		Current Year	Previous Year
B.	Unani Academic Course/fees	52,66,963.19	44,12,488.00
	Total	52,66,963.19	44,12,488.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule 16- Income from Publication
Schedule of Income forming part of Income & Expenditure a/c for the year ending 31st March 2025

	Current Year	Previous Year
• Income from sale of publication	2,54,090.00	1,79,505.00
Total	2,54,090.00	1,79,505.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule 17(2) - Interest earned Schedule of Income forming part of Income & Expenditure a/c for the year ending 31st March 2025

	Current Year	Previous Year
• On Saving Accounts	-	-
• On refundable advances	-	-
Total	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule 18- Other Income Schedule of Income forming part of Income & Expenditure a/c for the year ending 31st March 2025

Ledgers a/cs	Current Year	Previous Year
• OPD/Regn fee from patients	2,87,63,007.05	2,66,90,515.00
• RTI	372.00	238.00
• Sale of Raddi etc	2795.00	3,747.00
• Library user charges	5040.00	5,305.00
• Electricity charges	30793.00	23,307.00
• License fees	1,23,747.00	2,09,738.00
• DTL project	1,01,037.00	45,334.00
• Auction money	2,21,111.00	1,07,441.00
• Sale of Magazine	-	6,475.00
• Tax refund	36,73,460.00	-
• Sale of security paper	-	10,000.00
• Unani Funds	-	39,98,912.00
• Sale of Stamps	4216.00	150.00
• Scrap/Condemn items	-	12,768.00
• Misc. receipts	-	10,07,633.00
• Other receipts (Decentralized Instt)	-	3,20,706.00
• Recovery	2,75,076.00	-
• NPS Corpus Amount	-	1,88,16,352.62
• Water charges	15,967.00	-
• Parking fees	735.00	3,000.00
• Refund/Receipt	1,29,074.70	2,02,046.00
• Electricity recovery	-	1,659.00
• Unspent balance	-	9,07,964.15
Total	3,33,46,430.75	5,23,73,291.37

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Non-recurring/Capital expenditure (Schedule-19) Schedule of Expenditure forming part of Income & Expenditure a/c for the year ending 31st March 2025

<u>Non-recurring/Capital expenditure</u>	Current year	Previous year
• Machinery & Equipment	2,71,80,468.00	4,27,82,594.00
• Vehicles	19,45,966.00	-
• Furniture & Fixture	8,51,528.00	22,31,814.00
• Books & Journal	-	5,30,509.00
• Computers	38,92,855.00	39,16,410.00
• Building	41,21,152.00	-
Total	3,79,91,969.00	4,94,61,327.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Income & Expenditure a/c - Schedule 20- Establishment Expenses
Schedule of Expenditure forming part of Income & Expenditure a/c for the year ending 31st March 2025

(A)		Current Year	Previous Year
•	Salaries	75,24,43,550.00	71,53,88,543.00
•	Contribution to other fund NPS 3,89,99,468.00 Pension 20,79,33,285.00	24,69,32,753.00	32,05,89,112.00
•	Expenses on Employees Retirement Benefits	11,23,66,476.00	6,39,86,854.00
	Total (A)	111,17,42,779.00	109,99,64,509.00
(B)	TOTAL (A+B)	111,17,42,779.00	109,99,64,509.00

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Shakaib Hasan)
Consultant (IA)

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule 21 – Other Administrative Expenses etc. Schedule of Expenditure forming part of Income & Expenditure a/c for the year ending 31st March 2025

A.	Other Administrative expenses	Current year	Previous year
•	T.A	79,00,876.00	95,75,569.00
•	Wages including contractual staff remuneration	13,08,53,642.00	5,32,36,361.00
•	Office Expenses (stationary & printing, Electricity, water, Telephone, Cartage/freight, Advocate fees, Refreshment, Advertisement charges etc.	12,20,16,533.32	2,46,79,398.53
•	Rent & taxes (Rent of Building & Property Tax)	4,18,03,729.00	23,80,919.00
•	Maintenance & Repair, Petrol Diesel exps etc.	2,39,68,574.52	19,53,635.00
•	Information Technology (Recurring expenses i.e Repair of computers cartridge, Net charges, Website charges etc)	93,99,104.00	1,05,22,631.00
•	Consolidated expenses on a/c SCP/TSP wages/Remuneration of staff/stationary & other misc expenses/NER	9,46,43,726.00	6,51,29,050.00
•	General consolidation	-	20,40,86,426.65
•			
B.	Total Schedule -21 (A)	43,05,54,338.84	37,15,63,990.18
	Material & Supplies (Medicines, Chemicals, Glasswares & Lab investigation charges etc.)	15,95,58,712.00	11,36,62,905.00
	Total 21- (B)	15,95,58,712.00	11,36,62,905.00
C.	Other Charges		
	Medical expenses	1,40,54,279.15	58,81,136.00
	Survey expenses	-	39,46,042.00
	Arogya Fair	32,17,203.00	-
	Unani Academic Course	8,90,42,090.00	8,41,15,418.00
	Swatchta Action Plan	40,78,732.00	35,66,352.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

	Research Activities	3,73,33,931.00	3,37,52,302.00
	Training Programme	6,99,348.00	1,40,000.00
	Seminar	45,72,294.00	10,59,278.00
	Ethics Committee expenses	94,746.00	-
	Unani Day & Seminar	1,59,93,067.00	44,87,494.00
	Hindi pakhwada	4,50,783.00	5,51,048.00
	IEC expenses	-	12,920.00
	AHMIS	1,36,991.00	8,14,604.00
	CGHS Cont.	42,42,973.00	-
	Exhibition Mela	-	-
	IEC	14,580.00	-
	Ph.D Prog.	-	12,980.00
	NABH	3,21,655.00	1,92,515.00
	Hindi workshop	5,51,857.00	4,50,000.00
	Pharmacovigilance expense	55,880.00	-
	Total S.No.21(C)	17,48,60,409.15	13,89,82,089.00
	Grand Total Schedule 21 (A to C)	76,49,73,459.99	62,42,08,984.18

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Shakaib Hasan)
Consultant (IA)

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule 21(E) Schedule of Expenditure forming part of Income & Expenditure a/c for the year ending 31st March 2025

S.No. (D)	<u>Depreciation</u>	Current year CCRUM	Previous year CCRUM
(i)	Machinery & Equipment	1,19,17,899.00	95,06,953.00
(ii)	Furniture & Fixtures	29,24,214.00	30,73,345.00
(iii)	Computers	27,57,969.00	17,86,214.00
(iv)	Books & Journals	12,62,992.00	19,31,142.00
(v)	Vehicles	3,71,091.00	2,64,810.00
(vi)	Building	21,10,295.00	21,15,819.00
	Grand Total	2,13,44,460.00	1,86,78,283.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule of Receipts for the year ending 31st March 2025

S. No.	Opening balance		GIA		Bank interest	
	Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
	(1)	(1)	(2)	(2)	(3)	(3)
1						
(i) CCRUM Scheme a/c						
(a) Cash-in-hand (Imprest)		-	6,00,00,000.00	8,00,00,000.00	17,22,468.00	23,62,097.00
(b) Cash-in-hand (other than Imprest)	4,51,987.15	-	1,84,05,00,000.00	1,66,10,00,000.00		-
(c) Cash-at-bank	2,29,49,424.29	3,43,46,927.22	-	-	-	-
Total (CCRUM SCHEME A/C) S.No.1	2,34,01,411.44	3,43,46,927.22	1,90,05,00,000.00	1,74,10,00,000.00	17,22,468.00	23,62,097.00
2. Other Specific accounts						-
(i) IPR	26,519.00	2,77,985.00	-	2,51,466.00	11,675.00	62,445.00
(ii) Herb Garden a/c	2,64,252.00	2,64,252.00	-	-	-	-
(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
(iv) UPS a/c I	-	-	-	-	-	-
(v) DSOP	-	-	-	-	-	-
(vi) AIUM a/c	-	-	-	-	-	-
(vii) I.T A/c	-	24,15,961.00	-	-	-	-
(viii) National Conference on Unani Day	5,45,529.50	5,45,529.50	-	39,98,912.00	42,396.00	-
(ix) PMJVK a/c	2,46,67,090.65	4,86,63,000.00	-	-	7,25,209.07	11,75,380.65

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	0	0	0	0	0	0
	(xiv) South African a/c	0	0	0	0	0	0
	Total S.No. 2	2,55,03,391.15	5,21,66,727.50	42,50,378.00	7,79,280.07	12,37,825.65	12,37,825.65
1.	(i) NPS a/c	1,42,43,150.31	78,97,056.31	0	68,308.00	1,61,737.00	1,61,737.00
	(ii) CPF/GPF a/c	1,95,96,322.62	2,35,16,445.29	0	3,69,100.00	5,64,946.00	5,64,946.00
	(iii) GLS a/c	24,30,422.34	39,74,819.84	0	39,400.00	98,009.00	98,009.00
	(iv) Pension fund a/c	8,30,78,950.53	8,33,86,299.53	0	7,96,748.00	12,64,766.00	12,64,766.00
	Total S.No. 3	11,93,48,845.80	11,87,74,620.97	0	12,73,556.00	20,89,458.00	20,89,458.00
	Grand Total S.No. 1 to 3	16,82,53,648.39	20,52,88,275.69	1,90,05,00,000.00	1,74,52,50,378.00	37,75,304.07	56,89,380.65

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S. No.		Miscellaneous Receipts		Interest on refundable advances		Refunds against by adjustment of Advances pertaining to previous years	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)	(5)	(6)			
1.	CCRUM Scheme a/c	3,29,29,672.05	2,83,50,275.00	50,525.00	500.00	8,81,596.00	23,06,314.10
					66792.00		-
							-
	Total S.No.1	3,29,29,672.05	2,83,50,275.00	50,525.00	67,292.00	8,81,596.00	23,06,314.10
2.	Other Specific accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
	(iv) UPS a/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM a/c	-	-	-	-	-	-
	(vii) I.T A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	2,66,000.00	-	-	-	-	-
	(ix) PMJVK a/c	200.00	-	-	-	-	-
	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-	-	-
	(xiv) South African a/c	-	-	-	-	-	-
	Total S.No. 2	2,66,200.00	-	-	-	-	-
3.	(i) NPS a/c	-	-	-	-	-	-
	(ii) CPF/GPF a/c	-	-	-	-	-	-
	(iii) GIS a/c	-	-	-	-	-	-
	(iv) Pension fund a/c	-	1,14,116.00	-	-	-	-
		-	-	-	-	-	-
	Total S.No. 3	-	1,14,116.00	-	-	-	-
	Grand Total S.No. 1 to 3	3,31,95,872.05	2,84,64,391.00	50,525.00	67,292.00	8,81,596.00	23,06,314.10

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.		Recoveries of refundable advances		Sale of Council's publications	
		Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)	
1.	(i) CCRUM Scheme a/c	10,04,217.00	-	2,54,090.00	1,79,505.00
		-	-	-	-
	Total S.No.1	10,04,217.00	-	2,54,090.00	1,79,505.00
2.	Other Specific accounts	-	-	-	-
	(i)IPR	-	-	-	-
	(ii)Herb Garden a/c	-	-	-	-
	(iii)Pub. Of Text Books a/c	-	-	-	-
	(iv)UPS a/c I	-	-	-	-
	(v)DSOP	-	-	-	-
	(vi) AIUM a/c	-	-	-	-
	(vii) I.T A/c	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-
	(x) International Events conference a/c	-	-	-	-
	(xi) DST a/c	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-
	(xiv) South African a/c	-	-	-	-
	Total S.No. 2	-	-	-	-
1.	(i) NPS a/c	-	-	-	-
	(ii) CPF/GPF a/c	-	-	-	-
	(iii) GIS a/c	-	-	-	-
	(iv) Pension fund a/c	-	-	-	-
	Total S.No. 3	-	-	-	-
	Grand Total S.No. 1 to 3	1,04,217.00	-	2,54,090.00	1,79,505.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.		Recoveries for remittance		Recovery of subscription/advances		Interest on FDRs	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(09)		(10)		(11)	
1.	CCRUM Scheme a/c	1,04,06,172.00	1,94,04,187.00	-	-	-	-
	Health Scheme a/c			-	-	-	-
	Health Scheme a/c			-	-	-	-
	Total S.No.1	1,04,06,172.00	1,94,04,187.00	-	-	-	-
2.	Other Specific accounts	-	-	-	-	-	-
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
	(iv) UPS a/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIHUM a/c	-	-	-	-	-	-
	(vii) I.T A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-	-	-
	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-	-	-
	(xiv) South African a/c	-	-	-	-	-	-
	Total S.No. 2	-	-	-	-	-	-
3.	(i) NPS a/c	-	-	-	-	-	-
	(ii) CPF/GPF a/c	-	-	4,14,33,520.00	5,81,58,957.00	11,11,364.00	-
	(iii) GIS a/c	-	-	6,50,220.00	6,75,620.00	-	-
	(iv) Pension fund a/c	5,64,917.00	-	0	-	1,45,50,036.00	-
	Total S.No. 3	5,64,917.00	-	4,20,83,740.00	5,88,34,577.00	1,56,61,400.00	-
	Grand Total S.No. 1 to 3	1,09,71,089.00	1,94,04,187.00	4,20,83,740.00	5,88,34,577.00	1,56,61,400.00	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.		Receivable amount received		Security deposit lying with the Council	
		Current Year	Previous Year	Current Year	Previous Year
			(12)		(13)
1.	CCRUM Scheme a/c	13,67,939.00	26,93,960.00	10,000.00	1,06,500.00
	Total S.No.1	13,67,939.00	26,93,960.00	10,000.00	1,06,500.00
2.	Other Specific accounts				
	(i) IPR	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-
	(iv) UPS a/c I	-	-	-	-
	(v) DSOP	-	-	-	-
	(vi) AIUM a/c	-	-	-	-
	(vii) I.T A/c	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-
	(x) International Events conference a/c	-	-	-	-
	(xi) DST a/c	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-
	(xiv) South African a/c	-	-	-	-
	Total S.No. 2	-	-	-	-
3.	(i) NPS a/c	-	-	-	-
	(ii) CPF/GPF a/c	-	-	-	-
	(iii) GIS a/c	-	-	-	-
	(iv) Pension fund a/c	-	-	-	-
	Total S.No. 3	-	-	-	-
	Grand Total S.No. 1 to 3	13,67,939.00	26,93,960.00	10,000.00	1,06,500.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.		Unspent Inst./Unit		Academic Course fee		Amount received but payable to other Institute/Units	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(14)		(15)		(16)	
1.	(i) CCRUM Scheme a/c	2,26,17,984.06	-	52,66,963.19	44,12,488.00	24,67,504.00	-
				-	-	-	-
				-	-	-	-
				-	-	-	-
	Total S.No.1	2,26,17,984.06	-	52,66,963.19	44,12,488.00	24,67,504.00	-
2.	Other Specific accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
	(iv) UPS a/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIHUM a/c	-	-	-	-	-	-
	(vii) I.T A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-	-	-
	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-	-	-
	(xiv) South African a/c	-	-	-	-	-	-
	Total S.No. 2	-	-	-	-	-	-
3.	(i) NPS a/c	-	-	-	-	-	-
	(ii) CPF/GPF a/c	-	-	-	-	-	-
	(iii) GIS a/c	-	-	-	-	16,549.00	-
	(iv) Pension fund a/c	-	-	-	-	-	-
	Total S.No. 3	-	-	-	-	16,549.00	-
	Grand Total S.No. 1 to 3	2,26,17,984.06	-	52,66,963.19	44,12,488.00	24,84,053.00	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.		Investment received		LIC amount for disbursement	
		Current Year	Previous Year	Current Year	Previous Year
		(17)		(18)	
1.	CCRUM Scheme a/c				
		-	-	-	-
	Total S.No. 1	-	-	-	-
2.	Other Specific accounts				
	(i) IPR	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-
	(iv) UPS a/c I	-	-	-	-
	(v) DSOP	-	-	-	-
	(vi) AIHUM a/c	-	-	-	-
	(vii) I.T A/c	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-
	(x) International Events conference a/c	-	-	-	-
	(xi) DST a/c	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-
	(xiv) South African a/c	-	-	-	-
	Total S.No. 2	-	-	-	-
3.	(i) NPS a/c	-	61,84,357.00	-	-
	(ii) CPF/ GPF a/c	3,52,60,190.00	-	-	-
	(iii) GLS a/c	-	-	5,60,000.00	-
	(iv) Pension fund a/c	17,87,61,808.00	2,57,84,283.00	-	-
	Total S.No. 3	21,40,21,998.00	3,19,68,640.00	5,60,000.00	-
	Grand Total S.No. 1 to 3	21,40,21,998.00	3,19,68,640.00	5,60,000.00	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.		Pension fund transfer from Health account		Govt. contribution of Non-Pran Members		Receipts on Closing of Bank	
		Current Year	Previous year	Current Year	Previous Year	Current Year	Previous Year
		(19)		(20)		(21)	
1.	CCRUM Scheme a/c			-	-	-	-
	(i) Health Scheme	-		-	-	-	-
				-	-	-	-
	Total S.No. 1	-		-	-	-	-
2.	Other Specific accounts			-	-	-	-
	(i) IPR	-		-	-	-	-
	(ii) Herb Garden a/c	-		-	-	-	-
	(iii) Pub. Of Text Books a/c	-		-	-	-	-
	(iv) UPS a/c I	-		-	-	-	-
	(v) DSOP	-		-	-	-	-
	(vi) AIUM a/c	-		-	-	-	-
	(vii) I.T A/c	-		-	-	-	-
	(viii) National Conference on Unani Day	-		-	-	-	-
	(ix) PMJKV a/c	-		-	-	-	-
	(x) International Events conference a/c	-		-	-	-	-
	(xi) DST a/c	-		-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-		-	-	-	-
	(xiii) CRISM a/c	-		-	-	-	-
	(xiv) South African a/c	-		-	-	-	-
	Total S.No. 2	-		-	-	-	-
3.	(i) NPS a/c	-		-	-	-	-
	(ii) CPF/GPF a/c	-		-	-	-	-
	(iii) GIS a/c	-		-	-	-	-
	(iv) Pension fund a/c	20,79,33,285.00	28,14,96,741.00	-	-	-	-
	Total S.No. 3	20,79,33,285.00	28,14,96,741.00	-	-	-	-
	Grand Total S.No. 1 to 3	20,79,33,285.00	28,14,96,741.00	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.		NPS Corpus Amount		Unani Day Funds		Unspent Balance (Cr. Year)	
		Current Year	Previous year	Current Year	Previous Year	Current Year	Previous Year
		(22)		(23)	(24)		
1.	CCRUM Scheme a/c	22,93,418.85	3,20,40,648.62	-	39,98,912.00	-	1,24,74,386.50
				-		-	
	Total S.No. 1	22,93,418.85	3,20,40,648.62	-	39,98,912.00	-	1,24,74,386.50
2.	Other Specific accounts	-		-		-	
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
	(iv) UPS a/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM a/c	-	-	-	-	-	-
	(vii) I.T A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-	-	-
	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-	-	-
	(xiv) South African a/c	-	-	-	-	-	-
	Total S.No. 2	-	-	-	-	-	-
3.	(i) NPS a/c	-	-	-	-	-	-
	(ii) CPF/GPF a/c	-	-	-	-	-	-
	(iii) GIS a/c	-	-	-	-	-	-
	(iv) Pension fund a/c	1,43,11,005.00	-	-	-	-	-
	Total S.No. 3	1,43,11,005.00	-	-	-	-	-
	Grand Total S.No. 1 to 3	1,66,04,423.85	3,20,40,648.62	-	39,98,912.00	-	1,24,74,386.50

Sd/-
(Shakaib Hasan)
Consultant (IA)

**Sd/-
(Mohammad Parvez)
Administrative Officer**

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.		Interest refunded to Ministry received from NPCC		Total receipts	
		Current Year	Previous Year	Current Year	Previous Year
			(25)		(26)
1.	CCRUM Scheme a/c				
	(i) CCRUM Scheme	2,33,76,872.00	-	2,02,85,50,832.59	1,88,37,43,492.44
	Total S.No. 1	2,33,76,872.00	-	2,02,85,50,832.59	1,88,37,43,492.44
2.	Other Specific accounts	-	-	-	-
	(i) IPR	-	-	38,194.00	5,91,896.00
	(ii) Herb Garden a/c	-	-	2,64,252.00	2,64,252.00
	(iii) Pub. Of Text Books a/c	-	-	-	-
	(iv) UPS a/c I	-	-	-	-
	(v) DSOP	-	-	-	-
	(vi) AIUM a/c	-	-	-	-
	(vii) I.T A/c	-	-	-	24,15,961.00
	(viii) National Conference on Unani Day	-	-	8,53,925.50	45,44,441.50
	(ix) PM/VK a/c	-	-	2,53,92,499.72	4,98,38,380.65
	(x) International Events conference a/c	-	-	-	-
	(xi) DST a/c	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-
	(xiv) South African a/c	-	-	-	-
	Total S.No. 2	-	-	2,65,48,871.22	5,76,54,931.15
3.	(i) NPS a/c	-	-	1,43,11,458.31	1,42,43,150.31
	(ii) CPF/GPF a/c	-	-	9,77,70,496.62	8,22,40,348.29
	(iii) GIS a/c	-	-	36,96,591.34	47,48,448.84
	(iv) Pension fund a/c	-	-	49,99,96,749.53	39,20,46,205.53
	Total S.No. 3	-	-	61,57,75,295.80	49,32,78,152.97
	Grand Total S.No. 1 to 3	2,33,76,872.00	-	2,67,08,74,999.61	2,43,46,76,576.56

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Schedule of Payments for the year ending 31st March 2025

S.No.	Name of the Scheme	Establishment Expenses		Administrative Expenses		Material & Supplies Expenses	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
1.	(i) CCRUM scheme a/c	105,81,65,559.00	1,08,42,69,917.00	54,21,49,846.07	43,28,78,316.50	15,52,68,636.00	12,58,22,137.00
					3,00,96,032.00		
					1,97,25,656.00		
	Total S.No.1	105,81,65,559.00	1,08,42,69,917.00	54,21,49,846.07	48,27,00,004.53	15,52,68,636.00	12,58,22,137.00
2.	Other Specific accounts						
	(i) IPR	-	-	76.74	-	-	-
	(ii) Herb Garden a/c	-	-		-	-	-
	(iii) Pub. Of Text Books a/c	-	-		-	-	-
	(iv) UPS a/c I	-	-		-	-	-
	(v) DSOP	-	-		-	-	-
	(vi) AIUM a/c	-	-		-	-	-
	(vii) I.T A/c	-	-		-	-	-
	(viii) National Conference on Unani Day	-	-		-	-	-
	(ix) PMJVK a/c	-	-		-	-	-
	(x) International Events conference a/c	-	-		-	-	-
	(xi) DST a/c	-	-		-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-		-	-	-
	(xiii) CRISM a/c	-	-		-	-	-
	(xiv) South African a/c	-	-		-	-	-
	Total S.No. 2	-	-	76.74	-	-	-
3.	(i) NPS a/c	-	-	453.31	-	-	-
	(ii) GPF a/c	-	-	1105.12	3,019.67	-	-
	(iii) GIS a/c	-	-	0	4.50	-	-
	(iv) Pension fund a/c	5,29,84,667.00	-	0	873.00	-	-
	Total S. No.3	5,29,84,667.00	-	1558.43	3,897.17	-	-
	Total S.No. 1 to 3	111,11,50,226.00	1,08,42,69,917.00	54,21,51,481.24	48,27,03,901.70	15,52,68,636.00	12,58,22,137.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.	Name of the Scheme	Assets		Publications (Priced)		Advances to Government Servants	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
			(4)	(5)	(6)		
1.	CCRUM scheme a/c	1,19,75,452.00	1,29,64,843.00	-	-	-	9,25,849.07
			25,09,000.00	-	-	-	
	Total S.No.1	1,19,75,452.00	1,54,73,843.00	-	-	-	9,25,849.07
2.	Other Specific accounts						
	(i) IPR		-	-	-	-	-
	(ii) Herb Garden a/c		-	-	-	-	-
	(iii) Pub. Of Text Books a/c		-	-	-	-	-
	(iv) UPS a/c I		-	-	-	-	-
	(v) DSOP		-	-	-	-	-
	(vi) AIUM a/c		-	-	-	-	-
	(vii) I.T A/c		-	-	-	-	-
	(viii) National Conference on Unani Day		-	-	-	-	-
	(ix) PMJVK a/c		-	-	-	-	-
	(x) International Events conference a/c		-	-	-	-	-
	(xi) DST a/c		-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c		-	-	-	-	-
	(xiii) CRISM a/c		-	-	-	-	-
	(xiv) South African a/c		-	-	-	-	-
	Total S.No. 2			-	-	-	-
3.	(i) NPS a/c		-	-	-	-	-
	(ii) GPF a/c		-	-	-	-	-
	(iii) GLS a/c		-	-	-	-	-
	(iv) Pension fund a/c		-	-	-	-	-
	Total S.No. 3			-	-	-	-
	Total S.No. 1 to 3	1,19,75,452.00	1,54,73,843.00	0	0		9,25,849.07

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.	Name of the Scheme	Outstanding advances		Other charges		Capital Payment	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
1.	CCRUM scheme a/c	1,45,45,826.00	1,08,42,452.00	6,89,53,403.00	3,08,78,646.00	3,00,01,796.00	5,29,89,253.00
	Total S.No.1	1,45,45,826.00	1,08,42,452.00	6,89,53,403.00	3,08,78,646.00	6,00,01,796.00	25,00,000.00
2.	Other Specific accounts						5,54,89,253.00
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
	(iv) UPS a/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM a/c	-	-	-	-	-	-
	(vii) I.T A/c	-	-	-	9,65,542.00	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-	2,03,94,000.00	2,51,71,290.00
	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-	-	-
	(xiv) South African a/c	-	-	-	-	-	-
	Total S.No. 2	-	-	-	9,65,542.00	2,03,94,000.00	2,51,71,290.00
3.	(i) NPS a/c	-	-	-	-	-	-
	(ii) GPF a/c	-	-	-	-	-	-
	(iii) GIS a/c	-	-	-	-	-	-
	(iv) Pension fund a/c	-	-	-	-	-	-
	Total S.No.3	-	-	-	-	-	-
	Total S.No. 1 to 3	1,45,45,826.00	1,08,42,452.00	6,89,53,403.00	3,18,44,188.00	8,03,95,796.00	8,06,60,543.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.	Name of the Scheme	Remittance of Interest received from NPCC to Ministry		Remittance of recoveries		Interest earned remitted to Ministry for the year 2023-24	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(10)		(11)		(12)	
1.	CCRUM Scheme	2,33,76,872.00	-	-	-	26,55,151.00	-
	Total S.No.1	2,33,76,872.00	-	-	-	26,55,151.00	-
2.	Other Specific accounts	-	-	-	-	-	-
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
	(iv) UPS a/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM a/c	-	-	-	-	-	-
	(vii) I.T A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-	-	-
	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-	-	-
	(xiv) South African a/c	-	-	-	-	-	-
	Total S.No. 2	-	-	-	-	-	-
3.	(i) NPS a/c	-	-	-	-	-	-
	(ii) GPF a/c	-	-	-	-	-	-
	(iii) GIS a/c	-	-	600.00	-	-	-
	(iv) Pension fund a/c	-	-	1,57,00,780.00	1,64,87,977.00	-	-
	Total S.No. 3	-	-	1,57,01,380.00	1,64,87,977.00	-	-
	Total S.No. 1 to 3	2,33,76,872.00	-	1,57,01,380.00	1,64,87,977.00	26,55,151.00	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.	Name of the Scheme	NPS Employee Contribution paid to Non-Pran		Investments a/c		Received from LIC disbursed	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(13)		(14)		(15)	
1.	CCRUM Scheme	-	-	-	-	-	-
	Total S.No.1	-	-	-	-	-	-
2.	Other Specific accounts	-	-	-	-	-	-
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
	(iv) UPS a/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM a/c	-	-	-	-	-	-
	(vii) I.T A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK a/c	-	-	-	-	-	-
	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-	-	-
	(xiv) South African a/c	-	-	-	-	-	-
	Total S.No. 2	-	-	-	-	-	-
3.	(i) NPS a/c	-	-	-	-	-	-
	(ii) GPF a/c	-	-	-	-	5,60,000.00	-
	(iii) GIS a/c	-	-	-	-	-	-
	(iv) Pension fund a/c	-	-	10,68,10,000.00	-	-	-
	Total S.No. 3	-	-	10,68,10,000.00	-	5,60,000.00	-
	Grand total S.No. 1 to 3	-	-	10,68,10,000.00	-	5,60,000.00	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.	Name of the Scheme	Amount payable paid/Adjusted Current Year (16)	Other Misc. Payments/Transfer Current Year (17)	Refund of EMD Current Year (18)	Previous Year
1.	CCRUM Scheme				
	(i) CCRUM scheme a/c	-	-	-	2,38,998.00
		-	-	-	669.96
	Total S.No.1	-	-	-	2,38,998.00
2.	Other Specific accounts	-	-	-	-
	(i) IPR	-	-	-	-
	(ii) Herb Garden a/c	-	-	-	-
	(iii) Pub. Of Text Books a/c	-	-	-	-
	(iv) UPS a/c I	-	-	-	-
	(v) DSOP	-	-	-	-
	(vi) AIUM a/c	-	-	-	-
	(vii) I.T A/c	-	-	-	-
	(viii) National Conference on Unani Day	39,98,912.00	-	-	-
	(ix) PMJVK a/c	-	-	-	-
	(x) International Events conference a/c	-	-	-	-
	(xi) DST a/c	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-
	(xiv) South African a/c	-	-	-	-
	Total S.No. 2	39,98,912.00	-	-	-
3.	(i) NPS a/c	1,43,11,005.00	-	-	-
	(ii) GPF a/c	-	8,49,80,721.00	6,26,41,006.00	-
	(iii) GIS a/c	7,00,633.00	23,25,851.00	23,18,022.00	-
	(iv) Pension fund a/c	-	32,44,49,464.00	29,24,78,405.00	-
	Total S.No. 3	1,50,11,638.00	41,17,56,036.00	35,74,37,433.00	-
	Grand Total S.No.1 to 3	1,50,11,638.00	41,17,56,036.00	37,23,04,037.96	2,38,998.00

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Shakaib Hasan)
Consultant (IA)



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.	Name of the Scheme	NPS Corpus Amount Paid		Unspent balance transferred to Ministry		Fund Transfer on A/c of closure	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(19)		(20)	(21)		
1	CCRUM Scheme						
	(i) Health scheme a/c	10,55,900.00	1,32,24,296.00	-	2,56,10,081.00	-	-
	Health scheme a/c			-		-	-
	Health scheme a/c			-		-	-
	Total S.No.1	10,55,900.00	1,32,24,296.00	-	2,56,10,081.00	-	-
2.	Other Specific accounts						
	(i) IPR	-		-	5,65,377.00	-	-
	(ii) Herb Garden a/c	-		-		-	-
	(iii) Pub. Of Text Books a/c	-		-		-	-
	(iv) UPS a/c I	-		-		-	-
	(v) DSOP	-		-		-	-
	(vi) AIUM a/c	-		-		-	-
	(vii) I.T.A/c	-		-	14,50,419.00	-	-
	(viii) National Conference on Unani Day	-		-		-	-
	(ix) PMJVK a/c	-		-		-	-
	(x) International Events conference a/c	-		-		-	-
	(xi) DST a/c	-		-		-	-
	(xii) Pharmacovigilance workshop a/c	-		-		-	-
	(xiii) CRISM a/c	-		-		-	-
	(xiv) South African a/c	-		-		-	-
	Total S.No. 2	-	-	-	20,15,796.00	-	-
3.	(i) NPS a/c	-		-		-	-
	(ii) CPF/GPF a/c	-		-		-	-
	(iii) GIS a/c	-		-		-	-
	(iv) Pension fund a/c	-		-		-	-
	Total S.No. 3	-	-	-	-	-	-
	GRAND TOTAL S.NO.1 TO 3	10,55,900.00	1,32,24,296.00	-	2,76,25,877.00	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

S.No.	Name of the Scheme	Fund Transfer		Closing Balance		Total payments	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)	(23)	(24)	(25)	(26)	(27)
1	CCRUM Scheme						
	(i) CCRUM scheme a/c	11,51,065.00	-	8,92,51,326.52	2,34,01,411.44	2,02,85,50,832.59	1,88,37,43,493.00
	Total S.No.1	11,51,065.00	-	8,92,51,326.52	2,34,01,411.44	2,02,85,50,832.59	1,88,37,43,493.00
2.	Other Specific accounts						
	(i) IPR	-	-	38,11,726	26,51,900	38,194.00	5,91,896.00
	(ii) Herb Garden a/c	-	-	2,64,252.00	2,64,252.00	2,64,252.00	2,64,252.00
	(iii) Pub. Of Text Books a/c	-	-	-	-	-	-
	(iv) UPS a/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM a/c	-	-	-	-	-	-
	(vii) I.T A/c	-	-	-	-	-	24,15,961.00
	(viii) National Conference on Unani Day	-	-	8,53,925.50	5,45,529.50	8,53,925.50	45,44,441.50
	(ix) PMIVK a/c	-	-	49,98,499.72	2,46,67,090.65	2,53,92,499.72	4,98,38,380.65
	(x) International Events conference a/c	-	-	-	-	-	-
	(xi) DST a/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop a/c	-	-	-	-	-	-
	(xiii) CRISM a/c	-	-	-	-	-	-
	(xiv) South African a/c	-	-	-	-	-	-
	Total S.No. 2	-	-	61,54,794.48	2,55,03,391.15	2,65,48,871.22	5,76,54,931.15
3.	(i) NPS a/c	-	-	-	1,42,43,150.31	1,43,11,458.31	1,42,43,150.31
	(ii) CPF/GPF a/c	-	-	1,27,88,670.50	1,95,96,322.62	9,77,70,496.62	8,22,40,348.29
	(iii) GIS a/c	-	-	109,507.34	24,30,422.34	36,96,591.34	47,48,448.84
	(iv) Pension fund a/c	-	-	51,838.53	8,30,78,950.53	49,99,96,749.50	39,20,46,205.50
	Total S.No. 3	-	-	1,29,50,016.37	11,93,48,845.80	61,57,75,295.80	49,32,78,152.97
	GRAND TOTAL S.NO.1 TO 3	11,51,065.00	-	10,83,56,137.37	16,82,53,648.39	2,67,08,74,999.61	2,43,46,76,577.12

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry)

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Notes on accounts: -

1. Annual accounts of the Council for the year 2024-25 have been prepared on the uniform format of account for Central Autonomous Bodies (Non-profit organization).
2. The Central Council for Research in Unani Medicine is fully financed by Govt. of India Ministry of AYUSH through grant-in-aid. Therefore, income tax is not applicable on the organization.
3. The said accounts prepared on accrual basis.
4. Schedules are attached wherever necessary.
5. Depreciation has been charged on assets on diminishing balance method.
6. The construction works are done by the CPWD & PWD.
7. There is no valuation of Inventories since it is not a profit earning organization but a Research Organization under Ministry of AYUSH, Government of India.
8. A schedule of Investment prepared every year & given to audit which is duly reconciled with actual documents figures mentioning there the rate of interest duration amount & name of Institutions etc.
9. Retirement benefits are treated as per GOI Rules.
10. Depreciation has been charged under expenditure
11. Earmarked/Endowment fund has been shown separately in the Balance Sheet with necessary Schedule.
12. The annual accounts of the Council for the year 2024-25 have been approved by the competent authority i.e. Standing Finance Committee on 16.06.2025

Administrative Officer
CCRUM, New Delhi

APPENDIX- I

INSTITUTIONAL NETWORK OF CCRUM

1. **Central Council for Research in Unani Medicine**
61-65, Institutional Area, Opposite D Block, Janakpuri,
New Delhi – 110 058
Phone: +91-11-28521981, Fax: +91-11-28522965
E-mail: unanimedicine@gmail.com; unani-medicine@ccrum.res.in
2. **National Research Institute of Unani Medicine for Skin Disorders**
Opp. ESI Hospital, AG Colony Road Erragadda,
Hyderabad – 500 038 Telangana
Phone: +91-40-23811551, 23810246
E-mail: criumhyderabad@gmail.com
3. **Central Research Institute of Unani Medicine**
Basaha, Kursi Road, Lucknow – 226 026
Uttar Pradesh
Phone: +91-522-2361720
E-mail: ddcriumlko@gmail.com
4. **Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine**
Mohibbul Hasan House, Jamia Millia Islamia,
Okhla New Delhi – 110 025
E-mail: Iriumnew1986@gmail.com
5. **Regional Research Institute of Unani Medicine**
1, West Meda Church Street, Royapuram
Chennai – 600 013, Tamil Nadu
Phone: +91-44-25955519
E-mail: rriumchennai@gmail.com
6. **Regional Research Institute of Unani Medicine**
Chandbali Bypass Road, Near Rural Police Station,
Bhadrak – 756 100, Odisha
Phone: +91-6784-240289
E-mail: rriumbdk_unani@yahoo.co.in
7. **Regional Research Institute of Unani Medicine**
Guzri, Patna City, Patna – 800 008, Bihar
Phone: +91-612-2631106
E-mail: rriumpatna@gmail.com

8. **Regional Research Institute of Unani Medicine**
Shahjahan Manzil, Near AMU Riding Club, Qila Road,
Aligarh – 202 001, Uttar Pradesh
Phone: +91-571-2704781, 2701399
E-mail: rrium_aligarh@rediffmail.com
9. **Regional Research Institute of Unani Medicine**
Plot No. 38–39, Sector-18, Kharghar,
Navi Mumbai– 410 210, Maharashtra
Phone: +91-8652871023/2523
E-mail: rrium.mumbai@gmail.com, rrium.kharghar@gmail.com
10. **Regional Research Institute of Unani Medicine**
University of Kashmir Campus, Hazrat Bal Srinagar – 190 006,
Jammu & Kashmir
Phone: +91-194-2421604
E-mail: rrium.srinagar@gmail.com
11. **Regional Research Institute of Unani Medicine**
250A/29, GT Road (North), Liluah Howrah – 711 204,
West Bengal, Phone: +91-33-26550108
E-mail: kolrrium@gmail.com
12. **Regional Research Institute of Unani Medicine**
D-11/1, Abul Fazal Enclave, Jamia Nagar
New Delhi – 110 025, Phone: +91-11-26922759
E-mail: rridelhi@gmail.com
13. **Regional Research Institute of Unani Medicine**
Veterinary Bazar, Ghungoor, Silchar,
Assam 788014, (Cachar) Assam, Phone: +91-3843-267522
E-mail: rrcsilchar@gmail.com
14. **Drug Standardization Research Institute**
PLIM, Sector–23, Kamla Nehru Nagar,
Ghaziabad – 201 002, Uttar Pradesh
Phone: +91-120-2783029
E-mail: dsriccrum@gmail.com
15. **Drug Standardization Research Unit**
61-65, Institutional Area, Opposite D Block, Janakpuri,
New Delhi – 110 058
Phone: +91-11-28521981
E-Mail: dsru.newdelhi@gmail.com

16. Regional Research Centre

B-501/4, GTB Nagar, Opp. Dulhan Palace Kareli,
Prayagraj – 211 016, Uttar Pradesh
Phone: +91-532-2551223
E-mail: rrcallahabad@gmail.com

17. Clinical Research Unit

Kurupatil Nina Memorial, Near Panchayat Office, Edathala (N)
Alweye – 683 564, Kerala
Phone: +91-484-2836006
E-mail: crukerala@gmail.com

18. Clinical Research Unit

National Institute of Unani Medicine Kotigepaliya,
Magadi Main Road
Bengaluru – 560 091, Karnataka
Phone: +91-80-25480863
E-mail: crubangalore2000@yahoo.com

19. Clinical Research Unit

Dr. Abdul Haq Unani Medical College 40/23 Park Road,
Kurnool – 518 001 Andhra Pradesh
E-mail: cru.kurnool@gmail.com

20. Clinical Research Unit

Cantonment General Hospital,
Soti Ganj Begumpul,
Meerut – 250 001, Uttar Pradesh
Phone: +91-9012843253
E-mail: crumeerut@gmail.com

21. Clinical Research Unit

Gandhi Medical College,
Bhopal – 462 001, Madhya Pradesh
Phone: +91-755-2540590
E-mail: cruu_incharge@yahoo.com

22. Clinical Research Unit

SH Unani Tibbiya College, Ganpati Naka,
Burhanpur – 450 331, Madhya Pradesh
Phone: +91-7325-252250
E-mail: cruburhanpur@rediffmail.com

23. Clinical Research Unit

RRIH Building, Opp. Tribal Colony, New Checkon Road,
Imphal East – 795001, Manipur
Phone: +91- 8811907160, E-mail: cruimphal1@gmail.com

24. Clinical Research Unit

Old GMC Building, Ribandar, Goa – 403006
Maharashtra
Mobile: +91-7817054784
E-mail: unanisc.goa@gmail.com

25. Chemical Research Unit

Department of Research in Unani Medicine,
Near Office of Dean,
Faculty of Science, Aligarh Muslim University
Aligarh – 202 001, Uttar Pradesh

26. Unani Speciality Centre

(Extension Centre of RRIUM, New Delhi)
Deen Dayal Upadhyay Hospital
Ghantaghar, Harinagar
New Delhi – 110 064
E-mail: dduhospital0786@gmail.com

27. Unani Medical Centre

(Extension Centre of RRIUM, New Delhi)
VMMC & Safdarjung Hospital
New OPD Block, Ansari Nagar East, New Delhi – 110029
Phone: +91-11-26707121
E-mail: umcsafdarjung@gmail.com

28. Unani Medical Centre

(Extension Centre of RRIUM, New Delhi)
Dr. Ram Manohar Lohia Hospital
New Delhi – 110 001
Phone: +91-11-23404594
E-mail: unaniopdrmlh@gmail.com

29. Unani Medical Centre

(Extension Centre of RRIUM, Navi Mumbai)
JJ Hospital Compound, Byculla, Mumbai – 400 008, Maharashtra
Phone: +91-22-23718706
E-mail: rrium.mumbai@gmail.com

30. Ayush Wellness Centre (Unani Wing)

Presidents Estate, Rashtrapati Bhawan, New Delh – 110 001
Phone: +91-9682179404
E-mail: coordinatingofficer.awcrb@gmail.com



Central Council for Research in Unani Medicine

Ministry of Ayush, Government of India
 61-65, Institutional Area, Janakpuri, New Delhi - 110058
 Telephone : +91-11-28521981, 28525982
 Website : <https://ccrum.res.in>
 E-mail : unani-medicine@ccrum.res.in
unanimedicine@gmail.com